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Summary 
Snake venom contains a toxic mixture of enzymes, low molecular weight 
polypeptides, glycoproteins and metal ions that is capable of causing local tissue 
damage as well as multiple system failure. However, nerve growth factor (NGF) 
activity was first discovered in snake venom and two sarcoma tissues. The nerve 
growth factor from Naja sputatrix has been purified by gel filtration followed by 
reverse-phase high performance liquid chromatography (RP-HPLC). The protein 
showed a very high ability to induce neurite formation in PC12 cells relative to the 
mouse nerve growth factor. Two cDNAs encoding isoforms of NGF have been 
cloned and an active recombinant nerve growth factor, sputa NGF has been 
produced in E. coli as a his-tagged fusion protein. Sputa NGF was found to be non-
toxic in both in vivo and in vitro conditions. The induction of neurite outgrowth by 
this NGF has been found to involve the high affinity TrkA-p75NTR complex of 
receptors. The pro-survival mechanism of p75NTR was mediated by the activation of 
NFkB gene by a corresponding down regulation of IκB gene. Real-time PCR and 
protein profiling (SELDI-TOF) also confirmed that sputa NGF upregulates the 
expression of the endogenous NGF in PC12 cells. Preliminary microarray analysis 
has also shown that sputa NGF is capable of promoting additional beneficial effects 
such as the upregulation of arginine vasopresin receptor 1A, voltage-dependent T-
type calcium channel, etc.  Hence, sputa NGF forms a new and useful nerve growth 
factor. 
In addition to the sputa NGF, the precursor [Pro (R/G) NGF] was shown to behave 
in a similar manner to the mature NGF when expressed in stably transfected CHO 
cells. It was capable of eliciting neurites, but to a lesser extent (2-fold) than the 
mature NGF. In addition, it was also found to involve the high affinity TrkA-p75NTR 
   iii
complex of receptors to cause neurite extension. The overall fate of the cell when 
exposed to pro (R/G) NGF is survival. Both mature NGF and pro (R/G) lead to cell 
survival upon treatment in both serum-starved and ischemic conditions. However, 
when exposed to an apoptotic agent (i.e staurosporine), only the mature NGF 
enabled cell survival. Apart from the property of the pro (R/G) NGF, the pro-domain 
was investigated. Both fluorescence microscopy experiments, as well as caspase-3 
activity measurement indicated that pro-domain caused apoptosis and probably by 
the caspase pathway.  
Both real-time studies and western blot analysis for the three surface receptors 
(TrkA, p75NTR and sortilin) indicated that with mature NGF, both TrkA and sortilin 
expression were upregulated, while p75NTR was downregulated. Though sortilin 
expression is relatively high, but in the presence of TrkA, p75NTR formed a high-
affinity complex with TrkA, leaving minimal p75NTR to interact with the sortilin 
receptors. On the contrary, pro-domain had low expression levels of TrkA, while 
both p75NTR and sortilin were expressed in similar levels. The reduced expression of 
TrkA, allowed the interaction between p75NTR and sortilin, thereby activating the 
cell death pathway as observed in both caspase and DNA laddering studies. Hence, 
these functional studies indicated that the NGF-induced cell survival and death is far 
more complicated than previously appreciated. It depends on an intricate balance 
between precursor (ProNGF) and mature NGF, as well as the spatial and temporal 
expression of the three distinct receptors.  
Another potentially useful component from Naja sputatrix venom is neutral 
phospholipase A2 (nPLA2). Orgnotypic hippocampal cultures when exposed to 
ischemic conditions (oxygen-glucose deprivation) were protected when concurrently 
treated with PLA2. Real-time PCR studies of related apoptotic genes showed that 
   iv
anti-apoptotic genes (Bcl-2 and Bcl-XL) were upregulated, while apoptotic genes 
(Bax) were downregulated with PLA2. In addition, the mechanism of action of 
protection by PLA2 was most likely via group I glutamate metabotrophic receptors, 
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1.1 Nerve Growth Factor (NGF) 
Nerve growth factor (NGF) is among the first growth factor to be identified and 
characterized (Cohen et al., 1954).  Its name, NGF, is based on its ability to promote 
neuronal survival and neurite outgrowth of explanted sympathetic ganglia. NGF has 
been detected in various animals including snakes (Lipps, 1998; Guo et al., 1999; 
Kashima et al., 2002), human placental tissues (Goldstein, 1978) and bodily fluids 
(Lipps, 2000). Its activity was first detected from two sarcoma tissues and in snake 
venoms. However, the property of NGF was most extensively studied using NGF 
from the male mouse submandibular gland (mouse NGF; Kostiza and Meier, 1996). 
In the peripheral nervous system, NGF sensitive cells include neural crest 
deriviatives from sympathoadrenal origin: sympathetic neurons, para ganglia 
(carotid and abdominal paraganglia cells), chromaffin cells (normal and neoplastic, 
e.g. PC12 cells) and embryonic sensory neurons. While in the central nervous 
system, responsiveness to NGF is only restricted to cholinergic neurons from corpus 
striatum, basal forebrain and septum nucleus. Neurons in the basal forebrain project 
towards the hippocampus and cortex to obtain NGF. NGF is synthesized by the 
pyramidal cells of the hippocampal neurons of the dentate gyrus (Whittemore et al., 
1986; Ayer-Lelievre et al., 1988) and transported retrogradely from the 
hippocampus to the cholinergic septal neurons (Schwab et al., 1979) that do not 
synthesize NGF (Korsching et al., 1985). 
Since the discovery of NGF in 1954, more than 4000 papers have been published on 
its biochemical and biological activities. Fifty years of work have solved a few 
mysteries in this field, like the crystal structure of NGF (McDonald et al., 1991), its 
structural complex with its receptors (Wiesmann et al., 1999; He and Garcia, 2004), 
the paradoxical cell killing activities of one of the two NGF receptors (p75NTR), as 
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well as the unexpected involvement of NGF and other members of the neurotrophin 
family in synaptic plasticity, learning and memory (Huang and Reichardt, 2001). 
Just when some thought that all is known, the roller coaster resumes, sparked from a 
study by Lee et al. (2001) that the precursor NGF (proNGF) is not just an innocent 
bystander.  
 
1.1.1 Neurotrophin family 
Nerve growth factor (NGF) belongs to the neurotrophin family. Its other members 
include brain-derived neurotrophic factor (BDNF), neurotrophin 3 (NT-3), 
neurotrophin 4/5 (NT-4/5) and neurotrophin 6 (NT-6). All neurotrophins share a 
50% pair-wise sequence identity and function as growth factors that regulate the 
development, maintenance and survival of both central and peripheral nervous 
systems. Hence, this family has great potential as therapeutic targets for neurological 
disorders such as Alzheimer’s disease, amyotrophic lateral sclerosis (ALS), 
peripheral neuropathy and spinal cord injury. Neurotrophins exist as noncovalently 
associated homodimers that are capable of promoting either neuronal cell survival or 
death, based on the context of their cellular environment (Lewin and Barde, 1996).  
The pleiotrophic actions of neurotrophins are mediated by two structurally unrelated 
classes of receptors, the tropomyosin-related kinase (Trk) receptor tyrosine kinase 
(RTK) and the p75 neurotrophin receptor (p75NTR), a member of the tumor necrosis 
factor (TNF) receptor superfamily. Trk has three members (TrkA-C) and the 
presence of p75NTR helps to increase ligand selectivity to Trk receptors. Each 
neurotrophin is specific for different Trk receptors but all bind with same affinity to 
p75NTR. For instance, BDNF, NT-3 and NT-4/5 are able to bind to TrkB receptor, 
but in the presence of p75NTR, only BDNF caused a functional response (Bibel and 
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Barde, 1999). Similarly, both NT-3 and NGF are capable of binding to TrkA, but 
p75NTR restricts the signaling of TrkA to NGF only (Benedetti et al., 1994).  
 
1.1.2 Structure of NGF  
Most of the study on NGF was done using the mouse NGF and it exists as 
homodimer. Each monomer is made up of 118 amino acids with six cysteines and 
three disulfide bridges. The sequence can be divided into three parts: (a) a N-
terminal region that corresponds to the signal peptide, (b) a ‘pro’ domain part, 
whose function remains to be determined and (c) a carboxyl terminal that 
corresponds to the mature NGF. The primary structures of NGF (deduced from 
cDNA clones) are available for human, bovine, rat, chick and snake and comparison 
between them shows a high degree of homology among the different species 
(Whittemore et al., 1988). The sequence of the human NGF is shown in Fig. 1.1 (A).  
The three-dimensional structure of NGF was determined by X-ray crystallography 
and revealed a novel tertiary fold with two central pairs of anti-parallel β-stands that 
define the elongated shape of the molecule (McDonald et al., 1991; Fig. 1.1B). Each 
monomer is made up of β-stands (A-D) that are connected by a number of highly 
flexible hairpin loops (L1-L4). These loops are important for p75NTR binding (L1, 
L3 and L4) and TrkA specificity (L2 and L4). The three disulphide bridges of the 
molecule are clustered with two disulphide bridges and help to connect residues 
forming a ring structure for the third disulphide bridge to form a ‘cysteine’ motif. 
This motif helps to stabilize the fold and locks the molecules in their conformation 
(McDonald and Hendrickson., 1993).   
In the biologically active state, the two monomers are arranged in a parallel manner 
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Fig. 1.1: Sequence and structure of NGF.  (A) Secondary structure of NGF as 
indicated by Wiesmann et al (1999). NGF residues that are in contact with TrkA 
(domain 5) are indicated in red, while those for p75NTR are in green. (B) Ribbon 
structure of NGF monomer (PDB code: 1BFT). The termini, loop region (L1-4) are 
indicated in red and cysteine-knot motif (black arrow) at the top of molecule is 
shown in grey and yellow. (C) Ribbon structures of NGF dimers (PDB code: 1BET) 
bound together in parallel fashion. The loops for receptor binding: p75NTR (L1, L3 




NGF, it forms parallel dimers with both monomers assembled around a central 
twofold axis (Fig. 1.1C). The long axis of the dimer coincides with the twofold axis, 
giving NGF an overall dumbbell-like shape. The two central β-strands (AB and CD) 
from each of the monomers are packed against each other to form the ‘handle’ of the 
dumbbell. Residues from these four β-strands are responsible for the majority of the 
interactions that help to stabilize the dimer. The cysteine-knot motif, the N and C 
termini, and the third loop connecting strands B and C (L3) form one end of the 
dumbbell that face away from the membrane (Wiesmann et al., 1999), while the 
other end containing the three hairpin loops (L1, L2, and L4), as well as four short 
β-strands arranged in two antiparallel β-sheets face the membrane.  
 
1.1.3 Biosynthesis of NGF 
The structure, biosynthesis and biological activity of NGF from the male mouse 
submandibular glands (mouse NGF) has been extensively studied. Mouse NGF is 
encoded by a single gene of more than 45 kilobases (Ullrich et al., 1983), which 
consists of two separate promoters and four exons that are alternatively spliced to 
yield two major and two minor transcripts (Racke et al., 1996). Translation from the 
two major alternatively spliced transcripts produce prepro species of 34 and 27 kDa, 
while removal of the signal sequence later in the endoplasmic reticulum (ER) by 
membrane-bound signal peptidase reduces the translation products to proNGF 
species of 32 and 25kDa respectively (Darling et al; 1983; Ullrich et al; 1983; Selby 
et al., 1987; Edwards et al., 1988b). 
The first phase of glycosylation takes place in the ER and continues in the trans-




the prosegment and one in the mature segment. The function of N-glycosylation for 
pro- NGF is still unclear as both glycosylated (Suter et al; 1991) and unglycosylated 
proNGF (Chen et al., 1997; Fannestock et al., 2001) have been detected in tissues. 
ProNGF is cleaved within the TGN by furin or furin-like enzymes that act on the 
carboxyl terminal side of the multibasic sites (Hosaka et al., 1991) and later 
constitutively released (Dubois et al., 1995) as an active mature NGF. Recently, 
extracellullar cleavage of proNGF by both plasmin and matrix metalloprotease-7 
(MMP-7) have also been reported (Lee et al., 2001). Plasmin cleavage of proNGF 
produces the mature form, whereas MMP-7 results in a 17kDa intermediate (Darling 
et al., 1983; Dicou, 1989). The roles of proNGF have been thought to be for proper 
folding of the mature NGF and sorting it to either constitutive or secretory pathway 
(Suter et al., 1991). However, the functions of the precursors and their intermediates 
are still poorly understood, while the role of proNGF is debated by two separate 
groups (Lee et al., 2001 and Fahnestock et al., 2004). 
 
1.1.3.1 Debate on functionality of proNGF 
Lee et al (2001) created a furin-resistant proNGF protein by changing the two 
conserved arginine residues to alanine. Nevertheless, it was susceptible to cleavage 
by extracellular metalloproteases (MMP-7). Based on radioactive I125 binding 
studies, proNGF was found to bind to p75NTR with greater affinity than mature NGF. 
Competition binding assays indicated that proNGF exhibited an equilibrium binding 
constant of 10-10 M for p75NTR (five times more than mature NGF), while binding to 
TrkA receptors was less than mature NGF. The higher affinity binding of proNGF to 
p75NTR resulted in enhanced p75NTR-mediated apoptosis in a vascular smooth muscle 
cell line, while activation of TrkA, assessed by autophosphorylation and neurite 
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outgrowth in superior cervical ganglia (SCG) and PC12 cells were less for proNGF 
compared to mature NGF. The corresponding activation of p75NTR with increased 
affinity of proNGF shed new light into proNGF being a potential agonist for p75NTR-
mediated apoptosis (Lee et al., 2001).  
A similar study by Fahnestock (2004) on proNGF resulted in a striking contrast to 
that of Lee et al. (2001). To determine the biological function of proNGF, the 
precursor-processing site was mutagenized and expressed as an unprocessed, 
cleavage-resistant proNGF protein in insect cells. Survival and neurite outgrowth 
assays on murine superior cervical ganglion neurons and PC12 cells indicated that 
proNGF exhibited similar neurotrophic activity to mature 2.5S NGF, but is 
approximately five-fold less active. ProNGF also binds to the high-affinity receptor, 
TrkA, as determined by binding studies but is less active in promoting 
phosphorylation to TrkA and its downstream pathway.  
The cleavage-resistant proNGFs from the two separate groups are all mutated 
recombinant proteins. The different conclusions drawn by them showed that 
mutations made at different positions of the protein sequence may alter the property 
of the eventual proNGF molecule. However, for proNGF to be a true 
pathophysiological ligand for p75NTR NTR, it has to bind to p75  and subsequently 
activate cell death in vivo. Harrington et al. (2004) reported that after brain injury, 
proNGF was induced and secreted in an active form capable of triggering apoptosis 
in culture. They also demonstrated that proNGF binds to p75NTR in vivo and that the 
disruption of this binding rescued the injured adult corticospinal neurons. These data 
suggest that interference of proNGF and p75NTR interaction may be a potential 
therapy for disorders involving neuronal loss. This study further strengthened the 
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observation made by Lee et al. (2001), that proNGF is apoptotic in nature both in 
vitro and in vivo conditions (Harrington et al., 2004).  
 
1.2 NGF receptors  
NTRThe two receptors (TrkA and p75 ) are normally present in the same cell to 
modulate the response of neurons to NGF. The functions of these receptors vary 
from the sculpting of the developing nervous system to the regulation of the survival 
and regeneration of injured neurons. Surprisingly, TrkA receptors only activate 
positive signals (enhanced growth and survival) while p75NTR activate both positive 
and negative signals. The signals generated by both receptors can either enhance or 
oppose each other, resulting in a paradoxical relationship (Kaplan and Miller, 2000). 
 
1.2.1 Trk receptors 
The neurotrophins bind to two receptors: Trk and p75NTR. The Trk family is made 
up of three members (TrkA, B and C) in which neurotrophins bind directly and 
dimerize, resulting in the activation of the tyrosine kinases present in their 
cytoplasmic domains. However, each neurotrophin has specificity for different Trk 
receptors; NGF is the preferred ligand for TrkA, BDNF and NT-4 for TrkB and NT-
3 for TrkC. Since the discovery of the three-dimensional structures for Trk receptors 
(Ultsch et al., 1999) and complex between NGF and TrkA (Wiesmann et al., 1999), 
the most important site for ligand binding on the Trk receptor is localized at the 
most proximal immunoglobulin (Ig) domain of each receptor. This structural 
information has provided information on the interaction between neurotrophins and 




1.2.1.1.  Structure of Trk A and NGF 
The Trk family (TrkA, B and C) share the same structural architecture; with their 
extracellular portion made up of a cysteine-rich cluster (domain 1), three leucine-
rich repeats (domain 2), a second cysteine-rich cluster (domain 3) and two 
immunoglobulin (Ig)-like domains (domains 4 and 5) (Schneider and Schweiger, 
1991). The extracellular portion is linked by a single putative transmembrane helix 
to the intracellular tyrosine kinase domain. Though members of the Trk family only 
share a 50-55% sequence homology at extracellular regions (Lamballe et al., 1991), 
they share a conserved region (domain 5) that is common to all (Fig. 1.2A). This 
observation led to a suggestion that domain 5 could be an important ligand binding 
site. A number of studies focused on domains 4 and 5 of the Trk receptors, making 
use of truncated or chimeric versions of the receptors (Perez et al., 1995; 
MacDonald et al., 1996; Holden et al., 1997) and partial proteolytic digestion 
(Haniu et al., 1997). These studies from various groups confirmed that domain 5 
was the neurotrophin binding site and their results were supported by the three-
dimensional crystal structure of Ig domains on Trk (Ultsch et al., 1999).  
The crystal structure of the Ig domain on Trk receptors (Ultsch et al., 1999) 
provided the first ever structural information on Trk receptors. The overall structure 
of Trk receptors (e.g. TrkA; Fig 1.2B) shows two β-sheets that are packed on top of 
each other in a β sandwich arrangement. Each of these sheets is made up of four 
strands, in one sheet (A, B, E and D) and the other (G, F, C and C’). In addition, 
three loops (AB, EF and CC’) are located at the C-terminal pole of the domain, 
while another three loops (BC, DE and FG) at the opposite end. Two interesting 
observations were noted in this structure. Firstly, Ig-like domains are commonly 



























Fig. 1.2: Sequence and structure of domain 5 of TrkA receptors. (A) Secondary 
structure elements and numbering of domain 5 of the TrkA receptors based on 
Wiesmann et al., 1999.  TrkA residues which are in contact with NGF and in the 
NGF-TrkA-d5 complex are indicated in red. (B) Ribbon structure of domain 5 of 
Trk A (PDB code: 1WWA). The β sandwich core of the molecules is made up of 
ABED and CC’FG and the exposed disulfide bridges connect strands B and E 





surface, making it easily accessible to form a solvent-exposed disulfide bridge with 
strands B and E. Secondly, this involves strand A. Strand A can be divided into two 
pieces: A and A’ with A’ at the GFCC’ sheet. However, in Trk-d5, this A’ strand 
continues to be associated with ABED via hydrogen bonds. These two regions have 
also been identified by alanine-scanning experiments to be involved in ligand 
binding for both TrkA and TrkC (Urfer et al., 1998).  
The three-dimensional structure of the NGF-TrkA-d5 complex showed that the 
elongated, dumbbell-shaped NGF dimer is bound to 2 copies of domain 5 from 
TrkA via the central β sheet region (Fig. 1.3). This symmetric 2:2 stoichiometry 
helped established that observation that activation of Trk receptors by neurotrophin 
caused receptor dimerization (Wiesmann et al., 1999). Figure 1.3 shows the 
complex of NGF and Trk A (domain 5) structure with the orientation of the 
membrane surface at the bottom of the figure. Each of the symmetrical NGF-TrkA-
d5 interface is buried about 2220Å2 angstroms of the solvent-accessible surface. In 
each of these surfaces, two distinct patches are seen. The smaller patch (‘specificity 
patch’) consists of the N-terminus of NGF in contact with the surface of ABED 
sheet from TrkA-d5. This region is highly unique and responsible for the specificity 
of NGF to TrkA receptor. While the second patch (‘conserved patch’) is formed by 
residues from the central β-sheet of NGF and loops AB, C’D and EF of TrkA-d5. 
The sequence for this region is highly conserved among the neurotrophin family and 
is likely to be present in their respective complexes. The structural complex of NGF-
TrkA-d5 also showed that residues important for p75NTR binding are partially 
exposed; thereby supporting the notion that NGF can simultaneously bind to both 











Fig. 1.3: Crystal structure of complex between NGF and domain 5 of TrkA 
(PDB access code: 1WWW). The two NGF monomers are represented in red and 
blue, while the two copies of TrkA-d5 are in green. Most of the residues (ball and 
stick representation) essential for p75NTR binding are positively-charged and located 
in loops 1, 3 and 4 (L1, L3 and L4). The exposed disulfide bridge of TrkA-d5 that is 
in contact with the N-terminal helix of NGF is shown in green and yellow (indicated 
with black arrows). Most of the NGF residues shown are positively charged and for 







1.2.1.2 Trk receptor-mediated signaling mechanisms 
Tyrosine-kinase mediated signaling by the Trk receptors lead to both survival and 
differentiation in all neuronal populations. In general, the expression of Trk receptor 
is sufficient to channel towards a neurotrophin-dependent survival and 
differentiation response (Allsopp et al., 1994; Barrett and Bartlett, 1994). Binding of 
neurotrophin to Trk receptors lead to both receptor dimerization and kinase 
activation. These receptors contain 10 conserved tyrosine residues in their 
cytoplasmic domains, of which three (Y670, Y674 and Y675) are present in the 
autoregulatory loop of the kinase domain that help regulate tyrosine kinase activity 
(Stephens et al., 1994; Inagaki et al., 1995).  The remaining tyrosine residues once 
activated, promotes signaling by creating docking sites for adaptor proteins 
containing phosphotyrosine-binding (PTB) or src-homology-2 (SH-2) motifs 
(Pawson and Nash, 2000). These adaptor proteins couple Trk receptors to 
intracellular signaling cascades (Fig. 1.4) which includes the Ras/Erk (extracellular 
signal-regulated kinase) protein kinase pathway,  phosphatidylinositol-3-kinase (PI-
3K)/Akt pathway and phospholipase C (PLC)-γ1 (Reichardt and Fariῆas, 1997; 
Kaplan and Miller, 2000). The major sites for endogenous phosphorylation are two 
tyrosine residues, Y490 and Y785 that are located away from the kinase activation 
domain. Most research groups focused on Y490 and Y785 as they interact with the 











Fig. 1.4: Diagram of signal transduction pathway mediated by activated Trk 
receptors. The nomenclature for tyrosine residues of Trk receptors is based on the 
sequence of human TrkA. In the diagram, adaptor proteins are coloured orange, 
kinases in pink, small G proteins in green and transcription factors in blue. APS 
refers to adaptor molecule containing PH and SH2 domains; CHK, Csk homologue 
kinase; MEK, MAPK/ERK; P, serine/threonine (filled-phosphorylated); SNT, suc-1-









Signaling through Ras 
In most cases, Ras is responsible for 40-60% of the neurotrophin-dependent 
survival, but it does not act directly to promote survival. Instead, it acts by 
translating the neurotrophin-initiated signals into multiple signaling pathways. Ras 
activation is essential for the normal differentiation of PC12 cells and neurons. In 
addition, it also promotes survival of neurons via activation of either the PI3K/Akt 
pathway or the mitogen-activated protein kinase (MAPK)/ERK pathways. Transient 
versus prolonged activation of the MAP kinase pathway has been closely associated 
respectively, with a proliferation-inducing versus a differentiation-promoting 
response to neurotrophin application (Grewal et al., 1999). 
Neurotrophin signaling through Shc/Grb-2/SOS mediates transient activation of 
ERK pathway. Once Y490 is phosphorylated, it leads to a recruitment of the adaptor 
protein Shc via the Shc PTB domain (Stephens et al., 1994). Subsequently, Shc is 
phosphorylated by Trk, resulting in further recruitment of a complex of adaptor 
protein Grb-2 and the Ras exchange factor son of Sevenless (SOS). SOS, in turn 
would activate Ras releasing a cascade of downstream events; like activation of PI-
3K, c-raf/ERK and p38 MAP kinase/MAP-kinase-activated protein kinase 2 
pathways (Xing et al., 1996). The downstream targets of ERK kinases include the 
RSK kinases (ribosomal S6 kinase) and together with MAP-kinase-activated protein 
kinase 2, they phsophorylate CREB (cAMP-regulated enhancer binding protein) and 
other transcription factors (Xing et al., 1998). These transcription factors in turn 
control the expression of many genes known to be regulated by NGF and other 
neurotrophins, e.g. CREB regulates genes important for the prolonged neurotrophin-
dependent survival of neurons (Bonni et al., 1999; Riccio et al., 1999).  
 16
Chapter 1 
Several tyrosines on adaptor protein fibroblast growth receptor substrate (FRS-2) are 
phosphorylated by Trk which then function as binding sites for several additional 
proteins, including the adaptor protein Grb-2 and Crk, the protein phosphatase Src 
homology protein tyrosine phosphatase-2 (SH-PTP), the cyclin-dependent kinase 
substrate p13suc1 and Src. The binding of FRS-2 initiates a cascade of Crk, C3G, 
Rap-1 (small G-protein), B-ref respectively and eventually ERK signaling (York et 
al., 1998 and 2000; Nosaka et al., 1999). Activation of Erk is also facilitated by SH-
PTP-2, which appears to inactivate an inhibitor, perhaps Ras-GAP or MAPK 
phosphatase (Wright et al., 1997). FRS-2 also provides link to the Src family 
tyrosine kinases that are involved in receptor endocytosis as well as other cellular 
responses (Wilde et al., 1999; Beattie et al., 2000). In PC12 cells, the prolonged 
activation of ERK signaling and differentiation is dependent on the adaptor proteins 
attracted to phosphorylated Y490 on FRS-2, thereby activating distinct signaling 
pathway (York et al., 1998; Meakin et al., 1999). 
 
Signaling through PI3K 
The activation of the phosphatidylinositol-3-kinase (PI-3 kinase) is essential for the 
survival of many populations of neurons. Lipid products generated by PI3K will in 
turn, recruit many proteins containing the pleckstrin-homology domains to the 
membrane, including the Akt kinases and 3-phosphoinositide-dependent kinases 
(PDKs). Akt is activated at the membrane by PDK and it phosphorylates several 
proteins important in the control of cell survival (Datta et al., 1999; Yuan and 
Yankner, 2000). These include BAD (Bcl-2/Bcl-x-associated death promoter), IκB, 
the forkhead transcription factor (FKHRL1), glycogen synthase kinase (GSK) 3-β 
and human caspase-9 (Brunet et al., 1999).  
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BAD belongs to the Bcl-2 family and when unphosphorylated, promotes apoptosis 
by binding to Bcl-xL. The bcl-2 family is involved in pro- and anti-apoptosis 
signaling cascade. However, the phosphorylation of BAD by Akt/MAPKs results in 
its association with 14-3-3 proteins, preventing it from binding with Bcl-xL and 
subsequent apoptosis (Datta et al., 1997). Another target of Akt is IκB (inhibitor of 
NF-κB) and the phosphorylation of IκB is often followed by its degradation and 
activation of NF-κB. Transcription activated by nuclear NF-κB has been shown to 
promote neuronal survival (Middleton et al., 2000). 
PI-3 kinase is activated by Ras. In most neurons, Ras-dependent activation of PI-3 
kinase is the major pathway for neurotrophins to convey pro-survival signals 
(Vaillant et al., 1999). PI-3 kinase and its downstream signaling can also be 
activated through adaptor proteins (Shc, Grb-2 and Gab-1) in a Ras-independent 
manner (Holgado-Madruga et al., 1997). In some cells, but not PC12 cells, insulin 
receptor substrate (IRS)-1 has been phosphorylated in response to neurotrophins and 
in turn, able to recruit and activate PI-3 kinase (Yamada et al., 1997).  
 
Signaling through PLC-γ1 
Phosphorylation of Y785 on TrkA recruits PLC-γ1 to be phosphorylated and 
activated. Once PLC-γ1 is activated, it hydrolyses phosphatidylinositides to generate 
diacylglycerol (DAG) and inositol 1, 4, 5 triphosphate (IP3). IP3 induces the release 
of calcium stores, causing an increase in cytoplasmic Ca2+ levels and activating 
many calcium-dependent pathways. It has been shown that in PC12 cells, NGF 
activates a DAG-regulated protein kinase, protein kinase C (PKC)-δ that is 
important for activation of the ERK cascade and neurite outgrowth (Corbit et al., 
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1999). (PKC)-δ seems to act between Raf and MAPK/ERK in this signaling 
cascade.  
 
1.2.2 P75 neurotrophin receptors (p75NTR) 
NTRP75  belongs to the tumor necrosis factor family (TNF) receptor superfamily 
(TNFR). A family of cysteine-rich domain (CRD)-containing receptors. It is 
interesting that other members in the TNFR family bind trimeric ligands like TNF, 
while p75NTR binds dimeric neurotrophins thus suggesting a different ligand-
receptor recognition mechanism for p75NTR. The binding of neurotrophins to p75NTR 
result in two possible consequences. The first consequence is based on p75NTR’s 
interaction with neurotrophin alone; while the second is a combined effect of both 
Trk and p75NTR, in which p75NTR confers ligand selectivity to Trk receptors for 
neurotrophin binding (Bothwell, 1995, Hempstead, 2002, Huang and Reichardt, 
2003). Neurotrophin activation of p75NTR without the involvement of Trk receptors 
has shown to induce neuronal apoptosis and modulate cell survival (Dechant and 
Barde, 2002; Huang and Reichardt, 2003; Rabizadeh and Bredesen, 2003). Both 
outcomes seem to be mediated by a wide selection of intracellular signaling 
molecules downstream of p75NTR (e.g. nuclear factor κB (NF-κB), c-Jun N-terminal 
kinase (JNK)). A classically known "high affinity" complex is formed by both 
p75NTR and with Trk receptors on neuronal cells (Hempstead et al., 1991; Bothwell, 
1995). However, the molecular mechanisms of the cross talk are still unknown 
(Hempstead, 2002).   
NTRHowever, when p75  is expressed in the same cell as Trk receptors, the survival 
signaling predominates with exposure to neurotrophin. This is due to the enhanced 
affinity of neurotrophins to their specific Trk receptor (one of the function of 
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p75NTR) and activation of Akt pathway by Trk receptors that suppress the apoptotic 
signal initiated by p75NTR. This ‘Jekyll and Hyde’ nature of p75NTR is perplexing as 
this receptor sends out both apoptotic and pro-survival signals.  
 
1.2.2.1  Structure of p75NTR and NGF 
The sequence of the extracellular region of p75NTR (Fig. 1.5A) showed that it is 
made up of four cysteine-rich domains (CRDs) and has an elongated and kinked 
structure (Fig. 1.5B).The crystal structure of NGF in complex with the extracellular 
domain of p75NTR reveals a 2: 1 (NGF/p75NTR) stoichiometry (Fig. 1.5B; He and 
Gracia, 2004). Since unbound NGF (McDonald et al., 1991) is a symmetric 
homodimer, both sides of the molecule have equal tendency to bind to p75NTR. 
However, once one side of NGF has bound to p75NTR, the second potential p75-
binding site is altered by a conformational change caused by the p75NTR-NGF 
interaction. In the absence of neurotrophin, p75NTR exists as dimers on the cell 
surface (Grob et al., 1985; Jing et al., 1992). 
Upon binding with homodimer NGF, p75NTR’s overall structure is described as a 
roughly parallel configuration, in which the long axis of p75NTR aligns with the 
‘seam’ formed by the edge of the NGF dimerization interface (Fig. 1.5B). This 
complex is tethered together through two spatially separated binding epitopes, 
designated as “site I” and “site II”. Site I is the site of interaction between the wider 
end of the NGF dimer and CRD 1 and 2 of p75NTR. While site II is formed between 
the tapered end of the NGF dimer and CRD 3 and 4 domains of p75NTR. The 
opposite face of the NGF dimer has identical sets of residues and designated as 
“pseudosites I and II”. In addition, the binding sites for p75NTR require contributions 







Fig. 1.5: Sequence and structure of p75NTR. (A) Sequence of extracellular domain 
of p75NTR as adapted from Roux and Barker (2002). The grey box represents the 
signal peptide of p75NTR, while the blue bars indicate the extracellular cysteine-rich 
domains (denoted by CRD1-4). The extracellular N-linked glycosylation site is 
denoted by CHO.  (B) Crystal structure of NGF with p75NTR NTR. P75  binds along 
one side of the NGF homodimer. Backbone representation of NGF monomer A is 
coloured in green, while monomer B is blue and p75NTR in purple. The green sticks 




1.2.2.2  Functional roles of p75NTR
NTR P75 is involved in a wide array of cellular responses including apoptosis, neurite 
outgrowth (Yamashita et al., 1999) and myelination (Cosgaya et al., 2002). Upon 
stimulation with neurotrophin, it can activate multiple downstream signals; 
including the small GTP binding protein Rac, transcription factors NF-κB and the 
stress-activated kinase JNK (Fig. 1.6). The two main pathways (apoptosis and pro-
survival) activated by p75NTR will be discussed in detail.  
 
NTR receptor-mediated apoptotic signal 1.2.2.2.1. P75
It is now established that in the absence of Trk signaling, neurotrophin binding to 
p75NTR will activate apoptosis as seen in specific cell types (Roux and Barker, 
2002). Several studies have shown that neurotrophin binding to p75NTR had caused 
apoptosis, for instance in cultured Schwann cells (Syroid et al., 2000; Khursigara et 
al., 2001), oligodendrocytes (Casaccia-Bonnefil et al., 1996), motor neurons of 
embryonic spinal cord (Frade and Barde, 1999), hippocampal neurons (Friedman, 
2000), neuroblastoma cells (Bunone et al., 1997) and smooth muscle cells (Wang et 
al., 2000). Various insults to the nervous system can result in a p75NTR-dependent 
apoptotic program in motor neurons following lesions of the facial motor nerve 
(Ferri et al., 1998), hippocampal neurons after induction of seizures (Roux et al., 
1999), Schwann cells after axotomy (Syroid et al., 2000), cortico-spinal neurons 
after axotomy (Giehl et al., 2001) and oligodendrocytes after spinal cord injury 
(Beattie et al., 2002). In addition, increased p75NTR expression has been observed in 
patients with multiple sclerosis (Dowling et al., 1999) and Alzheimer’s disease 















NTR NTR signaling pathways. P75Fig. 1.6: p75  binds to a number of interacting 
proteins, including TRAF2, 4, and 6, NRAGE, SC-1, and RhoA, which play roles in 
cell survival, cell cycle regulation, and neurite outgrowth. It also increases ceramide 
levels and activates the JNK-p53-Bax cell death pathway (adapted from Kaplan and 










However, the physiological actions of p75NTR are not restricted to neural system, as 
recent in vivo and in vitro studies have found its involvement in non-neuronal tissues 
(i.e. vasculature; Wang et al., 2000).  
The mechanism by which p75NTR-mediated apoptosis is activated has not been fully 
solved, but stress-activated MAP kinase, c-jun N-terminal kinase, JNK has been 
shown to play an essential role (Yoon et al., 1998). The targets of JNK include the 
transcription factors c-jun, ATF-2 and p53. P75NTR-mediated apoptosis is shown to 
be independent of c-jun (Palmada et al., 2002), while blocking p53 has shown to 
prevent the death signal (Aloyz et al., 1998). Unlike other members of the TNF 
receptor family where apoptosis activates caspase-8, p75NTR does not. Only caspases 
(1, 3, 6 and 9) have been implicated in p75NTR-mediated cell death (Gu et al., 1999; 
Agerman et al., 2000; Troy et al., 2002). However, the mechanism of caspase 
activation upon neurotrophin binding to p75NTR and the role of JNK pathway 
remains to be determined. 
 
NTR 1.2.2.2.2 P75 receptor-mediated pro-survival signal 
The function of neurotrophin binding to p75NTR is to facilitate the pro-survival 
signals of the Trk receptors (Roux and Barker, 2002). In addition, it also has the 
ability to promote survival independent of Trk receptors. For example, neurotrophin 
binding to p75NTR has been shown to block the death of neuroblastoma cell (Oh et 
al., 1993; Cortazzo et al., 1996), of sensory neurons from tropic factor deprivation 
(Longo et al., 1997) and hippocampal neurons after glutamate receptor activation 
(Bui et al., 2002). In addition, studies with p75NTR-/- mice showed that this receptor 
is crucial for the survival of subplate neurons in the developing cortex (DeFreitas et 
al., 2001).  
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This finding that p75NTR can initiate both opposing pathways (apoptosis and pro-
survival) is not entirely shocking as other members of the TNF family can elicit both 
apoptotic and pro-survival signals. One of the best characterized anti-apoptotic 
signals generated is by the activation of the transcription factor, NF-κB (Karin and 
Lin, 2002). The activation of NF-κB after neurotrophin binding to p75NTR functions 
as a pro-survival signal in both Schwannoma cell line (Gentry et al., 2000) and 
primary Schwann cells (Khursigara et al., 2001) that only express p75NTR. 
Neurotrophin treatment also induced pro-survival signal via NF-κB in trigeminal 
(Hamanoue et al., 1999) and hippocampal neurons (Culmsee et al., 2002). However, 
in both PC12 cells (Taglialatela et al., 1997; Foehr et al., 2000; Wooten et al., 2001) 
and sympathetic neurons (Maggirwar et al., 1998) that coexpress both TrkA 
receptors and p75NTR, it is uncertain which receptor is responsible for NGF-
dependent induction of NF-κB that lead to overall cell survival.  
Another possible pathway for the pro-survival signal of p75NTR receptor is by the 
activation of the phosphatidyl inositol 3-kinase (PI3K)-Akt pathway (Roux et al., 
2001; Bui et al., 2002). Akt pathway is able to prevent apoptosis through 
phosphorylation-dependent inactivation of caspase-9, pro-death domain Bad and 
members of the Forkhead family of transcription factors (del Peso et al., 1997; 
Cardone et al., 1998; Brunet et al., 1999). It was shown that hippocampal neurons 
were protected by the activation of p75NTR after excitotoxic injury (Bui et al., 2002). 
Interestingly, activation of Akt also caused a corresponding activation of NF-κB 






NTR1.2.3 Cross-talk between TrkA and p75
Most cells coexpress both Trk receptors and p75NTR. Though these two receptors 
share no sequence similarity in either ligand-binding or cytoplasmic domains and 
each activates their own distinct neurotrophin-dependent signaling pathways, they 
collaborate to mediate the effects of neurotrophins. Individually, they interact with 
neurotrophins at similar affinity of about 10-9M (Rodriguez-Tebar et al., 1990, 1992; 
Kaplan et al., 1991) which is much lower than the observed high-affinity NGF 
binding sites (Kd ~ 10-11M) in PC12 cells and sensory neurons (Greene and Tischler, 
1976; Sutter et el., 1979; Rodriguez-Tebar et al., 1990, 1992). The presence of both 
receptors also increased the association rate of NGF to TrkA by 25-fold (Mahadeo et 
al., 1994). Hence, both receptors are required to form the high-affinity complex for 
neurotrophin binding (Hempstead et al., 1991).  
However, the precise molecular mechanisms that allow p75NTR to enhance NGF 
binding to TrkA and increase TrkA responsiveness to NGF remain uncertain. So far, 
two hypotheses have been proposed. P75NTR is proposed to either act as a co-
receptor that presents NGF to TrkA in a favorable binding conformation or has an 
allosteric effect on Trk that confers high-affinity binding to the TrkA receptor 
irrespective of NGF binding to p75NTR (Roux and Barker, 2002). The discovery of 
the complex structure of p75NTR and NGF (He and Garcia, 2004) confirmed the 
high-affinity binding site functional studies. Despite a clash between the TrkA-d5 
domain and p75NTR CRD2-3 junction, homodimer NGF is capable of binding to both 
TrkA and p75NTR simultaneously on opposite sides to form a trimolecular complex 
(Fig. 1.7). Furthermore, the p75NTR-induced NGF conformational changes on the 

















Fig. 1.7: Potential model of p75NTR-Trk-neurotrophin trimolecular complex. 
Diagram of cell surface equilibrium between various neurotrophin, p75NTR and TrkA 
receptor complexes and NGF is represented by tubes and receptors are represented 
as surfaces. From high to low TrkA/p75NTR ratio, the complex could choose to be 
2:2 NGF/TrkA, 1:2:1 TrkA/NGF/p75, 2:1 NGF/p75 and finally an unliganded p75 










NTRwhich p75  modulates TrkA ligand affinity and specificity for NGF (He and 
Garcia, 2004). 
NTRNumerous studies have clearly shown that the presence of p75  is capable of 
activating maximum Trk signaling (Roux and Barker, 2002); yet little is known 
about the influence of Trk on p75’s downstream effect. Coactivation of both 
receptors (Trk and p75NTR) has shown to block p75NTR induced apoptosis (Yoon et 
al., 1998) and is suggested to occur through Trk-dependent Ras activation, thereby 
blocking the pro-apoptotic p75NTR activated kinase (JNK; Kaplan and Miller, 2000). 
Similarly, the Trk activation of PI3K and the subsequent activation of the pro-
survival molecule Akt may be used to counteract pro-apoptotic signals from p75NTR 
(Kim et al., 2002). Another possible way whereby p75NTR independent signaling 
could be modified by Trk activation is by recruitment of p75NTR to the activated Trk 
complex. Adaptor molecules that connect the two receptors may alter the 
conformation of p75NTR or change the stoichiometry of the receptor complex, 
thereby preventing signal molecules from binding and subsequent activation of 
pathways. Two such adaptor molecules have been identified. 
The protein ankyrin repeat-rich membrane spanning (ARMS) was isolated from a 
yeast two-hybrid screen using the intracellular region of p75NTR as bait (Kong et al., 
2001). ARMS is a large protein (over 200-kDa), containing four potential 
transmembrane domains, N-terminal ankyrin repeats, a SAM domain and a potential 
PDZ binding domain at the extreme carboxyl terminus. Sensory neurons of the 
dorsal root ganglion (DRG) express ARMS into adulthood and in sympathetic 
neurons, it is also found to co-localize with both p75NTR and Trk receptors and is 
tyrosine phosphorylated in response to Trk activation by neurotrophin. Gentry et al 
(2004) observed that a ternary complex is formed between Trk, p75, and ARMS, 
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leading to a speculation that ARMS may be the link signaling between p75NTR and 
Trk, though functional effects of this connect remains to be determined. 
NTRA second adaptor protein, p62 may link both p75  and Trk receptors indirectly. 
P62 has shown to bind and alter the localization of the atypical protein kinase C 
(aPKC) in response to NGF (Samuels et al., 2001). These aPKCs are unique as they 
do not require DAG or Ca2+ ions for activity and are thought to function upstream of 
NF-κB (Diaz-Meco et al., 1994). In PC12 cells, the endogenous p62 has been shown 
to bind to both TrkA and p75NTR binding protein, TRAF6, to facilitate the activation 
of NF-κB by NGF (Wooten et al., 2001). The interaction of p62 with TrkA was also 
essential for TrkA internalization into endosomes (Geetha and Wooten, 2003), hence 
making this adaptor protein an important ‘bridge’ to facilitate synergistic signaling 
from the two receptors to promote survival and differentiation.  
 
1.3 Therapeutic applications of NGF 
Neurotrophins and their receptors are trophic factors known to play important roles 
in cutaneous tissues, nerve development and reconstruction after injury. Among the 
neurotrophins, the nerve growth factor (NGF) was one of the earliest used for 
clinical studies. NGF has been tested for potential therapeutic application in 
neuropathies of the central and peripheral nervous system and more recently in 
human corneal and cutaneous ulcers. This section will focus on the potential of NGF 
as a therapeutic agent in these three specific areas.   
 
1.3.1 Neuropathies of the peripheral nervous system 
Neurotrophin factors may play key roles in pathophysiological mechanisms of 
human neuropathies. NGF is trophic to small-diameter sensory fibers and regulates 
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nociception. The most common causes of human peripheral neuropathies world-
wide are genetic neuropathy, leprous neuropathy, diabetes neuropathy and traumatic 
neuropathy and pain (Anand et al., 1991, 1994, 1996; Anand, 1997).  
 
1.3.1.1  Genetic neuropathy 
The failure of trophic interaction between the target organ and its innervation may 
result in nerve dysfunction, degeneration and abnormal regeneration. In hereditary 
sensory and autonomic neuropathy type IV (HSAN IV) or congenital insensitivity to 
pain and anhidrosis (CIPA), mutations of the NGF receptor (TrkA) have been found 
(Indo et al., 1996). CIPA is an autosomal recessive disorder that is characterized 
with failure to develop protective sensation which leads to non-painful injury and 
trophic mutilation, loss of sweating which result in fever and mental retardation. In 
this disorder, the three types of NGF-dependent neurons; sensory, sympathetic and 
cholinergic forebrain are affected. However, the mutations only cause a partial loss-
in-function as larger sensory fibers and autonomic control of blood pressure are 
unaffected. Hence, recombinant human NGF could restore nociception in some 
patients.  
 
1.3.1.2  Leprous neuropathy 
Leprosy affects between 10-15 million people. Early reports stated that the nerve 
lesions present in both human and rodent leprosy occur in both unmyelinated fibers 
and Schwann cells (Shetty et al., 1988). These lesions show hypoalgesia and 
hypopigmentation and hypohidrosis. The present treatment is with anti-bacterial 
drugs. However, the failure to regenerate nerves, especially nociceptor sprouting 
within the skin that aids trophic changes remains a major cause of disability. NGF 
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levels are decreased in skin and nerves of leprosy-affected human (Anand et al., 
1994). While sensory loss in leprosy skin is the consequence of invasions of 
Mycobacterium leprae of Schwann cells related to the unmyelinated fibers and early 
loss of cutaneous pain sensation (in the presence of nerve fibers and inflammation) 
is a characteristic of leprosy that remains unsolved. NGF is normally produced by 
basal keratinocytes and acts via Trk A receptor present on nociceptive nerve fibers 
to increase their sensitivity, especially during inflammation. A study that compared 
NGF and TrkA reactivity between normal and leprosy-affected patients (Facer et al., 
1998; 2000) showed a marked increase in TrkA staining in normal patients, 
suggesting that recombinant human NGF treatment may help restore pain sensation.  
 
1.3.1.3  Diabetic sensory polyneuropathy 
Sensory and autonomic polyneuropathy is a common form of neuropathy in diabetic 
patients and there is presently no specific and effective treatment for it. NGF 
immunostaining showed strong staining in the basal keratinocyte layer in control 
skin and decreased staining in diabetic skin.  In early human diabetic neuropathy 
skin, both NGF levels and axon-reflex vasodilatation are decreased significantly 
(Anand et al., 1996). Axon-reflex vasodilatation is a test of unmyelinated afferent 
fibers to stimulant, capsaicin. Intradermal application of capsaicin would induce 
flare and activate nociceptive fibers, leading to increased capillary flux (measured 
by laser Doppler; Anand, 1992). The reduced level of NGF in the target organ and 
decreased axonal transport may reduce the sensitivity to warm/heat pain. Since both 
the loss of nociception and axon-reflex vasodilatation caused foot ulceration 
(Parkhouse and Le Quesne, 1988), a major and serious complication in diabetic 
patients, treatment with NGF may cause relief.  
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Two sets of phase II clinical trials suggested that recombinant human NGF (rhNGF) 
administration was effective at ameliorating the symptoms associated with both 
diabetic polyneuropathy and HIV-related neuropathy (McArthur et al., 2000). 
However, a large-scale phase III clinical trial (Apfel et al., 2000) of 1019 patients 
randomized to receive either rhNGF or placebo for 48 weeks failed to confirm the 
earlier indications of efficacy. Among the explanations offered for the discrepancy 
between the two sets of trials were a robust placebo effect, inadequate dosage, 
different study populations, and changes to the formulation of rhNGF for the phase 
III trial. As a result, the pharmaceutical company, Genentech has decided not to 
proceed with further development of rhNGF (Apfel, 2002). 
 
1.3.1.4  Traumatic neuropathy and pain 
About less than 10% of patients with diabetic neuropathy would develop clinically 
significant persistent pain (Thomas and Tomlinson, 1993). In some patients, the pain 
is ironically controlled with treatment for diabetes, but mostly it is self-limiting. In 
injured nerve trunks, NGF levels are acutely reduced. However, neuropathic patients 
with chronic skin hyperalgesia showed marked increase in NGF levels. Hence, anti-
NGF agents may provide relief to pain.  
 
1.3.2 Neuropathies of the central nervous system  
The ability of neurotrophins to prevent or reduce neuronal degeneration in animal 
models of neurodegenerative diseases has led to several clinical trials. However, one 
of the main obstacles is the mode of delivery. There must be sufficiently high doses 
of neurotrophin factors at the target regions of the brain to efficiently modify the 
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disease processes, but delivery has to be specific to targeted areas to minimize 
adverse effects.  
Also, the entry of NGF protein to the brain is restricted by the blood-brain barrier 
and making it difficult to exert and assess its potential therapeutic effects. At 
present, several approaches have been developed to introduce NGF to the brain in a 
continuous manner such as continuous minipump (Williams et al., 1986) 
microsphere carriers (Mahoney and Saltzman, 1999), polymeric implants (Powell et 
al., 1990; Yamamoto et al., 1992) and liposomes (Zou et al., 1999). All these 
systems allowed a controlled NGF delivery to a localized area of the brain over a 
prolonged period of time.  
 
1.3.2.1  Alzheimer’s disease (AD) 
AD is the most common neurodegenerative disorder affecting 4 million people in 
the United States alone. Its prevalence is set to increase in the next 25 years and 
effective therapies are urgently needed to prevent or slow down the progressive 
neuronal degeneration in AD. The hallmark features of this disease include 
neurofillary tangles and amyloid plaques. However, the mechanism leading to the 
widespread degeneration of synapses and neurons remain unanswered. One of the 
neuronal populations badly affected in AD is the cholinergic neurons of the basal 
forebrain (Whitehouse et al., 1982; Perry et al., 1997). The only drugs available 
target the cholinergic system by inhibiting acetylcholine degradation, to compensate 
for the loss of cholinergic neurons in AD.  
Studies have shown NGF to be a potential therapeutic agent for AD. NGF is 
produced in the adult hippocampus and neocortex (Korsching et al., 1985); infusing 
NGF to the ventricles prevented lesion-induced degeneration of cholinergic neurons 
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(Hefti, 1986) and reduced the atrophy of basal forebrain cholinergic neurons in aged 
rat brain (Fischer et al., 1987). Furthermore, NGF improved age-related impairments 
in learning and memory (Fischer et al., 1987). In these studies, NGF was delivered 
to the brain by intracerebroventricular infusions. This technique allowed NGF to 
reach the targeted cholinergic neurons in the basal forebrain, but was not specific 
enough; thereby causing adverse effects. Hence, a more spatially restrictive and 
targeted manner of NGF delivery was needed and ex vivo gene therapy was 
explored. 
The recent phase I clinical trial on the therapeutic application of NGF in 
Alzheimer’s disease (AD) used ex vivo NGF gene delivery method. Eight patients 
with mild AD were enrolled and had autologous fibroblasts that were genetically 
modified to express the human NGF implanted into their forebrains. The outcome 
was based on assessment of cognitive function, serial MRI scans and PET scans. 
These results showed improvement in the rate of cognitive decline and the group 
was warranted to continue the next phase of investigation that is still ongoing 
(Tusztnski et al., 2005).  
 
1.3.3 Corneal and cutaneous ulcers 
About 4% of the world’s population suffers from burns and chronic skin ulcers. 
Cutaneous wound is known to elicit a series of typically cellular responses that 
include clotting, inflammatory infiltration, reepithelialization, the formation of 
granulation tissue (including new blood vessels), followed by tissue remodeling and 
wound contraction. Human corneal neurotrophic ulcer is an ocular disorder that is 
caused by a variety of endogenous and exogenous insults that may lead to eventual 
blindness. Enrollment of patients for the study was based on the corneal ulcer that is 
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unresponsive to conventional therapy. All patients (n=65) with corneal ulcer treated 
with NGF were completed healed. Hence, the recovery of corneal ulcers with NGF 
led to a suggestion that progressive corneal damage was a result of insufficient NGF 
levels (synthesis, release or utilization; Aloe, 2004). A recent study suggested that 
the mechanism of healing was by the modulation of functional activities of 
fibroblastic-keratocytes by NGF (Micera et al., 2006).  
Cutaneous ulcers can be caused by diseases (e.g. rheumatoid arthritis, systemic 
sclerosis and diabetes) and pressure (due to lack of mobility in old people). In both 
rheumatoid arthritis and systemic sclerosis, vasculitis is a common cutaneous 
disorder. It is characterized by skin inflammation, damage of peripheral blood 
vessels and local tissue necrosis (Dahn, 1998; Tuveri et al., 2000). Patients with 
ulcers (n=4) were treated with NGF topically after showing no response to 
conventional treatment. The treatment with NGF showed progressive improvement 
and reaching complete recovery at eight weeks. A study by Tuveri et al. (2006) 
showed that NGF can promote healing of human corneal, cutaneous diabetic and 
pressure ulcers. Hence, there is great potential for NGF as a therapeutic agent in the 
treatment of corneal and cutaneous ulcers.  
 
1.4 NGF from snakes 
Snake venoms are one of the first sources from which NGF was isolated. Though 
NGF activity was observed in mouse sarcoma tissues, it was uncertain as whether 
the nerve growth promoting activity of mouse sarcoma tissues was due to proteins 
acting directly or indirectly via nucleic acid. Hence, Cohen and Levi-Montalcini 
(1956) used dried moccasin snake venom that possess phosphodiesterase activity, 
but free from nucleic acid contamination. To their surprise, they found that the crude 
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venom (Agkistrodon piscivorus) was approximately 3000-6000 times as active as 
crude tumor homogenate in promoting fibre outgrowth in spinal ganglia in vitro. 
NGF is present primarily in three families of venomous snakes – Viperidae, 
Crotalidae and Elapidae (Hogue-Angeletti and Bradshaw, 1979). Snake NGF, 
especially those from cobras have been reported to be superior in inducing neurite 
outgrowth in pheochromocytoma (PC12) cells when compared with NGFs from 
other snakes (Lipps, 1998). Server et al. (1976) mentioned that NGFs from cobra, 
Naja naja and mouse submandibular gland were able to elicit neurite outgrowth 
from chick embryonic dorsal root ganglion.  
 
1.4.1 Venomous snakes 
There are five families of venomous snakes, made up of colubrids (Colubridae), 
elapids (Elapidae), sea snakes (Hydrophiidae), true vipers (Viperidae) and pit vipers 
(Crotalidae). The largest family is the colubrids (1,500 species) that consists a few 
venomous members, whereas members in elapids (170 species), sea snakes (50 
species), true vipers (40 species) and pit vipers (140 species) are all venomous 
(Edstrom, 1992). Snakes are equipped with venom apparatus (Fig. 1.8) to inflict 
serious bites in their victims to immobilize and ultimately kill them. The typical 
apparatus consists of a venom gland, venom duct and one or more fangs located on 
each side of the head. Venom is produced in paired modified salivary glands that are 
located superficially beneath the scales in the posterior part of the head and eyes. 
The gland is linked to the fangs by a duct and contraction of muscles around the 
gland compresses the gland, forcing the flow of the venom along the duct to the fang 
and is primed for an attack (Minton, 1990).  Snake venoms consist of complex 
























Fig. 1.8: Snake venom gland apparatus. It comprises of venom gland, venom duct 
and fang(s). The venom is produced in the venom gland (modified salivary gland) 
and linked to the fangs by the venom duct. Contraction of compressor muscles 
around the gland forces the venom from the duct to the fangs and the snake is 
















polypeptides present are responsible for the formidable array of toxic properties of 
the venom. At present, there are a total of 25 different enzymes identified in snake 
venoms alone, with the number varying with different species. The individual 
enzymes and their possible roles are stated in Table 1.1. 
 
1.4.2 The Elapids  
The elapids include the most poisonous and dangerous snakes in the world and are 
represented by 200 members. Its members include coral snakes, cobras, kraits, 
mambas and some of the Australian snakes. They are proteroglyphous snakes 
characterized by nonmovable, rather short fangs situated anteriorly in the upper jaw 
and connected to large venom glands. One of its members, the king cobra 
(Ophiophagus Hannah) is the largest of the venomous snakes reaching a length of 5 
meters at maturity. It inhabits sparsely populated areas and is seldom in contact with 
humans. However, with its enormous size and strong venom, it is capable of killing 
a man in a few minutes. In addition, the black-necked spitting cobra (Naja 
nigricollis) and South Africa spitting cobra (Hemachatus haemachatus) are 
commonly found in Africa. They are characterized by the strange habit of spitting 
venom at the attacker, often targeting the eyes at great accuracy. The venom is 
discharged as two fine jets targeted at the enemy from a distance of 1.5 to 2.5 
meters. Once the venom is in contact with the eyes, it causes serious lesions.  
There is a very high proportion of venomous and dangerous snakes in Australia, 
mostly elapids. The strongly built Taipan (Oxyuranus scutellatus) has an average 
length of 2.5 meters and very long fangs that produce large amount of extremely 
potent venom a presynaptically acting neurotoxin (β-toxin) and various necrotic 




Enzymes found in most snake venoms 
Phospholipase A Ribonuclease 2






Enzymes found in crotalid and/or viperid venoms 
 
Endopeptidase Thrombin like enzymes 
Arginine ester hydrolase Factor X and/or V activator 
Kininogenase Metalloproteinases 
Fibrinogenase Serine proteinases 
Heparinase Fibrinogenase 
Collagenase Prothrombin activator 
 Elastase 
 









Table 1.1: Enzymes commonly found in snake venoms.   





Another notorious Australian venomous snake is the Death Adder (Acanthophis 
antarcticus) that inhabits the bushland and looks like a viper with a broad head, 
thick neck and fat body, measuring to about 1m in length. It lures its prey by the 
twitching of its tail. However, it does not attack human unless provoked (Edstrom, 
1992).  
 
1.4.3 Naja Sputatrix and its venom 
The Naja sputatrix (N. sputatrix) or the Malayan spitting cobra is found in 
Peninsular Malaysia, Singapore, Java, Bali, Lombok, Flores, Komodo and the 
Celebes Islands of Indonesia. It is capable of spitting venom up to 1.6m accurately, 
often targeting the eyes of aggressor. The venom causes pain and discomfort to the 
eyes or open wounds of the victim and needs to be washed out as soon as possible to 
prevent permanent damage (Tweedie, 1983; Gopalakrishnakone et al., 1990). Apart 
from rainy seasons, in which it is most active, the N. sputatrix like most cobras is 
normally non-aggressive and will avoid contact with human beings. However, when 
cornered, it will give the warning display and bite only if the display is ignored by 
the intruder. However, the young cobras are very aggressive. The snake is found in a 
variety of habitats ranging from forested areas and grasslands to human habitations. 
Its preferred time for hunting and moving around are evenings and it feeds mainly 
on frogs, toads, small rodents and ants.  
Envenomation by N. sputatrix results in local necrosis with systemic manifestations 
characteristic of myoneural curare-like (neurotoxic) and cardiovascular effects 
(Reid, 1964 and Viravan et al., 1986). These effects are caused mainly by the toxic 
components present in N. sputatrix venom. The toxic component includes 
neurotoxins, phospholipase A and cardiotoxin in a ratio of 3%, 18% and 60% by 2 
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weight of crude venom respectively (Tan, 1983), while the rest is made up of non-
toxic components, one of which is the nerve growth factor (NGF). N. sputatrix 
venom contains three isoforms of both phospholipase A2 enzymes (sputatrix PLA2-
1, PLA -2 and PLA2 2-3; Tan and Armugam, 1989a, b) and cardiotoxins (sputa-
cardiotoxins A, B and C; Tan, 1982) that have been successfully characterized. It 
was observed that during N. sputatrix envenomation, the victim suffers from local 
necrosis, hemolysis and cardiotoxicity. These effects are probably due to a 
synergistic action of cardiotoxin and phospholipase A  as reported by various groups2  
(Tan and Arunmozhiarasi, 1990; Harvey, 1991; Fletcher and Jiang, 1993 and 
Ownby, 1993). In addition to the two toxins, N. sputatrix venom also contains two 
types of postsynaptic neurotoxins (NTXs), sputa-neurotoxin 1 and -2. 
 
1.5 Aims of this project 
This project attempts to study the effects of NGF from animal venom. (1) An initial 
screen will be carried out on venomous sources (e.g. snake, bees and scorpions) 
present in the laboratory to identify a source with the highest NGF activity and will 
be selected via PC12 cells bioassay. (2) A venom containing NGF with the highest 
activity will be selected and purified using gel filtration and reverse phase high 
performance liquid chromatography (RP-HPLC). (3) This protein will be 
characterized by N-terminal sequencing, mass spectrometry and will also be tested 
for its biological activity. (4) A cDNA encoding the NGF will be cloned from the 
RNA isolated from the venom gland, sequenced and the protein will be expressed as 
a recombinant NGF in both bacterial (E. coli) and mammalian (CHO) cells. The 
NGF protein expressed in   E. coli will be histidine-tagged (easy purification with 
nickel beads) and purified using denaturing (8M urea) conditions. It will later be 
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refolded into functional NGF protein for subsequent gene and protein expression 
studies in relation to mouse NGF. (5) The effects of recombinant NGF will be 
accessed at both the gene (real-time PCR and microarray) and protein (western blot 
and SELDI-TOF) levels.  
(6) With the debate over the nature of proNGF being apoptotic or neurotrophic, 
cDNA constructs containing different segment of the NGF gene will be transfected 
into CHO cells for investigation. The Tet On/Off system will be used to regulate the 
expression of the proteins. These secretory proteins will be collected from the CHO 
media and introduced to PC12 cells to access their effects on both normal and 
ischemic cells. Their effects will be assessed by neurite outgrowth, cytotoxicity tests 
(LDH), changes in gene (real-time PCR) and protein (caspase assay) levels. (7) 
Another venom component -phospholipase A2 was found to be neuroprotective by a 
fellow colleague (Cher, 2005), will be examined using the methods that have been 






























2.1  Materials 
2.1.1  Bacteria and media 
Escherichia coli DH5α and M15 strains were used to produce the recombinant sputa 
NGF. Long term storage of bacterial stocks was carried out in LB broth with 40% 
glycerol at -20°C. Media were supplemented with appropriate antibiotics to maintain 
bacteria containing plasmid DNA. All bacterial culture media were sterilized by 
autoclaving. Thermo-labile media supplements like antibiotics were subjected to 










Broth was adjusted to pH 7.0 with 1M NaOH prior to autoclaving. 
 
LB-agar 
Agar (Gibco) was added to a final concentration of 1.5% (w/v) to LB broth and 
mixed well before autoclaving. Approximately 25ml of cooled molten agar (55°C) 
was poured into each 90mm sterile petri dish. It was placed on levelled surface and 
allowed to set at room temperature. The LB-agar plates were stored inverted in 







Bacto-tryptone 2% (w/v) 
Yeast extract 0.5% (w/v) 






The pH was adjusted to 7.0 with 1M NaOH. The autoclaved media was cooled to 
50°C and filter-sterilized glucose was added to a final concentration of 0.02mM. 
 
2.1.2  Plasmids 
Plasmids 
Plasmids used in this study were pQE30 (Qiagen Company, U.S.A.), 
pcDNA4/TO/myc-His and pcDNA6/TR (Invitrogen Company, U.S.A.). pQE30 was 
used as vector to express recombinant sputa NGF as a histidine-tagged fusion 
protein. One major advantage of using this vector is that the histidine tag is 
conformation-independent. This feature makes it very easy to purify the fusion 
protein-of-interest even under denaturing conditions. The histidine tag is also small 
and poorly immunogenic. In addition, the uninduced expression level can be 
controlled by lac repressor, expressed by an endogenous pREP4 vector in M15 host 
strain.  
Both the pcDNA4/TO/myc-HisA and pcDNA6/TR plasmids allowed a tetracycline-
regulated expression of the gene of interest in mammalian host cell. In this study, the 
tetracycline (Tet) on/off system was used to decipher the role of the precursor sputa 
NGF protein (Chapter 4). Three mutated cDNA constructs containing the sputa NGF 
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gene were cloned individually into the pcDNA4/TO/myc-HisA and later co-
transfected with pcDNA6/TR into CHO cells. The pcDNA4/TO/myc-HisA contains 
two tetracycline operator (TetO2) sites within the human CMV promoter for the 
tetracycline-regulated gene expression (Yao et al., 1998). The TetO2 serves as 
binding sites for the 4 Tet repressor molecules (comprising of 2 Tet repressor 
homodimers) that confer tetracycline-responsiveness to the gene of interest (i.e., 
sputa NGF mutants). The Tet repressor is expressed from pcDNA6/TR. When these 
two vectors are co-transfected together, the gene expression can be induced by 
addition of tetracycline (1µg/ml). 
Long term storage of plasmid DNA was carried out in TE buffer at -20°C. Plasmids 
used daily were stored in TE buffer at 4°C to minimize the deleterious effect of 








Buffer was sterilized by autoclaving and stored at room temperature. 
 
2.1.2.1  Reagents for plasmid isolation 
Solution 1: Resuspension buffer 
Glucose 
Tris-HCl (pH 8.0) 







Solution 1 without glucose was sterilized by autoclaving and filter-sterilized glucose 
was added later to the cooled sterile solution and stored at 4°C for routine use and at 
-20°C for extended storage.  
 
Solution 2: Lysis buffer 
NaOH 0.2M 
SDS 1% (w/v) 
 
Solution 2 was prepared fresh before use each time. 
 
Solution 3: Precipitation buffer 
Potassium acetate 




Solution 3 was stored at 4°C. 
 
2.1.3  Antibiotics 
Working concentration for ampicillin was 100mg/ml. For Tet-On induced 
eukaryotic gene expression, the final tetracycline concentration in the media was 
1µg/ml. Both zeocin (Invitrogen, U.S.A.) and blasticidine (Invitrogen, U.S.A.) were 
used for selection and maintenance of stable clones. Working concentrations for pro- 
domain stable clones were zeocin (100µg/ml) and blasticidine (2.5µg/ml), while the 
others (mature NGF and pro (R/G) NGF) stable clones were maintained in zeocin 
(500µg/ml) and blasticidine (10µg/ml). The concentrated antibiotics stocks were 
aliquoted into small volumes and kept at -20°C. 
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Ampicillin (in water) 100mg/ml 
Tetracycline (in absolute ethanol) 1mg/ml (kept in dark) 
Zeocin 100mg/ml  
Blastidicidine 10mg/ml 
 
2.1.4  Cell lines and culture media 
Both Pheochromocytoma (PC12) and Chinese hamster ovary (CHO) cells were 
obtained from the American Type Culture Collection (ATCC, U.S.A.) and cultured 
in complete Dulbecco’s Modified Eagle’s medium (DMEM). They were maintained 
in a 37°C incubator with 5% CO2.  
 
Saline 
NaCl (0.9%, w/v) was diluted in sterile, deionized water and autoclaved. Once 
cooled, it was kept at room temperature 
 
Complete DMEM (1L) 
DMEM 
























Freezing medium (100ml) 
Basal DMEM 30ml 





Powered medium was dissolved in deionized water and sterile-filtered with 0.22µm 
filter and stored in 4°C. Before use, medium was warmed up at the 37°C water bath. 
Cells were stocked with freezing medium and 10% sterile glycerol and kept in  
-80°C. Glucose-free basal DMEM for studies on oxygen-glucose deprivation (OGD) 
was purchased from Gibco-BRL (Paisley, U.K.). 
 
2.1.5  Organotypic hippocampal cultures 
Exactly 10-day-old Wistar rat pups were obtained from the Laboratory Animal 
Centre (National University of Singapore, Singapore). The actual date of birth of 
rats were noted and delivered to department on the 10th day. All animals were 
handled according to the guidelines (Howard-Jones, 1995) given by the council for 
International Organization of Medical Sciences (CIOMS) on animal experimentation 
(WHO, Geneva, Switzerland).  
Minimal essential medium (MEM) with Earle’s salt, but without glutamine was 
purchased from Cambrex and Hanks balanced salt solution (HBSS) from Gibco-
BRL (Paisley, U.K.). Horse serum, D-glucose, L-glutamic acid and propidium 
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iodide were from Sigma Chemical Company Ltd (Poole, Dorset, U.K.) and MK-801 
from ICN Biochemicals (Thames, Oxfordshire, U.K.).  Six well plates were 
purchased from Nunc International (Hereford, U.K.), the microporous 
transmembrane biopore membrane was from Millipore Corp (Watford, 
Hertfordshire, U.K.) and the McIlwain tissue chopper from Mickle Laboratory 
Engineerging Co. Ltd (Guildford, Surrey, U.K.).  
 
Anesthesia-Chloral hydrate 
Chloral hydrate (3.5%, w/v) was dissolved in sterile, deionized water and used to 
cause euthanasia to the rats. 
 
Dissection media 
Dissection media was prepared by using MEM with 5mg/ml of glucose and kept in 
ice throughout the whole dissection procedure. The amount used for each rat pup’s 

































Propidium iodide (PI) 
Propidium iodide was dissolved in deionized water to 1mg/ml and filter sterilized by 
a 0.22µm filter and kept in aliquots at 4°C protected from light. 
 
Source of glutamate agonists 
Glutamate, KA, NMDA, and AMPA agonists were from Sigma Chemical Company 
Ltd. Metabotrophic agonists and antagonists were purchased from Tocris Cookson 
Inc.       
 
2.1.6  Naja sputatrix venom 
Lyophilized N. sputatrix crude venom was reconstituted in sterile saline and stored 
at -20°C. Dilutions from the stock venom were all carried out using sterile saline 
solution. 
 
2.1.7  Buffers and solutions 










The individual components were mixed together in 1L of sterile, deionized water 
and solution adjusted to pH 8.0. 
 
TE buffer 
Tris-HCl (pH 7.4) 
EDTA (pH 8.0) 
10mM 
1mM 
The buffer was sterilized by autoclaving and stored at room temperature. 
 
2.1.8  Reagents for DNA and RNA isolation 
Ethanol 
Ethanol (75%, v/v) was diluted in sterile, deionized water.  
 
2.1.8.1  Reagents for DNA gel electrophoresis 
TBE running buffer (10X) 
Tris base  











DNA loading buffer (10X) 
Ficoll 400  20% (w/v) 
Bromophenol Blue  0.25% (w/v)  
EDTA (pH 8.0)  0.1M 
 
Ethidium bromide 
Ethidium bromide was dissolved in deionized water to a concentration of 10mg/ml 
and stored at room temperature (25°C), protected from light. The final working 
concentration was 0.1µg/ml. 
 
2.1.8.2  Reagents for the RNA gel electrophoresis 
MOPS running buffer (10X) 
MOPS (pH 7.0)  
Sodium acetate  











In the fume hood, DEPC was added to the water and shook vigorously to mix. The 







Formamide (500ml) was stirred with 500mg of Dowex XG8 resin for 1h and filtered 
through Whatman No.1 paper. Deionized foramide was stored at room temperature 
and protected from light.  
 
Formaldehyde 
Formaldehyde (37%, v/v) was prepared and stored at room temperature and 
protected from light.  
 
RNA sample buffer 
Deionized formamide  10µl 
37% formaldehyde  3.5µl 
10X MOPS  2.0µl 
 
RNA loading buffer 
Glycerol  
Bromophenol Blue  
EDTA (pH8.0)  
50% (v/v)  
0.4% (w/v)  
1mM 
 
2.1.9  Reagents for real-time polymerase chain reaction (Real-time  
  PCR) 
Reverse transcription (RT) master mix 
RT buffer (10X) 10µl 
MgCl2 (25mM) 110µl 
dNTPs  100µl 
(25mM of each dATP, dCTP, dGTP and dUTP)  
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Random hexamers (224µM) 25µl 
RNase inhibitor (20 U/µl) 10µl 
Reverse transcriptase (50U/µl) 12.5µl 
DEPC-treated water  142.5µl 
 
Solution was prepared for 50 reactions and stored at -20°C until use. 
 
2.1.10  Reagents for oligonucleotide microarray 
RLT buffer 





This solution was prepared just prior to use. It is stable at room temperature for 1h.  
 
2-(N-Morpholino) ethanesulfonic acid [MES] stock buffer (12X) 
MES free acid monohydrate 




The solution was made up to the desired volume with deionized water and sterilized 
by filtration through a 0.22µm filter. It was stored at 4°C and protected from light. 
The solution was discarded when it turned yellowish. 
 
Fragmentation buffer (5X) 
Tris-acetate (pH 8.1)  200mM 





The solution was made up to the desired volume with DEPC-treated water and 
sterilized by filtration through a 0.22µm filter. It was aliquoted into small volumes 
and stored a room temperature.  
 
Hybridization buffer (2X) 
12 X MES Stock buffer   0.1M 





The solution was made up to the desired volume with deionized water and filter 
sterilized by a 0.22µm filter. It was stored at 4°C and protected from light. 
 










The solution was made up to the desired volume with deionized water and sterilized 





Stringent wash buffer (Wash buffer B) 
12X MES Stock Buffer  0.1M  
NaCl  0.1M  
Tween-20  0.01% (v/v) 
 
The solution was made up to the desired volume with deionized water and sterilized 
using a 0.22µm filter. It was stored in the dark at 4°C. 
 
Stain buffer 







The solution was made up to the desired volume with deionized water and sterilized 
using a 0.22µm filter. It was stored in the dark at 4°C. 
 
Goat IgG Stock 
The antibody stock (10mg/ml) was resuspended in 5ml PBS and stored at 4°C. 
 
2.1.11  Reagents for the isolation of proteins 
Lysis buffer (SDS-PAGE) 
NaCl  
Tris-Cl (pH 7.6) 











NaF  50mM 
Sodium pyrophosphate  10mM 
 
When probing for phosphotyrosine, 0.1mM sodium orthovanadate was added to the 
lysis buffer.  
 
Lysis buffer (SELDI-TOF) 
Urea 50mM 
Tris-HCl (pH 7.4)  8M 
NaCl  0.4mM 
Sucrose  0.25M 
EDTA  1mM 
 
2.1.12  Reagents for purification of histidine-tagged fusion proteins by 









The solution was made up to the desired volume with deionized water and adjusted 




Wash buffer  




The solution was made up to the desired volume with deionized water and adjusted 










The solution was made up to the desired volume with deionized water and adjusted 
to an overall pH of 5.0. 
 
Denaturing buffer  
Urea  
Tris-HCl 







The solution was made up to the desired volume with deionized water and overall 





The QIAexpress Ni-NTA protein purification system (Qiagen) is based on the 
selectivity of the Ni-NTA (nickel-nitriloacetic acid) resin for proteins containing an 
affinity tag of six consecutive histidine residues- the 6XHis tag. This system was 
used for the purification of histidine-tagged recombinant sputa NGF.  
 
2.1.13  Reagents for Tris-tricine SDS-PAGE (Protein gel) 
Gel buffer stock 
Tris-HCl (pH 8.4) 3M 
 
Cathode buffer (upper electrode buffer) 
Tris base  0.1M 
Tricine  0.1M  
SDS (pH 8.25)  0.1% 
 
Anode buffer (lower electrode buffer) 
Tris-HCl (pH 8.9) 0.2M 
 
SDS-PAGE loading buffer 













Coomassie blue staining solution 
Methanol  
Deionized water  
Glacial acetic acid  
Coomassie Blue R-250  







Deionized water  
Glacial acetic acid  




2.1.14  Reagents for Western blotting 
Transfer buffer 







TBS buffer (10X) 





Stock of TBS (10X) buffer was diluted 10-fold with deionized water and Tween-20 




Skim milk (1%, w/v) was diluted with TBST buffer and prepared prior to use.  
 
2.1.15  Reagents for MTT cell viability assay 
3-(4, 5-demethylthiazole-2-yl)-2, 5-diphenyl tetrazolium bromide (MTT, 0.5mg/ml) 
was prepared fresh, dissolved in basal DMEM (Section 2.1.4) and kept away from 
light.  
 
2.1.16  Kit for apoptotic, necrotic and healthy cells assay 
The 3-dye (FITC-Annexin V, Ethidium homodimer III and Hoechst 33342) kit was 
purchased from Biotium, Inc (CA, U.S.A.) and carried out based on the 
manufacturer’s protocol. 
 
2.1.17  Cytotoxicity assay (LDH) 
Release of the cytoplasmic enzyme lactate dehydrogenase into the culture medium 
was used as a measure of cytotoxicity. The enzyme released was determined using a 
lactate dehydrogenase detection kit (Roche Molecular Biochemicals).  
 
2.1.18  Reagents for caspase-3 activity assay 
Cell lysis buffer 








Pepstatin A 10µg/ml 
Leupeptin 20µg/ml 


















Protease inhibitors (PMSF, aprotinin, pepstatin A and leupeptin) were added to the 












2.2  Methods 
2.2.1  Electrophoresis 
2.2.1.1  DNA gel electrophoresis  
The principle of DNA gel electrophoresis is to separate different sizes of DNA 
molecules. This method can be used for separation, identification and purification of 
DNA fragments. The percentage of agarose in the gel used is dependent on the sizes 
of DNA fragments to be separated, higher percentage agarose gels are used for 
separation of low molecular weight DNA molecules and vice versa. In routine gel 
electrophoresis, gels were made with 0.7 to 1.5% (w/v) electrophoresis grade 
agarose melted in 50ml of 1 X TBE buffer (Section 2.1.8.1) containing 0.1µg/ml of 
ethidium bromide. The molten agarose was cooled to 60°C and poured into a 
horizontal gel-casting tray. An appropriate “comb” was inserted immediately to the 
molten agarose to cast the wells (for loading DNA samples later) and left to set for 
30min. Once the gel had set, the “comb” was removed and the gel together with its 
tray was submerged in the electrophoresis tank containing 0.5 X TBE buffer 
(Section 2.1.8.1) and DNA samples premixed with the appropriate amount of 10 X 
loading buffer was loaded into the wells. Electrophoresis was normally carried out at 
5V/cm field strength together with a known ladder and migration of DNA fragments 
were visualized under UV light. The DNA fragment-of-interest was later excised 
from the agarose gel and purified by Qiagen gel-extraction kit. 
 
2.2.1.1.1 DNA extraction from agarose gels 
The QIAquick Gel Extraction kit (Qiagen) was used for the extraction and 
purification of DNA fragments electrophoresed on 1 X TBE (Section 2.1.8.1) 
agarose gel. The DNA fragment-of-interest was excised from the gel under UV with 
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a clean, sharp scalpel. The size of the excised gel was minimized as much as 
possible by trimming the excess gel. The gel slice was weighed and 3 volumes of 
buffer QG (Qiagen) was added to 1 volume of gel for DNA fragments of 100bp to 
4kb. After the gel has completely dissolved, one volume of isopropanol was added 
to increase the yield of DNA fragments <500bp and >4kb. The sample was later 
applied into QIAquick spin column (attached to a collection tube) and centrifuged at 
10,000 x g for 1min. The flow-through in the collection tube was discarded. Column 
was later washed once with 0.75ml of buffer PE (Qiagen), followed by 
centrifugation at 10,000 x g for 1min and flow-through discarded. The spin column 
was then placed into a clean 1.5ml microfuge and the bound DNA was eluted by 
addition of either 50µl of 10mM Tris-HCl (pH 8.5) or TE buffer to the center of the 
spin column matrix and centrifuge at 10,000 x g for 1min. The eluted DNA is 
suitable for most downstream applications such as restriction digestion, labeling, 
ligation, PCR and sequencing.  
 
2.2.1.2  RNA gel electrophoresis  
Ribonucleic acids were separated by electrophoresis in agarose gels containing 
formaldehyde. This is necessary to determine the integrity of the RNA isolated. 
Electrophoresis grade agarose (1% w/v) was melted in 43.5ml of sterile, deionised 
water and cooled to 60°C in a water bath, once cooled 5ml of 10 X MOPS (Section 
2.1.8.2) running buffer, 0.7ml of formaldehyde and 1µl of 10mg/ml ethidium 
bromide (Section 2.1.8.1) were added. The molten agarose was poured into a 
horizontal gel-casting tray and an appropriate ‘comb’ inserted immediately to create 
wells for sample loading. Once the gel is set, the ‘comb’ was removed and the gel 
submerged into the electrophoresis tank containing 1 X MOPS running buffer on its 
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tray. RNA samples were prepared as described as in section 2.1.8.2 and incubated 
for 10min at 65°C in a water bath prior to loading. Migration of the bands was 
visualized using a UV illuminator. 
 
2.2.2  Enzymatic reactions 
2.2.2.1  Restriction endonuclease digestion of DNA 
Restriction of DNA is normally carried out in a total volume of 20µl using 
appropriate buffers as recommended by the enzyme manufacturers. A typical 
digestion mixture is made up of: 
 
DNA in TE or water 2µg 
Restriction enzyme buffer (10X) 2µl 
Restriction enzyme  
(5-10U/µg of DNA) 
1µl 
Sterile water  Top up to 20µl 
 
2.2.2.2  Ligation 
Ligation reactions were carried out with a vector: insert molar ratio of approximately 
1:3 to increase the ligation efficiency and reduce the occurrence of multiple inserts. 
In general, 100ng of the appropriate plasmid vector was used in a 20µl reaction 
mixture [7mM Tris-HCl (pH 7.5), 7mM β-mercaptoethanol and 0.5mM ATP.T4 







2.2.3  Purification of nerve growth factor and phospholipase A2 from 
 crude venom 
Phospholipase A2 (PLA2) was purified from Naja sputatrix crude venom using 
Sephadex G-100 gel filtration chromatography (Amersham Biosciences, England) 
followed by reversed phase high performance liquid chromatography (RP-HPLC; 
Akta Explorer, Amersham Pharmacia; Armugam et al., 1997). Purified fractions 
were quantitated using Bradford assay (Section 2.2.8.2). Nerve growth factor (NGF) 
was purified in a similar manner. Freeze-dried Naja sputatrix crude venom (50mg) 
was reconstituted in 1ml of water and subjected to gel filtration followed by RP-
HPLC (Vision systems; Applied Biosystems, Foster City, C.A., U.S.A.) using a 
Sephasil C18 column. Individual fractions were tested for neurite outgrowth on 
PC12 cells and fractions showing neurite outgrowth were used for further studies. 
  
2.2.4  Methods for DNA cloning 
2.2.4.1  Isolation of total cellular RNA from snake 
An adult snake (N. sputatrix) from the Singapore Zoological Gardens (Singapore) 
was kept undisturbed and later milked. Venom was collected, freeze-dried and 
stored at -20°C. Venom glands from the same snake were frozen in liquid nitrogen 
immediately after euthanasia and stored at -85°C. Total RNA was isolated from the 
venom glands in a single step using the Trizol® reagent (Invitrogen, Carlsbad, CA. 
U.S.A.) according to the manufacturer’s instructions. Briefly, the excised snake 
tissues (100mg) were first homogenized in 1ml Trizol® reagent. The contents were 
vortexed and allowed to stand at room temperature for 10min. Mixture was 
centrifuged at 14,000rpm for 10min at 4°C. The aqueous phase was transferred into 
fresh tubes, in which 200µl of chloroform was added and subsequently vortexed for 
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15sec. The mixture was further centrifuged at 12,000rpm for 10min at 4°C. 
Resultant pellet was washed with 100µl of 75% ice-cold ethanol. The supernatant 
was discarded and the pellet was dried at 37°C for 10min. The RNA was fully 
dissolved in 25µl of DEPC-treated water by heating in a 60°C water bath for 10min. 
The concentration of each RNA preparation was determined by measuring 
absorbance at the wavelength of 260nm and integrity checked by RNA gel 
electrophoresis (Section 2.2.1.2).  
 
2.2.4.2  Reverse Transcription Polymerase Chain Reaction (RT-PCR) 
Oligonucleotide primers synthesized by Oswel DNA services (Southampton, U.K.) 
were based on the sequences at the 5’ and 3’ untranslated regions of cDNA encoding 
NGF in Agkistrodon halys Pallas and the sense and antisense primers were: 5’-ctg 
gtg cat acg cta atg tcc atg-3’ and 5’-aat cta gaa taa ttt aca gg(ct) tg(at) ggt a-3’ 
respectively (Guo et al., 1999). Total RNA (3µg) was reverse transcribed using 10 
units of MuMLV reverse transcriptase, 40ng of antisense primer, 2µl of reverse 
transcription buffer [100mM Tris-HCl (pH 8.4); 250mM KCl; 12.5mM MgCl2 and 
0.5mg/ml BSA] in a total volume of 10µl at 42°C for 1h. All the reverse transcribed 
products (10µl) were used for the polymerase chain reaction (PCR). PCR was 
carried out for 30 cycles with each cycle consisting of a denaturing step (94°C for 
1min), an annealing step (50°C for 1min) and an elongation step (72°C for 2min) 
followed by a final extension step (72°C  for 10min), using a Perkin Elmer Cetus 
thermal cycler (Model 480). The reaction mixture contained 250µmol each of 
dNTPs, 10µmol of sense and antisense primers each in a final 50µl reaction buffer 
[50mM KCl, 10mM Tris-HCl (pH 8.3), 1.5mM MgCl2 and 0.1mg/ml gelatin] and 1 
unit of Taq DNA polymerase (Armugam et al., 1997).  
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2.2.4.3  Cloning  
The PCR products were cloned into pT7Blue (R) vector (Novagen, Madison, WI. 
USA) using the procedures described by the supplier. This vector has been 
specifically designed for cloning of PCR products. It has a single 3’ dT residue at 
each end of the insert site into which DNA when amplified by Taq polymerase 
would leave single 3’ dA overhangs, which could be ligated. A typical 10µl ligation 
mixture consists of: 
 
TA vector 50ng 
Purified PCR products 70ng 
Ligase buffer (10x) 1µl 
T4 DNA ligase (400U/µl) 0.5µl 
 
Reactions were carried out at 16°C for overnight, prior to transformation. 
 
2.2.4.4  Transformation 
Competent cells from the -70°C were thawed on ice. The ligation mixture (10µl) 
was added into competent cells (DH5α; 100µl) and mixed gently. The reaction 
mixture was kept on ice for 30min. Cells were subjected to heat-shock at 42°C for 
90s, transferred to a 10ml culture tube and 200µl SOC was added. The cells were 
incubated at 37°C for 1h before plating on LB-ampicillin (50µg/ml) agar plate 
supplemented with IPTG and X-Gal according to Sambrook et al. (1989) for growth 





2.2.4.5  Plasmid DNA isolation 
Plasmid DNA from bacterial culture was prepared by alkaline lysis method of 
Birnboim and Doly (1979). A 1.5ml overnight bacterial culture in L-broth 
containing ampicillin was centrifuged at 10,000 x g for 20s and the supernatant 
discarded. The pellet was resuspended in 100µl of cold solution I (Section 2.1.2.1) 
by vortexing and left at room temperature for 5min. 200µl of freshly prepared 
solution II (Section 2.1.2.1) was added to the supernatant and mixed by inversion or 
tapping and left on ice for 5min. Cold solution III (150µl; section 2.1.2.1) was added 
and the nucleic acid pelleted by centrifugation at 10,000 x g for 10min. The 
supernatant was transferred into a new tube. Plasmid DNA was precipitated by 
adding an equal volume of isopropanol and left at room temperature for 30min, 
followed by centrifugation at 10, 000 x g for 15min. The pellet was washed twice in 
70% ethanol; vacuum dried and dissolved in 50µl TE buffer (Section 2.1.7) 
containing DNAase-free pancreatic RNase A at 20µg/ml. The recombinant plasmids 
from the transformants were subjected to Sanger dideoxy DNA sequencing. 
 
2.2.4.6  Sanger Dideoxy DNA sequencing 
Cloned DNA fragments were sequenced using the cycle-sequencing technique and 
the sequencing was carried out in an automated DNA sequencer (Model 3100; 
Applied Biosystems) using M13/pUC forward and reverse primers. The cycle 
sequencing method is a combination of traditional Sanger-Dideoxy sequencing 






2.2.4.6.1  Sequencing reaction 
The sequencing reaction is essentially polymerase chain reaction (PCR) which uses 
the ABI PRISM™ Dye Terminator cycle sequencing kit (ABI), appropriate primer 
and a good quality, double-stranded DNA template. Apart from the Taq DNA 
polymerase and the deoxynucleotides, the sequencing premix also contains 
fluorescence-tagged dideoxynucleotides, which would emit different fluorescence, 
based on which dideoxynucleotide, when hit by the laser. Reactions were carried out 
in a volume of 20µl and comprised of: 
 
Double stranded template DNA 500ng  
Premix solution 8µl 
Primer (M13/pUC; 6.4ρmol) 4µl 
Sterile water Top up to 20µl 
 
Prior to the thermal cycling, the reaction mixture was overlaid with 50µl mineral oil 
to reduce evaporation. The following PCR profile was carried out for 25 cycles: 
 
96°C (DNA denaturation) 
50°C (Primer annealing) 





2.2.4.6.2  Purification of sequencing products 
The cycle-sequencing products need to be cleaned and concentrated prior to 
sequencing. The volume of the sequencing reaction was top up to 100µl by addition 
of sterile water and the sequencing products were ethanol precipitated. Equal 
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volume of phenol was added and vortexed at low speed. After brief centrifugation to 
separate the phases, the upper aqueous layer was transferred to a fresh 1.5ml tube. 
Equal volume of chloroform was added, vortexed briefly and centrifuged to separate 
the phases. The upper phase was transferred to a fresh tube and 1/10 volumes of 3M 
sodium acetate (pH 4.5), 2 volumes of ice-cold 95% ethanol and 20µg glycogen 
were added. The resultant pellet was washed in 100µl of ice-cold 80% ethanol and 
centrifuged at 10,000 x g for 5min. The pellet was vacuum dried and stored in dark 
at -20°C until use. 
 
2.2.5  Expression and purification of recombinant sputa NGF protein from E. 
 coli.  
The cDNA-encoding NGF was amplified using the sense and anti-sense primers, 5’-
cctggatccgaagatcatcctgtg-3’ and 5’-ctcaagctttcagtttccagtt-3’, respectively and 
subcloned into pQE-30 expression vector (Qiagen, Chatsworth, CA, U.S.A.) 
between BamHI and HindIII sites. The resultant recombinant protein has histidine 
residues tagged at its N-terminal, allowing easy purification by nickel beads. E coli, 
DH5α was used as host strain for the expression of his-tagged recombinant sputa 
NGF proteins. 20ml of overnight bacterial culture was used to inoculate into 1L of 
LB media supplemented with ampicillin (100mg/L). Once the optical density of the 
LB media reached 0.5-0.6 OD measured at 600nm, the recombinant protein 
production was induced by addition of 1mM IPTG (final concentration).  
After 3h of induction, cells were harvested by centrifugation. The cell pellet was 
resuspended in lysis buffer (Section 2.1.12) and disrupted by sonication 6 X 10s 
with 10s pauses at 200-300W. The lysate was kept on ice at all times. The lysate was 
centrifuged at 10,000 x g at 4°C for 20-30min. The supernatant was collected, kept 
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on ice and incubated with nickel beads (with rotation) for 30min at ice-cold 
condition. For his-tagged fusion protein, the clarified protein supernatant (together 
with beads) was loaded into an empty column. The non-specific proteins were 
removed by wash buffer (pH 6.3; Section 2.1.12) and fusion proteins were eluted 
using elution buffer (pH 5.0; Section 2.1.12). Purified proteins were checked on 
SDS-PAGE gels and concentration determined by Bradford assay (Section 2.2.8.2). 
 
2.2.5.1  Refolding of recombinant sputa NGF 
Purified proteins from various batches were pooled together and urea was removed 
by overnight dialysis with 1 X PBS (pH 8.0; Section 2.1.7). Protein was 
concentrated by speed-vac and then fully denatured by dilution with 5 volumes of 
denaturing buffer (Section 2.1.12) and incubated for two hours at room temperature. 
In vitro renaturation of unfolded proteins was performed overnight at room 
temperature (25°C) by dialysis in the following buffer: 1 X PBS (pH 8.0) containing 
4mM GSH and 2mM GSSG. Protein concentration was determined by Bradford 
assay (Section 2.2.8.2) and its activity by bioassay using PC12 cells. 
 
2.2.5.2  Circular dichroism (CD) 
The CD spectra for both native and recombinant sputa NGF were recorded on a 
Jasco spectropolarimeter, model J715, equipped with an interfaced personal 
computer. The instrument was regularly calibrated with ammonium d-10-
camphorsulphonate. The results were expressed as mean residue ellipticity, [θ], 
which is defined as [θ] = θ/60lc, where θ is the observed ellipticity in degrees, c is 
the concentration in dmol/L, l is the length of the light path in cm and constant 60 is 
the number of amino acid residues in the protein. All the CD spectra were measured 
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with the appropriate concentrations using 0.1cm path-length cells. Data was 
collected and averaged from at least five recordings to be considered acceptable.  
 
2.2.6   Expression of recombinant sputa NGF protein from mammalian 
 CHO cells  
Oligonucleotide primers were synthesized by Oswel DNA services (Southampton, 
U.K.) based on the sputa NGF cDNA sequence. The cDNA encoding mature NGF, 
pro (R/G) NGF and pro-domain were amplified by PCR using gene specific primers 
that contained restriction sites for KpnI and XhoI (Fig. 2.1).  The positive clones 
were then restricted with enzymes (KpnI and XhoI) and subcloned into pcDNA4 that 
was restricted with the respective endonuclease.  Reactions were carried out at 16°C 
for overnight. 
 
2.2.6.1  DNA transfection 
CHO cells were maintained in complete DMEM (Section 2.1.4) and the Tet on/off 
system was used. The ratio of 6: 1 for TR: TO respectively was used for all 
transfection experiments. Prior to transfection, 2 x 105 of CHO cells were seeded in 
a T25 flask. After 16-18h, two solutions were prepared in sterile 2ml tubes for 
transfection.  Solution ‘A’ contained 3µg of total DNA mixed with 300µl OPTI-
MEM (Gibco) and solution ‘B’  contained 18µl of lipofectamine (Invitrogen) mixed 
with 300µl OPTI-MEM. Solution ‘B’ was added to Solution ‘A” and the mixture 
was tapped gently every 10min for a total of 45min (to allow DNA-liposome 
complexes to form) at room temperature. Meanwhile, the CHO cells were rinsed 








GCTCTGGTGCATACGCTAATGTCCATGCTGTGCTACACTCTGATTATAGCATTTCTGATT - 60  
 A  L  V  H  T  L  M  S  M  L  C  Y  T  L  I  I  A  F  L  I    
GGCATATGGGCAGTACCAAAGTCTGAAGATAATGCCCCTCTGGGCTCCCCTGCAACGTCT - 120 
 G  I  W  A  V  P  K  S  E  D  N  A  P  L  G  S  P  A  T  S    
GACCTTTCCGACACCAGCTGTGCTCAAACTCACGAGGGTCTGAAAACATCTCGAAACACA - 180 
 D  L  S  D  T  S  C  A  Q  T  H  E  G  L  K  T  S  R  N  T    
GATCAGCGCCATCCAGCTCCTAGAAGTCAGAGGATCAAGCAATTTGGATCAGCATCAAAC - 240 
 D  Q  R  H  P  A  P  R  S  Q  R  I  K  Q  F  G  S  A  S  N    
ATCATTGTGGATCCCAAGCTTTTTCAGAAGAGGCGGTTCCAGTCGCCTCGTGTTCTGTTC - 300 
 I  I  V  D  P  K  L  F  Q  K  R  R  F  Q  S  P  R  V  L  F    
AGCACTCAGCCCCCACCATTGTCAAGAGATGAGCAAAGTGTGGAGTTCCTGGACAATGAA - 360 
 S  T  Q  P  P  P  L  S  R  D  E  Q  S  V  E  F  L  D  N  E    
GACGCTCTTAACAGGAATATCCGGGCCAAA
 
Fig 2.1: Gene-specific primers for NGF mutants. 2 sets of primers were used and 
highlighted in blue and grey. All forward primers had Kpn1 site at the 5’ end, while 
reverse primers had Xho1 site at the 3’ end. The signal peptide and mutated furin 






CGTGAAACTCATCCTGTGCATAACCGAGGG - 420 
R  E  T  H  P  V  H  N  R  G     D  A  L  N  R  N  I  R  A  K  
GAATATTCTGTGTGTGACAGTATCAGTGTCTGGGTTGCCAACAAAACCACAGCAACGGAC - 480 
 E  Y  S  V  C  D  S  I  S  V  W  V  A  N  K  T  T  A  T  D    
ATCAAAGGCAAACCGGTGACTGTGATGGTAGATGTAAATCTTAATAACCATGTCTACAAG - 540 
 I  K  G  K  P  V  T  V  M  V  D  V  N  L  N  N  H  V  Y  K    
CAGTACTTTTTTGAAACCAAGTGCAGAAATCCAAATCCAGTACCAAGTGGGTGCAGGGGC - 600 
 Q  Y  F  F  E  T  K  C  R  N  P  N  P  V  P  S  G  C  R  G    
ATTGATTCCAGGCATTGGAATTCTTATTGCACGACAACACACACATTTGTCAAGGCATTA - 660 
 I  D  S  R  H  W  N  S  Y  C  T  T  T  H  T  F  V  K  A  L    
ACCATGGAAGGCAATCGGGCATCCTGGCGCTTCATTCGGATTGACACTGCCTGTGTGTGC - 720 
 T  M  E  G  N  R  A  S  W  R  F  I  R  I  D  T  A  C  V  C    
GTAATCAGTAGAAAAACTGAGAACTTCTGATGGACCATTGATTGCTCCAATACTCACTT - 781  
 V  I  S  R  K  T  E  N  F  *   
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added to each T25 flask. For each transfection 1ml of basal DMEM was added to the 
DNA-liposome mixture to rinse and added gently to the rinsed cells. The cells were 
incubated for 5h at 37°C in CO2 incubator. After 5h, the media was removed and 
replaced with complete DMEM (Section 2.1.4).  
 
2.2.6.2   Generation of stable NGF clones 
The Tet on/off system allowed the gene of interest to be regulated by tetracycline. 
The two plasmids (pcDNA4/TO/myc-His; TO and pcDNA6/TR; TR) were co-
transfected into CHO cells and allowed to recover in complete DMEM overnight. 
The following day, the transfected cells were subjected to dual selection with 
selective medium [complete DMEM containing both blasticidine (TR) and zeocin 
(TO; 500µg/ml) antibiotics]. For the cells to survive in the selective media, only 
successfully transfected cells, which contained both TR and TO plasmids were 
resistant to the antibiotics selection. The selective media was changed every 3-4 
days until cell foci were identified.  The resistant cells were transferred to 24-well 
plates and grown to confluence and only surviving clones were selected for 
quantification by real-time PCR (Section 2.2.7.2.1). After 6 weeks of selection and 
purification, the stably transfected CHO cells were expanded and established as a 
cell line.  
 
2.2.6.3  Quantitation of plasmid copy number in stable CHO   
  transfectants 
Total DNA from the cells was isolated and gene-specific primers to mature NGF 
(NGF) and pro-domain (Table. 2.1) were used to quantitate the plasmid copy 
















interest Sense primer Antisense primer 
Bax 5’-actccccccgagaggtctt-3’ 5’-cccagttgaagttgccatca-3’ 
Bcl-2 5’-tgggatgcctttgtggaacta-3’ 5’-gacagccaggagaaatcaaacag-3’ 
Bcl-XL 5’-gaaaggccaggagcgtttc-3’ 5’-agcagaactacaccagccacagt-3’ 
β-actin 5'-agggaaatcgtgcgtgaca-3' 5'- gccatctcctgctcgaagtc-3' 
IκB 5'-gctgcccgagagtgcggat-3' 5'-cagtcatcgtagggcaactcatc-3' 
Homer 5’-caggacgctttccgcagtaa-3’ 5’-cccgcaattctgttagttcaat-3’ 
Pro-domain 5’-agttccagtcgcctcgtgtt-3’ 5’-ccacactttcctcatctcttgaca-3’ 
Sortilin 5’-ttacagcatctcccagaagctaa-3’ 5’-atgcccacggcattgg-3’ 
TrkA 5'-catggagaacccacagtacttcag-3' 5'-ctagctcccacttgagaatgatgtc-3' 
NGF 5'-catggtacaatccctttcaac-3' 5'-ccaacccacacactgacactg-3' 
NF-κB 5'-gaagagtcctttcaatggaccaa-3' 5'-tcgggaaggcacagcaata-3' 
P75NTR 5'-gtggtcgtgggccttgtg-3' 5'-gcgccttgtttattttgtttgc-3' 
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with known amount of DNA was used to determine amount of DNA in the clones.  
A CT (cycle threshold) value of 2.0 was found to be equivalent to 150ng of DNA. 
Hence, a CT of 2.0 was used to select clones for all three different constructs. 
 
2.2.6.4  Induction of expressed proteins in cell culture media 
One day prior to induction, the stable transfected CHO cells were reseeded into T75 
flasks (2.8 x 106 cells) and grown in selective medium (complete DMEM with 
zeocin and blasticidin). The following day, the medium was changed to induction 
medium (basal DMEM with tetracycline; 1µg/ml) and left for 16-18h. The medium 
was collected and depleted of cells by centrifugation and introduced into PC12 cells 
for functional studies. 
 
2.2.7  Gene expression studies 
2.2.7.1 Isolation of total cellular RNA from PC12 cells and 
 hippocampal  tissue slices 
Total RNA from both PC12 cells and hippocampal tissues were extracted by a 
single-step method using Trizol® reagent (Invitrogen, Carlsbad, CA. U.S.A) 
according to the manufacturer’s instructions. Briefly, the samples were homogenized 
in 1ml of Trizol® reagent per well from 6-well plate and vortexed. Saturated 
chloroform (0.5ml per 1ml of Trizol® reagent) was added to the homogenates and 
the samples were shaken vigorously for 15s and allowed to stand at room 
temperature for 2-3min. The mixture was centrifuged at 13,000rpm for 15min and 
the aqueous phase transferred to fresh tubes, in which Rnase-free Dnase I was added 
and the samples were incubated in 37°C water bath for 20min. Total RNA was 
precipitated with 500µl of isopropanol at -80°C for 20min and centrifuged at 
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13,000rpm for 15min. Resultant pellet was washed with 75% ice-cold ethanol. The 
supernatant was discarded and the pellet was dried at 37°C for 20min. The RNA was 
dissolved in DEPC-treated water by heating in a 60°C water bath for 10min. The 
concentration of each RNA preparation was determined by measuring absorbance at 
the wavelength of 260nm and integrity checked by RNA gel. 
 
2.2.7.2  Quantitative real-time polymerase chain reaction (real-time  
  PCR) 
The introduction of real-time PCR technology has significantly improved and 
simplified the quantitation of nucleic acids (Klein, 2002). The unique feature of this 
technology lies in the real time monitoring of the amplification process using 
fluorescent techniques (Heid et al., 1996) such that PCR products are detected as 
they accumulate. The information obtained can be used to quantitate the initial 
amounts of template molecules (mRNA) with high precision over a wide range of 
concentrations. The major advantages of real-time PCR in relation to other similar 
techniques are attributed to its wide dynamic range, significantly higher reliability 
and increased accuracy of detection relative to end-point determinations (Wilhelm 
and Pingoud, 2003).  
 
2.2.7.2.1  Principles of real-time PCR 
Quantitative real-time PCR systems are based on a set of primers and/or probes that 
accounts for its high specificity. Fluorescence signals that are proportional to the 
amount of PCR product can be generated by fluorescent dyes that are specific for 




SYBR® green I is the most frequent dye used in real-time PCR and it largely binds 
to sequence independent to the minor groove of dsDNA (Morrison et al., 1998). The 
binding affinity of SYBR® green I is more than 100-times higher than that of 
ethidium bromide and the fluorescence of the bound dye is more than 1000-fold 
greater than that of free dye, making it suitable for monitoring product accumulation 
during PCR. Assays using SYBR® green I detection must be carefully optimized to 
reduce the quantification of non-specific products. Changes in the expression of 
various genes due to venom components were quantitated using a kinetic PCR 
protocol which monitors transcript amplication in real-time. In this project, the 
SYBR® green assay was used and described below:  
Gene-specific PCR primers were designed using the PrimerExpress 2.0 (Applied 
Biosystems, U.S.A) software according to their corresponding mRNA sequences. 
The primers were designed to yield amplicons of less than 100bp and synthesized by 
Alpha-DNA (Montreal, Quebec, Canada). Ribosomal RNA (18S) was used as an 
internal calibrator. The primer sequences are listed in Table 2.1. A two-step RT 
(reverse-transcription)-PCR was used. Reverse transcription of total RNA was first 
carried out to generate cDNA strands. The reaction was set up as follows: 
 
Reverse transcription master mix 
(Section 2.1.9) 
12 µl 
Total RNA (100ng/µl)  
 
3µl
The reverse transcription reaction was carried out at 25°C for 10min, 37°C for 






The following reaction was set up for the SYBR® green assay: 
SYBR® green mastermix 
Forward primer (gene of interest) 
Reverse primer (gene of interest) 
cDNA  





Top up to a final volume of 75µl 
 
The amplification was performed at 50°C for 2min and 95°C for 10min followed by 
40 cycles at 94°C for 15s and 60°C for 1min per cycle. All reactions were carried 
out in triplicate using the ABI Prism 7000 SDS (Applied Biosystems, U.S.A). 
 
2.2.7.3  Oligonucleotide microarray 
A microarray can be imagined as a minature gene hybridization or detection assay 
with cDNAs or oligonucleotides as probes. All procedures were carried out 
according to the protocols described in the GeneChip™ expression analysis 
technical manual (Affymetrix, Santa Clara, CA). 
  
2.2.7.3.1  Principles of microarray 
The production of arrays begins with the selection of probes to be used and is 
typically selected from databases like GenBank, dbEST and Unigene (Duggan et al., 
1999). Complementary DNA arrays are produced by spotting PCR products 
(approximately 0.6-2.4 kb) representing specific genes onto a matrix, which can 
either be glass or a membrane. The printing is carried out by a robot and the DNA is 
cross-linked to the matrix by ultraviolet irradiation. The state of bound DNA is ill-
defined and can be deposited as double-stranded, intra-strand cross-linked to some 
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extent and even have multiple constraining contacts with the matrix along its length. 
Hence, oligonucleotides make better hybridization probes and such arrays are 
typically manufactured by a process known as photolithography (Lipshutz et al., 
1999). In this case, the nucleotides (25-80 bases in length) are deposited on a glass 
substrate or ‘chip’. Both platforms are extremely high throughput and sequences 
representing whole genomes have been deposited on the matrix or chip.  
Each element on an array contains a DNA sequence from one gene and is used to 
measure the expression of its corresponding mRNA in a cell or tissue sample. 
Messenger RNA from control and experimental samples are used to synthesize 
fluorescently-labeled cDNA or cRNA probes, which are then hybridized to the 
microarray. Frequently, total RNA pools are labeled (rather than mRNA) to 
maximize the amount of message that can be obtained from a single sample. The 
fluorescent signal from the hybridized probes is measured by a laser scanner capable 
of detecting emission from a variety of dyes. To normalize the results, the intensity 
signals from the control and experimental samples can be compared to deduce the 
expression of a particular gene, whether it has been upregulated, downregulated, 
unchanged or even absent (Barett and Kawasaki, 2003). The sensitivity of the assay 
is very high, with reports of microarrays being able to detect one mRNA per cell. In 
most cases, the gene identification obtained from an array is validated by other 
methods such as northern blot analysis (Bustin, 2000), competitive reverse 
transcription PCR (Vanden Heuvel et al., 1993) or real-time PCR (Schulze and 






2.2.7.3.2  cDNA probe preparation 
Total RNA clean-up 
The RNA clean-up was done using the RNeasy mini kit (Qiagen, Germany) and 
both RLT and RPE buffers were included in the kit. Total RNA were isolated from 
control and treated (mouse or sputa NGF) PC12 cells and cleaned up using RNeasy 
spin columns (Qiagen, Germany) before cDNA synthesis. The final volume of total 
RNA was made up to 100µl with sterile, deionized water. RLT buffer (section 
2.1.10; 350µl) was added into the RNA and transferred into a spin column. The 
sample was subsequently centrifuged for 2min and the eluant collected and reloaded 
into the spin column and a further centrifuged for 2min. The resulting eluant was 
discarded and 500µl of RPE buffer was added to wash the RNA. The sample was 
centrifuged for 2min and eluant discarded. The column was air-dried until the β-
mercaptoethanol had evaporated. RNase-free water (15-30µl) was added into the 
column, followed by centrifugation for 2-3min to elute the RNA. The clean RNA 
was quantitated spectrophotometrically at 260nm. 
 
First strand cDNA synthesis 
To synthesis the first strand cDNA , the T7-(dT) primer was allowed to hybridize to 
the poly(A) tails of the mRNA molecules in  a reaction that was set up as follows: 
 
Total RNA 








The reaction mixture was incubated at 70°C for 10min after which the sample was 
pulsed and put on ice. Subsequently, following reagents were added to the reaction 
mixture and incubated at 37°C for 2min. 
 
5X first strand cDNA buffer  
DTT (100mM) 





SuperScript II reverse transcriptase (1µl) was added to initiate the synthesis and the 
sample was incubated at 37°C for 1h. The reaction mix was terminated on ice. 
 
Second strand cDNA synthesis 
Synthesis of the second cDNA strand was carried out immediately after the first 
strand synthesis. The following were added to the first stand cDNAs: 
 
5X second strand reaction buffer  
dNTP mix (10mM) 
30µl 
3µl 
E. coli DNA ligase (10U/µl) 1µl 
E. coli DNA polymerase I (10U/µl)  4µl 
E. coli RNase H (2U/µl) 1µl 
DEPC water  91µl 
 
The reaction mixture was incubated at 16°C for 2h in a cooled water bath after 
thorough mixing. This was followed by addition of 2µl (10U) of T4 DNA 
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polymerase and incubation at 16°C for an additional 5min. The reaction was 
terminated by addition of 10µl of 0.5M EDTA. 
 
2.2.7.3.3  Clean-up of double stranded cDNA 
The synthesized cDNA was cleaned up in two-step procedure. In the first step, phase 
lock gel (PLG: Qiagen, Germany)-phenol/chloroform extraction was carried out to 
remove unwanted proteins, followed by ethanol precipitation to recover the cDNA. 
The PLG formed an inert, sealed barrier between the aqueous and organic phases of 
phenol-chloroform extractions. The solid barrier allowed more complete recovery of 
the sample (aqueous phase) and minimized interface contamination of the sample. A 
standard phenol/chloroform extraction can be performed as an alterative to the PLG 
procedure. The PLG tube was spun briefly for 12,000 x g for 20-30sec. Phenol-
chloroform: isoamyl alcohol (162µl) in a 25:24:1 ratio saturated with 10mM Tris-
HCl (pH 8.0) was added to the final cDNA synthesis preparation. The contents were 
vortexed briefly and the entire cDNA-phenol/chloroform mixture was added to the 
PLG tube. This suspension was centrifuged at 12,000 x g for 2min. The upper 
aqueous phase was transferred to a fresh tube. In the proceeding step, 2.5 volumes of 
absolute ethanol were added to the sample and vortexed. The mixture was 
centrifuged at 12,000 x g for 20min. The supernatant was removed and pellet 
washed with 0.5ml of ice-cold 80% ethanol. The pellet was washed twice and later 
air-dried. Finally, the pellet was resuspended in 12µl of RNase-free water. 
 
2.2.7.3.4 Synthesis of biotin-labeled cRNA 
This procedure is important for the production of large amounts of hybridizable 
biotin-labeled RNA targets by in vitro transcription from bacteriophage T7 RNA 
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polymerase promoter. By using T7 RNA polymerase and biotin-labeled nucleotides, 
large amounts of single-stranded non-radioactive RNA molecules can be produced 
within a short incubation period. RNA-DNA hybrids have a higher melting 
temperature than corresponding DNA-DNA hybrids, therefore single stranded RNA 
targets offer higher target avidity and greater sensitivity than DNA probes. The in 
vitro transcription reaction (Bioarray, Enzo Diagnostics Inc, U.S.A) was set up as 
follows:  
 
Template cDNA  
Reaction buffer (10X) 
1µg 
4µl 




RNase inhibitor mix (10X) 
T7 RNA polymerase (20X) 
Sterile, deionized water  
4µl 
2µl 
Top up to a final volume of 40µl 
 
The reaction mixture was incubated in 37°C water bath for 4-5h with tapping every 
40min. The cRNA was stored at -20°C.  
 
2.2.7.3.5  Clean-up and quantification of in vitro transcription (IVT) 
 products 
The IVT clean-up reaction is essential to remove unincorporated NTPs and was 
carried out as described as in the section above (Section 2.2.7.3.4). The eluted cRNA 
was quantitated using the spectrophotometer. Since total cellular RNA was the 
starting material, adjusted cRNA yield was calculated to reflect carryover of 
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unlabeled total RNA. Using an estimated 100% carryover, the following formula 
was used to determine the adjusted cRNA yield.  
 
Adjusted cRNA yield = RNAm- (total RNAi) (y) 
RNAm = amount of cRNA measured after IVT (µg) 
Total RNAi = starting amount of RNA (µg) 
Y = Fraction of cDNA reaction used in IVT 
 
The minimum concentration of purified cRNA that was required was 0.6µg/µl. 
 
2.2.7.3.6  Fragmentation of cRNA for target preparation 
The adjusted amount of cRNA was fragmentated and the reaction was set up as 
follows: 
 
Clean cRNA  
5 X Fragmentation buffer  
(Section 2.1.10)  
20µg 
8µl  
RNase-free water  Top up to a final volume of 40µl 
 
The final concentration of RNA in the fragmentation mixture ranges from 0.5µg/µl 
to 2µg/µl and full-length cRNA was broken down into 35-200 base fragments by 
metal-induced hydrolysis. The fragmentation mixture was incubated at 94°C for 
35min and the reaction was terminated in ice. The undiluted, fragmented sample 





2.2.7.3.7 Eukaryotic target hybridization 
The hybridization cocktail for a single probe array-hybridization was prepared as 
follows: 
 
Fragmented cRNA  15µg 
Control oligonucleotide B (3nM) 25µl 
Eukaryotic hybridization controls 
(20X) 
15µl 
Herring sperm DNA (10 mg/ml) 
Acetylated BSA (50 mg/ml) 
Hybridization buffer (2X;  




Sterile deionised water  Top up to a final volume of 300µl 
 
The frozen stock of 20 X GeneChip® Eukaryotic hybridization control cocktail 
(Affymetrix) was heated at 65°C for 5min to completely resuspend the cRNA before 
storing in aliquots. It contains the genes bioB, bioC, bioD and cre which code for 
prokaryotic enzymes. These enzymes serve as hybridization controls when mixed 
with the labeled eukaryotic cRNA samples. These controls were spiked into the 
samples to monitor the efficiency of target preparation, hybridization, washing and 
staining. The probe array was equilibrated to room temperature immediately before 
use. The hybridization cocktail was heated to 99°C for 5 min in a heat block while 
the probe array was filled with 80µl or 200µl (for test and whole-genome chips 
respectively. Test chips were first run to ascertain the quality of the prepared cRNA 
before they are hybridized on the whole-genome chip) of 1 X hybridization buffer 
and incubated at 45°C for 10min with rotation. The hybridization cocktail was 
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transferred to a 45°C heat block and incubated for 5min. The cocktail was 
centrifuged at 13,000 x g for 5min to precipitate any insoluble material from the 
hybridization mixture. The buffer solution was removed from the probe array 
cartridge and filled with 80µl or 200µl of hybridization cocktail supernatant. The 
probe array was placed in a rotisserie box in a 45°C oven and rotated at 60rpm for 
16h. 
 
2.2.7.3.8 Washing, staining and scanning 
After 16h, the hybridization cocktail was removed from the probe array and stored at 
-70°C. The probe array was filled with 80µl or 200µl of Buffer A (Section 2.1.10). 
An antibody amplification wash and stain procedure was employed. Streptavidin 
phycoerythrin (SAPE) staining reagent was prepared and stored in the dark at 4°C. 
The stain buffer was prepared for each probe array as follows: 
 
2X MES Stain buffer (Section 2.1.10) 600µl 
Acetylated BSA (50 mg/ml) 48µl 
SAPE (1 mg/ml) 12µl
Sterile, deionised water   540µl 
 
The stain solution was mixed well and divided into two aliquots of 600µl each to be 
used for first and third staining steps respectively. An antibody mixture for the 
second phase of staining was prepared as follows: 
 
2X MES stain buffer  300µl 
Acetylated BSA (50 mg/ml) 24µl 
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Normal goat IgG (10 mg/ml) 6µl 
Biotinylated antibody (0.5 mg/ml) 3.6µl 
Sterile, deionized water  266.4µl
 
The fluidics protocols, ‘Micro1v1’ and ‘EukGE WS2v4’ (Affymetrix® Microarray 
Suite 5.0, USA) were selected to wash and stain the test and whole-genome chips, 
respectively, using the GeneChip® Fluidics Station 400. At the end of the fluidics 
protocols, the probe arrays were scanned and the resulting image was stored as a .dat 
file.  
 
2.2.7.3.9 Microarray data analysis 
In the initial phase of analysis, a grid was automatically placed over the .dat file 
demarcating each probe cell. One of the probe array library files, the .cif file, was 
used by Microarray Suite 5.0 to determine the appropriate grid size to be used. The 
alignment of the grid was confirmed by zooming in on each of the four corners and 
on the centre of the image. If the grid was not aligned properly, the alignment was 
adjusted by placing the cursor on an outside edge or corner of the grid. The cursor 
image was changed to a small double-headed arrow and the grid was adjusted. The 
software then analyzed the hybridization intensity from the GeneChip® expression 
probe arrays where the data from each array were scaled to an average intensity of 
800. The gene expression levels from treated and control samples were compared 
using an expression comparison analysis that calculated a set of comparison metrics. 
Some of the metrics which were used by a decision matrix to determine a Difference 
Call for each transcript; Increased (I), Decrease (D), Marginally Increased (MI), 
Marginally Decreased (MD) or No Change (NC). Only the ‘I’ and ‘D’ transcript 
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levels calls were taken into consideration for further analyses in all microarray 
experiments.  
 
2.2.7.4  Applications of gene expression studies 
As the numbers of uncharacterized open reading frames are identified in different 
organisms by various genome sequencing projects, an important question arises as to 
whether the expression pattern of a gene can be used to predict the functional role of 
its protein and its involvement in physiology or pathogenesis of certain diseases. An 
increasingly common approach involved using the gene expression behaviour 
observed over multiple experiments to first cluster the genes into groups, followed 
by assignment of tentative roles to unknown genes in a biological process, based on 
the same clustering group as known genes (Lockhart and Winzeler, 2000). The basic 
assumption underlying this approach is that genes with similar expression 
behaviours are likely to be related functionally. The validity of this method has been 
demonstrated for many genes in Saccharomyces cerevisiae (Eisen et al., 1998 and 
Chu et al., 1998). Changes in normal cellular physiology and the corresponding 
changes in gene expression are also important to help decipher and define the 
relationships between the genes and related pathways (Marton et al., 1998 and 
Winzeler et al., 1999). However, it should be noted that not all cellular events are 
reflected in the mRNA level. In addition, gene expression data can be used to 
identify new cis-regulatory elements and transcriptional units, given the strong 
correlations between the specific sequence motifs in promoter regions and gene 
expression patterns (Wolfsberg, 1999).  
Apart from being an important tool in basic research and target discovery, gene 
expression analysis has other specific applications. In areas such as biomarker 
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determination- to find genes that correlate with and presage disease progression, 
pharmacology- to determine differences in gene expression in tissues exposed to 
various doses of drug compounds, toxicogenomics- to find gene expression patterns 
in a model tissue or organism exposed to toxin compounds and their use as early 
predictors of adverse effects in humans, target selectivity- to define a compound by 
the gene expression pattern it elicits in a target tissue and compare it with other 
compounds based on the pattern, prognostic tests- to find a set of genes that is able 
to accurately differentiate one disease from the rest and disease subclass 
determination-to find multiple subcategories of tumors in a single clinical diagnosis 
(Butte, 2002).  
In particular, gene expression studies have been extremely useful in dissecting the 
molecular mechanism underlying cancer behaviour (Morcellin et al., 2003; 
Weeraratna et al., 2004). For instance, the molecular profiling of cutaneous 
melanoma allowed for the identification of a more motile group of tumours 
histopathologically indistinguishable from their less aggressive counterparts (Bittner 
et al., 2000). Real-time PCR has also been used to detect and quantitate tumor cells 
during cancer remission, circulating T cells after anti-cancer therapy and DNA copy-
number to determine the extent of genomic imbalance that underlies most 
malignancies (Morcellin et al., 2003). 
 
2.2.8  Protein analysis  
2.2.8.1  Protein Isolation from cells 
Total protein was isolated from cells with lysis buffer (Section 2.1.11), vortexed and 
left in ice for further 15min. The insoluble material was removed by centrifugation 
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at 10,000 rpm for 10min at 4°C. Supernatant containing the protein and was 
quantitated by Bradford method (Section 2.2.8.2).  
 
2.2.8.2  Protein determination using the Bradford method 
Bradford’s reagent (Bio-Rad Laboratories, U.S.A) was diluted 5-fold with deionized 
water and 1ml of diluted reagent was added to each protein sample. Absorbance at 
the wavelength of 595nm was measured after incubation at room temperature for 
10min. Bovine serum albumin (2-10µg) was used as standards. 
 
2.2.8.3  Tris-tricine SDS-PAGE 
Tris-tricine SDS-PAGE was carried out according to the method of Schagger and 
von Jagow (1987). Preparation of 10ml and 5ml solutions of 12% resolving and 5% 
stacking gels respectively was carried out as follows: 
 
Stock solution Resolving gel (ml) Stacking gel (ml) 
Acrylamide, 40% 3.0 0.625
Gel buffer  
(Section 2.1.13) 
3.33 1.25 
10% SDS 0.1 0.05 
Glycerol 1.1 - 
Deionized water    2.4 2.85 
 
TEMED (10µl) and 10% (w/v) ammonium persulfate (100µl) were added to the 
solutions which were quickly mixed and added to a gel caster. The resolving gel was 
allowed to set before the stacking gel mixture was added. The gel was fixed to the 
vertical electrophoresis unit which was filled with the upper and lower electrode 
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buffers (Section 2.1.13). Protein samples (70µg) were mixed with an equal volume 
of SDS-PAGE loading buffer (Section 2.1.13) and boiled for 10min. Electrophoresis 
was carried out at 120V until the dye ran out into the buffer. To confirm equivalent 
loading of samples, separate sets of gel were run simultaneously and stained with 
Coomassie Brilliant Blue followed by destaining (Section 2.1.13). 
 
2.2.8.4  Western blotting 
The SDS-PAGE gel (Section 2.2.8.3) was soaked twice in transfer buffer (Section 
2.1.14) for 15min each time. Nitrocellulose membrane was cut to cover the gel 
sufficiently and was also soaked in transfer buffer for 30min, together with the 
scotchbrite and 2 sheets of 3MM paper. They were assembled in the following 
order: scotchbrite, 3MM paper, gel, nitrocellulose membrane, 3MM paper and 
scotchbrite. When the nitrocellulose membrane was placed on the gel, air bubbles 
were rolled out with a glass tube. The blotting assembly was then secured in the 
transfer apparatus that was half-filled with pre-cooled (-20°C) transfer buffer and 
electro-transfer was carried out at 110V for 1h.  
At the end of blotting, the apparatus was disassembled and the nitrocellulose 
membrane was blocked for 1h with shaking, in blocking solution (Section 2.1.14). 
This is followed by incubation overnight at 4°C with either monoclonal anti-
phosphotyrosine (AG10; Upstate Biological, Lake Placid, N.Y., U.S.A.) or 
polyclonal anti-TrkA or anti-p75NTR (Advanced Targeting Systems, San Diego, CA, 
U.S.A.) or anti-sortilin (BD Biosciences, Franklin Lakes, N.J., U.S.A.) at 1µg/ml or 
monoclonal anti-β-actin (Sigma Chemicals, St Louis, MO, U.S.A.) at a dilution of 
1:2500.  Anti-β-actin was used as a reference for quantification. All antibodies were 
diluted in 0.5% blocking solution. After three washes of 10min each in TBST 
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(Section 2.1.14), membranes were incubated for 1h at room temperature with either 
horseradish peroxidase-conjugated goat anti-rabbit (polyclonal) or rabbit anti-mouse 
(monoclonal) at a dilution of 1:50,000 in 0.5% blocking solution, washed twice for 
10min each in TBST and visualized via enhanced chemiluminescence (Supersignal; 
Pierce, U.S.A) with suitable exposure times (Kodak-MS film). Films of western 
blots were scanned (Acer SWZ3300U) and labeling intensities of bands were 
quantitated using AIS software (Synoptics Imaging Systems). 
 
2.2.8.5  Principles of protein profiling by surface-enhanced laser- 
  desorption- ionization time- of-flight (SELDI-TOF)  
The arrays are 10mm wide and 80mm in length and have either 8 or 16 spot 
surfaces. After the sample preparation, a few microlitres of sample (total proteins) 
are bound onto the chemically treated surface of the chip by incubating the sample 
over a short period of time. The surfaces of the arrays have different specific 
properties, classical and specialized affinity capture surfaces. Classical surfaces 
include normal phase for general binding; hydrophobic surfaces for reversed-phase 
capture; cation- and anion- exchange surfaces and immobilized metal affinity 
capture (IMAC) for metal-binding proteins. Specialized affinity capture surfaces 
allow specific protein of interest to be covalent immobilized on pre-activated surface 
arrays, enabling customized experiments to investigate antibody-antigen, DNA-
protein, receptor-ligand and other molecular interactions.  
Proteins or other analytes are retained on the surface of the ProteinChip Array by 
means of specific surface chemistries of by bimolecular covalently bound to the 
array. The specific capture of the subset of proteins in the sample occurs through 
simple chemical interactions or protein-protein interactions. After binding, the array 
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is washed thoroughly to remove any impurities and unbound proteins. An Energy 
Absorbing Molecule (EAM) solution is applied to the sample retained on the chip 
surface and is important to mediate the ionization of the sample. It could be 1±-
cyano-4-hydroxycinnaminic acid (CHCA) which generates matrix ions less than 800 
Daltons (Da) or sinnapinic acid (SPA) which generates higher mass to charge ratio 
ions, typically less than 2000 Da. The EAM (e.g SPA) was applied to the chip 
surface in a saturated solution  of 10% acetonitrile and 1% trifluoacetic acid and 
allowed to dry, thereby leaving a crude crystal forms that included both the protein 
(or other analyte of interest) and a large molar excess of EAM molecules. Protein 
chip was placed into the ProteinChip reader for mass spectrometric analysis.  
The ProteinChip reader has a laser that is directed to the chip surface, causing the 
desorbed proteins to be launched as charge ions by the addition of (usually) one 
proton. The vacuum chamber has an acceleration region and a free flight region 
known as the drift tube and ions leaving the source are accelerated to the same 
energy to the drift tube by a voltage of 20kV applied across the surface of the chip. 
The time-of-flight (TOF) for each ion is analyzed to determine the mass to charge 
ratio (m/z) and due to the different velocities exhibited by various masses, they 
arrive at the detector at different times. The accuracy of the ProteinChip reader at 
measuring the molecular mass is aided by regular calibration using samples of 
known molecular weight and can be done either by adding known proteins to the 
chip containing the sample (internal calibration) or running the standards through 
the machine on separate chip (external calibration). The computer programme 
attached to the analyzer then measures the time-of-flight and gives a mass to charge 
ratio. All procedures were carried out according to the protocols described in the 
Ciphergen ProteinChip® System users guide (Palo Alto, C.A., U.S.A.).  
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2.2.8.5.1 Sample preparation for SELDI-TOF 
Treatment with NGF (mouse or sputa) caused neurite outgrowth in PC12 cells. Cells 
were rinsed with sterile saline (Section 2.1.4) and scraped by the rubber policeman 
and resuspended in 50µl of chilled lysis buffer (Section 2.1.11). They were vortexed 
and incubated on ice for 15min. The supernatant was collected and total protein 
quantitated using Bradford assay (Section 2.2.8.2).   
 
2.2.8.5.2  SELDI-TOF  
Prior to total proteins fractionation on Ciphergen hydrophobic reverse-phase chip 
(H4 Protein Chip™), each spot on the protein chip was outlined with a hydrophobic 
pen and allowed to air dry. The spots were pre-treated with 5µl of acetonitrile (20% 
acetonitrile diluted with 1 X PBS; Section 2.1.7). Acetonitrile was removed and 
replaced with 5µg of total protein (suspended in 20% acetonitrile). The spots have to 
remain moist even during the sample exchange. The chip was incubated in a 
humidity chamber for about 90min. 2µl of standard was loaded followed by washing 
with 5µl of binding buffer (20% acetonitrile) five times. Chip was left to air dry. To 
mediate the ionization of the sample, 0.5µl of saturated sinapinic acid was added to 
each spot. Upon activation, the chip is ready for analysis using the SELDI-TOF MS 
(Protein Biology System II) from Ciphergen (Palo Alto, CA, U.S.A.). 
 
2.2.8.5.3  SELDI-TOF analysis 
Public databases were used to help identity a protein of interest using the mass 
values of its internally calibrated peptides. To increase the chances of protein 
identification, only the masses of peptides derived from the protein of interest were 





2.2.8.5.4 Applications of SELDI-TOF 
The field of proteomics is rapidly progressing and development of new technologies 
in the last decade has greatly enhanced the knowledge in this field. Yet, developing 
a comprehensive library of the human proteome is still considered a more daunting 
task than the human genome project. The rising need for new methods to identify 
disease biomarkers is underscored by the survival rate of patients diagnosed at the 
early stages of cancer. SELDI-TOF is a novel approach to biomarker discovery by a 
combination of both chromatography and mass spectrometry techniques. One of the 
main features is its ability to provide a rapid protein expression profile from a 
variety of both biological and clinical sample. It has been used for biomarker 
identification, as well as for the study of protein-protein and protein-DNA 
interactions. The flexibility of SELDI-TOF has allowed it to be used in projects 
ranging from the identification of potential diagnostic markers for cancers (e.g. 
prostate, bladder, breast and ovarian) and Alzheimer’s disease, to the study of 
biomolecular interactions and even the characterization of post-translational 
modifications (Issaq et al., 2002).  
 
2.2.9  Biochemical assays 
2.2.9.1  Detection of DNA fragmentation 
PC12 cells were seeded at a density of 5 x 105/well of 6-well plates and incubated at 
37°C overnight at 37°C and serum-starved for 16-18h prior to treatment. They were 
treated with either condition media from CHO cells (mature NGF or pro (R/G) NGF 
or pro-domain) or STS for 16-18h at 37°C. Genomic DNA was isolated using 
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DNAzol® Reagent (GibcoBRL, Life Technologies, USA), which is a novel 
guanidine-detergent lysing solution that permits the selective precipitation of DNA 
from the cell lysate. The medium was first discarded and cells were washed twice 
with saline (Section 2.1.4). DNAzol® reagent (500µl) was added to each well and 
the cells were completely lysed by gently pipetting the lysate. Cell debris was 
removed by centrifugating the lysate at 10,000 x g for 10min, after which the 
supernatant was retained and 0.5ml of absolute ethanol per 1ml of DNAzol® used, 
was added. The samples were mixed by inversion and incubated at room 
temperature for 2 min. Genomic DNA was precipitated by centrifugation at 4,000 x 
g for 2 min at room temperature. The supernatant was discarded and the pellet was 
washed twice with 75% ice-cold ethanol. The DNA pellet was dried at 37°C, 
dissolved in sterile, deionized water and quantitated spectrophotometrically at a 
wavelength of 260nm before electrophoresis. Cleaved DNA typically appears as a 
“ladder” consisting of non-random, oligonucleosomal fragment lengths when 
electrophoresed. The DNA gel was set and ran according to section 2.2.1.1. 
 
2.2.9.2  MTT cell viability test 
This is basically a colorimetric assay that measures the reduction of MTT into an 
insoluble formazan product by the activity of mitochondrial enzymes in viable cells. 
2 X 105 PC12 cells were seeded in 24-well plates and incubated overnight at 37°C in 
complete DMEM (Section 2.1.4). The next day, cells were exposed to either normal 
or ischemic condition known as oxygen-glucose deprivation (OGD). During OGD, 
cells were deprived of oxygen and glucose and incubated in a 95%N2/O2 chamber. 
The cells were allowed to recover in glucose-containing basal DMEM (Section 
2.1.4) in 95%CO2/O2 conditions for 24h prior to MTT test. The media was also 
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collected for LDH assay. Before the MTT assay, cells were washed twice with 
sterile saline (Section 2.1.4) and MTT solution (300µl/well of 24-well plate; Section 
2.1.15) was added. The cells were incubated at 37°C for 60min. Subsequently, the 
MTT-containing medium was removed and the resulting crystals of formazan were 
dissolved in 200µl of DMSO. Complete dissolution of crystals was achieved by 
shaking the plates gently at room temperature for 10min. 100µl of dissolved crystal 
solution was transferred to 96-well plate for reading and scanning. Blanks were set 
up in wells that did not contain cells. Absorbance at a wavelength of 550nm was 
measured using a multi-plate scanning spectrophotometer (Model 680 Microplate 
Reader). 
 
2.2.9.3  LDH (lactate dehydrogenase) cytotoxicity test 
The cytotoxicity detection kit is a fast and simple colorimetric alternative to 
quantitate cytotoxicity/cytolysis based on measurement of LDH activity released 
from damaged cells. LDH is a stable cytoplasmic enzyme present in all cells and 
rapidly released into the cell culture supernatant upon damage to the plasma 
membrane. Cell culture media was collected and centrifuged for 10min at maximum 
speed to remove all cells. The supernatant was collected and 100µl was added to 
each well of 96-well plate. Each treatment was done in triplicates. Meanwhile, the 
reaction mixture (catalyst and dye solution) was prepared according to the 
manufacturer’s instructions and kept on ice. 100µl of reaction mixture was added to 
each well and mixed.  Total lactate dehydrogenase activity was determined by lysing 
cells in 2% Triton X-100 in basal DMEM and measuring the total amount of lactate 
dehydrogenase in the medium. Absorbance at a wavelength of 550nm was measured 
using a multi-plate scanning spectrophotometer (Model 680 Microplate Reader) in a 
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kinetic assay for 30min. Absorbance values were expressed as a percentage of total 
cellular lactate dehydrogenase in the cell lysate relative to Triton. 
 
2.2.9.4  Assay for the determination of caspase-3 activity 
A hallmark feature of apoptosis is the fragmentation of genome and cleavage or 
degradation of several cellular proteins. Members of the caspase family of proteases 
have been found to be crucial mediators of the biochemical events associated with 
apoptosis. In particular, the activation of caspase-3 was shown to be important for 
the initiation of apoptosis. Cells were scraped by the rubber policeman and 
resuspended in 50µl of chilled lysis buffer (Section 2.1.18) and incubated on ice for 
10min. Protein concentration of the lysates were determined by Bradford method 
(Section 2.2.8.2) and 40µl of the 2 X reaction buffer (Section 2.1.18) followed by 
4µl of 1mM DEVD-[7-amino-4-trifluoromethyl-coumarin] (ALEXIS Biochemicals, 
U.S.A), were added to an equal volume of each sample. The lysates were incubated 
at 37°C for 30min and caspase activity was determined by measuring the relative 
fluorescence units (RFU) at a wavelength of 505nm following excitation at 400nm 
using a spectrofluorimeter (SpectraMax GeminiEM, Molecular Devices). 
 
2.2.9.5  Annexin V / Ethidium homodimer III / Hoechst nuclear staining 
A quantification kit (Biotium, U.S.A.) that enabled the differentiation of apoptotic, 
necrotic and healthy cells was used. The two major processes of cell death are 
apoptosis and necrosis. The morphological assessment of cell death was carried out 
using Ethidium homodimer III/Annexin V/Hoechst 33342 dyes on the basis of cell 
membrane permeability and chromatin condensation. Apoptotic cells typically have 
intact membranes and condensed, fragmented chromatin whilst necrotic cells have 
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disrupted cell membranes and enlarged nuclei. At the onset of apoptosis, 
phosphotidylserince (PS) which is normally found in the integral part of the plasma 
membrane becomes translocated to the extracellular face. The human anticoagulant, 
annexin V, is a 35kDa Ca2+-dependent phospholipid protein with high affinity for 
PS. Annexin-V is labeled with fluorescein (FITC) and able to stain cells green by 
binding to PS exposed on the outer leaflet.  
Necrosis normally results from a severe cellular insult. Both internal organelle and 
plasma membrane integrity are lost, resulting in spilling of cytosolic and organellar 
contents into the surrounding environment. Ethidium homodimer III (EtD-III) is a 
highly positively charged nucleic acid probe, which is impermeable to live cells or 
apoptotic cells, but stains necrotic cells with red fluorescence. While Hoechst 33342 
is a cell membrane-permeable, minor groove-binding DNA stain that emits bright 
blue fluorescence upon binding to DNA and used to stain the nuclei of living cells. 
In apoptotic cells, the condensation of DNA can be detected using Hoechst 33342.  
Cells were seeded, treated and rinsed with sterile saline (Section 2.1.4) on 24-well 
plates prior to staining. They were later incubated with dye solution (200µl per well) 
for 15min at room temperature. The dye solution was made up of 5µl of FITC-
Annexin V, 1µl of Ethidium Homodimer III and 5µl of Hoechst 33342 per 100µl of 
1 X binding buffer. The stained cells were protected from light till visualized by 
fluorescence microscopy (DM IRB, Leica).  
 
2.2.10  Organotypic hippocampal culture 
2.2.10.1   Obtaining hippocampal slices from rats 
Organotypic hippocampal slice cultures were prepared according to the method by 
Stoppini et al. (Stoppini et al., 1991). For these experiments exactly 10-day-old 
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Wistar rats were anesthetized and subsequently decapitated. The skin over the top of 
the skull was cut with a scalpel in a longitudinal cut from the nose to the neck. This 
was pulled back to expose the skull, which was then cut horizontally with scissors. 
The top part of the brain was removed using a blunt-end forceps and quickly 
transferred to ice-cold dissection media (Section 2.1.5). The anterior cortex was 
removed and the remaining cortex was pulled back, exposing the hippocampal 
formation. The hippocampus was freed at its temporal and septal ends, and the 
remaining white matter removed. The hippocampus was transferred to a 50ml petri 
dish, containing dissection media.   
The pair of hippocampi (per rat) were placed on the stage of a McIlwain tissue 
chopper and cut perpendicular to the long axis to give transverse slices. A thickness 
of 350μm was used; if slices were thinner, they are more difficult to plate out onto 
the membranes. The slices are then returned to in 4oC dissection media and 
separated using a paddle Pasteur pipette (Alpha Laboratories, U.K.). This allowed 
tissue debris and potentially toxic substances, such as excitatory amino acids to 
diffuse away. The slices were placed onto culture plate inserts (Millicell with pore 
size of 0.4μm), consisting of a microporous transmembrane bio pore membrane. 
Each membrane had 4 hippocampal slices, each from a separate rat. The membrane 
was placed in 6-well plates that contained 1ml of complete MEM (Section 2.1.5; 
Gahwiler et al., 1997). The slices were exposed to both oxygen and nutrients as the 
membrane was at the surface of the media. All hippocampal slices were checked 













Fig. 2.2: Structure of CA1-3 region of hippocampal slice obtained for cultures. 
CA1: Cornus Ammonis 1, CA3: Cornus Ammonis 3, DG: Dentate Gyrus (adapted 











2.2.10.2  Maintenance of hippocampal slices 
The slices favoured were those from the septal half, as these contained the dentate 
gyrus with an angular apex. These restricted the loss of the CA1 during glutamate 
experiments. The organotypic hippocampal cultures were maintained in 
95%O2/5%CO2 at 37°C incubator. The media, complete MEM (Section 2.1.5) was 
changed every 3 or 4 days, replacing 1ml with a fresh 1ml of medium. Diffusion of 
medium through the membrane is sufficient to ensure survival. However the volume 
of 1ml is crucial, as more than this can cause the cultures to drown. These cultures 
were allowed to cultivate in vitro for 14 days. At the end of this period the 
hippocampal slices had stabilised and thinned out, to about 150μm, (due in part to a 
general spreading of the tissue and to death of neurons at the cut surface of the 
slice). The various subgroups of neurons in each of these slices can be identified by 
this stage allowing pharmacological studies to be performed (Gahwiler, 1984 and 
Stoppini et al., 1991).  
 
2.2.10.3 Procedure for analysing cell damage 
To analyse cell death, the fluorescent exclusion dye propidium iodide (PI; 5µg/ml) 
named due to its inability to enter healthy intact cells, was used. Plasma membrane 
integrity, which is lost in necrotic but not apoptotic cells, was probed by the 
exclusion dye propidium iodide. The PI enters the cells and upon binding to the 
DNA becomes concentrated in the nucleus rendering it highly fluorescent. PI 
fluorescence was detected using a confocal laser scanning microscope equipped with 
an argon laser. A simultaneous transmission image was collected on a second 
channel and used to identify cell subfields within each culture. Images were saved as 
‘TIFF’ files and subsequently analysed using the Image Pro Plus analysis software. 
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Cell death was quantified using the following method. The areas of the CA1-3 
subfields were determined from the transmission image, on which they were clearly 
identifiable. Using an interactive drawing tool, the CA1-3 region was divided into 
two polygons: 1) CA1 and 2) CA2-3 regions of each culture were outlined as areas 
of interests (AOIs). The same two polygons were kept for all analysis, thereby 
maintaining a constant AOI. The area of each cell field expressing PI fluorescence 
above the background level was counted using the ‘density mean’ function present 
in the software. This function counts two-dimensional arrays of pixels of the AOI 
outlined. Results were expressed as percentage survival in relation to the treatment 
with maximum damage in each case. 
 
Statistical Analysis 
The results are expressed as mean + SEM., n indicating the number of slices. In the 
statistical comparison, analysis of variance (ANOVA) was used to evaluate the 
overall difference between the groups. The differences between each treatment 
group versus insult (e.g. OGD, glutamate, etc.) were analyzed using the unpaired 











2.3  Chemicals and reagents 
Standard analytical grade laboratory chemicals for the preparation of general 
reagents obtained from Merck, Damstadt, Germany and BDH, Poole, U.K. 
Molecular biology work was carried out using molecular biology grade chemicals. 
Sources of specialty reagents used were mentioned in the text while others were 
obtained from: 
 
Alpha DNA, U.S.A. 
Random hexamers 
 
Amersham International plc, U.K. 
E coli DNA polymerase I (Klenow fragment) 
T4 polynucleotide kinase 
DNA restriction enzymes 
Nitrocellulose membrane 
 
Applied biosystems, U.S.A. 
Reagents for reverse transcription and real-time PCR 
 
Boehringer Mannheim, Germany 
Deoxyribonucleotides (dATP, dCTP, dGTP, dTTP and dUTP) 
Taq DNA polymerase 
 
Biorad, Hercules, C.A., U.S.A. 







Gibco-BRL, Gaitherssburg, M.D., U.S.A. 
Agar  
Agarose 




Invitrogen, Life Technologies, U.S.A. 
Acetylated BSA 
Reagents for oligonucleotide microarray cDNA synthesis 
 




Kodak Eastman, U.S.A. 






Molecular Probes Inc., U.S.A. 
R-Phycoerythrin Streptavidin (SAPE) 
 
New England Biolabs, Beverly, M.A., U.S.A. 




RNAse-free DNAase I  
Sephadex G-100  
 
Promega 
M-MLV reverse transcriptase 
 
Promega Corporation U.S.A. 
Herring sperm DNA 
 








DMEM basal medium 
DTT 
Ethidium bromide 




MES free acid monohydrate 















































3.1  Introduction 
Since the discovery of nerve growth factor (NGF) activity in snake venoms by 
Cohen and Levi-Montalcini (1956), snake venoms have been considered rich 
sources of NGF (Kostiza and Meier, 1996). Snake NGFs are found mainly in 
venoms of the Elapidae, Viperidae, and Crotalidae families (Lipps, 1998). 
However, the neuronal influence of snake venom NGFs as well as other non-
mammalian NGFs on the developing nervous system and on the maintenance of the 
neurons is completely unclear. In fact, it has not been demonstrated whether NGF is 
of any importance for the reptile nervous system or not (Kostiza and Meier, 1996).  
The yield of NGF from Naja naja atra snake was calculated to be in the range of 
0.2%-0.5% (w/w; Kostiza et al., 1995), while that of mouse 7S NGF from 
submandibular gland homogenate was found in a range of 0.002%-0.0025% (w/w;  
Longo et al., 1989). Despite snake venom being the first source of NGF, the 
physical and biochemical properties of NGF were deduced from the NGF of male 
mouse submandibular gland (mouse NGF; Lipps, 1998). The amino acid homology 
between NGF from snakes and rodents is about 60%. Snake NGFs, particularly 
those from cobras were reported to be superior in inducing neurite outgrowth on 
PC12 cells as compared to NGFs derived from other types of snakes (Lipps, 1998). 
In addition, Server et al (1976) reported that NGFs from cobra (Naja naja) and 
mouse submandibular glands were able to elicit neurite outgrowth from chick 
embryonic dorsal root ganglion.  
However, the biological effects elicited by NGF are best studied using the 
pheochromocytoma cell line (PC12). PC12 cells express both TrkA and p75NTR 
receptors and in response to NGF will differentiate into cells, resembling 
sympathetic neurons, making it an ideal tool to study the intracellular and 
Chapter 3 
 111
biochemical events following NGF binding to surface receptors (Kaplan and Miller, 
1997). NGF is required for the survival of the differentiated cells. Both p75NTR and 
TrkA receptors act synergistically to mediate the trophic effects of NGF. Co-
expression of p75NTR has also been found to enhance the biological response of cells 
expressing TrkA (Culmsee et al., 2002). Interestingly, the TrkA receptor activates 
positive signals such as increased survival and growth, while the p75NTR receptor is 
known to activate both positive and negative signals. Complexes of p75NTR with 
TrkA are found to enhance the neurotrophin binding affinity and TrkA-associated 
signaling pathway (Casaccia-Bonnefil et al., 1999). In addition, neuroprotection by 
NGF and activation of NF-κB (a pro-survival transcription factor) have shown to be 
dependent on the expression of p75NTR in PC12 cells (Bui et al., 2002).  
This chapter describes the cloning and sequencing of two new cDNAs encoding 
NGF from the venom glands of a Malayan spitting cobra- Naja sputatrix. In 
addition, I expressed one of the cDNAs as a histidine-tagged fusion protein in E coli. 
and investigated its downstream pathways in relation to mouse 7S-NGF.  
 
3.2  Methods of NGF purification from snake venoms 
Snake venom NGF was found to be made up of a homodimeric complex of β-
subunits, which share comparable biological activities with NGF of other species 
(Siigur et al., 1992). The similarity of its activity and sequence with other known 
NGFs (McDonald et al., 1991; Alkin and Bradshaw, 1993) led to the suggestion that 
purification methods should be similar to those of mouse NGF (Longo et al., 1989). 
Some of the purification methods for purifying NGF from snake venoms include; 
centrifugation, dialysis, lyophilization, ionophoresis, HPLC chromatography, 
monoclonal antibodies chromatography, gel filtration, ion (cation/anion) exchange 
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chromatography, starch gel electrophoresis, preparative gel electrophoresis and RP-
HPLC chromatography (Angeletti, 1970; Mohamed et al., 1970; Siigur et al., 1987; 
Smith et al., 1992). Following the purification method used to obtain NGF from the 
venom of Chinese cobra, Naja Naja Atra (Kostiza et al., 1995), this study made use 
of a two-step purification method, involving gel filtration followed by RP-HPLC to 
obtain pure NGF from crude venoms. 
 
3.2.1  Gel filtration 
Gel filtration is a technique that separates proteins in a mixture according to their 
molecular weights. The first stage of crude venom purification was performed on 
Biogel 100. The elution profile of the protein mixture was monitored by measuring 
the absorbance of the resultant fractions at a wavelength of 280nm. Two major 
peaks were obtained from the chromatogram and were designated P1 and P2 (Fig. 
3.1A). The first peak, P1 consisted of high molecular weight proteins (14-50kDa) 
while the P2 contained the low molecular weight proteins (4-10kDa). Each fraction 
(100ng/ml) was tested for its ability to promote neurite growth in PC12 cells (Table 
3.1). The corresponding fraction was also subjected to SDS-PAGE analysis to verify 
their homogeneity and to determine the molecular mass.  
 
3.2.2  RP-HPLC 
Hydrophobic chromatography involved the interaction of non-polar regions of a 
protein with the non-polar surface of the binding matrix. In RP-HPLC, the stationary 
phase is hydrophobic (non-polar) while the mobile phase is polar. This will result in 







Fig. 3.1: Purification of native NGF from venom of Naja sputatrix. (A) Gel- 
filtration chromatography of crude venom. (B) Reversed phase HPLC 
chromatography of active fraction obtained from gel filtration. Inset shows the 











































stationary phase while the hydrophilic constituents would flow through. The 
hydrophobic components are subsequently eluted.  
In the final stages of purification, the fraction showing the highest neurite outgrowth 
was purified further by RP-HPLC (Fig. 3.1B). It was loaded onto a C18 (Nucleosil) 
reverse phase-HPLC column and the elution profiles were monitored by measuring 
the absorbance of the resultant peak at a wavelength of 280nm. One homogenous 
protein peak was obtained and it showed neurite outgrowth at 1ng/ml (Table 3.1). 
This active protein was 14kDa in size (Fig. 3.1B insert). The N-terminal amino acid 
sequence of this protein was found to be -ETHPVHNRGEYSV- and the protein was 
found to be non-lethal up to 1μg/g in mouse.  
 
3.3 Screening of NGF activity from venom fractions using PC12 cells 
PC12 cells have been used as the prime dopaminergic cellular tool in molecular 
neuroscience for investigating NGF mechanism of action (Vaudry et al., 2002) and 
in in vitro cell death studies. It is the most established bioassay to detect NGF 
activity from fractions and thus normally used for screening fractions from 
chromatographic procedures (Greene and Rukenstein, 1989). PC12 bioassay was 
proven to be sensitive enough to detect NGF even in highly diluted venom fractions 
at concentrations where cytotoxic contaminations of the pre-purified fractions were 
ineffective (Kostiza et al., 1995). Venoms from several Elapids, Naja sputatrix, 
Bungarus candidus, Pseudonaja textilis, Austrelaps superbus as well as venoms 
from Chinese and Indian scorpions (Buthus martensi Karsch, Mesobuthus tumulus) 
and honey bee (Apis mellifera) were tested for neurite outgrowth in PC12 cells. β-
Nerve Growth Factor (7Sβ-NGF) from the mouse submaxillary gland was used as a 




Table 3.1: Neurite outgrowth in PC12 cells. Protein concentrations at 100ng/ml 
were used unless otherwise stated. ‘+++’ denotes number of neurites observed in 
positive control (mouse NGF), while ‘++++’ denotes 50% increase in the number of 
neurites observed as compared to mouse NGF.  
 
Sample Neurite outgrowth 
Mouse NGF (positive control; 100ng/ml) +++ 
Bungarus candidus (250ng/ml) ++ 
Naja sputatrix (250ng/ml) ++++ 
Austrelaps superbus (250ng/ml) ++ 
Pseudonaja textilis (250ng/ml) +++ 
Chinese scorpion (250ng/ml) ++ 
Indian scorpion (250ng/ml) + 
Bee venom (250ng/ml) ++ 
Biogel P10 gel fractions of N. sputatrix (Fig. 3.1A) 
Fraction 27 ++ 
Fraction 28 +++ 
Fraction 29 ++ 
Fraction 30 +++ 
Fraction 31 (1ng/ml) +++++ 
Fraction 33 ++ 
Fraction 34 Lysis 
Fraction 35 Lysis  
Fraction 36 Lysis  
HPLC fractions (Fig. 3.1B) 
Fraction 3 - 
Fraction 4 - 
Fraction 5 + 
Fraction 6 ++ 
Fraction 7 +++++ 
Fraction 8 (1ng/ml) ++++++ 
Fraction 9 +++ 
Fraction 10 + 
Denatured and refolded recombinant nerve growth factor (NGF) 
Denatured recombinant NGF (100ng/ml) ++ 
Refolded recombinant NGF (100ng/ml) ++++ 
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cell body were counted as neurites and at least 100 cells were analyzed for each 
condition from each of the three independent experiments (Koike et al., 2006). The 
highest neurite outgrowth was observed for N. sputatrix crude venom at 250ng/ml. 
Mouse NGF (7S) showed a comparable activity at 100ng/ml (Table 3.1). N. 
sputatrix was selected to be the snake with venom having the highest NGF activity 
and a recombinant protein was to be synthesized. 
 
3.4  cDNA cloning of the nerve growth factor from N. sputatrix 
Once Naja sputatarix was identified as the snake containing the highest amount of 
NGF activity, total RNA was extracted from its venom gland, reversed transcribed 
and amplified using gene specific primers. A 700bp fragment of PCR products was 
obtained. The cDNA was subcloned and 30 positive clones were sequenced. All 
clones showed the presence of cDNA encoding nerve growth factor. The cDNA 
encoded for a 22 amino acid signal peptide, a 112 amino acid pro-domain and a 
mature NGF protein consisting of 117 amino acid residues. Analysis of the 
sequences indicated the presence of two isoforms (nsNGFI and II) of venom nerve 
growth factor (Fig. 3.2).  
 
3.5  Expression of NGF in E. coli 
In this study, two new cDNAs encoding the NGF in the venom glands of a spitting 
cobra, Naja sputatrix were cloned and sequenced. Due to its higher homology to the 
mammalian homolog, nsNGFI was selected for the expression as a recombinant 
protein in E. coli and termed “sputa NGF”. The cDNA encoding the mature protein 
of nsNGFI was subcloned into pQE30 expression vector in-frame with the (His)6-tag 





bmngf           MSMLCYTLIIAFLIGIWAAPKSEDNVPLGSPAKSDFSDTNCAQTHEGLKTSRNTDQHHPT 
nsngfI          MSMLCYTLIIAFLIGIWAVPKSEDNAPLGSPATSDLSDTSCAQTHEGLKTSRNTDQRHPA 
agpngf          MSMLCYTLIIAFLIGVWAAPKSEDNVPLGSPATSDLSDTSCAKTHEALKTSRNTDQHYPA 
mousengf        MSMLFYTLITAFLIGVQAEPYTDSNVPEGDSVPEAHWTKLQHSLDTALRRARSAPTAPIA 
humNGF          MSMLFYTLITAFLIGIQAEPHSESNVPAGHTIPQVHWTKLQHSLDTALRRARSAPAAAIA 
                **** **** *****  * *    * * *                  *   *         
                 ++++++++++ +                                +         + 
nsngfII         PQKAEDQELRTAANIIVDPKLFQKRQFQSPRVLFSTQPPLLSRDEESVEFLDNEDS-LNR 
bmngf           PKKSEDQELGSAANIIVDPKLFQKRRFQSPRVLFSTQPPPLSRDEQSVKFLDTEDT-LNR 
nsngfI          PRSQRIKQFGSASNIIVDPKLFQKRRFQSPRVLFSTQPPPLSRDEQSVEFLDNEDA-LNR 
agpngf          PKKAEDQEFGSAANIIVDPKLFQKRRFQSPRVLFSTQPPPLSRDEQ---SVDNVNS-LNR 
mousengf        AR-----VTGQTRNITVDPRLFKKRRLHSPRVLFSTQPPPTSSDTLDLDFQAHGTIPFNR 
humNGF          AR-----VAGQTRNITVDPRLFKKRRLRSPRVLFSTQPPREAADTQDLDFEVGGAAPFNR 
                             ** *** ** **   ***********    *              ** 
                       +      +  +     + +  ++         ++    ++   + +            
nsngfII         NIRAKRED-HPVHNLGEHSVCDSVSAWVT-KTTATDIKGNTVTVMENVNLDNKVYKQYFF 
bmngf           NIWANNEN-HPVHNQGEHSVCDSISVWVTNKTKATDIKGNTVTVMVDVNLNNEVYKQYFF 
nsngfI          NIRAKRET-HPVHNRGEYSVCDSISVWVANKTTATDIKGKPVTVMVDVNLNNHVYKQYFF 
agpngf          NIRAKRED-HPVHNRGEYSVCDSVSVWVGNKTTATDIRGNLVTVMVDVNLNNNVYKQYFF 
mousengf        THRSKRSSTHPVFHMGEFSVCDSVSVWVGDKTTATDIKGKEVTVLAEVNINNSVFRQYFF 
humNGF          THRSKRSSSHPIFHRGEFSVCDSVSVWVGDKTTATDIKGKEVMVLGEVNINNSVFKQYFF 
                    ^^   **    ** ***** * **  ** **** *  * *   **  * *  **** 
                    +              +       +    +        +                ++ 
nsngfII         ETKCKNPNPVPSGCRGIDSSHWNSYCTETDTFIKALTMEGNQASWRFIRIDTACVCVITK 
bmngf           ETKCRNPNPVPSGCRGIDSRHWNSYCTTTDTFVKALTMEGNRASWRFIRIDTACVCVISR 
nsngfI          ETKCRNPNPVPSGCRGIDSRHWNSYCTTTHTFVKALTMEGNRASWRFIRIDTACVCVISR 
agpngf          ETKCRNPNPVPTTCGGIDARHWNSYCTTTHTFVKALTMEDNQASWRFIRIDTACVCVISR 
mousengf        ETKCRASNPVESGCRGIDSKHWNSYCTTTHTFVKALTTDEKQAAWRFIRIDTACVCVLSR 
humNGF          ETKCRDPNPVDSGCRGIDSKHWNSYCTTTHTFVKALTMDGKQAAWRFIRIDTACVCVLSR 
                ****   ***   * ***  ******* * ** ****     * *************    
                  + + 
nsngfII         KTGNN-- 
bmngf           KTENFPP 
nsngfI          KTENF-- 
agpngf          KNENFG- 
mousengf        KATRRG- 
humNGF          KAVRRA- 
                *      
 
 
Fig. 3.2: Comparison of amino acid sequences of various NGF. Sputa nsngf I&II 
refer to the two isoforms of NGF from Naja sputatrix; bmNGF is from Bungarus 
multicinctus (S56212); agpngf is from Agkistrodon halys pallas (Guo et al., 1999); 
mousengf (K01759) and human ngf (humNGF, X52599). The pro NGF region is 
underlined and the mature peptides are in bold letters. Identical amino acids are 
shown by (*) and the proteolytic cleavage site (KR) for the mature peptide is 








was induced with 1mM of IPTG for 3h at 37°C and several clones were selected for 
a preliminary analysis of the induction efficiency. The expressed fusion protein was 
analyzed on 12% SDS-PAGE (Fig. 3.3, lanes 2 and 3). 
 
3.6  Production of recombinant sputa NGF 
Expression of recombinant NGF was carried out as mentioned in section 2.2.5. The 
eluted histidine-tagged protein from the Ni-NTA column were subjected to SDS-
PAGE analysis (Fig. 3.3, lane 4) and a protein of about 20kDa was obtained, which 
constitute the mass of sputa NGF plus the (His)6-tag. Sputa NGF protein was 
denatured fully (to expose all the cysteine residues) in 8M urea and β-
mercaptoethanol and later subjected to in vitro refolding in the presence of oxidized 
and reduced glutathione (Fig. 3.3, lane 5). The yield of properly refolded protein is 
about 3mg/L. However, both denatured and refolded recombinant NGFs varied in 
their potency to induce neurite outgrowth on PC12 cells (Table 3.1). The CD 
spectrum of the refolded protein was found to correlate well with that of the native 
NGF protein (Fig. 3.4). 
 
3.7  Biological activity of recombinant sputa NGF 
Apart from its expression, recombinant sputa NGF was tested for its biological 
activity by incubation with PC12 cells, with mouse NGF as a reference. Neurite 
outgrowth was observed after an overnight incubation with either mouse NGF or 
recombinant sputa NGF (Fig. 3.5). A quantification of neurite outgrowth in the 
presence of native Naja sputatrix NGF has also been found to induce neurite 
outgrowth in PC12 cells in a dose-dependent manner, but at a relatively lower 







Fig. 3.3: Expression, purification and folding of recombinant NGF (sputa 
NGF). SDS PAGE analysis of sputa NGF protein: lane 1 represents protein 
molecular mass standards with sizes indicated in kilodaltons (kDa); lane 2 refers to 
E. coli cell lysate before induction; lane 3; E. coli cell lysate (inclusion bodies) after 
3h induction with 1mM of IPTG; lane 4 refers to purified sputa NGF after affinity 
chromatography with Ni-NTA column and lane 5; refolded sputa NGF after dialysis.



































Fig. 3.4: Circular dichroism (CD) spectrum of NGF. (A) Spectrum of refolded 































Fig. 3.5: Neurite extension after treatment with mouse and sputa NGF.  PC12 
cells at 1x106 were plated and grown overnight. Following day, cells were treated 
with either mouse or sputa NGF, at 200ng/ml for 16-18h. Untreated control PC12 
cells do not have any neurites (A), while neurite extensions were observed upon 
treatment with mouse NGF (B) and sputa NGF (C) at 200ng/ml.  
 









Fig. 3.6: Percentage of neurite-bearing cells. PC12 cells were treated with (A) 
native sputa NGF in a dose-dependent manner and the percentage of neurite-bearing 
cells were tabulated. (B) A similar dose-dependent experiment was carried out using 
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neurite outgrowth was done for mouse and recombinant sputa NGF, by counting the 
number of neurite-bearing cells expressed in percentage, both for (i) dose-dependent 
manner (Fig. 3.6B) and (ii) time-dependent manner (Fig. 3.7). The results showed 
that the recombinant sputa NGF exhibited a comparable activity with that of mouse 
NGF at 200ng/ml and the optimum time for neurite extension is between 16-18 
hours. The optimized time (16-18h) and dose (200ng/ml) of sputa NGF treatment 
were used for subsequent experiments.  
 
3.8  Activation of TrkA receptors  
PC12 cells contain both NGF receptors (TrkA and p75NTR) and were used to analyze 
receptor activation. Western blot analysis of the PC12 cells treated separately with 
the mouse and sputa NGF for 15 minutes showed that the sputa NGF increased the 
production of the precursor gp110trkA receptors compared to the mouse NGF. 
However, the mature gp140trkA receptor was found in equal amounts for both 
treatments (Fig. 3.8A and B).  
 
3.9  Real-time PCR analysis after NGF treatment 
To detect the regulation of genes upon treatment with NGF, PC12 cells were treated 
with either mouse NGF or sputa NGF (200ng/ml) for 16-18h. Neurites were 
observed with treatment and total RNA was extracted. The regulation of genes was 
assessed by real-time PCR. In addition to receptor genes (TrkA and p75NTR), the 
expression patterns of endogenous NGF, NFκB and IκB were accessed. The 
expression of IκB (inhibitor of NFκB gene) was found to be negatively regulated, 
while an interesting elevated expression of the endogenous NGF gene was noted 












Fig. 3.7: Time dependent manner of neurite-bearing cells. PC12 cells were 
incubated for various time intervals indicated at 200ng/ml with either mouse NGF 
(filled boxes) or recombinant sputa NGF (empty boxes) and the number of neurites 
was counted the following day. The percentage of neurites were tabulated against 
time, by 16-18 hours, maximum number of neurites were obtained. This timing was 
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Fig. 3.8: Activation of TrkA receptor determined by western blot. (A) Cells 
were treated for 15min and total protein extracted. Equal amounts of protein was 
separated on a 7.5% SDS-PAGE and subsequently blotted onto nitrocellulose 
membrane. (i) Phosphorylated TrkA receptors (gp110 and gp140) were detected 
using monoclonal anti-phosphotyrosine antibody. The same membrane was stripped 
and probed with (ii) anti-TrkA and (iii) anti-beta-actin antibodies. (B) Densitometry 
analysis shows the ratios of the phsophorylated TrkA and beta actin (internal 
control) levels and lane 1: mouse NGF-treated cells; lane 2: sputa NGF-treated cells 
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Fig. 3.9: Quantitative real-time PCR gene analysis using SYBR Green assay. 
Total RNA from treated (mouse and sputa NGF) and untreated PC12 cells was used 
to study the expression of 5 genes, TrkA, p75NTR, NF-κB, IκB and endogenous 
NGF. Values are expressed as ± SEM, experiments performed in triplicates and *: p-
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sympathetic neurons are known to induce pro-survival signal via NF-κB 
(Taglialatela et al., 1997; Maggirwar et al., 1998; Foehr et al., 2000; Wooten et al., 
2001). In addition, several studies have shown neurotrophin factors, including NGF, 
constitute an important class of endogenous modulators of excitotoxicity (Mattson et 
al., 1993). Hence, an up-regulation of NFκB and endogenous NGF genes by sputa 
NGF treatment may have potential neuroprotective roles.  
 
3.10  Protein profiling (SELDI-TOF) analysis 
Proteins regulated upon treatment of NGF (sputa or mouse) treatment were detected 
by protein chip (SELDI-TOF) and mouse NGF was used as a reference. Protein 
profiling results identified 5 proteins that showed significant changes upon NGF 
treatment (Fig. 3.10). The analysis showed changes in expression of both growth-
related (NGF precursor and neurogranin) and an apoptotic protein (BAD). Cells 
treated with sputa NGF (Fig. 3.10A) showed a decrease (~6-fold) in an 8kDa protein 
and an increase (~2-fold) in an 11.4kDa protein. Cells treated with mouse NGF (Fig. 
3.10B) showed a down regulation (~10-fold) of a 13.9 kDa protein. Comparison 
between sputa NGF and mouse NGF treatments (Fig. 3.10C) showed that sputa NGF 
caused an increase in the growth-associated proteins like A-kinase anchoring protein 
(11.4 kDa) and the endogenous NGF precursor (13.9 kDa) as compared to pro-
apoptotic protein (BAD). Expression of protein at 8kDa (possibly neurogranin) was 
greatly decreased (~5-fold), whereas proteins at 22.3kDa (BAD) and 67.2kDa (SHP-







Fig. 3.10: Protein profiling analysis. Total protein extracts from cells treated with 
either mouse NGF or sputa NGF for 16-18 hours were used. (A) Protein profiles 
obtained from cells treated with sputa NGF versus untreated control. (B) Protein 
profiles obtained from cells treated with mouse NGF versus untreated control. (C) 


























60000 65000 70000 75




































60000 65000 70000 75


















60000 65000 70000 7500








5000 10000 15000 20000 25000





















3.11  Microarray analysis of NGF treated PC12 cells 
The global gene expression upon treatment with both NGFs was studied using 
oligoprobe microarrays. The genes whose expression is altered by 2-fold or more 
were taken as significant (Li et al., 2004) from about 730 genes examined in our 
study. These probe sets were subjected to self-organizing map (Data Mining Tool; 
Affymetrix, USA) clustering and were grouped according to their expression 
patterns. The genes were also further assigned to categories according to their 
biological functions. Some of them are shown in Table 3.2. The majority of these 





















Description mouse NGF 
(fold-change) 
sputa NGF  
(fold-
change) 
Cell cycle growth arrest and DNA-damage-inducible 
45 alpha 3.63  3.18 
 proliferating cell nuclear antigen -2.07 -1.74 
 ret proto-oncogene 2.87 2.91 
 ret proto-oncogene 4.06 4.41 
 cyclin-dependent kinase inhibitor 1A 4.99 4.26 
 growth associated protein 43 2.27 2.10 
Apoptosis apoptotic death agonist BID 3.36 2.85 
 Bcl-2-like-1 2.22 1.77 
 
Eicosanoid 
synthesis prostaglandins-endoperoxide synthase 1 4.59 2.36 
 interleukin 12 p35 subunit 6.19 4.72 
 
Transcription 
factors core promoter element binding protein 2.53 1.57 
 fos-like antigen 1 8.57  3.51 
 nuclear transcriptional factor-Y-beta 2.01 1.14 
 
ISL1 transcriptional factor, LIM/ 
homeodomain 1 2.75 1.74 
 global ischemia induced protein GIIG15B -2.38 -2.07 
 DNA polymerase beta 2.20  1.88 
 GATA binding protein 4 1.39 2.17 
 myelin transcription factor 1-like -2.20 -1.33 
 
signal transducer and activator of 
transcription 3 2.04 1.66 
 activating transcription factor 3 2.2 -1.54 
 early growth response 1 15.14 12.91 
Translational 
factors eukaryotic initiation factor-5 2.03 1.60 
 eukaryotic initiation factor-2B, subunit 3 2.04 1.82 
 
Others meprin 1 alpha 2.55 2.10 
 cathepsin E 11.08 8.22 
 mast cell protease 7 88.65 71.51 
 plysia ras-related homolog A2 2.69 2.33 
 small GTP-binding protein rab5 2.20  1.79 
 GTP cyclohydrolase 1 3.20 2.10 
 phospholipase D 2.41 2.55 
 kinesin family member 1B 1.45 2.01 
 procollagen, type XII, alpha 1 2.30 1.41 
 integrin beta 1 2.31 2.39 
 insulin receptor substrate 1 2.06 1.27 
 
double cortin and calcium/calmodulin-
dependent protein kinase-like 1 2.69 1.84 
 
gap junction membrane channel protein beta 
5 2.79 2.04 
 Jun-B oncogene 2.28 2.39 
 opiod receptor-like 2.13 2.73 




 purinergic receptor P2X, ligand-gated ion 
channel 2 -2.91 -1.59 
 purinergic receptor P2X, G-protein coupled 
2 2.06 2.11 
 adenosine monophosphate deaminase 3 2.48 1.85 
 myelin basic protein 1.04 2.35 
 prolactin receptor 2.17 1.54 
 serum-inducible kinase 7.26 3.12 
 syntaxin 2.71 1.45 
 dynamin 1 -2.07 -1.39 
 guanosine diphosphate dissociation inhibitor 
3 2.17 2.39 
 annexin 5 3.03 2.77 
 neural receptor protein-tyrosine kinase 9.19 3.16 
 moesin 2.97 2.48 
 vesicle-associated membrane protein, 
associated protein B and C 1.71 2.10  
 ADP-ribosylation-like 4 2.71 2.28 
 solute carrier family 1, member 3 6.28 4.99 
 solute carrier family 9, member 4 -1.44 2.23 
 syndecan 1 2.95 2.39 
 myosin IXA 2.22 1.99 
 potassium inwardly rectifying channel, 
subfamily J, member 6 2.20 1.95 
 protein kinase, cAMP dependent regulatory, 
type I, alpha 2.53 2.08 
 coated vesicle membrane protein 2.00 1.89 
 regulator of G-protein signaling protein 2 2.25 1.38 
 cold inducible RNA-binding protein 1.97 2.30 
 microtubule-associated protein 1b 2.31 1.29 
 acid phosphatase 5 2.01 1.91 
 profilin II 2.38 2.06 
 glutamate receptor, ionotrophic, NMDA2C -2.50 -1.91 
 lysosomal membrane glycoprotein 2 -1.97 -2.20 
 nerve growth factor receptor-associated 
protein -2.03 -1.55 
    
Calcium-related 
pathway very low density lipoprotein receptor 2.16 1.83 
 very low density lipoprotein receptor 2.57 2.00 
 very low density lipoprotein receptor 2.22 2.10 
 calcium binding protein p22 3.66 2.19 
 S-100 related protein, clone 42C 3.36 2.71 
 S-100 related protein A4 2.06 1.95 
 cadherin -3.14 -2.33 
 calcium channel, voltage-dependent, T-
type, alpha II subunit 5.54 7.21 
 protein phosphatase 3, regulatory subunit B, 
alpha isoform, type 1 2.23 1.78 




Table 3.2: Classification of genes obtained from microarray. Genes were 
grouped based on their biological functions. Notable changes in gene expression 
































4.1  Introduction 
NGF belongs to the neurotrophin family and is synthesized as immature precursors 
that are proteolytically cleaved intracellularly by furin and other proconvertases, to 
release mature ligands. The function of the NGF precursor was initially thought to 
be for protein folding and regulation of neurotrophin secretion (Suter, 1991 and 
Rattenholl et al., 2001). However, the function of the NGF precursor was recently 
challenged by two independent groups. Fahnestock et al. (2001) proved it to be 
neurotrophic, while Lee et al. (2001) proved it to be apoptotic (2001). The debate 
from the two groups was elaborated in detail in section 1.1.3.1.  This chapter 
attempts to investigate the function of the pro-domain of sputa NGF protein using 
PC12 cells. 
 
4.2  Analysis of sequence by bioinformatics tools 
The sequence of NGF from Naja sputatrix (nsNGFI; chapter 3) was compared to the 
other two mammalian counterparts (mouse and human NGFs) using bioinformatics 
tools. NsNGFI showed about 70% homology to the mammalian NGFs at the mature 
protein region and hence was chosen for expression in E. coli as a recombinant 
protein. The entire sequence containing both the pro-domain and mature regions 
were compared between the three NGFs. NetNES 1.1 analyses (Fig. 4.1A) revealed 
that nsNGF I had one site for nuclear export signal (NES) whereas the mammalian 
NGFs had none. In addition, other post-translational modifications were compared. 
Potential amino acid residues that could be phosphorylated include serine, threonine 
and tyrosine. NetPhos 2.0 server predicted that nsNGFI and human NGF had 9 
serine and 4 threonine residues, whereas mouse NGF had 11 serine, 7 threonine and 





Fig. 4.1A: Prediction of potential leucine-rich nuclear export signal (NES) by 
NESbase version 1.0 database. It was used to predict potential NES sites from 
protein sequences. There is one predicted site for NES in (i) Naja sputatrix NGF 










Fig. 4.1B: Prediction of potential phosphorylation sites by NetPhos 2.0 server. It 
was used to predict potential serine, threonine and tyrosine phosphorylation sites 
from NGF protein sequences. The server predicted that (i) Naja sputatrix NGF 
(nsngfI) has 9 serine and 4 threonine residues, (ii) mouse NGF has 11 serine, 7 
threonine and 1 thyrosine residues while (iii) human NGF (humngf) has 9 serine and 








had 2 possible N-glycosylation sites (Fig. 4.1C), while nsNGFI had none. In 
addition, there were 3 possible O-glycosylation sites (Fig. 4.1D) for both mouse 
NGF and nsNGFI, and none for human NGF. The precursor NGF is usually cleaved 
at the -1 and -2 sites by furin to become a mature NGF (Heymach et al., 1996). 
Hence it is of interest to determine the number of possible furin-cleavage sites. 
NsNGFI has only one furin-cleavage site, whereas the mammalian NGFs have two 
possible sites (Fig. 4.1E). To study the effect of proNGF, the furin-cleavage site for 
nsNGFI was mutated to impair intracellular proteolysis. A combination of all the 
possible post-translational modifications is shown in Fig. 4.1F, hence there may be 
variation in function of proNGF from Naja sputatrix as compared to mouse NGF, as 
there are differences in their post-translational modifications.  
 
4.3  Plasmid construction 
Three constructs were created to carry out the study of the pro-domain of sputa NGF 
and are represented in Fig. 4.2A. In the subsequent experiments, the following terms 
will be used to describe the different mutants of sputa NGF: mature NGF (sequence 
of full-length sputa NGF with pro-domain and the signal peptide); pro (R/G) NGF 
(sequence of full-length NGF with a mutation at the furin cleavage site with pro- 
domain and signal peptide) and pro-domain (sequence of pro-domain with the 
signal peptide).  
The mature NGF and its corresponding constructs were amplified by PCR from a 
full-length sputa NGF cDNA sequence. The primers used to amplify these fragments 
contained restriction sites for KpnI and XhoI. The positive clones were then 
restricted with enzymes (KpnI and XhoI) and subcloned into pcDNA4 (Fig. 4.2B). 







Fig. 4.1C: Prediction of potential N-glycosylation sites by NetNglyc 1.0 server. It 
was used to predict N-glycosylation sites in human proteins using artificial neural 
networks that examine the sequence context of Asn-Xaa-Ser/Thr sequences. Result 
showed that (i) Naja sputatrix NGF (nsngfI) has none; while both (ii) mouse NGF 










Fig. 4.1D: Prediction of potential O-glycosylation sites by NetOglyc 3.1 server. 
Its prediction is based on neural network predictions of mucin type GalNAc O-
glycosylation sites in mammalian proteins. Results showed that (i) Naja sputatrix 
NGF (nsngfI) and (ii) mouse NGF have three, while (iii) human NGF (humngf) has 









Fig. 4.1E: Prediction of potential furin-cleavage sites by ProP 1.0 server. It 
predicts arginine and lysine propeptide cleavage sites in eukaryotic protein 
sequences using an ensemble of neural networks and furin-specific is set as the 
default. Results showed that the propeptide for (i) Naja sputatrix NGF (nsngfI) is 
cleaved at one site while both (ii) mouse NGF and (iii) human NGF (humngf) are 












Fig. 4.1F: Clustal alignment of NGFs. NGF protein sequences from Naja Sputatrix 
(nsngfI), mouse NGF (mousengf) and human (humngf) were compared by multiple 
sequence alignment with the ClustalW program (Thompson et al. 1994). The signal 
peptide region is coloured in green, furin-cleavage sites in red, N-glycosylation in 
blue and O-glycosylation in purple. The pro-domain region is underlined and the 
mature peptides are in bold letters. Identical amino acids are shown by (*) and the 











nsngfI          MSMLCYTLIIAFLIGIWAVPKSEDNAPLGSPATSDLSDTSCAQTHEGLKTSRNTDQRHPA 
mousengf        MSMLFYTLITAFLIGVQAEPYTDSNVPEGDSVPEAHWTKLQHSLDTALRRARSAPTAPIA 
humngf          MSMLFYTLITAFLIGIQAEPHSESNVPAGHTIPQVHWTKLQHSLDTALRRARSAPAAAIA 
                **** **** *****: * * ::.*.* * .  .    .   . . .*: :*.:     : 
 
nsngfI          PRSQRIKQFGSASNIIVDPKLFQKRRFQSPRVLFSTQPPPLSRDEQSVEFLDNEDA-LNR 
mousengf        AR-----VTGQTRNITVDPRLFKKRRLHSPRVLFSTQPPPTSSDTLDLDFQAHGTIPFNR 
humngf          AR-----VAGQTRNITVDPRLFKKRRLRSPRVLFSTQPPREAADTQDLDFEVGGAAPFNR 
                .:         : ** ***:**:**:::***********  : *             :** 
 
nsngfI          NIRAKRET-HPVHNRGEYSVCDSISVWVANKTTATDIKGKPVTVMVDVNLNNHVYKQYFF 
mousengf        THRSKRSSTHPVFHMGEFSVCDSVSVWVGDKTTATDIKGKEVTVLAEVNINNSVFRQYFF 
humngf          THRSKRSSSHPIFHRGEFSVCDSVSVWVGDKTTATDIKGKEVMVLGEVNINNSVFKQYFF 
                .  ::..  **:.: **.*****:*.**  **.****:*: * *: :**::* *::**** 
 
nsngfI          ETKCRNPNPVPSGCRGIDSRHWNSYCTTTHTFVKALTMEGNRASWRFIRIDTACVCVISR 
mousengf        ETKCRASNPVESGCRGIDSKHWNSYCTTTHTFVKALTTDEKQAAWRFIRIDTACVCVLSR 
humngf          ETKCRDPNPVDSGCRGIDSKHWNSYCTTTHTFVKALTMDGKQAAWRFIRIDTACVCVLSR 
                ****: .*** : * ***: ******* *.**:**** : ::*:*************::: 
 
nsngfI          KTENF-- 
mousengf        KATRRG- 
humngf          KAVRRA- 
                *  .    
 
predicted N-glycosylation site 
predicted O-glycosylation site 











Fig. 4.2A: Plasmid construction. (i) The signal peptide, pro-domain and active 
NGF segment are represented by “sp”, “pro” and “NGF” respectively. NGF cDNAs 
are denoted as: (1) Pro-domain refers to the sequence from the signal peptide to the 
pro-domain. (2) Pro (R/G) NGF refers to the sequence of full-length NGF with the 
furin cleavage site mutated from R to G, thereby restricting the release of mature 
NGF sequence from the pro-domain. (3) Mature NGF refers to the sequence of the 
full length NGF including the furin cleavage site. The three cDNAs were cloned into 
pcDNA4 plasmids.  (ii) Deduced amino acids sequence of NsNGFI. The signal 
peptide region is highlighted in yellow, ‘pro’ region in green, the furin cleavage site 
in blue and the remaining sequence refers to the mature NGF 
 Pro sp1: Pro domain 
2: Pro (R/G) NGF  Pro sp  NGF R/G
3: Mature NGF  Pro sp  NGF 
GCTCTGGTGCATACGCTAATGTCCATGCTGTGCTACACTCTGATTATAGCATTTCTGATT - 60  
 A  L  V  H  T  L  M  S  M  L  C  Y  T  L  I  I  A  F  L  I 
GGCATATGGGCAGTACCAAAGTCTGAAGATAATGCCCCTCTGGGCTCCCCTGCAACGTCT - 120  
 G  I  W  A  V  P  K  S  E  D  N  A  P  L  G  S  P  A  T  S    
GACCTTTCCGACACCAGCTGTGCTCAAACTCACGAGGGTCTGAAAACATCTCGAAACACA - 180  
 D  L  S  D  T  S  C  A  Q  T  H  E  G  L  K  T  S  R  N  T    
GATCAGCGCCATCCAGCTCCTAGAAGTCAGAGGATCAAGCAATTTGGATCAGCATCAAAC - 240  
 D  Q  R  H  P  A  P  R  S  Q  R  I  K  Q  F  G  S  A  S  N    
ATCATTGTGGATCCCAAGCTTTTTCAGAAGAGGCGGTTCCAGTCGCCTCGTGTTCTGTTC - 300  
 I  I  V  D  P  K  L  F  Q  K  R  R  F  Q  S  P  R  V  L  F    
AGCACTCAGCCCCCACCATTGTCAAGAGATGAGCAAAGTGTGGAGTTCCTGGACAATGAA - 360  
 S  T  Q  P  P  P  L  S  R  D  E  Q  S  V  E  F  L  D  N  E    
GACGCTCTTAACAGGAATATCCGGGCCAAACGTGAAACTCATCCTGTGCATAACCGAGGG - 420  
 D  A  L  N  R  N  I  R  A  K  R  E  T  H  P  V  H  N  R  G    
GAATATTCTGTGTGTGACAGTATCAGTGTCTGGGTTGCCAACAAAACCACAGCAACGGAC - 480  
 E  Y  S  V  C  D  S  I  S  V  W  V  A  N  K  T  T  A  T  D    
ATCAAAGGCAAACCGGTGACTGTGATGGTAGATGTAAATCTTAATAACCATGTCTACAAG - 540  
 I  K  G  K  P  V  T  V  M  V  D  V  N  L  N  N  H  V  Y  K    
CAGTACTTTTTTGAAACCAAGTGCAGAAATCCAAATCCAGTACCAAGTGGGTGCAGGGGC - 600  
 Q  Y  F  F  E  T  K  C  R  N  P  N  P  V  P  S  G  C  R  G    
ATTGATTCCAGGCATTGGAATTCTTATTGCACGACAACACACACATTTGTCAAGGCATTA - 660  
 I  D  S  R  H  W  N  S  Y  C  T  T  T  H  T  F  V  K  A  L    
ACCATGGAAGGCAATCGGGCATCCTGGCGCTTCATTCGGATTGACACTGCCTGTGTGTGC - 720  
 T  M  E  G  N  R  A  S  W  R  F  I  R  I  D  T  A  C  V  C    
GTAATCAGTAGAAAAACTGAGAACTTCTGATGGACCATTGATTGCTCCAATACTCACTT - 781  







 Fig. 4.2B: pcDNA4 constructs. (i) The PCR products were cloned into pT7 Blue 
(R) vector. The three constructs (1-3) were individually cloned into the vector. (ii) 
Each of the constructs (1-3) were restricted by KpnI and XhoI and individually 


















NGF cDNA constructs 








incorporated by site-directed mutagenesis of pcDNA-NGF. The mutation was 
verified by loss of restriction enzyme site and sequencing of both strands.  
 
4.3.1  Tet on/off system in CHO cells 
The pcDNA4/TO/myc-His vector contains two tetracycline operator 2 (TetO2) 
binding sites with the human CMV promoter for the tetracycline-regulated 
expression of the target gene of interest (Yao et al., 1998). The TetO2 sequences 
serve as binding sites for 4 Tet repressor molecules (comprising two Tet repressor 
homodimers) and confer tetracycline-reponsiveness to NGF genes. The Tet 
repressor is expressed from the pcDNA6/TR (Fig. 4.2Cii) plasmid. In the absence of 
tetracycline, the expression of cloned gene is repressed by the binding of Tet 
repressor homodimers to the TetO2 sequences. Addition of tetracycline to the cells 
will remove the Tet repressor homodimer from the CMV/TetO2 promoter in the 
pcDNA4/TO/myc-His (Fig. 4.2Ci) and allows high level of expression of the NGF 
genes. As gene regulation can be stringently regulated by the Tet repressor, this 
system was also used for the investigation of other cytotoxic proteins in eukaryotic 
cells (Massie et al., 1998; Nakagawa et al., 1999; Pollock et al., 2000).  
The three cDNAs recombinant pcDNA4/TO/myc-His-A tetracycline inducible 
vector constructs containing the mature NGF, pro (R/G) NGF and pro-domain 
sequences were transfected separately into CHO cells via lipofectamine™ reagent. 
The pcDNA6/TR plasmid was also transfected.  
 
4.3.2  Generation of stable cell line that is tetracycline-regulated 
CHO cells that have successfully incorporated both TO (zeocin-resistant) and TR 






Fig. 4.2C: Plasmids used for Tet on/off system and its detailed description 
(adapted from Invitrogen Inc, U.S.A). (i) The cloning site used in this study for 
constructs (1-3) is indicated on the Tet-on plasmid: pcDNA4/TO/myc-His A. (ii) 




CMV promoter: bases 232-819 
Rabbit β-globin intron II (IVS): bases 1028-1600 
TetR gene : ases 1684-2340 
SV40 early polyadenylation sequence : bases 2346-2477 
F1 origin : bases : 2897-3325 
SV40 promoter and origin : bases 3335-2675 
EM-7 promoter: bases 3715-3781 
Blasticidin resistance gene: bases 3782-4180 
SV40 early polyadenylation sequence: bases 4338-4468 
pUC origin: bases 4851-5521 
bla promoter: bases 6521-6625 (complementary strand) 
Ampicillin (bla) resisitance gene: bases 5666-6526 
(complementary strand)  
CMV promoter: bases 232-958 
Tetracycline operator 2 (2X TetO2) 
sequences: bases 820-859 
CMV Forward priming site: bases 769-789 
Multiple cloning site: bases 968-1089 
c-myc epitope: bases 1073-1102 
Polyhistidine (6XHis) tag: bases 1118-1135
BGH reverse priming site : bases 1158-
1175 
BGH polyadenylation sequence : bases 
1164-1388 
f1 origin : bases 1434-1862 
SV40 promoter and origin: bases 2824-
2954 
pUC origin : bases 3337-4010 
(complementary strand) 
bla promoter: bases 5016-5114 
(complementary strand) 
Ampicillin (bla) resistance gene: bases 






selective medium was made up of complete DMEM with antibiotics (zeocin; 
500µg/ml and blasticidin; 10µg/ml) and used to select for the dual-resistant cells. 
The medium was changed every 3-4 days until all untransfected control cells were 
eliminated. About one week after transfection of CHO cells with NGF expression 
vector and dual selection by antibiotics (blasticidin and zeocin), cells were serially 
diluted in the zeocin-blasticidine complete DMEM and the remaining surviving cells 
were reseeded into 96-well plates (~ 1 cell per well). A total of 67 clones for each 
mature NGF and pro (R/G) NGF, as well as 19 clones for pro-domain were 
obtained. All the clones were subjected to real-time PCR for quantitation of the 
plasmid copy number. 
 
4.3.3  Selection of clones with equal copy number 
Real-time PCR using specific primers (Table 2.1) to the sputa mature NGF and pro-
domain sequences were used to access the plasmid copy number in each clone. The 
DNA from each clone was isolated and used for real-time PCR by SYBR Green 
assay. The clones were selected based on their CT (cycle threshold) values, the lower 
the CT, the higher is the copy number. Hence, CT of 2.0 was selected to normalize 
the amount of all the three different constructs. Fig. 4.3A shows the results from the 
67 clones containing the mature NGF cDNA. Based on the CT of 2.0, two clones (F1 
and F6) were chosen. Fig. 4.3B shows the results obtained from the 67 clones 
containing the pro(R/G) NGF cDNA. Among these, M36 and M38 were chosen as 
representatives. Similarly, for pro-domain, of the 19 clones, S2 and S7 were selected 
with their CT values closed to 2.0 (Fig. 4.3C). From the standardization assay carried 
out using known amount of DNA, a CT value of 2.0 was found to be equivalent to 











Fig. 4.3A: Quantitation of plasmid copy number by real-time PCR of mature 
NGF. Real-time PCR using the SYBR Green assay and primers specific for mature 
NGF was used to quantitate the amount of plasmid. The larger the CT value, the 
lesser the copy number of plasmid. The CT value of 2.0 (red line) was taken to select 
clones for comparison with the other two constructs. For mature NGF, the clones F1 
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Fig. 4.3B: Quantitation of plasmid copy number by real-time PCR of Pro(R/G) 
NGF. Pro (R/G) NGF has both pro-domain and mature NGF, so primers specific for 
mature NGF was used to quantitate the amount of plasmid via real-time PCR 
(SYBR Green assay). The larger the CT value, the lesser the copy number of 
plasmid. The CT value of 2.0 (red line) was taken to select clones for comparison 
with the other two constructs. For pro (R/G) NGF, the clones M36 and M38 were 
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Fig. 4.3C: Quantitation of plasmid copy number by real-time PCR of pro-
domain. Primers specific for pro-domain were used to quantitate the amount of 
plasmid via real-time PCR (SYBR Green assay). The larger the CT value, the lesser 
the copy number of plasmid. The CT value of 2.0 (red line) was taken to select 
clones for comparison with the other two constructs. For pro-domain, the clones S2 
















1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19










4.3.4  Expression of recombinant proteins from stable transfectants 
Stable clones for the three constructs were selected based on the same plasmid copy 
number as determined by real-time PCR. Two clones from each construct were 
chosen; mature NGF (F1 and F6), pro (R/G) NGF (M36 and M38) and pro-domain 
(S2 and S7). The stable clones were grown in complete DMEM with antibiotics 
(zeocin; 500µg/ml and blasticidine; 10µg/ml) and protein expression was induced in 
serum-free DMEM using 1µg/ml tetracycline for 16-18h.  The media were collected 
separately and depleted of cells by centrifugation. In subsequent experiments, the 
same conditions were used to obtain conditioned CHO media containing either 
mature NGF, pro (R/G) NGF or pro-domain.  
 
4.4  Neurite outgrowth activity of sputa NGF proteins on PC12 cells 
The neurite outgrowth bioassay was done on PC12 cells to determine the different 
levels of NGF activity between the three constructs. PC12 cells were seeded at a 
density of 1 X 105 cells/well in 24-well plates with 0.5ml of complete DMEM per 
well. The cells were then subjected to serum starvation for 24 hours prior to 
treatment with conditioned CHO media containing either mature NGF or pro (R/G) 
NGF or pro-domain for further 16-18h. Neurite outgrowth (percentage of cells with 
neurites > 2 x cell’s diameter in a representative visual field) was observed in PC12 
cells after 16-18 hours incubation. Among these three constructs, only conditioned 
CHO media expressing mature NGF and pro (R/G) NGF proteins were able to elicit 
neurites in PC12 cells that were similar to those in exogenous treatments of sputa 
NGF. However, the extent of neurites was more for the mature NGF compared to 
the pro (R/G) NGF. The control conditioned media (untransfected CHO cells) did 




the mature NGF and pro (R/G) NGF treatment were due to the presence of 
recombinant protein overexpressed by CHO stable clones, rather than the 
conditioned media from CHO cells (Fig. 4.4).  
 
4.4.1  Competitive antibody inhibition  
To show the presence of the expressed protein from CHO cells, 2 x 104 PC12 cells 
were seeded on 96-well plate and treated concurrently with conditioned media from 
CHO cells containing either mature NGF or pro (R/G) NGF, together with 
antibodies specific for either sputa NGF (anti-NsNGF) or pro-domain (anti-pro). 
Cells were incubated for 16-18h at 37°C and observation of the neurite outgrowth 
was made the next day. In Fig. 4.5A, neurites (representative of neurites indicated 
with yellow arrows) were observed for treatments with mature and pro (R/G) NGF.  
An anti-proNGF antibody, termed as anti-pro in this study, was purchased from 
Chemicon, Millipore (U.S.A). This antibody was derived from the pro domain of 
NGF and shown to be proNGF specific and not to deplete the mature NGF (Beattie 
et al., 2002). The other antibody (called anti-NsNGF) was synthesized by directing 
against a peptide corresponding to the mature domain of the NGF 
(VMENVNLDNKVYKQKC) in rabbits. The synthesis and production of the 
polyclonal anti-NsNGF was done by Abgent, Inc (U.S.A.). Treatment with either 
anti-pro or anti-NsNGF antibodies blocked neurite outgrowth for pro (R/G) NGF, 
while only anti-NsNGF antibody blocked the neurite outgrowth for mature NGF. 
Hence, the anti-NsNGF antibody was efficient in blocking neurite outgrowth for 
both mature and pro (R/G) treatments and anti-pro for pro (R/G) NGF.  
Total RNAs from samples treated concurrently with either anti-NsNGF or anti-pro 









Fig. 4.4: Neurite outgrowth of PC12 cells after incubation with conditioned 
media from CHO media. All treatments were carried out in serum-free media and 
incubated for 16-18h. PC12 cells were treated with conditioned CHO media 
containing mature NGF, pro (R/G) NGF and pro-domain, as well as CHO media 
alone. PC12 cells were incubated with CHO media alone and no neurites were 
observed, similar to untreated control. Staurosporine (0.5µM) was used as a marker 
for apoptosis. Under normal light microscope, treatment with mature NGF and pro 
(R/G) NGF treatments resulted in neurites formation, while there were more neurites 
(yellow arrows) in mature NGF compared to pro (R/G) NGF. In pro-domain 
treatment, there were no neurites and cells do not look healthy. Photomicrographs 
are shown in x200 magnification and representative of 3 independent experiments, 
performed in triplicates.   
 
 
STS CHO media Untreated control 






Fig. 4.5A: Competitive antibody inhibition on neurite outgrowth of PC12 cells. 
PC12 cells were seeded on 96-well plate and exposed to CHO media containing 
mature NGF (F1 and F6) and pro (R/G) NGF (M36 and M38), together with the 
anti-NsNGF(~43ug) and anti-pro (1µl/100µl of media) antibodies for 16-18h. 
Neurites (indicated by yellow arrows) were observed the following day. 
Photomicrographs were obtained at x200 magnification and are representative of 3 
independent experiments, performed in triplicate.  
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sortilin) were quantitated by real-time PCR (Fig. 4.5B). Inhibition by anti-NsNGF 
antibodies (Fig. 4.5Bi), caused mature NGF’s effect on TrkA and p75NTR to be 
greatly reduced, whereas, pro (R/G) NGF caused an increased in expression for both 
receptors. Similarly, inhibition by anti-pro antibodies for both pro (R/G) NGF and 
pro-domain led to an increase in TrkA, p75NTR and sortilin expression (Fig. 4.5Bii). 
The drastic change in gene expression for these three genes (TrkA, p75NTR and 
sortilin) by both anti-NsNGF and anti-pro antibodies treatments is possibly due to 
the efficient blocking of mature NGF, pro (R/G) NGF and pro-domain action.   
 
4.4.2  Analysis of cell death by fluorescence microscopy 
PC12 cells treated with conditioned media from CHO cells (mature NGF, pro (R/G) 
NGF and pro domain) for 16-18h were later stained with three dyes (Annexin V, 
Ethidium Homodimer III and Hoechst 33342) and staurosporine (STS) at 0.5µM 
was used as positive marker for apoptosis. One major event in the course of 
apoptosis is the shift of phosphatidylserine (PS) from the inner to the outer leaflet of 
the cell membrane. PS externalization can be examined by staining cells green with 
the FITC-conjugated Annexin V, a protein that binds to PS with high affinity 
(Thiagarajan and Tait, 1990). Ethidium homodimer III is impermeable to both 
healthy and apoptotic cells, but will stain necrotic cells with red fluorescence, while 
Hoechst 33342 will show the condensation of nuclei, a hallmark of apoptosis. Under 
normal light microscope, cells grown in complete DMEM showed minimal death, 
however, with basal DMEM (media used for induction of stable CHO cells), there is 
a basal level of cell death. Treatment with mature NGF and pro (R/G) NGF showed 
a sharp reduction in cells stained with the Annexin V (green) and Ethidium 





Fig. 4.5B: Quantitative gene analysis using SYBR Green assay. PC12 cells were 
incubated with (i) anti-NsNGF (~43ug)  or (ii) anti-pro (1µl/100µl of media) 
antibodies concurrently with conditioned CHO media containing mature NGF, pro 
(R/G) NGF and pro-domain for 16-18h. Antibodies were added in excess. RNAs 
from the treated and untreated samples were isolated and used to study the 
expression of receptor genes: TrkA, p75NTR and sortilin. Values are expressed as ± 
SEM and *: p-value <0.01 and #: p-value < 0.05 by unpaired Student’s t-test. The 











CHO media CHO media + anti-
NsNGF
Mature NGF Mature NGF + anti-
NsNGF






























CHO media CHO media + anti-
pro
Pro (R/G) NGF Pro (R/G) NGF +
anti-pro



















The treatment with pro-domain showed increased in cell death, with more cells 
stained green and red (Fig. 4.6A). Cells were also stained with Hoechst 33342 to 
detect DNA condensation upon apoptosis. With Hoechst staining, both pro-domain 
and staurosporine treated cells were visibly fragmented and condensed (Fig. 4.6B), 
leading to a possibility that pro-domain caused cell death by apoptosis.  
 
4.4.3  Assessment of cell death by lactate dehydrogenase (LDH) and 
 caspase assay 
LDH assay is based on the measurement of LDH activity released from damaged 
cells. It is a stable cytoplasmic enzyme present in all cells and rapidly released into 
cell culture media upon damage to the plasma membrane. It can be used as a 
measure of cell cytotoxicity. Likewise, caspases are activated by death receptors at 
the cell surface or by cytochrome c, which leaks into the mitochondria. The cleaved 
caspase substrates are themselves mediators that activate downstream events in 
apoptosis. As caspases play a very important role in the apoptotic process, a 
fluorogenic cleavage assay was used to determine the activity of the specific 
caspase, caspase-3, after PC12 cells were treated. 
In Fig. 4.7Ai, LDH assay showed that PC12 cells treated with conditioned media 
from CHO cells, in particular, those containing the mature NGF (F1 and F6) and pro 
(R/G) NGF (M36 and M38) were significantly reduced as compared to control. 
Conditioned media from CHO cells alone had no significant increase; hence the 
reduction is solely due to the overexpressed NGF proteins. Pro-domain (S2 and S7) 
treatment caused a significant increase in both LDH and caspase activities as 









Fig. 4.6A: Annexin V/ Ethidium Homodimer III staining of PC12 cells after 
incubation with conditioned media from CHO media. After treatment, the PC12 
cells were stained with 3 dyes: FITC-conjugated Annexin V (green) and Ethidium 
Homodimer III (red), and Hoechst 33342 (blue). Results when viewed using green 
filter. Cells were stained with green and red dyes and staurosporine (0.5µM) was 
used as a marker for apoptosis. Cells positive for green fluorescence only are 
apoptotic whilst those that are positive for both green and red are necrotic. Mature 
NGF and pro (R/G) NGF are able to protect from basal necrosis of the serum-
starved PC12 cells when compared to untreated control. Pro-domain and 
staurosporine-treated cells have both apoptotic and necrotic cells. Photomicrographs 
are shown in x200 magnification and representative of 3 independent experiments, 


















Fig. 4.6B: Hoechst 33342 staining of PC12 cells after incubation with 
conditioned media from CHO media. After treatment, the PC12 cells were stained 
with 3 dyes: FITC-conjugated Annexin V (green) and Ethidium Homodimer III 
(red), and Hoechst 33342 (blue). Results obtained when viewed under blue filter 
showed no DNA fragmentation for all treatments except for staurosporine (0.5µM) 
and pro-domain.  In these two treatments, the chromatins of the apoptotic cells are 
visibly fragmented and condensed (white arrows). Photomicrographs are shown in 
x400 magnification and representative of 3 independent experiments, performed in 
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Fig. 4.7A: Determination of cell death using (i) LDH assay and (ii) caspase 
assay. PC12 cells were assessed for cell death via two assays after treatment (16-
18h) with conditioned media from CHO stable transfectants (mature NGF, pro (R/G) 
NGF and pro-domain). Mature NGF represented by F1 and F6; pro R/G NGF 
represented by M36 and M38 and pro-domain by S2 and S7.  (i) LDH assay showed 
that both mature NGF and pro (R/G) NGF have significantly lower death as 
compared to pro-domain.  ANOVA was done in relation to untreated control and *: 
p-value < 0.01. (ii) Caspase assay showed that both mature NGF and pro (R/G) NGF 
have significantly lower caspase activity as compared to pro-domain. ANOVA was 


















































In addition, the decrease in caspase activity for both mature NGF (F1 and F6) and 
pro NGF (R/G) NGF were observed to be 2-fold lower than the control, while that of  
pro-domain (S2 and S7) was higher than the control (Fig. 4.7Aii). Based on the 
results obtained from LDH, caspase assay and Hoechst staining (fluorescent 
microscopy), pro-domain was shown to cause cell death via apoptosis.  
 
4.4.4  Detection of oligonucleosomal DNA fragmentation 
In addition to the previous experiments, one of the hallmarks of apoptosis is the 
internucleosomal cleavage of DNA (Wyllie, 1980). PC12 cells were treated with 
conditioned media from CHO containing either mature NGF (F1 and F6) or pro 
(R/G) NGF (M36 and M38) or pro-domain (S2 and S7) for 16-18h and DNA 
extracted for determination of the occurrence of DNA fragmentation. Cells treated 
with staurosporine (0.5µM and 1µM) for 16-18h were used as positive controls. 
Oligonucleosomal fragmentation was observed in cells treated with pro-domain (S2 
and S7) and STS (0.5µM and 1µM). In addition, cells treated with CHO media alone 
had a slight amount of fragmentation, most probably due to the serum-free media. 
On the contrary, no DNA fragmentation was observed in mature NGF (F1 and F6) 
and pro (R/G) NGF (M36 and M38; Fig. 4.7B). Hence, pro-domain caused DNA 
fragmentation by apoptosis; while both mature NGF and pro (R/G) protected the 
cells from the slight apoptosis due to the serum-free medium.  
 
4.4.5  Inhibition by caspase-3-specific inhibitor 
Since pro-domain caused cell death by apoptosis, it was of interest to determine 
whether it was mediated by caspase. PC12 cells were pretreated with 100µM of 










Fig. 4.7B: Treatment with CHO media containing mature NGF/pro (R/G) 
NGF/ pro-domain or STS treatment. PC12 cells were seeded in 6-well plates and 
exposed to CHO media containing mature NGF (F1 and F6) or pro (R/G) NGF 
(M36 and M38) or pro-domain (S2 or S7) or STS (0.5µM or 1µM) at 37°C for 16-
18h. The control was cells in CHO media alone. DNA was isolated from the cells 
and electrophoresed on a 1% agarose gel. The DNA from S2, S7 and STS (0.5µM 
and 1µM) displayed a ‘ladder’ of short fragments, indicating that internucleosomal 
cleavage had taken place. There is a less intense ‘ladder’ in the CHO media, 
possibly due to it being in serum-free media. In contrast, cells treated with F1, F6, 
M36 and M38 appeared as a ‘smear’ with no visible fragmentation. Results are 












followed by treatment with conditioned media from CHO containing pro-domain 
(S2 and S7) and staurosporine (0.5µM) as a positive control. Fig. 4.7Ci showed that 
there was a significant decrease in LDH activity when incubated with inhibitor prior 
to treatment with both pro-domains and staurosporine (0.5µM). However, the 
reduction varied between pro-domains and staurosporine. Concurrent treatment with 
staurosporine and inhibitor had a 19% reduction of caspase activity, while S2 and S7 
had 10.3% and 14.7% reduction respectively. Similarly, the same trend was 
observed for caspase assay (Fig. 4.7Cii). The percentage of caspase-related death 
was inhibited by 64.2% for staurosporine, while S2 and S7 had 26% and 36.4% 
respectively. Hence, pro-domain caused apoptosis via caspase-mediated cell death.  
 
4.4.6  Real-time PCR analysis  
PC12 cells were treated with CHO conditioned media containing mature NGF, pro 
(R/G) NGF and pro-domain for 16-18h. The total RNA was extracted and gene 
expression pattern of four genes (TrkA, p75NTR, sortilin and bcl-2) were quantitated 
by real-time PCR (Fig. 4.8A). Neurotrophin precursors (e.g. NGF and BDNF) are 
known to induce neuronal apoptosis via activation of a receptor complex of p75NTR 
and sortilin (Kaplan and Miller, 2004). Hence, apart from the NGF receptors (TrkA 
and p75NTR), sortilin and bcl-2 (pro-survival gene) were also investigated. TrkA and 
p75NTR were upregulated upon treatment with both mature and pro (R/G) NGFs, 
while downregulated with pro-domain and staurosporine treatments. Bcl-2, was only 
upregulated for both pro-domain and staurosporine treatment. Hence, these two 
treatments may have caused cell death, leading to a compensatory mechanism for 
the cell to survive. Sortilin gene was downregulated in all treatments and all results 




Fig. 4.7C: Inhibition by caspase-specific inhibitor (DEVD-CHO). PC12 cells 
were pretreated with caspase3-specific inhibitor (DEVD-CHO) at 100µM for 2 
hours prior to treatment with conditioned CHO media from pro-domain (S2 and S7) 
for 16-18h, staurosporine (0.5µM) was used as a positive control. The values are 
expressed as a percentage to staurosporine-treated ± SEM and data points are means 
of 3 independent experiments, performed in triplicates. (i) LDH assay showed both 
pro-domain (S2 and S7) are decreased when treated concurrently with DEVD-CHO 
with #: p < 0.05 and *: p < 0.01 by unpaired Student’s t-test. (ii) Caspase assay 
showed a greater decrease than LDH in death due to pro-domain (S2 and S7) on 
PC12 cells when treated concurrently with DEVD-CHO. P-value in relation to 



































































Fig. 4.8A: Quantitative real-time PCR analysis via SYBR Green assay. The 
RNA from the treated PC12 cells was used to study the expression of four genes: 
TrkA, p75NTR, Sortilin and Bcl-2. PC12 cells were treated with either conditioned 
media from CHO cells (mature NGF, pro (R/G) NGF and pro-domain) individually 
or staurosporine (0.5µM) for 16-18h. Values are expressed as ± SEM, experiments 











































4.4.7  Western blot analysis of NGF receptor proteins 
Western blot analysis of PC12 cells treated individually with CHO conditioned 
media containing mature NGF, pro (R/G) NGF or pro-domain for 15min showed 
TrkA to be highly phosphorylated with mature NGF, followed by pro (R/G) NGF 
and pro-domain (Fig. 4.8B). Recombinant sputa NGF (200ng/ml) was used as a 
positive control. Hence, both mature and pro (R/G) NGFs caused an activation of 
TrkA receptors in a similar manner as sputa NGF, with an increased production of 
the mature gp140trkA receptors. Apart from this, western blot analysis was done on 
PC12 cells treated individually with CHO conditioned media containing mature 
NGF, pro (R/G) NGF or pro-domain for 16-18h.  
Treatment with mature NGF caused a greater increase in both mature (gp140trkA) 
and precursor (gp110trkA) TrkA, when compared to pro (R/G) NGF (Fig. 4.8C). 
However, mature NGF treatment caused a lesser increase in p75NTR expression when 
compared to pro (R/G) NGF treatment. Treatment with pro-domain caused an 
increase in p75NTR protein and minimal level of TrkA (gp110 and gp140). The 
presence of TrkA will activate the pro-survival pathway and together with p75NTR 
form the high-affinity complex with NGF (Roux and Barker, 2002). However, once 
it is absent or minimal, the apoptotic pathway of p75NTR will predominate, as 
observed in pro-domain treatment.   Sortilin expression is relatively the same across 
the three treatments (mature NGF, pro (R/G) NGF and pro-domain). Beta-actin was 
used an internal control to show equal loading of samples (Fig. 4.8C). In addition, 









Fig. 4.8B: Activation of TrkA receptor as determined by western blot analysis.  
PC12 cells were treated with conditioned CHO media containing mature NGF, pro 
(R/G) NGF and pro-domain, as well as a positive control: sputa NGF (200ng/ml) for 
15min and the total protein extracted. Equal amount of protein from each treatment 
was separated on a 10% SDS/PAGE gel and subsequently blotted onto nitrocellulose 
membrane. (i) Phosphorylated TrkA (gp140 and gp110) were detected using 
monoclonal anti-phosphotyrosine antibody. The same membrane was stripped and 
probed with anti-TrkA and anti-beta-actin antibodies. (ii) Ratios of the 























































Fig. 4.8C: Receptor protein expressions after treatment with conditioned CHO 
media containing mature NGF, pro (R/G) NGF and pro-domain. PC12 cells 
were treated for 16-18h and the total protein extracted. Equal amount of protein 
were separated on a 10% SDS/PAGE gel and subsequently blotted onto 
nitrocellulose membrane.  (i) Membrane was probed with anti-TrkA, anti-p75 and 
beta-actin antibodies. It was later stripped and probed with anti-sortilin antibodies as 
it is about 100kDa, similar to TrkA (110kDa). Beta-actin was used to as a internal 
control. (ii) Relative fold change in protein expression compared to cell treated with 
CHO media alone were measured by by densitometry. Western blot analysis showed 
that pro-domain caused a significant reduction in TrkA (gp110 and 140). Values are 
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4.4.8  Specific inhibition of receptor proteins by antibodies 
PC12 cells were incubated with antibodies specific to TrkA, p75NTR and sortilin 
separately for 4h at 4°C prior to treatment with condition CHO media containing 
mature NGF or pro (R/G) NGF or pro-domain for a further 16-18h at 37°C. 
Concentration of antibodies for TrkA and p75NTR was 2µg/ml, while that for sortilin 
was 1µg/ml. The following day, the number of neurites was counted and both MTT 
and LDH assays performed. Under normal conditions, only mature NGF and pro 
(R/G) NGF would produce neurites and pro (R/G) NGF produced 2-fold less than 
mature NGF (Fig. 4.9A). In addition, inhibition by both TrkA and p75NTR antibodies 
reduced the number of neurites drastically for both mature and pro (R/G) NGFs 
treatments. A combination of antibodies to both p75NTR and sortilin also caused a 
reduction in the number of neurites (Fig. 4.9A). Inhibition of sortilin receptors alone 
has no effect on neurite outgrowth for both mature and pro (R/G) NGFs treatments. 
MTT viability assay was used to determine the effect of both mature and pro (R/G) 
NGFs (pro-survival) with antibodies, while LDH assay for pro-domain (apoptotic).  
LDH assay showed that concurrent treatment with all the three antibodies (anti-
TrkA, p75NTR and sortlin) and pro-domain led to a decrease in the cytotoxic effect 
(Fig. 4.9B).  MTT assay showed that inhibition by anti-TrkA did not cause any 
significant change for all treatments; however, anti-p75NTR caused a reduction in cell 
viability in both mature and pro (R/G) NGFs treatments (Fig. 4.9C).  
 
4.5  Oxygen-glucose deprivation (OGD) of PC12 cells  
Ischemic stroke causes a significant amount of cell damage resulting from an 
insufficient supply of glucose and oxygen to brain tissue (Lipton, 1999). PC12 cells 









Fig. 4.9A: Inhibition of receptors by specific antibodies and its effect on neurite 
outgrowth. PC 12 cells were incubated with anti-TrkA (2µg/ml), anti-p75NTR 
(2µg/ml) and anti-sortilin (1µg/ml) antibodies separately for 4h at 4°C. Antibodies 
were used in excess. In addition, a combination of anti-p75NTR and anti-sortilin was 
used. This was followed by incubation with conditioned CHO media containing 
mature NGF, pro (R/G) NGF and pro-domain for 24h at 37°C. Both mature and pro 
(R/G) NGFs have their number of neurites significantly reduced upon addition of 
antibodies specific to p75NTR and TrkA. ANOVA was done in relation to the 















































Fig. 4.9B: Inhibition of receptors by specific antibodies and its effect on cell 
death by LDH assay. PC 12 cells were incubated with anti-TrkA (2µg/ml), anti-
p75NTR (2µg/ml) and anti-sortilin (1µg/ml) antibodies separately for 4h at 4°C. 
Antibodies were used in excess. In addition, a combination of anti-p75NTR and anti-
sortilin was used. This was followed by incubation with conditioned CHO media 
containing mature NGF, pro (R/G) NGF and pro-domain for 24h at 37°C. Results 
are representative of triplicate experiments and expressed as LDH absorbance . 

















































Fig. 4.9C: Inhibition of receptors by specific antibodies and its effect on cell 
death by MTT viability assay. PC 12 cells were incubated with anti-TrkA 
(2µg/ml), anti-p75NTR (2µg/ml) and anti-sortilin (1µg/ml) separately for 4h at 4°C. 
Antibodies were used in excess. In addition, a combination of anti-p75NTR and anti-
sortilin was used. This was followed by incubation with conditioned CHO media 
containing mature NGF, pro (R/G) NGF and pro-domain for 24h at 37°C. Results 
are representative of triplicate experiments and expressed as MTT absorbance . 
ANOVA was done in relation to the untreated control and *: p-value < 0.01 and #: 






































neuronal cell death after ischemic insult to develop potential neuroprotective agents 
(Abu-Raya et al., 1993).  In addition, they have also been employed to study the 
mechanisms of neuronal survival after ischemic conditions (Abu-Raya et al., 1999; 
Tabakman et al., 2002). Hence, PC12 cells were used as an in vitro model of 
ischemia to decipher the effects of the mature NGF or pro (R/G) NGF or pro-
domain.  
The whole procedure of the oxygen-glucose deprivation experiment is illustrated in 
Figure 4.10Ai. Prior to induction of OGD, PC12 cells were seeded at a density of 2 
x 105 cells/well of 24-well plate with complete DMEM. For the induction of OGD, 
cells were washed twice with freshly nitrogen-saturated, serum-free DMEM without 
glucose (0.3ml) and placed in the anaerobic chamber. The serum free DMEM 
without glucose was saturated with nitrogen by bubbling nitrogen gas into the media 
for 30min at 37°C. The plates were later placed in the 95% N2/5% CO2 chamber, the 
chamber was flushed for 10min at a flow-rate of 3L/min. A constant flow of 
nitrogen was maintained throughout the experiment. Sister plates containing serum-
free DMEM with glucose were placed in 95% O2/5%CO2 incubator. After OGD 
treatment, media was changed to serum-free DMEM for a further 24 hours for 
reperfusion and MTT assay.  
MTT assay is based on the ability of viable cells to reduce MTT (C, N-diphenyl-
N’4-5-dimethyl thiazol-2-yl tetrazolium bromide) to insoluble colored formazan 
crystals, which can be detected spectrophotometrically. PC12 cells were exposed to 
various time interval of OGD and cell viability was determined by MTT assay (Fig. 
4.10Aii).  A time-dependent experiment was used to determine the length of OGD 














Fig. 4.10A: Oxygen-glucose deprivation (OGD) experiment. (i) Time scale for 
(OGD) experiment. (ii) Time-dependent of OGD exposure for PC12 cells. Cell 
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4.5.1  Classification of the mode of cell death  
Before the investigation in the role of mature NGF, pro (R/G) NGF and pro-domain, 
it is important to clearly define the hallmark features between the two types of cell 
death- apoptosis and necrosis. Apoptosis was originally described as a progress that 
serves to eliminate damaged cells in a multi-cellular organism without affecting 
neighbouring cells by inflammatory reactions, i.e., without the release of 
intracellular material from the dying cells into the extracellular space (Saunders, 
1966). This can be achieved by maintaining the integrity of the cell membrane while 
packaging the dying cells into smaller bodies and triggering the phagocytic activity 
of the neighbouring cells. On the other hand, necrosis is characterized by the loss of 
membrane integrity and spillage of enzymes and cellular debris that initiate an 
inflammatory reaction. This is an early event that may be accompanied by features 
characteristic of apoptosis, such as DNA fragmentation. However, the final goal of 
avoiding detrimental effects on neighbouring tissue or cells is not achieved by 
necrosis (Dartsch et al., 2002).  
Therefore, two points are crucial for the distinction between apoptosis and necrosis. 
Firstly, apoptosis is characterized by the occurrence of DNA fragmentation, nuclear 
changes or other hallmarks with concomitant maintenance of membrane integrity. 
Secondly, it involves the exposure of phosphatidylserine which acts as the signal for 
phagocytic elimination of the apoptotic bodies. All these morphological changes 
take place downstream to caspases and caspase activation is also a pre-requisite. On 
the contrary, necrosis is cell death characterized by the early loss of membrane 
integrity which may or may not show traits like DNA fragmentation or caspase 




obviously absent in standard cell culture experiments and even apoptotic cells will 
eventually lose their membrane integrity.   
 
4.5.2  Cell morphology with OGD and CHO conditioned media 
After PC12 cells were exposed to OGD, they were treated with conditioned CHO 
media containing either mature NGF, or pro (R/G) NGF or pro-domain. Both mature 
NGF and pro (R/G) NGF were still capable of forming neurites, with a larger 
percentage for mature NGF treatment (Fig. 4.10Bi). The cells were later stained with 
three dyes: Annexin V (green), Ethidium Homodimer III (red) and Hoechst 33342 
(blue). In Fig. 4.10Bii, cells treated with both mature and pro (R/G) NGFs had a 
reduction in the number of cells stained green and red (both apoptotic and necrosis). 
The number of green-stained cells was in this decreasing order: pro-domain > pro 
(R/G) NGF > mature NGF. When stained with Hoechst (blue; Fig. 4.10Biii), there 
was no significant change in DNA condensation for all treatments, apart for 
treatment with pro-domain with DNA condensation.  
 
4.5.3  Assessment of cell death by lactate dehydrogenase (LDH) and 
 caspase assay for cells exposed to OGD 
In Fig. 4.10Ci, LDH assay showed a decrease in cell death for both mature NGF (F1 
and F6) and pro (R/G) NGF (M36 and M38), while no significant change for pro-
domain (S2 and S7). However, when assayed for caspase activity (Fig. 4.10Cii), 
both mature and pro (R/G) NGF were reduced significantly, while pro-domain 
increased in caspase activity. Hence, both mature and pro (R/G) NGF were able to 













Fig. 4.10Bi: Cell morphology of PC12 cells exposed to OGD and post-treated 
with conditioned CHO media with NGF proteins. After exposure to OGD, PC12 
cells were treated with conditioned CHO media containing mature NGF, pro (R/G) 
NGF and pro-domain for 16-18h. Neurites were observed for the mature and pro 
(R/G) NGF treatments and the cells appeared to be healthy, while treatment with the 
pro-domain resulted in more rounded dead cells as compared to OGD alone.  
Photomicrographs were obtained at x200 magnification and are representative of 3 
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Fig. 4.10Bii: Annexin V/ Ethidium Homodimer III staining of PC12 cells 
exposed to OGD and post-treated with conditioned CHO media with NGF 
proteins. After treatment, the PC12 cells were stained with 3 dyes: FITC-conjugated 
Annexin V (green) and Ethidium Homodimer III (red), and Hoechst 33342 (blue) 
and viewed using green filter. The extent of cell damage was in this order: mature 
NGF < pro (R/G) NGF < pro-domain. Both mature and pro (R/G) NGFs were able 
to rescue the cells from the ischemic (OGD) treatment. Photomicrographs were 
obtained at x200 magnification and are representative of 3 independent experiments, 
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Fig. 4.10Biii: Hoechst 33342 staining of PC12 cells after exposure to OGD and 
post-treated with conditioned CHO media with NGF proteins. After treatment, 
the PC12 cells were stained with 3 dyes: FITC-conjugated Annexin V (green) and 
Ethidium Homodimer III (red), and Hoechst 33342 (blue) and viewed using the blue 
filter. With Hoeshst 33342 staining, the chromatins of the apoptotic cells with pro-
domain are visibly fragmented and condensed (arrows). Nuclei of cells treated with 
mature and pro (R/G) NGFs look normal. Photomicrographs were obtained at x400 
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Fig. 4.10C: Determination of cell death of OGD-exposed PC12 cells. Two assays 
were used: (i) LDH assay and (ii) caspase assay. PC12 cells were assessed for cell 
death after exposure to OGD and post-treatment (16-18h) with conditioned CHO 
media containing mature NGF (F1 and F6), pro (R/G) NGF (M36 and M38) and 
pro-domain (S2 and S7).  (i) LDH assay showed that both mature NGF and pro 
(R/G) NGF have significantly lower death as compared to pro-domain.  ANOVA 
was done in relation to untreated control and *, p-value < 0.01. (ii) Caspase assay 
showed that both mature NGF and pro (R/G) NGF have significantly lower caspase 
activity as compared to pro-domain. ANOVA was done in relation to untreated 
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4.5.4  Real-time PCR analysis for cells exposed to OGD 
After OGD exposure, PC12 cells were treated with CHO conditioned media 
containing mature NGF, pro (R/G) NGF and pro-domain for 16-18h. The total RNA 
was extracted and used to check for genes regulated upon treatment. The eight genes 
were TrkA, p75NTR, sortilin, NF-κB, IκB, Bcl-2, Bcl-XL and Bax (Fig. 4.10D). By 
studying the regulation of these genes by real-time PCR, the possible pathway 
activated by mature NGF, pro (R/G) NGF and pro-domain can be determined.  NGF 
receptors (Trk A and p75) are highly expressed with mature NGF treatment and 
decreased with pro (R/G) NGF and pro-domain. Sortilin expression is only increased 
by pro-domain treatment, possibly activating the apoptotic pathway. This is 
supported by upregulation in both NFκB and IκB expression, NFκB is a 
transcription factor important for cell survival. However, the high increased in IκB 
levels may indicate the cell’s compensatory mechanism to survival. This is 
supported by the regulation of pro-survival genes (Bcl-2 and Bcl-XL), they are 
increased in pro-domain, but decreased for both mature and pro (R/G) NGF. While, 
the apoptotic Bax is decreased only with pro-domain treatment. 
 
4.6  Staurosporine-induced apoptosis on PC12 cells 
The protein kinase C inhibitor staurosporine is widely used to induce apoptosis in 
neuronal and nonneuronal cells (Krohn et al., 1998, 1999). In comparison with other 
insults like the exposure to glutamate or ischemia-like conditions where both types 
of cell death, apoptosis and necrosis, could be observed (Cheung et al., 1998), 
staurosporine selectively induces apoptosis including the activation of caspases, the 
release of cytochrome c from the mitochondria into the cytosol and the activation of 









Fig. 4.10D: Quantitative real-time PCR (SYBR green) analysis of PC12 cells 
exposed to OGD. Total RNA from the treated PC12 cells was used to study the 
expression of eight genes: TrkA, p75NTR, sortilin, NFκB, IκB, Bcl-2, Bax and Bcl-
XL. PC12 cells were treated with conditioned CHO media containing mature NGF 
(F1 and F6), pro (R/G) NGF (M36 and M38) and pro-domain (S2 and S7) 
individually for 16-18h. Values are expressed as ± SEM, experiments performed in 



























































staurosporine-induced apoptosis and accessed whether the NGF proteins [mature 
NGF, pro (R/G) NGF and pro-domain] could reduce apoptosis. 
 
4.6.1  Cell morphology with staurosporine 
PC12 cells were treated with 0.5µM of staurosporine (STS) concurrently with CHO 
media containing mature NGF (F1 and F6), pro (R/G) NGF (M36 and M38) and 
pro-domain (S2 and S7). More neurites were seen which appeared longer, upon 
treatment with mature NGF, it seems like the cells were not affected with the STS in 
the media. Pro (R/G) NGF had a fewer neurites, but cells still appeared healthy. 
However, treatment with pro-domain increased the amount of rounded, dead cells as 
compared to STS alone. Hence, only mature NGF and pro (R/G) NGF was able to 
rescue the cells from staurosporine-induced apoptosis (Fig. 4.11Ai). 
The treated PC12 cells were later stained with three dyes (Annexin V, Ethidium 
Homodimer III and Hoechst 33342). In Fig. 4.11Aii, the cells were viewed for 
Annexin V (green) and Ethidium Homodimer III (red) labeling, when merged 
together, the nucleus appeared orange. When treated with STS alone, the number of 
apoptotic cells (green) was comparable to with CHO media, indicating that the 
conditioned media was neutral. However, when cells were exposed to treatment with 
mature NGF, the number of cells stained green (apoptotic) was greatly reduced. The 
number of green-stained cells was in this order: STS = pro-domain > pro (R/G) NGF 
> mature NGF. Hence, only mature NGF was able to protect the cells from STS. 
In Fig. 4.11Aiii, cells were viewed for Hoechst 33342 (blue) labeling. Treatment 
with STS resulted in a condensation of the DNA in the nuclei, as indicated by white 












Fig. 4.11Ai: Cell morphology of staurosporine (STS)-induced apoptosis on 
PC12 cells when treated concurrently with conditioned CHO media with 
overexpressed NGF proteins. PC12 cells were treated concurrently with STS 
(0.5µM) and conditioned CHO media containing mature NGF, pro (R/G) NGF and 
pro-domain for 16-18h. Staurosporine treatment caused neurites and hence no 
comparison will be made to the quantity of neurites. Treatment with mature and pro 
(R/G) NGFs, the cells looked healthy, while treatment with the pro-domain resulted 
in more rounded dead cells as compared to STS alone.  Photomicrographs were 
obtained at x200 magnification and are representative of 3 independent experiments, 
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Fig. 4.11Aii: Annexin V/ Ethidium Homodimer III staining of PC12 cells 
treated concurrently with staurosporine (STS) and conditioned CHO media 
with NGF proteins. After treatment, the PC12 cells were stained with 3 dyes: 
FITC-conjugated Annexin V (green) and Ethidium Homodimer III (red), and 
Hoechst 33342 (blue) and viewed using green filter. Staining with Annexin V and 
Ethidium Homodimer III showed the extent of cell damage to be of this order: 
mature NGF < pro (R/G) NGF < pro-domain. Only mature NGF was able to rescue 
the cells from the toxic staurosporine treatment. Photomicrographs were obtained at 
x200 magnification and are representative of 3 independent experiments, performed 
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Fig. 4.11Aiii: Hoechst 33342 staining of PC12 cells treated concurrently with 
staurosporine (STS) and conditioned CHO media with NGF proteins. After 
treatment, the PC12 cells were stained with 3 dyes: FITC-conjugated Annexin V 
(green) and Ethidium Homodimer III (red), and Hoechst 33342 (blue) and viewed 
using blue filter. With Hoeshst 33342 staining, the chromatins of the apoptotic cells 
are visibly fragmented and condensed (arrows). Control cell nuclei look healthy. 
Photomicrographs were obtained at x400 magnification and are representative of 3 
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pro (R/G) NGF > mature NGF. Similarly, only mature NGF was able to protect the 
cells from STS. 
 
4.6.2  Assessment of cell death by lactate dehydrogenase (LDH) assay 
PC12 cells were treated concurrently with staurosporine (STS; 0.5µM) and the CHO 
conditioned media containing mature NGF (F1 and F6), pro (R/G) NGF (M36 and 
M38) and pro-domain (S2 and S7) for 16-18h. The media was collected, deprived of 
cells by centrifugation and assayed for LDH activity. The LDH activity was 
significantly decreased for mature NGF (F1 and F6) and increased for pro-domain 
(S7; Fig. 4.11B). This result corresponded to the cell morphology observed by three-
dye staining in the section above (section 4.6.1), the mature NGF (F1 and F6) 
protected against staurosporine-induced death, while pro-domain (S2 and S7) 






































Fig. 4.11B: Determination of cell death using LDH assay. PC12 cells were treated 
concurrently with staurosporine (0.5µM) and CHO conditioned media containing 
mature NGF (F1 and F6), pro (R/G) NGF (M36 and M38) and pro-domain (S2 and 
S7) for 16-18h. Media was collected and assayed for LDH activity. ANOVA was 
done in relation to staurosporine (0.5µM) and *: p-value < 0.01 and #: p-value < 












































































Effect of nPLA2 on ischemia and 
 its possible mechanism of action 
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5.1  Introduction 
 
Phospholipase A2 (PLA2) constitutes a superfamily of enzymes that catalyze the 
hydrolysis of the phospholipids sn-2 ester bond, thereby generating a free fatty acid 
and lysophospholipid. Snake venoms are rich sources of PLA2 enzymes and often 
contain a large number of isozymes. There are currently several hundred snake 
venom PLA2 enzymes that have been purified and characterized. They share similar 
catalytic function and properties of hydrolyzing phospholipids. However, in contrast 
to mammalian PLA2 enzymes, most snake venoms are toxic and induce a wide 
spectrum of pharmacological effects by interfering with the normal physiological 
processes. Among these pharmacological effects, only neurotoxic, myotoxic and 
anticoagulant have been well-studied (Kini, 1997).  
Stroke is the third cause of death in Europe and North America after heart disease 
and cancer and non-fatal strokes are the commonest cause of disability. Brain 
ischemia occurs when the supply of glucose and oxygen to the brain is disrupted. 
Glutamate excitotoxicity plays a critical role in brain ischemia, which in turn, causes 
depolarization of neurons and the release of large amount of glutamate. 
Approximately about 3-4 minutes after an ischemic attack, the concentration of 
glutamate increases by up to 10 to 100-fold (Choi, 1992; Nagasawa and Kogure, 
1989). This is followed by a rise in intracellular calcium, which initiates a whole 
cascade of biochemical changes that eventually leads to cell necrosis and apoptosis. 
These in turn, lead to later consequences including cerebral edema and inflammation 
(Choi, 1988), which can further enhance the damages.  
Reperfusion itself can cause damage by the production of free radicals and other 
reactive species when the oxygenation is restored. The secondary injury usually 
takes a few hours to develop and this window of time has the potential for 
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therapeutic intervention. Neuroprotective treatments have been investigated through 
the use of compounds that (a) reduce the intracellular accumulation of calcium 
(Choi, 1992; Kristian and Siesjo., 1998), (b) inhibit free radical formation (Zhao et 
al., 1994), and (c) activate neurotrophic factors such as nerve growth factor (NGF; 
Hsu et al., 1993) and brain-derived neurotrophic factor (BDNF; Schabitz, et al., 
1997). However, all these drugs used presently for stroke therapy are not 
convincingly successful and hence there is a need for new therapeutic strategies.  
Many aspects of ischemic neurodegeneration have been demonstrated in animal 
models; however, they represent a complex environment to dissect the cellular and 
molecular mechanisms involved in ischaemic neurodegeneration. Although cell 
culture systems are further from in vivo situation, they represent a more defined 
microenvironment. Most studies have used mixed neuronal and glial cultures to 
investigate the effects of oxygen and/or glucose deprivation (Goldberg et al., 1987; 
Rothman, 1988; Monyer et al., 1989; Swanson and Choi, 1993), but the regional 
organization and neuronal connectivity are lost in most mixed cultures.  On the 
contrary, these are substantially retained in organotypic hippocampal cultures 
(Gahwiler, 1984; Stoppini et al., 1991). In addition, organotypic hippocampal 
cultures retain a similar glutamate receptor population as those found in adult 
animals (Bahr et al., 1995).  
The study of the agonist properties of glutamate is further complicated by the brain’s 
high affinity, high capacity transport system for glutamate. In brief, direct injection 
of glutamate into the brain is not toxic (Mcbean and Roberts, 1985). This problem 
can be overcome by using in vitro systems, including brain slices (i.e. organotypic 
hippocampal culture) and cultures, in which higher concentrations of glutamate can 
be maintained and the effect of the transport can be overcome. Glutamate receptors 
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that mediate these injuries (e.g. cerebral ischemia, head trauma and prolonged 
seizures) are divided into a number of types based on their selectivity to different 
agonists. As the endogenous ligand, glutamate activates all these receptors, 
including the NMDA receptor family, the AMPA/kainate receptor family and the 
metabotrophic (mGluR) receptor family (Vornov et al., 1995).  
Since glutamate-mediated mechanisms play an integral role in the generation of 
ischemic damage, organotypic hippocampal cultures were used to investigate the 
effect of PLA2 on ischemia and its possible mechanism of action. This study will be 
divided into three main sections, effect of nPLA2 (a neutral phospholipase A2 from 
Naja sputatrix) on organotypic hippocampal cultures when exposed to 1) ischemic 
conditions (i.e. oxygen-glucose deprivation; OGD); 2) glutamate (pretreatment, 
concurrent and post-treatment) and 3) specific glutamate receptor agonists (i.e., 
NMDA, KA, AMPA and mGluRs). 
 
5.2  Effect of NGF and PLA2 on PC12 cells exposed to OGD   
  conditions 
Two components (NGF and PLA2) from the venom of Naja sputatrix were tested for 
their ability to protect against ischemic conditions using PC12 cells and organotypic 
hippocampal culture models. PC12 cells were post-treated with either NGF (mouse 
and sputa) at 200ng/ml or PLA2 (1µg/ml or 2µg/ml) for 16-18h after subjecting to 
hypoxia (lower oxygen) conditions. Both sputa NGF (200ng/ml) and PLA2 (1µg/ml 
and 2µg/ml) caused an increase in cell survival (Fig. 5.1A). Similarly, PC12 cells 
when subjected to ischemic conditions (OGD) for 1.5h and both sputa NGF 
(200ng/ml) and PLA2 (2µg/ml) protected the cells as seen by MTT assay (Fig. 




Fig. 5.1: Effect of PC12 cells and organotypic hippocampal cultures with NGF 
and PLA2. PC12 cells were exposed to (A) hypoxia and (B) OGD conditions and 
post-treated with mouse NGF and sputa NGF (200ng/ml) and PLA2 (1µg/ml and 
2µg/ml). MTT assay showed that sputa NGF and PLA2 caused increase in survival 
for hypoxia and OGD condition. (C) LDH assay on media from organotypic 
hippocampal cells. LDH activity is reduced for both PLA2 and sputa NGF 
(200ng/ml) treatments. Values obtained are expressed as ± SEM. #: p-value < 0.05 
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2µg/ml) on organotypic hippocampal cultures exposed to OGD showed a decrease 
in LDH activity (Fig. 5.1C). Hence, both sputa NGF (200ng/ml) and PLA2 (1 and 
2µg) have shown to protect the cells from both hypoxia and OGD.  
 
5.3  Oxygen-glucose deprivation- a model for ischemia 
Fourteen-day old organotypic hippocampal cultures were placed in serum-free 
media for 16h prior to OGD treatment. Before initiation of treatment, cultures were 
placed in basal MEM (Section 2.1.5) containing 5µg/ml PI for 3hours and imaged. 
Any cultures in which PI fluorescence was detected at this time were excluded from 
further study. Simulated ischemia (combined hypoxia and hypoglycemia) was 
induced by placing the cultures in basal MEM (devoid of glucose) containing 
5µg/ml PI which had previously been saturated with 95%N2/5%CO2. The culture 
was then placed in an air-tight chamber equipped with inlet and outlet valves and 
95%N2/5%CO2 and was flushed with 95%N2/5%CO2 for 10min to ensure maximal 
removal of oxygen. The chamber was maintained at 37°C throughout the whole 
experiment.  
After OGD treatment, cultures were returned to glucose-containing basal MEM and 
placed in cell culture incubator for further 24h. All cultures were imaged 24h later. 
Regional patterns of neuronal injury in the organotypic cultures were observed by 
performing all experiments in the presence of propidium iodide, a polar, fluorescent 
dye that does not stain cells with normal membrane integrity. However, once the 
membrane is injured, the dye enters the cells and binds to nucleic acids and 
accumulates, rendering the cell brightly fluorescent (Vornov et al., 1994).  
In the initial experiments, the time-dependent curve for OGD incubation was 
established using cytotoxicity assay- lactate dehydrogenase assay (LDH). 3 plates of 
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culture were placed in the chamber for varied time interval (from 1h to 3h) and the 
medium was collected and assayed for LDH activity. Fig. 5.2 showed that 1h OGD 
treatment caused 27.1% death, while 2h OGD treatment caused about 98% death. 
Hence, about 1.5h OGD would cause approximately 50-60% death and this timing 
was used to access the effect of PLA2 on OGD-treated cultures.  
 
5.4  Effect of PLA2 on cultures exposed to OGD  
For subsequent experiments, PLA2 will be referred as: 0.5µg/ml = 0.38µM; 1µg/ml 
= 0.75µM and 2µg/ml = 1.5µM. The results of the concurrent treatment of PLA2 
(0.75µM and 1.5µM) and OGD showed that PLA2 (0.75µM) was able to rescue both 
CA1 and CA3 from OGD damage to about 58% and 94%, respectively (Fig. 5.3). 
However, PLA2 (1.5µM) was better at rescuing the hippocampal cultures from OGD 
damage. Its protection was ~95% and similar to the MK801 (antagonist for NMDA 
receptor). Hence, this dose of PLA2 (1.5µM) was used for subsequent experiments. 
Treatments with PLA2 (0.75µM and 1.5µM) and MK801 (0.19mM) only were non-
toxic to the cultures.  
 
5.5  Real-time quantitation of gene expression 
The expression of four genes (Homer, Bcl-2, Bcl-XL and Bax) was quantitated by 
real-time PCR to elucidate the possible mechanism of action of PLA2’s 
neuroprotection against the OGD damage (Fig. 5.4).   Specific primers were used for 
the SYBR green assay. The relative expression of each gene in cultures treated with 
either PLA2 (0.75µM or 1.5µM) or MK801 (0.19mM) was obtained after 
normalizing against an internal control (18S ribosomal RNA) and a calibrator, in 






Fig. 5.2: Time-course of oxygen-glucose deprivation (OGD) on hippocampal 
organotypic cultures.  Media from the cultures were collected and assayed for 
LDH activity. The percentage of death was calculated and the time needed to cause 
50% damage was determined. Time dependent manner of cell death of hippocampal 
organotypic cultures from 1-3 hours was carried out and 1.5h was fixed as 50% cell 
death. In subsequent experiments, the time of incubation for OGD was kept at 1.5h. 
Results are a representative of 4 independent experiments and values obtained are 
expressed as percentage of the maximum percentage of death (3h) ± SEM. #: p-
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Fig. 5.3: Effect on concurrent treatment of PLA2 on OGD-induced cell 
death. (A) PI fluorescence of treated groups and (B) corresponding percentage 
survival graphs. The percentage damage to the CA1 and CA3 neuronal cell fields 
are expressed as a percentage of area expressing fluorescence compared with the 
untreated control cultures and 1.5h OGD taken as maximum damage. Each point 
represents the mean ± SEM (n=8). #: p-value < 0.05 and *: p-value < 0.01 versus 
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Fig. 5.4: Quantitative gene analysis via SYBR Green assay. The total RNA was 
isolated from the treated samples and used to study the expression of five genes: 
NFκB, Homer, Bcl-2, Bcl-XL and Bax. Except for the Bax gene, the rest of the genes 
were upregulated with PLA2 and MK801 treatments. Each measurement was 
performed in triplicate and the data is a representative of duplicate experiments. 













































apoptotic genes (Bcl-2 and Bcl-XL) were both upregulated in all treatments, while the 
apoptotic gene (Bax) was downregulated in all treatments. The coupling of Homer 
with group I glutamate metabotrophic (mGluR) has been implicated in mGluR 
trafficking and clustering (Ango et al., 2000 and 2002). Expression of the Homer 
gene was upregulated in all treatments; PLA2 (dose-dependent) and MK801. Hence, 
upon treatment with PLA2 (1.5µM) or MK801 (0.19mM), the pro-survival genes 
(Bcl-2 and Bcl-XL) that also act by promoting cell survival are upregulated, while the 
pro-apoptotic gene (Bax) is downregulated. These genes, together with upregulation 
of the Homer gene, suggested that the addition of PLA2 into cultures when exposed 
to OGD, mediated an overall protective effect, acting via the mGluR pathway.   
 
5.6  Effect of concurrent PLA2 on glutamate-induced neuronal cell  
  death 
Fourteen-day organotypic cultures were prepared prior to treatment as described in 
section 5.3. 5mM glutamate was suggested by Elliott-Hunt et al. (2002) to cause 
significant and consistent levels of neurotoxicity; the survival rate of neurons for 
both CA1 and CA3 regions was approximately 40 ± 15%. In this study, a similar 
pattern was observed in with 5mM glutamate 30-50% damage for both CA1 and 3. 
Addition of 10mM glutamate resulted in total death, and was used as a positive 
control. No cell death was observed in the cultures using basal MEM alone.  
The specificity of this effect was confirmed with a specific inhibitor for the NMDA 
receptors (MK801) which prevented glutamate-induced neuronal cell death. The 
concentration was based on 625µg per adult rat; each rat has about 10ml of blood. 
Hence, for 1ml of basal medium 62.5µg of MK801 was used. In order to study the 
effect of PLA2 on glutamate-induced neurotoxicity, PLA2 was incubated 
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concurrently at concentrations of 0.38µM, 0.75µM and 1.5µM for 3h, together with 
5mM of glutamate for 3 hours. Figure 5.5 showed that at both concentrations of 
PLA2 (0.75µM and 1.5µM), concurrent treatment of PLA2 with 5mM glutamate 
have shown to protected CA3 dose-dependently, that is similar to protection by 
MK801. PLA2 (0.38µM) offered less protection than both PLA2 (0.75µM and 
1.5µM). PLA2 is not toxic to the hippocampal cultures. In fact, when PLA2 was 
tested against glutamate-induced (5mM) neuronal cell, results showed (Fig. 5.5) that 
PLA2 (0.75µM and 1.5µM) protected CA3 regions better than MK801 when added 
immediately after the 3h insult. 
 
5.7  Effect of post-treatment PLA2 on glutamate-induced neuronal  
  cell death 
Since a concurrent treatment of PLA2 was able to efficiently reduce the damage by 
glutamate (Section 5.6), it was tested further by post-treatment. Cultures were 
incubated with 5mM glutamate for 3 hours and post-treated with PLA2 at 0.38µM, 
0.75µM and 1.5µM for additional 24 hours. The cultures were later imaged and 
results shown in Figure 5.6. Post treatment with MK801 (0.19mM) and PLA2 
(0.38µM) were unable to protect the cultures from glutamate damage, while PLA2 
(0.75µM and 1.5µM) were still able to significantly protect the CA3 region from 
damage. Hence, this results showed that PLA2 (0.75µM and 1.5µM) were better than 
MK801, in reducing damage induced by glutamate.  
 
5.8  PLA2 and neuronal cell death by AMPA/KA/NMDA 
The principal excitatory transmitter in the central nervous system, glutamate, acts 
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Fig. 5.5: The effect of concurrent dose-dependent PLA2 on glutamate-induced 
neuronal cell death. (A) PI fluorescence of treated groups and (B) corresponding 
percentage survival graphs. Organotypic hippocampal cultures were incubated with 
MK801 (0.19mM) and various doses of PLA2 (0.38µM, 0.75µM and 1.5µM) 
separately and found to be non-toxic to the cultures. When treated concurrently with 
glutamate, PLA2 (0.38µM, 0.75µM and 1.5µM) was able to protect the CA3 region 
from glutamate damage. The damage of the CA1 and CA3 neuronal cell fields are 
expressed as a percentage of the area expressing fluorescence as compared with the 
untreated control cultures and 10mM glutamate was taken as maximum damage. 
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Fig. 5.6: The effect of post-treatment of dose-dependent PLA2 on glutamate-
induced neuronal cell death. (A) PI fluorescence of treated groups and (B) 
corresponding percentage survival graphs. Organotypic hippocampal cultures were 
incubated with MK801 (0.19mM) and various doses of PLA2 (0.38µm, 0.75µm and 
1.5µM) separately and found to be non-toxic to the cultures. When treated after 
glutamate insult, only PLA2 at 0.75µM and 1.5 µM concentrations were able to 
protect the CA3 region from glutamate damage. It was better than MK801. In 
subsequent studies, the concentration of PLA2 of 1.5µM was used. The damage of 
the CA1 and CA3 neuronal cell fields are expressed as a percentage of the area 
expressing fluorescence as compared with the untreated control cultures and 10mM 
glutamate was taken as maximum damage. Each point represents the mean ± SEM 



















respective classical glutamate receptor agonists: 2-amino-3-hydroxy-5-methyl-4-
isoxazole propionic acid (AMPA), kainic acid (KA) and N-methyl-D-aspartate 
(NMDA). The excitotoxic effects of glutamate and its agonists have been studied in 
various experiments in vivo (Nadler et al., 1978; Sheardown et al., 1990; Lees and 
Leong, 1993) and in vitro (Jensen et al., 1998) models. Together with glutamate 
receptor antagonists, they have provided evidence that activation of glutamate 
receptors plays a key role in various neurodegenerative diseases and conditions 
(Choi, 1992 and Dawson et al., 1995). The concentration of agonists (10µM AMPA, 
100µM KA and 20µM NMDA) were based on the 50% PI uptake from Kristensten 
et al. (2001). These agonists were concurrently treated with PLA2 (1.5µM) for 3h. 
Addition of 40µM NMDA has resulted in total death, and as such was used as a 
positive control. It is known that susceptibility of the different hippocampal 
subfields (CA1 and CA3) vary for different agonists. AMPA caused damage to both 
CA1 and CA3 regions, while KA and NMDA caused more damage to the CA3 and 
CA1, respectively. Figure 5.7 shows the effect of PLA2 (1.5µM) on hippocampal 
cultures when treated concurrently with the agonists. For the AMPA (10µM) 
treatment, the addition of PLA2 caused significant protection for both the CA1 and 
CA3 regions. While with KA (100µM) treatment, the addition of PLA2 provided 
protection to CA3 but no significant change to the CA1 region. The protection of 
PLA2 on NMDA-treated cultures was similar to that observed for glutamate-
mediated damage, i.e., protection for both CA1 and CA3 regions with PLA2.  Hence, 
the mechanism of action of PLA2 was most likely via the glutamate-NMDA 
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Fig. 5.7: The effect of PLA2 (1.5µM) and concurrent treatments with 
AMPA/KA/NMDA on hippocampal cultures. (A) PI fluorescence of treated 
groups and (B) corresponding percentage survival graphs. Organotypic hippocampal 
cultures were incubated with glutamate agonists (AMPA at 10µM; KA at 100µM 
and NMDA at 20µM) separately and also concurrently with PLA2 (1.5µM). PLA2 
(1.5µM) was able to reduce the damage by AMPA (both CA1 and CA3 region), KA 
(CA3 region) and NMDA (both CA1 and CA3 regions). The damage of the CA1 
and CA3 neuronal cell fields are expressed as a percentage of the area expressing 
fluorescence as compared with the untreated control cultures and 40µM of NMDA 
was taken as the maximum damage. Each point represents the mean ± SEM (n=8). 




















5.9  Effects of PLA2 with group I metabotropic glutamate receptors 
 (mGluRs)   
Apart from interacting with the above-mentioned ionotropic glutamate receptors, 
glutamate also interacts with metabotropic glutamate receptors (mGluRs). The role 
of ionotropic glutamate receptors in neuronal cell death following brain ischemia is 
well-established (Gill and Logde, 1997; McCulloch, 1991). Recent evidence 
suggests that mGluRs, which are G-protein coupled receptors, may provide an 
effective alternative approach for neuroprotection against ischemic nerve cell death 
(Kalda et al., 2000). Since glutamate toxicity is mediated by excessive activation of 
NMDA receptors, the role of mGluR will be studied in relation to NMDA toxicity. 
There are eight mGluR subtypes which have been divided into three major groups 
on the basis of sequence homology, signal transduction pathways and 
pharmacological sensitivities. The group I mGluR includes mGluR1 and mGLuR5; 
activation of these receptors causes the stimulation of phospholipase C, resulting in 
phosphoinositide (PI) hydrolysis and intracellular calcium mobilization (Pin and 
Duvoisin, 1995 and Schoepp et al., 1999). Since the PLA2 and mGluR are known to 
mobilize calcium ions for activity, there is a possibility of a cross-talk/relationship 
between them. To determine the possible involvement of group I mGluR in the 
protective property of PLA2, selective mGluR1 and mGluR5 agonists/ antagonists 
were utilized. To investigate the possible role of mGluR5 receptor, the mGluR5 
agonist (R, S)-2-chloro-5-hydroxyphenylglycine (CHPG) and antagonist 6-methyl-
2-(phenylethylnyl)-pyridine (MPEP) were used. CHPG has been shown to activate 
only mGluR5, but not mGluR1. MPEP is described as a selective non-competitive 
mGluR5 antagonist that acts by interacting with the transmembrane domains II and 
VI of mGluR5 receptor (Pagano et al., 2000), making it less sensitive to the 
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surrounding concentration of glutamate. At present, there is no specific agonist that 
activates mGluR1, hence a non-specific group I mGluR agonist, (S)-3,5-
dihydroxyphenylglycine (DHPG) that activates both mGluR1 and mGluR5 was 
used. As a comparison, selective antagonist of mGluR1,  
7-hydroxyiminocyclopropan[b]chromen-1a-carboxylic acid ethyl ester (CPCCOEt) 
was used. In this study, CP was used as a term to represent CPCCOEt. Cultures were 
treated with PLA2 (1.5µM) for 30min prior to group I mGluR agonist/antagonist 
(DHPG/CHPG/MPEP/CP; 10µM) application and subsequently together with PLA2 
(1.5µM) for further 2h, followed by a final 30min exposure to 50µM of NMDA. The 
treated cultures were then transferred to a fresh basal MEM containing 5µg/ml PI for 
further 24h. Control cultures were subjected to NMDA treatment, followed by a 
transfer to fresh basal MEM containing PI. Concurrent treatments of PLA2 (1.5µM) 
with mGluR agonists (DHPG or CHPG) resulted in protection at the CA1 region, 
while concurrent treatment of PLA2 (1.5µM) together with antagonist for mGluR5 
(MPEP) resulted in protection of both CA1 and CA3 regions (Fig. 5.8). Hence, the 
inhibition of mGluR5 did not block the protective effect of PLA2 (1.5µM). In 
support of this conclusion, the antagonist for mGluR1, CP, when added together 
with PLA2 (1.5µM) was not able to protect the cultures from NMDA damage, 
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Fig. 5.8: The effect of PLA2 (1.5µM) and concurrent treatments with glutamate 
metabotrophic agonist/antagonists (DHPG/CHPG/MPEP/CP) on hippocampal 
cultures. (A) PI fluorescence of treated groups and (B) corresponding percentage 
survival graphs. Cultures were treated with PLA2 (1.5µM) for 30min and later 
concurrently with the selective metabotrophic agonists/antagonists 
(DHPG/CHPG/MPEP/CP) at 10µM for 2h and finally a 30min exposure to 50µM 
NMDA. PLA2 (1.5µM) was able to reduce the damage by DHPG (CA1 region), 
CHPG (CA1 region) and MPEP (both CA1 and CA3 regions), but no significant 
improvement for CP. The damage of the CA1 and CA3 neuronal cell fields are 
expressed as a percentage of the area expressing fluorescence as compared with the 
untreated control cultures and 100µM of NMDA was taken as the maximum 
damage. Each point represents the mean ± SEM (n=8). *: p-value < 0.01 and #: p-





























6.1  Snake venom and its components  
Snakes and their venoms have fascinated man since time immemorial and the use of 
venom in the treatment of different pathophysiological conditions has been 
mentioned in Ayurveda, homeopathy and folk medicine. Snake venom contains a 
toxic mixture of enzymes, low molecular weight polypeptides, glycoproteins and 
metal ions that are capable of causing local tissue damage as well as multiple system 
failure. Hence, the venom serves to immobilize and digest the prey and at the same 
time, defend against predators. From these complex mixtures of pharmacologically 
active proteins and polypeptides, several hundreds of toxins have been purified and 
characterized. Apart from contributing significantly to the understanding of snake 
venom toxicity and medical management of snake bite, the study of these toxins (e.g 
NGF and PLA2) have also provided numerous research tools in deciphering the 
intricate details of various physiological processes at the molecular levels. The 
medical importance of snake venom components in the treatment of various disease 
conditions also serves to emphasize the growing interest in and the need for toxin 
research (Koh et al., 2006).  
 
6.2  Functional studies of mature NGF from Naja sputatrix 
NGF activity was first described in two sarcoma tissues and in snake venoms, but 
the physical and biochemical properties have been deduced from the male mouse 
submaxillary gland (β-NGF). Mouse NGF has been widely studied and is 
commercially available. Lipps (1998) reported that the NGFs from venomous 
sources are of the highest potency, especially those from snakes, they approximately 
1000-fold more active than the commercially available mouse NGF. The crude 
venom (250ng/ml) from 4 untested snakes when assayed for neurite outgrowth on 
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PC12 cells showed that the venom of Naja sputatrix, Malayan spitting cobra, 
exhibited the highest activity. This was followed by the venom from an Australian 
elapid, Pseudonaja textiles (Table 3.1). Thus the NGF from N. sputatrix venom was 
purified and its activity and properties were compared with that of the mouse NGF. 
The molecular weight of the native sputa NGF was found to be 14kDa, indicating 
that it is a monomer belonging to β-NGF family as suggested by Inoue et al. (1991).  
The cDNA encoding NGF from Agkistrodon halys Pallas has been reported 
previously (Guo et al., 1999). In this project, the cloning of cDNAs encoding two 
isoforms of sputa NGF from N. sputatrix was done. Each cDNA encoded a signal 
peptide, pro-domain and the mature protein. The mature protein coding region for N. 
sputatrix was identified from its N-terminal amino acid sequence as well as from the 
amino acid sequence of N. atra NGF (Inoue et al., 1991; Kostiza et al., 1995) 
Comparison of sequences from the venom-derived NGFs with that of mouse NGF 
showed distinct variations at their N-terminal ends (Fig. 3.2). The snake NGF shows 
higher homology (~80%) to the mammalian derived nerve growth factors, 
suggesting similar function to the mammalian homolog. The venom-derived NGFs 
showed almost 80-90% homology among them and the two isoforms of N sputatrix, 
NGF (nsNGFI, nsNGFII) showed about 80% homology between them. The nsNGFI 
and nsNGFII showed 70% and 60% homology to the mammalian NGF, 
respectively. While the mature protein region for both the nsNGFI and II showed 
high homology, the pro-region showed considerable variation among them. Based 
on its higher homology to the mammalian NGF, nsNGFI was selected for the 
expression as a recombinant protein in E. coli and termed ‘sputa NGF’. 
Furthermore, the refolded recombinant protein (sputa NGF) showed a similar CD 
spectrum to that of the native NGF protein (Fig. 3.4), indicating that sputa NGF 
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contains the same amount of secondary structure elements as the native NGF 
protein. Hence, it appears that sputa NGF have 2 pairs of β-sheets that are linked by 
3 disulfide bonds. It was refolded in redox solution containing 2mM oxidized 
glutathione and 4mM reduced glutathione and showed enhanced activity compared 
to the unfolded NGF (Table 3.1). In addition, this refolded sputa NGF was found to 
be non-toxic to PC12 cells at 1μg/ml and was able to bring about enhanced neurite 
outgrowth in a dose dependant manner from 10ng/ml to 100ng/ml (Fig. 3.6B).  
 
6.2.1  Expression of TrkA and p75 receptors 
The sputa NGF was found to elicit neurite outgrowth via the TrkA-p75NTR complex. 
Two protein forms of TrkA that predominate in cell extracts are a) 110-kDa N-
glycosylated precursor form, gp110TrkA and b) 140-kDa fully matured form, 
gp140TrkA (Martin-Zanca et al., 1989). PC12 cells are known to respond rapidly to 
NGF, within minutes with a reproducible burst of tyrosine phosphorylation of many 
cellular proteins and including the TrkA receptors. We observed that the ratio of 
gp140TrkA to gp110TrkA decreased upon treatment with both mouse and sputa NGF. 
This decrease of ratio is attributed to the purpose of replenishing the mature 
gp140TrkA at the cell surface as reported by Jullien et al. (2002). TrkA and p75NTR 
receptors work in concert to coordinate and modulate responses of neurons to NGF. 
A competitive study using specific receptor antibodies on the percentage of neurite 
outgrowth showed that sputa NGF is more sensitive to receptor inhibition compared 
to that of mouse NGF. Reduced TrkA activation in both PC12 cells and sympathetic 
neurons has been observed upon addition of p75NTR-specific antibodies (Kimpinski 
et al., 1999). The authors have also shown that any alteration in the optimal TrkA-
p75NTR interaction or direct activation of p75NTR at the expense of TrkA will result in 
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an inhibition of NGF dependent neurite outgrowth in adult sensory neurons. In the 
present study, inhibition by TrkA and p75NTR receptor-specific antibodies caused a 
reduction in neurite outgrowth for both mouse and sputa NGF by 34% and 70% for 
TrkA and 10% and 40% for p75NTR, respectively. Thus, the greater reduction in 
neurite formation upon sputa NGF treatment implicates that sputa NGF is specific to 
TrkA and p75NTR and stimulates signaling using the TrkA-p75NTR high affinity 
complex as in the case of mouse NGF. This antibody based competitive study is in 
agreement with the quantitative analysis of the receptor (TrkA and p75NTR) genes 
examined via real-time PCR. The expression of both receptors was higher with sputa 
NGF than with mouse NGF. Activation of TrkA and p75NTR has been reported to 
induce the expression of NFκB, which in turn is known to cause neurite extension in 
PC12 cells (Foehr et al., 2000). Real-time PCR (Fig. 3.9) showed a down regulation 
of the NFκB inhibitor, IκB in both NGF treatments implying that NFκB will be 
made available to activate and promote neurite extension in PC12 cells and such 
NGF-induced increase in NFκB is beneficial for the survival of neurons (Maggirwar 
et al., 2000).  
Protein profiling and real-time PCR results confirmed that an endogenous NGF 
synthesis is upregulated upon treatment with sputa NGF.  Results from microarray 
analysis also showed arginine vasopressin receptor 1A (V1a) gene expression to be 
higher for sputa NGF treatment (20.25-fold change) compared to mouse NGF (5.43-
fold change). In addition, arginine vasopressin is known to act mainly through the 
V1a receptor and to enhance NGF secretion in vascular smooth muscles and rat 
brain cells (Tuttle et al., 1993 and Zhou et al., 1997). Hence, sputa NGF could 
possibly be acting via V1a receptor to enhance the endogenous NGF production, an 
effect that will prove to be useful in conditions that require neuronal regeneration 
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and differentiation. Several studies have shown that neurotrophic factors including 
NGF constitute an important class of endogenous modulators of excitotoxicity, and 
are known to protect neurons against injury from several causes (Mattson et al., 
1993). NGF has caused increase in glutathione levels of PC12 cells (Palmer et al., 
1994) and hence upregulation (endogenous NGF genes) by sputa NGF may have 
potential neuroprotective roles.  
 
6.2.2  Global gene and protein analysis  
Microarray analysis (Table 3.2) showed for the first time the global changes in gene 
expression upon treatment with either mouse NGF or sputa NGF on PC12 cells. This 
study also yielded comparable data between the two NGFs. The differentiation 
pathway upon NGF treatment is characterized by expression of immediate early 
genes (such as early growth response 1, Egr 1; and serum-inducible kinase, Snk) and 
delayed response genes (such as Fos-like antigen, fra-1 and prostangladins-
endoperoxide synthase 1). It was shown that Egr 1 acts via the ERK pathway to 
eventually produce neurite outgrowth in PC12 cells (Harada et al., 2001). Liby et 
al., (2001) have shown that Snk has a role in cell proliferation. Expression of 
transcription factors, Fra-1 may participate in long-term neural responses (Paratcha 
et al., 2000); while over-expression of activating transcription factor 3 (ATF3) 
inhibited apoptosis (Nakagomi et al., 2003). Enhanced expression of transcription 
factors (Fra-1, ATF3 and Egr 1) may also cause subsequent increase in cathepsin E 
(CE) expression (Cook et al., 2001). This explains the increase in CE observed in 
this study (Table 3.2). CE is an aspartic proteinase that has been implicated in 
antigen processing in the class II major histocompatibility complex pathway and is 
known to be upregulated late in B cell activation (Sealy et al., 1996). The concurrent 
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upregulation of mast cell protease 7 in this study is in agreement with the previously 
reported effects of NGF on mast-cell development and differentiation (Welker et al., 
2000).  
Arginine vasopressin receptor 1A (V1a) was observed to be highly expressed by 
sputa NGF treatment when compared to mouse NGF. V1a receptor is a widely 
distributed and known to regulate nearly all the physiological actions of the 
neuropeptide, vasopressin (AVP), except antidiuresis (V2) and corticotrophin 
secretion (V1b; Hawtin et al., 2001). In addition to these, channel transporter genes 
(solute carrier family 1, member 3; SLC1A3, voltage-dependent calcium channel 
and purinergic P2X receptors) were found to be affected by the NGF treatment. 
Mouse NGF activated both the expression of SLC1A3 and P2X receptor genes, 
while sputa NGF activated the voltage-dependent calcium channel gene. The 
SLC1A3 gene encodes the glutamate receptor GLAST that is responsible for 
removal of glutamate to terminate neurotransmission and prevent neuronal cell death 
(Takai et al., 1995), while the expression of voltage-dependent calcium channel 
subunit II is restricted to neuronal tissues for the maintenance of the neuronal 
physiology (Chemin et al., 2001). Downregulation of P2X receptor was observed in 
both NGF treatments in this study. This proved to be beneficial as P2X is postulated 
to be involved in astrocyte-mediated inflammation and neurodegeneration (Gendron 
et al., 2003). Upregulation of interleukin 12 (IL-12) and prostaglandin-peroxide 
synthase 1 seen in both cases also supports their beneficial roles. Prostaglandin-
peroxide synthase 1 is believed to have a physiological role in neuronal 
differentiation of PC12 cells (Kaplan et al., 1997). Similarly, IL-12 is known to play 
an important role in neuronal regeneration (Lin et al., 2000).  
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Protein profiling results showed that treatment with sputa NGF enhanced the 
production of growth-associated proteins such as A-kinase anchor protein (Fig. 
3.10).  The A-kinase anchor protein (AKAP, 11.4kDa) belongs to a family of 
scaffolding proteins that bind to the regulatory subunits of protein kinase A (PKA), 
which regulates the phosphorylation of various proteins including those involved in 
synaptic. AKAP induction is known to stimulate PKA-dependent phosphorylation of 
the proapoptotic protein BAD (protein at 22.3kDa, thereby inhibiting the release of 
cytochrome c from mitochondria and protecting the cells from apoptosis (Affaitati et 
al., 2003). Though sputa NGF showed a marginal increase in BAD protein than 
mouse NGF, with AKAP upregulated about two fold than BAD, the pro-apoptotic 
property of BAD could be suppressed. This interpretation was confirmed 
experimentally by measuring for caspase activity on PC12 cells treated with sputa 
NGF. No caspase activity could be determined in these cells. 
The mechanisms by which NGF exerts its neuroprotective effects are presently 
unknown. However, in vitro studies have shown that NGF can stabilize intracellular 
calcium by preventing accumulation of intracellular calcium and subsequent 
neuronal damage (Kirschner et al., 1996). The protein profiling results (Fig. 3.10) 
showed a downregulation in neurogranin (Ng; 8kDa). Ng is a neural-specific Ca2+-
sensitive calmodulin-binding (CaM) protein. It is believed that phosphorylated Ng 
has the potential to modulate neuronal free Ca2+ and CaM levels (Pak et al., 2000). 
Gene knockout experiments leading to total absence of Ng have resulted in 
deficiency of hippocampal synaptic plasticity and hippocampus dependent spatial 
learning (Pak et al., 2000). McNamara et al (2002) predicted that elevation in Ng 
expression would perturb Ca2+-CaM signaling that may in turn impair the formation 
and/or maintenance of synapses. Thus, a reduced level of free Ng detected upon 
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treatment with sputa NGF indicates that a basal level of intracellular Ca2+ is 
maintained for neuronal differentiation and function.  
Protein tyrosine phosphatase (SHP-1; 67.2kDa) was identified as a phosphotyrosine 
phosphatase that negatively regulates the expression of TrkA. It was shown in 
sympathetic neurons that expression of SHP-1 induces apoptosis and TrkA 
dephosphorylation (Marsh et al., 2003). Hence, a downregulation of SHP-1 
expression is also in agreement with TrkA activation upon treatment with both 
NGFs. Microarray and protein profiling analyses showed an increase in the 
expression of V1a (vasopressin) receptor and AKAP respectively, with sputa NGF 
treatment. AKAP, apart from regulating the phosphorylation of BAD, also 
phosphorylates other proteins (e.g. cAMP-specific phosphodiesterase-4D; PDE4D). 
The increase of V1a expression would indicate a response to vasopressin release. In 
response to vasopressin, PDE4D is activated through PKA thereby causing a 
reduction in osmotic water permeability. AKAP co-localized with PKA and PDE4D 
and therefore has a role in the regulation of water (Stefan et al., 2007). Hence, sputa 
NGF treatment could possible act via V1a receptor to enhance the endogenous NGF 
production (protein-profiling) and concurrently reduce the water permeability.  
 
6.3  Functional studies of precursor NGF from Naja sputatrix 
NGF belongs to the neurotrophin family that regulates neuronal survival and 
synaptic plasticity (Patapoutian and Reichardt, 2001). They are synthesized as 
precursors (proneurotrophins) that are proteolytically cleaved to a mature, 
biologically active neurotrophin (Edwards et al., 1988a). Due to their low expression 
levels, little is known about their processing and secretion by neurons and non-
neuronal cells in vivo. However, when expressed in heterologous cells, 
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proneurotrophins are secreted and cleaved intracellularly by furin or proconvertases 
at a highly conserved dibasic amino acid cleavage side for secretion as a stable, 
noncovalent dimer (Heymach and Shooter, 1995; Mowla et al., 2001). Until 
recently, the functions for the neurotrophin prodomains have been limited to 
promoting the folding of the mature domain (Suter et al., 1991; Kolbeck et al., 1994; 
Rattenholl et al., 2001) and to sorting neurotrophins to either constitutive or 
regulated secretory pathway (Farhadi et al., 2000). However, sequence comparison 
of the prodomains revealed regions that are highly conserved across species, 
suggesting that they may mediate additional biological actions (Heinrich and Lum, 
2000). ProNGF has long been postulated to contain biologically active peptide that 
could induce phosphorylation of the tyrosine residue of the TrkA receptor protein 
(Dicou et al., 1997). On the other hand, secreted proNGF has been reported to 
activate cell death in brain following an injury via p75NTR and sortilin receptors 
(Nykjaer et al., 2004), thus indicating a pathophysiological role for the proNGF 
during CNS injury. Similarly, in vitro studies showed that proNGF is a high affinity 
ligand to p75NTR and capable of inducing p75NTR-dependent apoptosis in cultured 
neurons with minimal activation of TrkA-mediated differentiation or survival (Lee 
et al., 2001).  In contrast, Fahnestock et al (2004) have shown that the proNGF is 
abundant in CNS tissues where mature NGF is undetected. The author has 
demonstrated that this proNGF is responsible for the biological activity normally 
attributed by mature NGF, in the CNS tissues. The death inducing property, if any, 






6.3.1  Sequence comparison of NGFs from other species 
Sequence comparison between Naja sputatrix (nsNGF I) and its mammalian 
counterparts (mouse and human NGFs) shows about 50% homology and the greatest 
relatedness is in the mature protein sequence (Fig. 4.1F). Differences in the 
prodomain region may be due to mature human β-NGF forming a complex with its 
α- and γ- subunits, whereas there is only one report of complex formation for the 
snake venom NGFs (Perez-Polo et al., 1978). Bioinformatics predictions on the 
NGF sequences from Naja sputatrix (nsNGF I), mouse (mNGF) and human 
(humNGF) revealed the potential differences in post-translational modification. 
ProNGF is post-translationally processed in the trans-Golgi network that may 
include covalent modification (e.g. phosphorylation, N-glycosylation, O-
glycosylation, etc.) and proteolytic cleavage from precursor.  Figure 4.1A shows a 
comparison of possible leucine-rich nuclear export signal (NES) between the three 
NGFs. Protein NES are hydrophobic-rich sequences with a characteristic spacing of 
leucine, isoleucine, valine, and/or phenylalanine. Leucine-rich NES consists of four 
or five hydrophobic residues within a region that is ~10 amino acids in length. The 
widely accepted NES consensus is LX2,3[LIVFM]X2,3LX[LI] (la Cour et al. 2003). 
At present, there are about 75 experimentally validated protein NES that have been 
identified and compiled in the NESbase version 1.0 database (la Cour et al. 2003). 
NetNES 1.1 program disclosed a putative NES for nsNGFI and none for mouse and 
human.  
The potential sites for N-glycosylation were based on NetNglyc 1.0 database. Asn23 
of the mature protein has been postulated as the glycosylation site in venom NGFs 
since it forms an N-glycosylation consensus sequence (NXS/T) (Kornfield et al., 
1985; Gavel and von Heijne, 1990) and is absent from the unglycosylated 
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mammalian and cobra NGFs. Analysis of the elapid NGF amino acid sequences 
deduced from the cDNAs showed the presence of Asn23 in most snakes (Earl et al., 
2006), likewise this sequence was present in nsNGFI (Fig. 4.1F). However, NGF 
purified from N. sputatrix venom migrated at 14kDa by SDS-PAGE despite the 
presence of Asn23 in the corresponding sequence (Koh et al., 2004), suggests that 
the glycosylation site is unmodified. Similarly, results obtained from the 
bioinformatics prediction showed no potential N-glycosylation site for nsNGFI, but 
mouse and human NGFs had two possible sites (Fig. 4.1C).  
ProNGF is also processed by proteases that recognize the dibasic and tetrabasic 
cleavage sites flanking the sequence for mature NGF (Greene et al., 1968; Edwards 
et al., 1988a; Seidah et al., 1996). The major furin-cleavage site for the processing 
of precursor to mature NGF is known to be located at the -1 and -2 positions 
(Heymach et al., 1996). Most of the recent studies on proNGF had been done on 
proNGF mutated at this site. Based on the ProP 1.0 database, it disclosed a putative 
furin-cleavage site for nsNGF I, but two sites for both mouse and human (Fig. 4.1B). 
In addition, NetPhos 2.0 server also predicted differences in the number of residues 
phosphorylated between the three NGFs (nsNGF I, human and mouse).  
 
6.3.2  Cloning and expression of mature NGF, pro (R/G) NGF and pro-
  domain 
A cytosine-to-guanine mutation in the nsNGFI cDNA was designed to convert the 
arginine (R) residue at the -1 position in the proNGF polypeptide to a glycine (G) 
residue, thereby removing the basic cleavage site required to process proNGF to 
mature NGF. Recombinant wild-type (cleavable) NGF (mature NGF) or cleavage-
resistant proNGF [pro (R/G) NGF] or pro-domain only were used to transfect CHO 
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cells. Both the mature and pro (R/G) NGFs produced neurites in PC12 cells, but a 
reduced number of neurites were observed for pro (R/G) treatment (Fig. 4.4). This 
was also reported by Lee et al. (2001). Through specific antibody inhibition of 
neurite outgrowth and real-time PCR, the presence and specificity of mature, pro 
(R/G) NGF and pro-domain were determined. 
 
6.3.3  Effects of mature NGF, pro (R/G) NGF and pro-domain on 
 healthy PC12 cells based on morphology and biochemical assays 
Prior to treatment with the mature NGF, pro (R/G) NGF or pro-domain individually,  
PC12 cells were serum starved for 16-18h. There are basically two reasons for 
serum starvation; 1) NGF activity is due to the conditioned CHO media added and 
not the serum and 2) to show that NGF is able to act as a surviving factor against 
cell death. Neurites were observed for both mature and pro (R/G) NGF treatments, 
but none for pro-domain treatment (Fig. 4.4). Hence, the neurite-promoting activity 
is most likely from the NGF domain, as only mature and pro (R/G) NGFs contained 
it, while it is absent in pro-domain. Morphological structures (Fig. 4.4), biochemical 
analyses (Fig. 4.7A) and DNA laddering (Fig. 4.7B) indicated that pro-domain 
caused apoptosis. Pro-domain caused a loss of membrane integrity, DNA 
fragmentation and also an increase in both LDH and caspase activities. Pretreatment 
with a selective capase inhibitor, Ac-DEVD-CHO, followed by pro-domain 
treatment caused a decrease in caspase activity (Fig. 4.7C), indicating that pro-
domain caused apoptosis via the caspase-mediated cell death pathway.  
In normal and serum-deprived PC12 cells, treatment with both mature and pro (R/G) 
NGFs showed a neuroprotective effect. There were reductions in the loss of 
membrane integrity and also a decrease in both LDH and caspase activity (Fig. 
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4.7A). In addition, they [mature and pro (R/G) NGFs] protected the cells against 
DNA fragmentation (Fig. 4.7B). Taken together, both mature and pro (R/G) NGFs 
were capable of protecting the cells from the serum-deprived conditions. Hence, the 
presence of the pro-domain in pro (R/G) NGF did not block the neuroprotective 
effect of the NGF domain. In both morphological and biochemical studies, 
staurosporine (STS) was used as a positive control. This leads to a suggestion that 
when NGF-domain is present, the overall effect is dictated by the NGF-domain [in 
pro (R/G) NGF], leading to pro-survival and neuroprotection. However, once the 
NGF-domain is removed (in pro-domain), the overall effect is cell death via 
apoptosis. This hypothesis was tested in the receptor studies (TrkA, p75NTR and 
sortilin) in the section 6.3.5.  
 
6.3.4  Effects of mature NGF, pro (R/G) NGF and pro-domain on 
 healthy PC12 cells based gene and protein expression assays 
The cellular responses of neurotrophin (mature or precursor) are mediated by three 
distinct receptor classes (TrkA, p75NTR and sortilin). The various combination of 
receptors would then dictate and regulate the final fate of the cell (survival or death; 
Nykjaer et al., 2004). P75NTR is the common receptor required for the formation of 
the high-affinity binding sites and there are two possible outcomes depending on the 
“partner” receptor it binds to. It could either bind (1) with TrkA that binds to NGF, 
thereby activating the pro-survival pathway (Roux and Barker, 2002) or (2) with 
sortilin that binds proNGF and the complex is required for proNGF-mediated 
apoptosis (Nykjaer et al., 2004). The interaction of these three receptors was studied 




The quantitative analysis by real-time PCR (Fig. 4.8A) of the NGF receptor genes 
(TrkA and p75NTR) is greatly increased for both mature and pro (R/G) NGFs, but 
higher for the mature NGF. The high expression levels of both receptors indicate the 
formation of the high-affinity complex with NGF (Roux and Barker, 2002), but 
since TrkA is present, the pro-survival pathway will most likely predominate. 
Sortilin is expressed in areas where NGF and proNGF, have well-characterized 
effects (Sarret et al., 2003; Hermans-Borgmeyer et al., 1999). While NGF regulates 
cell survival and cell death via binding to two different receptors TrkA and p75NTR 
(Chao, 2003), proNGF selectively induces apoptosis through p75NTR but not TrkA 
(Lee et al., 2001). It has been reported that sortilin acts as a co-receptor and 
molecular switch governing the p75NTR-mediated pro-apoptotic signal induced by 
proNGF. Hence, the gene regulation of the sortilin gene can give us a clue as to how 
and which pathway is activated. If sortilin gene is expressed at low levels for all the 
three treatments [mature NGF, pro (R/G) NGF and pro-domain], thereby indicating 
no formation of complex with p75NTR and hence no activation of the apoptosis 
pathway.  
Apoptosis can be divided into extrinsic pathway, initiated through death receptors 
such as Fas, and the cell intrinsic pathway, which is initiated when cells are 
subjected to DNA damage, growth factor deprivation, etc. (Strasser et al., 1995). 
The cell intrinsic pathway is regulated by the Bcl-2 family of proteins. This family 
consists of both anti-apoptotic and pro-apoptotic members. One of the major anti-
apoptotic members is Bcl-2 that exerts its effect at the mitochondrial outer 
membrane where they contribute to maintenance of membrane integrity. In the 
absence of apoptotic stimuli, anti-apoptotic Bcl-2 proteins protect the mitochondrial 
outer membrane from the pro-apoptotic activity (Lindsten et al., 2005). Upon 
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treatment with mature and pro (R/G) NGFs, the expression of Bcl-2 gene was 
downregulated, while treatment with pro-domain and staurosporine (positive 
marker) resulted in an upregulation of Bcl-2 gene. The upregulation of Bcl-2 gene 
could be a compensatory mechanism of the cell to survive, when faced with death-
inducing agents (i.e. pro-domain and staurosporine) the Bcl-2 gene is increased to 
overcome the cell death signals. Western blot analysis (Fig. 4.8B) showed activation 
of TrkA for both mature and pro (R/G) NGFs treatments and is in agreement to the 
real-time results. Treatment of PC12 cells for 16-18h caused an increase in TrkA 
expression for both mature and pro (R/G) NGFs and none for pro-domain treatment 
(Fig. 4.8C). The expression of p75NTR was greatly increased for pro (R/G) NGF, 
much more than mature NGF. This could be attributed to the property of proNGF 
being a high-affinity ligand for p75NTR as observed by Lee et al (2001). In addition, 
the sortilin protein was upregulated for all treatments. Since p75NTR is a common 
receptor needed by both TrkA and sortilin, it plays an important for in this balance 
of cell survival and death. In mature NGF treatment, though sortilin and TrkA are 
upregulated, TrkA is increased about 3-fold more than sortilin (Fig. 4.8C). The 
presence of TrkA and together with NGF will cause the pro-survival pathway to 
predominate. The similar pattern was observed for pro (R/G) NGF, with the 
expression level of TrkA being much higher than sortilin. However, with pro-
domain treatment, there is relatively low expression of TrkA and high expression of 
p75NTR, thereby causing the formation of the high-affinity complex between p75NTR 
and sortilin and activating the apoptosis pathway.  Apart from the decreased levels 
of TrkA needed to allow formation of p75-sortilin complex, the availability of 
p75NTR receptors could be crucial. In the presence of TrkA and NGF, p75NTR would 
combine with TrkA to form high-affinity binding sites for NGF, reducing the 
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amount left to bind to sortilin (in mature NGF). Hence, the overall fate of the cell is 
pro-survival.  
To determine the possible complexes formed between the three receptors, specific 
antibodies to the receptors were used to inhibit their actions. PC12 cells were treated 
concurrently with specific antibodies to the receptors (TrkA, p75NTR and sortilin) 
and the percentage of neurites determined (Fig. 4.9A). Treatment with anti-TrkA 
and anti-p75 antibodies caused a great reduction in neurite for both mature and pro 
(R/G) NGF. Hence, these two receptors are involved and needed in the neurite 
formation. Inhibition of sortilin has no effect, as it is not involved in the formation 
of the high-affinity complex (NGF, TrkA and p75NTR). When both anti-sortilin and 
anti-p75NTR antibodies were used in both mature and pro (R/G) NGFs treatments, the 
number of neurites was decreased, leading to an indication that both sortilin and 
p75NTR may be involved in the neurite formation. Pro-domain did not cause neurite 
outgrowth, but LDH assay (Fig. 4.9B) showed that inhibition by all the three 
antibodies increased the cell survival. MTT assay (Fig. 4.9C) showed that inhibition 
with anti-p75 antibody caused a large decrease in cell survival for both mature and 
pro (R/G) NGFs. This is most likely due to the lack of p75NTR for the formation of 
high-affinity complex to bind with TrkA that activate the cell survival pathway.   
Taken together, these studies showed that the pro-domain is apoptotic, while the 
mature and pro (R/G) NGFs are neuroprotective. Differences observed in their 
function could be attributed to the differences in their structures. Pro-domain of 
NGF is covalently linked to the mature part to promote oxidative structure formation 
and to confer a pro-apoptotic activity to the NGF (Lee et al., 2001; Rattenholl et al., 
2001). In addition, spectroscopic analyses revealed that on the NGF domain, a 
surface area around the tryptophan residue (Trp21) interacted with pro-domain and 
 227
Chapter 6 
also participated in the binding of TrkA and p75NTR receptors (Kliemannel et al., 
2007). Hence, the presence of Trp21 in both pro (R/G) NGF and mature NGF 
(contain the NGF domain) allowed them to bind to TrkA and p75NTR and to activate 
the pro-survival pathway. On the other hand, the absence of Trp21 in the pro-domain 
(without the NGF domain) encouraged the interaction between p75NTR and sortilin 
that activated the apoptotic pathway.  
 
6.3.5  Oxygen-glucose deprivation- a model for ischemia 
A fluorescence staining of the cells with Annexin V and Ethidium Homodimer III, 
showed that with OGD exposure, a higher percentage of cells undergo necrosis and 
apoptosis (Fig. 4.10Bii). Koubi et al (2005) also reported that PC12 cell death 
occurs by early necrosis upon exposure to OGD and later by delayed apoptosis 
during reperfusion. Figure 4.10Bii showed that both mature and the pro (R/G) NGF 
were able to protect the cells against OGD exposure, but pro (R/G) NGF to a lesser 
extent, while the pro-domain seemed to enhanced the damage. This observation was 
also observed in biochemical assays (Fig. 4.10C; LDH and caspase). Both mature 
and pro (R/G) NGF reduced the level of cytotoxicity for both assays, while pro-
domain enhanced the level of cytotoxicity. This is most likely due to the presence of 
the NGF domain, leading to neuroprotection, whereas the pro-domain caused 
enhanced cell death. Quantitative gene analysis of the genes showed that NGF 
receptors (TrkA and p75NTR) were reduced in expression from mature NGF to pro-
domain (Fig. 4.10D). The reduction in expression is probably due to the reduction in 
forming the high-affinity complex and the activation of the pro-survival pathway 
(Roux and Barker, 2002). Without the NGF domain for pro-domain, the level of 
both TrkA and p75NTR was very low compared to the rest. Sortilin expression for 
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mature and pro (R/G) NGFs were relatively low, this is probably due to the lack of 
binding by both pro (R/G) NGF and p75NTR to activate the apoptotic pathway. It has 
been reported that sortilin acts as a co-receptor and molecular switch governing the 
p75NTR-mediated pro-apoptotic signal as induced by proNGF (Nykjaer et al., 2004). 
The expression of sortilin was increased upon treatment with conditioned CHO 
media containing the pro-domain. This increase, together with p75NTR will most 
likely activate the apoptotic pathway. This is supported by the increased in 
expression for NF-κB, IκB, Bcl-2 and Bcl-XL genes. The reason for the increased in 
these genes could be a compensatory mechanism for the cell to survive. In addition, 
the Bcl-2 family of proteins (e.g. anti-apoptotic Bcl-2 and Bcl-XL; pro-apoptotic Bax 
and Bcl-XS) has been suggested to play a role in ischemic-induced apoptosis. 
Overexpression of Bcl-2 reduces apoptosis during ischemia in vivo (Wang et al., 
1999; Kitagawa et al., 1998). Hence, the expression of anti-apoptotic genes (Bcl-2 
and Bcl-XL) may help the cells to survive. From the gene expression patterns for the 
three treatments (mature NGF, pro (R/G) NGF and pro-domain), it gives us a clue 
about the possible mechanism of action that they exert their effects. Both mature and 
pro (R/G) NGFs are neuroprotective to OGD-exposure cells, while pro-domain 
enhanced the OGD damage and hence the cell’s compensatory mechanism sets in to 
rescue. 
 
6.3.6  Staurosporine-induced cell death of PC12 cells 
Staurosporine (STS), a microbial alkaloid, has been reported to induce apoptosis in 
mammalian cells at micromolar concentrations (Jacobson et al., 1993; Zhang et al., 
1996) by inhibiting protein kinases. Treatment of PC12 cells with STS resulted in 
membrane blebbing, DNA fragmentation and chromatin condensation. 
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Staurosporine (STS) at 0.5µM was used as a positive marker for apoptosis in this 
study to study effect of mature NGF, pro (R/G) NGF and pro-domain when treated 
with STS. However, in this study, there will be no comparison on the ability to cause 
neurite outgrowth as STS is capable of causing neurite outgrowth in PC12 cells. 
However, activation of the STS-activated kinase with the induction of neurite 
outgrowth did not require Ras function, while Ras was required for the activation of 
ERK pathway and neurite outgrowth by NGF (Yao et al., 1997). Morphological 
studies (Fig. 4.11Aii) with Annexin V and Ethidium Homodimer III showed that 
with mature NGF, the extent of apoptosis by STS was reduced greatly. There was no 
change for pro (R/G) NGF, but an increased death with pro-domain treated 
concurrently with STS. Hoechst staining also showed DNA condensation for all 
treatments, except for mature NGF (Fig. 4.11Aiii).  The LDH assay also showed that 
mature NGF was able to reduce the cytotoxicity caused by STS treatment (Fig. 
4.11B). Taken together, the results showed that mature NGF was capable of 
protecting the cells from STS, whereas pro (R/G) NGF and pro-domain were not 
able to protect the cells. This showed that only mature NGF was capable of 
protecting the cells against STS-mediated apoptosis.   
 
6.4  Two potential neuroprotective agents from snake venom 
In ischemic (OGD) condition, two components (NGF and PLA2) from the venom of 
Naja sputatrix provided protection to PC12 cells and organotypic hippocampal 
cultures. Post-treatment of PC12 cells with either sputa NGF or PLA2 individually 
after hypoxia, resulted in an increase in survival as determined by MTT assay (Fig. 
5.1A). Similarly, PC12 cells when subjected to OGD, showed better survival when 
post-treated with either PLA2 or sputa NGF individually (Fig. 5.1B). Tabakman et al 
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(2005) reported that pretreatment of PC12 cells with NGF prior to OGD exposure, 
resulted in 30% neuroprotection. OGD –induced PC12 cell death is largely due to 
apoptosis (Jiang et al., 2005; Koubi et al., 2005). Hence, it is tempting to suggest 
that the neuroprotective effect of NGF is related to a reduction in OGD-induced 
apoptosis. NGF-induced neuroprotection, in the OGD model, supports the role of 
NGF as a neuroprotective agent in the nervous system as previously documented in 
a variety of in vitro neuronal insults (Rukenstein et al., 1991; Boniece and Wagner, 
1995; Pan et al., 1997).  
Organotypic hippocampal culture is a good model to study as it maintains the 
physiological glial-neuronal relationship (Stoppini et al., 1991). The concurrent 
treatment with NGFs (mouse and sputa), as well as PLA2, resulted in protection 
against the OGD exposure, as observed from LDH assay (Fig. 5.1C). The protection 
by NGF has also been shown in different neurodegenerative disease models. For 
instance, treatment with neurotrophins (BDNF and NGF) helped to reduce the 
severity and death of the neurons (Zhang and Pardridge, 2006).  Hence, a controlled 
increase in brain NGF levels may be beneficial in ameliorating certain 
neurodegenerative diseases such as Alzheimer’s disease (Williams et al., 2006). At 
present, the major obstacle in the therapeutic use of NGF for stroke, Alzheimer’s 
disease and other brain diseases is its inability of the human recombinant NGF to 
cross the blood-brain barrier. Therefore, the development of novel delivery 
technologies for proteins such as NGF will provide the way for this important 
neurotrophin to the clinic. Compared to NGF as a neuroprotective agent for 
neurodegenerative diseases, PLA2 is relatively new. Since PLA2 is able to protect 
against hypoxia and OGD in PC12 cells, as well as in organotypic hippocampal 
cultures, its possible mechanism of action was investigated.  
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6.4.1  Effect of PLA2 on cultures exposed to OGD conditions 
PLA2, a component found in Naja sputatrix venom has a neuroprotective effect in 
ischemic injury and a possible underlying mechanism by which this neuroprotection 
occurs was proposed. The organotypic hippocampal cultures were used to examine 
its effects in an in vitro model of ‘ischemic-like’ insult’ using OGD as they provide 
good experimental system to mimic the pathophysiological pathways in living 
tissues (Stoppini et al., 1991). In particular, hippocampal slice cultures combined 
with OGD could provide a surrogate system to investigate cell loss following 
ischemic injury to the brain. Using this model, it was shown that PLA2 at 0.75µM 
promoted about 60% and 95% survival at the CA1 and CA3 regions, respectively, 
whereas PLA2 at 1.5µM showed 95% protection for both regions (Fig. 5.3). The 
results for PLA2 (1.5µM) was similar to what was observed for MK801, a selective 
non-competitive antagonist of NMDA receptor channel. MK801 was used as a 
positive marker for neuroprotection as it has been shown to be highly 
neuroprotective in both models of ischemia and hypoxia (Wong et al., 1986; Pringle 
et al., 1997).  
Since apoptosis is implicated in ischemia (Love, 2003), the apoptotic genes were 
investigated. In addition, the Bcl-2 family of proteins (e.g. anti-apoptotic Bcl-2 and 
Bcl-XL; pro-apoptotic Bcl-XS and Bax) has been suggested to play a role in ischemia-
induced apoptosis. Quantitative gene analysis of these apoptotic genes (Fig. 5.4) 
showed that concurrent treatment with either PLA2 (0.75µM and 1.5µM) or MK801 
(0.19mM) on cultures subjected to OGD caused an upregulation of both anti-
apoptotic genes (Bcl-2 and Bcl-XL), but a downregulation of apoptotic gene (Bax).  
Bax can homodimerize with itself and heterodimerize with Bcl-2 or Bcl-XL. It 
appears that Bax homodimers activate apoptosis, while heterodimers inhibit the 
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process (Adams and Cory, 1998). The high expression of both anti-apoptotic genes 
(Bcl-2 and Bcl-XL), could possibly cause heterodimers to form, thereby inhibiting 
apoptosis and promoting neuroprotection. Moreover, an elevated intracellular ratio 
of Bax to Bcl-2 occurs during increased apoptotic cell death (Zha and Reed, 1997), 
while in vivo ischemia studies showed that overexpression of Bcl-2 reduces 
apoptosis (Wang et al., 1999; Kitagawa et al., 1998). Taken together, the 
quantitative real-time PCR results showed that apoptosis is reduced upon treatment 
with PLA2. In addition to genes related to apoptosis, the possible pathway of mGluR 
was investigated. Homer proteins (Homer 1b, 1c, 2 and 3) induce dendritic 
localization of group I mGluRs and receptor clustering, either internally or on the 
plasma membrane (Kammermeier, 2006). The Homer gene (Fig. 5.4) was 
upregulated for both PLA2 (0.75µM and 1.5µM) or MK801 (0.19mM) treatments on 
OGD cultures, thereby indicating a possible link between PLA2 and group I 
mGluRs. 
 
6.4.2  Effect of PLA2 on glutamate-mediated insult 
Neurotransmitter such as glutamate has been implicated as potential neurotoxic 
agents in several neurological disorders including ischemia, epilepsy and 
neurodegenerative diseases. However, the molecular mechanisms underlying 
glutamate toxicity in these disorders are not well understood, but it has been shown 
that accumulation of Ca2+ induced cell death by both necrosis and apoptosis. PLA2 
was tested for its neuroprotective ability at three different phases of glutamate insult. 
PLA2 was added either before (pretreatment), during (concurrent) or after (post-
treatment) glutamate insult. Pretreatment with PLA2 did not cause any 
neuroprotection, but MK801 provided protection against glutamate insult (results 
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not included). Concurrent treatment with PLA2 caused a protection against 
glutamate insult in a dose-dependent manner (Fig. 5.5), while post-treatment showed 
protection with PLA2 and none for MK801 (Fig. 5.6).  The glutamate studies 
showed that PLA2 mechanism of action for neuroprotection is possibly through an 
indirect pathway that blocks the downstream toxic effects of glutamate.  
Agonists to the three classes of glutamate ionotrophic receptors; AMPA, NMDA 
and KA were treated concurrently with PLA2 (Fig. 5.7).  PLA2 was able to protect 
the CA3 regions for all the three, but CA1 for only NMDA and AMPA. PLA2 was 
able to partially protect against AMPA excitotoxicity. Since AMPA receptors are 
involved in the neuroprotection by PLA2, this suggests an involvement of KA 
receptors. In accordance with this, the activation of KA receptors, which are 
predominantly expressed in CA3, may account for the selective neuroprotection by 
PLA2.  During the concurrent treatment with PLA2 and NMDA (Fig. 5.7), PLA2 
protected both the CA1 and CA3 regions. This may be explained by the general high 
permeability of NMDA receptors to Ca2+ (Moriyoshi et al., 1991; Wahl et al., 1989) 
as compared to AMPA (Keinanen et al., 1990; Sommer et al., 1990; Hollmann et 
al., 1991; Jonas and Burnashev, 1995) and KA (Wisden and Seeburg, 1993; 
Nakanishi and Masu, 1994; Jorgensen et al., 1995; Bernard et al., 1999). The 
neuroprotective role of PLA2 most likely involved Ca2+, hence a reduction in Ca2+ 
permeability, may restrict its action.  
Among the three ionotrophic receptors, NMDA has the most similar pattern of 
protection to glutamate as both CA1 and CA3 are protected. Unlike ionotrophic 
glutamate receptors, mGluRs do not activate ion channel directly but instead activate 
second messenger mechanisms. The group I mGluRs are unique from the other 
mGluRs, in that certain splice variants (mGluR1a and mGluR5a and b) are directly 
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connected to the IP3- and ryanodine receptors on the endoplasmic reticulum by 
postsynaptic proteins termed Homer (Tu et al., 1998; Xiao et al., 1998). Coupling of 
Homer to group I mGluRs have also been implicated in mGluR trafficking and 
clustering (Ango et al., 2000 and 2002). Through the Homer proteins, group I 
mGluRs can bind directly to NMDA receptors (Tu et al., 1998). Apart from their 
ability to increase intracellular Ca2+, group I mGluRs have also shown to negatively 
modulate K+ channels as well as activate cationic channels (Pin and Duvoisin, 1995; 
Chung et al., 2000). Real-time PCR results on the cultures exposed to OGD and 
concurrently treated with PLA2 showed a possible involvement of Homer (Fig. 5.3). 
The activation of group I mGluRs was prior to the NMDA exposure, because no 
neuroprotection was observed if DHPG was added 2h immediately after the insult 
(Blaabjerg et al., 2003). Co-application of a group I mGluR agonist and NMDA may 
potentiate NMDA responses through phosphorylation of the NMDA receptors, 
causing a relief of the Mg2+ block and increasing the Ca2+ influx through the 
associated channel to a toxic level (Bruno et al., 1995). However, a pretreatment 
with the group I mGluR agonist would increase intracellular Ca2+ causing inhibition 
of NMDA receptors or result in their internalization (Synder  et al., 2001), so that 
subsequent exposure would yield a decreased response. The results showed that 
activation of group 1 mGluR by both DHPG and CHPG maintained the protection of 
PLA2 (Fig. 5.8). Similarly, treatment with group I mGluR antagonists, MPEP that 
selectively blocked mGluR5, still allowed PLA2 to be neuroprotective. However, 
concurrent treatment with an mGluR1-specfic antagonist, CP, blocked totally the 
neuroprotective effect of PLA2. Hence, the possible mechanism of action for the 




6.5  Conclusion 
Since historical days, the inherent toxicity and diversity of snake venoms and its 
constituents have always fascinated scientists. It is essentially a cocktail of 
compounds, composed mainly of proteins that the snake uses for attack and defense. 
At present, there is substantial amount of information available on the composition 
and distinct toxicities of snake venoms. In addition, the structure, function, 
molecular biology, chemistry and pharmacology of venom toxins have been well-
documented. However, the exact mechanism and targets of many snake venom and 
its toxins remain ambiguous. This project investigated a potentially useful 
component from the venom of Naja sputatrix – NGF, as well as the functional roles 
for both mature and precursor NGF. In addition, the possible mechanism of action of 
another component, PLA2 was deciphered.  
Sputa NGF seems to exert potentially life-sustaining and neuroprotective (e.g. NFκB 
and endogenous NGF genes) effects in a manner similar to that of mouse NGF. The 
survival-promoting effects have been observed at both gene (microarray) and protein 
(SELDI-TOF) levels. Sputa NGF was also found to increase the expression of 
vasopressin 1A receptor and endogenous NGF genes as well as the NGF precursor 
and the AKAP proteins. However, both neurogranin and SHP-1 proteins have been 
found to be downregulated upon treatment with sputa NGF. Real-time PCR analysis 
has revealed additional pro-survival effects of sputa NGF such as enhanced 
expression of NFκB and the endogenous NGF genes. These effects could have 
potential neuroprotective roles. In this project, the functional studies of the sputa 
NGF (mature NGF expressed in E. coli) was thoroughly studied at both gene and 
protein levels and proved to be a preferable substitute to mouse NGF.  
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Three different physiological conditions were used to study the functional role of the 
precursor NGF [pro (R/G) NGF]; normal, ischemic (OGD) and apoptotic (STS) 
conditions. In all these conditions, apart from pro (R/G) NGF, both mature NGF and 
pro-domain were also tested. In the normal conditions, pro (R/G) NGF behaved in a 
manner similar to mature NGF as shown by the biochemical assays (LDH and 
caspase) and cell morphology studies. Under ischemic conditions, pro (R/G) NGF 
was able to protect the cells from the OGD exposure, but to a lesser extent than 
mature NGF, while in apoptotic conditions (STS) it could not protect the cells from 
cell death. A comparison between the three conditions showed that pro (R/G) NGF 
was able to protect the cells in normal serum-deprived and ischemic conditions, but 
not for the apoptotic condition. On the contrary, pro-domain caused an increased in 
cell damage for all three conditions. Real-time studies showed that all three (mature 
NGF, pro (R/G) NGF and pro-domain) were capable of activating both TrkA and 
p75NTR, in decreasing order. However, western blot protein analysis showed that pro 
(R/G) NGF caused an upregulation of p75NTR more than the mature NGF and pro-
domain treatments, owning possibly to its higher affinity to p75NTR. Hence, the 
possible role of pro (R/G) NGF is to balance cell death or survival depending on the 
in vitro and in vivo conditions of the cell, whereby in healthy and ischemic 
conditions it supports survival while in apoptotic, it triggers the cell-death pathway. 
PLA2 provided protection against glutamate and OGD-mediated cell death in 
organotypic hippocampal cultures. Real-time PCR results showed that treatment 
with PLA2 resulted in an upregulation of anti-apoptotic genes (Bcl-2 and Bcl-XL) and 
a down-regulation of apoptotic gene (Bax), leading to a possible overall reduction in 
apoptosis-mediated cell death. Using specific agonists and antagonists to the 
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ionotrophic and metabotrophic glutamate receptors, the possible receptor involved in 
neuroprotection by PLA2 was determined to be mGluR1.  
The results of this study highlighted the beneficial components from snake venom, 
in particular NGF and its precursor, in both physiological and pathophysiological 
states.  
 
6.6  Future studies 
This study has just unraveled the “treasure box” of NGF from snake venom as a 
potential therapeutic agent against ischemia and that the precursor of NGF is not just 
an innocent bystander. The microarray results of PC12 cells treated with either sputa 
or mouse NGF (Chapter 3) could be further substantiated with real-time PCR and 
western blot analysis.  In addition, the activation of TrkA receptors could also be 
proven by immunoprecipitation method to ascertain the identity of the tyrosine 
phosphorylated protein (TrkA). More studies will be necessary to fully comprehend 
the delicate balance between the mature and precursor NGF in deciding the overall 
fate of the cell (survival or death). In the proNGF study (Chapter 4), apart from 
using bioinformatics tools to predict the glycosylation status of nsNGF and mouse 
NGF, deglycosylation using N- and O-glycosidases could also show the presence of 
O- and N-glycosylation in these proteins. The function of the pro (R/G) NGF was 
found to behave in a similar manner as the mature NGF, but less robust in promoting 
neuroprotection in apoptotic conditions (STS). Much work is needed to understand 
the difference between the two [mature and pro (R/G) NGF], possibly by studying 
the downstream proteins in the pro-survival pathway. In addition, the pro-domain 
was found to be apoptotic and proteins in the caspase pathway could be investigated. 
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The interaction between the three receptors (TrkA, p75NTR and sortilin) could be 
confirmed by silencing the gene individually (siRNA) and observing the overall 
effect of the cell (neurotrophic or apoptotic).  
For the PLA2 (Chapter 5) study, the possible receptor was found to be mGluR1, but 
more work is needed to validate it, either by western blot or real-time PCR on the 
pathway. To confirm the interaction of mGluR1 and PLA2, the expression of 
mGluR1 could be silenced (siRNA). In addition, a neuroarray (DNA microchip with 
genes from the brain) to determine the genes regulated by NGF and PLA2 treatments 
separately, will be required to gain a broader understanding of their biological 
effects. Organotypic hippocampal cultures subjected to OGD/glutamate insult can be 
treated separately with different forms of NGF [mature NGF, pro (R/G) NGF and 
pro-domain], as well as with PLA2. The total RNA isolated can be used in 
microarray studies. These studies will definitely uncover useful and beneficial 
effects that may be extended for the development of therapeutic agents for disease 




























































Abu-Raya, S., Trembovler, V., Shohami, E. and Lazarovici, P. (1993) A tissue 
culture ischemic device to study eicosanoid release by pheochromocytoma PC12 
cultures. J Neurosci Methods. 50: 197-203. 
 
Abu-Raya, S., Blaugrund, E. and Trembovler, V., Shohami, E. and Lazarovici, 
P. (1999) Rasagiline, a monoamine oxidase-B inhibitor, protects NGF-
differentiated PC12 cells against oxygen-glucose deprivation. J Neurosci Res. 5: 
456-463.  
 
Adams, J.M. and Cory, S. (1998) The Bcl-2 protein family: arbiters of cell 
survival. Science 281: 1322-1326. 
 
Affaitati, A., Cardone, L., Cristofaro, T., Carlucci, A., Ginsberg, M.D., Varrone, 
S., Gottesman, M.E., Avvedimento, E.V. and Feliciello, A. (2003) Essential role 
of A-kinase anchor protein 121 for cAMP signaling to mitochondria. J Biol 
Chem. 278: 4286-4294. 
 
Agerman, K., Baudet, C., Fundin, B., Willson, C. and Ernfors, P. (2000) 
Attenuation of a caspase-3 dependent cell death in NT4- and p75- deficient 
embryonic sensory neurons. Mol Cell Neurosci. 16: 258-268.  
 
Alkin, J.G. and Bradshaw, R.A. (1993) Nerve growth factor and related 
substances: structure and mechanism of action. In: Neurotrophin factors. 
Loughlin, S.E and Fallon, J.H. (Eds). San Diego, California, USA: Academic 
Press Inc. pp: 120-180. 
 
Allsopp, T.E., Robinson, M., Wyatt, S. and Davies, A.M. (1994) TrkA mediates 
an NGF survival response in NGF-independent sensory neurons but not in 
parasympathetic neurons. Gene Ther. 1: S59. 
 
Aloe, L. (2004) Nerve growth factor, human skin ulcers and vascularization. Our 
experience. Prog Brain Res. 146: 515-522. 
 
Aloyz, R.S., Bamji, S.X., Pozniak, C.D., Toma, J.G., Atwal, J., Kaplan, D.R. and 
Miller, F.D. (1998) p53 is essential for developmental neuron death as regulated 
by the TrkA and p75 neurotrophin receptors. J Cell Biol. 143:1691-1703. 
 
Anand, P. (1992) The skin axon-reflex vasodilation-mechanism, testing and 
implications in autonomic disorders. In: Bannister, R. and Mathias, C. (Eds). 
Autonomic failure, 3rd edition. Oxford University Press, Oxford, pp: 479-488.  
 
Anand, P. (1997) The role of neurotrophic factors in leprosy and other human 
peripheral neuropathies. In: Antia, N.H. and Shetty,V.P. (Eds). The peripheral 
nerve in leprosy and other neuropathies. Oxford University Press Delhi, pp: 
231-240.  
 
Anand, P., Rudge, P., Mathias, C.J., Springall, D.R., Ghatei, M.A., Naher-Noe, 
M., Sharief, M., Misra, V.P., Polak, J.M., Bloom, S.R. and Thomas, P.K. (1991) 
A new autonomic and sensory neuropathy with loss of sympathetic adrenergic 
function and sensory neuropeptides. Lancet 337: 1253-1254.  
 241
References 
Anand, P., Pandya, S., Ladiwala, U., Singhal, B., Sinicropi, D.V. and Williams-
Chestnut, R.E. (1994) Depletion of nerve growth factor in leprosy. Lancet 344: 
129-130.  
 
Anand, P., Terenghi, G., Warner, G., Kopelman, P., Williams-Chestnut, R., and 
Sinicropi, D.V. (1996) The role of endogenous nerve growth factor in human 
diabetic neuropathy. Nat Med. 2: 703-707.  
 
Angeletti, R.A. (1970) Nerve growth factor from cobra venom. Proc Natl Acad 
Sci USA 65: 668-674. 
 
Ango, F., Pin, J.P., Tu, J.C., Xiao, B., Worley, P.F. and Bockaert, J. and Fagni, 
L. (2000) Dendritic and axonal targeting of type 5 metabotrophic glutamate 
receptor is regulated by homer 1 proteins and neuronal excitation. J Neurosci. 
20: 8710-8716.  
 
Ango, F., Robbe, D., Tu, J.C., Xiao, B., Worley, P.F., Pin, J.P., Bockaert, J. 
Fagni, L.  (2002) Homer-dependent cell surface expression of metabotrophic 
glutamate receptor type 5 in neurons. Mol Cell Neurosci. 20: 323-329. 
 
Apfel, S.C., Schwartz, S., Adornato, B.T., Freeman, R., Biton, V., Rendell, M., 
Vinik, A., Giuliani, M., Stevens, J.C., Barbano, R. and Dyck, P.J. (2000) 
Efficacy and safety of recombinant human nerve growth factor in patients with 
diabetic polyneuropathy: A randomized controlled trial. rhNGF Clinical 
Investigator Group. JAMA. 284: 2215-2221.   
 
Apfel, S.C. (2002) Nerve growth factor for the treatment of diabetic neuropathy: 
what went wrong, what went right, and what does the future hold? Int Rev 
Neurobiol. 50: 393-413. 
 
Armugam, A., Earnest, L., Chung, M.C., Gopalakrishnakone, P., Tan C.H., Tan, 
N.H. and Jeyaseelan, K. (1997) Cloning and characterization of cDNAs 
encoding three isoforms of phospholipase A2 in Malayan spitting cobra (Naja 
naja sputatrix) venom. Toxicon 35: 27-37.  
 
Ayer-LeLievre, C., Olson, L., Ebendal, T., Seiger, A. and Persson, H. (1988) 
Expression of the beta-nerve growth factor gene in hippocampal neurons. 
Science 240: 1339-41.
 
Bahr, B.A., Kessler, M., Rivera, S., Vanderklish, P.W., Hall, R.A., Mutneja, 
M.S., Gall, C. and Hoffman, K.B. (1995) Stable maintenance of glutmate 
receptors and other synaptic components in long-term hippocampal slices. 
Hippocampus 5: 425-439. 
 
 
Barrett, G.L. and Bartlett, P.F. (1994) The p75 nerve growth factor receptor 
mediates survival or death depending on the stage of sensory neuron 




Barett, J.C. and Kawasaki, E.S. (2003) Microarrays: the use of oligonucleotides 
and cDNA for the analysis of gene expression. Drug Discovery Today 8: 134-
141.  
 
Beattie, E.C., Howe, C.L., Wilde, A., Brodsky, F.M. and Mobley, W.C. (2000) 
NGF signals through TrkA to increase clathrin at the plasma membrane and 
enhance clathrin-mediated membrane trafficking. J Neurosci. 20: 7325-7333. 
 
Beattie M. S., Harrington A. W., Lee R., Kim J. Y., Boyce S. L. and Longo F. 
M. et al. (2002) ProNGF induces p75-mediated death of oligodendrocytes 
following spinal cord injury. Neuron 36: 375–386. 
 
Benedetti, M., Levi, A. and Chao, M.V. (1994) Differential expression of nerve 
growth factor receptors leads to altered binding affinity and neurotrophin 
responsiveness. Proc Natl Acad Sci USA 90: 7859-7863.  
 
Beraud, C., Henzel, W.J. and Baeuerle, P.A. (1999) Involvement of regulatory 
and catalytic subunits of phosphoinositide-3-kinase in NF-kappaB activation. 
Proc Natl Acad Sci USA 96: 429-434.  
 
Bernard, A., Fehat, L., Dessi, F., Charton, G., Represa, A., Ben Ari, Y. and  
Khrestchatisky, M. (1999)  Q/R editing of the rat GluR5 and GluR6 kainate 
receptors in vivo and in vitro: evidence for independent developmental, 
pathological and cellular regulation. Eur J Neurosci. 11: 604-616.  
 
Bibel M. and Barde, Y.A. (2000) Neurotrophins: key regulators of cell fate and 
cell shape in the vertebrate nervous system. Genes Dev. 14: 2919-2937. 
 
Birnboim, H.C. and Doly, J. (1979) A rapid alkaline extraction procedure for 
screening recombinant plasmid DNA. Nucleic Acids Res. 7: 1513-1523.  
 
Bittner, M., Meltzer, P., Chen, Y., Jiang, Y., Seftor, E., Hendrix, M., 
Radmacher, M., Simon, R., Yakhini, Z., Ben-Dor, A., Sampas, N., Dougherty, 
E., Wang, E., Marincola, F., Gooden, C., Lueders, J., Glatfelter, A., Pollock, P., 
Carpten, J., Gillanders, E., Leja, D., Dietrich, K., Beaudry, C., Berens, M., 
Alberts, D. and Sondak, V. (2000) Molecular classification of cutaneous 
malignant melanoma by gene expression profiling. Nature 406: 536-540.  
 
 
Blaabjerg, M., Fang, L., Zimmer, J. and Baskys, A. (2003) Neuroprotection 
against NMDA excitotoxicity by group I metabotrophic glutamate receptors is 
associated with reduction of NMDA stimulated currents. Exp Neurol. 183: 573-
580.  
 
Boniece, I.R. and Wagner, J.A. (1995) NGF protects PC12 cells against 
ischemia by a mechanism that requires the N-kinase. J Neurosci Res. 40: 1-9. 
 
Bonni, A., Brunet, A., West, A.E., Datta, S.R., Takasu, M.A. and Greenberg, 
M.E. (1999) Cell survival promoted by the Ras-MAPK signaling pathway by 
transcription-dependent and –independent mechanisms. Science 286:1358-1362. 
 243
References 
Bothwell, M. (1995) Functional interactions of neurotrophins and neurotrophin 
receptors. Annu Rev Neurosci. 18: 223-253. 
 
Brunet, A., Bonni, A., Zigmond, M. J., Lin, M. Z., Juo, P., Hu, L. S., Anderson, 
M.J., Arden, K.C., Blenis, J. and Greenberg, M.E. (1999) Akt promotes cell 
survival by phosphorylating and inhibiting a Forkhead transcription factor. Cell 
96: 857-868. 
 
Bruno, V. Copani, A., Knopfel, T., Kuhn, R., Casabona, G., Dell’Albani, P. 
Condorelli, D.F. and Nicoletti, F. (1995) Activation of metebotrophic gluatamate 
receptors coupled to inositol phospholipids hydrolysis amplifies NMDA-induced 
neuronal degeneration in culture cortical cells. Neuropharmacology 34: 1089-
1098.  
 
Bui, N.T., Konig, H.G., Culmsee, C., Bauerbach, E., Poppe, M., Krieglstein, J. 
and Prehn, J.H. (2002) p75 neurotrophin receptor is required for constitutive and 
NGF-induced survival signaling in PC12 cells and rat hippocampal neurons. J 
Neurochem. 81: 594-605.  
 
Bunone, G., Mariotti, A., Compagni, A., Morandi, E. and Della, V.G. (1997) 
Induction of apoptosis by p75 neurotrophin receptor in human neuroblastoma 
cells. Oncogene 14: 1463-1470. 
 
Bustin, S.A. (2000) Absolute quantitation of mRNA using real-time reverse 
transription polymerase chain reaction assays. J Mol Endocrinol. 25: 169-193.   
 
Butte, A. (2002) The use and analysis of microarrays. Nat Rev. 1: 951-960.   
 
Cardone, M. H., Roy, N., Stennicke, H. R., Salvesen, G. S., Franke, T. F., 
Stanbridge, E. et al. (1998) Regulation of cell death protease caspase-9 by 
phosphorylation. Science 282: 1318-1321. 
 
Casaccia-Bonnefil, P., Carter, B. D., Dobrowsky, R. T. and Chao, M. V. (1996) 
Death of oligodendrocytes mediated by the interaction of nerve growth factor 
with its receptor p75. Nature 383: 716-719. 
 
Casaccia-Bonnefil, P., Gu, C. and Chao, M.V. (1999) Neurotrophins in cell 
survival/death decisions. Adv Exp Med Biol. 468: 275-282. 
 
Chao, M.V. (2003) Neurotrophins and their receptors: a convergence point for 
many signalling pathways. Nat Rev Neurosci. 4: 299-309.   
 
Chemin, J., Monteil, A., Dubel, S., Nargeot, J. and Lory, P. (2001) The alpha1I 
T-type calcium channel exhibits faster gating properties when overexpressed in 
neuroblastoma/glioma NG 108-15 cells. Eur J Neurosci 14: 1678-1686. 
  
Chen, Y., Dicou, E., and Djakiew, D. (1997) Characterization of nerve growth 
factor precursor expression in rat spermatids and the trophic effects of nerve 
growth factor in the maintenance of Sertoli cell viability. Mol Cell Endocrinol. 
127: 129-136.  
 244
References 
Cher, C.D.N. (2005). Molecular mechanisms underlying the pharmacological 
activities of Naja Sputatrix venom. PhD thesis, National University of 
Singapore. Pp: 175-190.  
 
Cheung, A.T., Bavaria, J.E., Weiss, S.J., Patterson, T. and Stecker, M.M. (1998) 
Neurophysiologic effects of retrograde cerebral perfusion used for aortic 
reconstruction. J Cardiothorac Vasc Anesth. 12: 252-259. 
 
Choi, D.W. (1988) Glutamate neurotoxicity and diseases of the nervous system. 
Neuron 1: 623-634. Review. 
 
Choi, D.W. (1992) Excitotoxic cell death. J Neurobiol. 23: 1261-1276. Review. 
 
Chu, S., DeRisi, J., Eisen, M., Mulholland, J., Botstein, D., Brown, P.O. and 
Herskowitx, I. (1998) The transcriptional program of sporulation in budding 
yeast. Science 282: 699-705.  
 
Chuang, S.C., Bianchi, R. and Wong, R.K. (2000) Group I mGluR activation 
turns on a voltage-gated inward current in hippocampal pyramidal cells. J 
Neurophysiol. 83: 2844-2853.  
 
Cohen, S., Levi-Montalcini, R. and Hamburger, V. (1954) A nerve growth-
stimulating factor isolated from sarcomas 37 and 180. Proc Natl Acad Sci USA 
40: 1014-1018.  
 
Cohen S. and Levi-Montalcini R. (1956) A nerve growth growth-stimulating 
factor isolated from snake venom. Proc Natl Acad Sci U S A 42: 571-574. 
 
Cook, M., Caswell, R.C., Richards, R.J., Kay, J. and Tatnell, P.J. (2001) 
Regulation of human and mouse procathepsin E gene expression. Eur J Biochem 
268: 2658-2668. 
 
Corbit, K.C., Foster, D.A. and Rosner, M.R. (1999) Protein kinase Cδ mediates 
neurogenic but not mitogenic activation of mitogen-activated protein kinase in 
neuronal cells. Mol Cell Biol. 19: 4209–4218. 
 
Cortazzo, M.H., Kassis, E.S., Sproul, K.A. and Schor, N.F. (1996) Nerve growth 
factor (NGF)-mediated protection of neural crest cells from antimitotic agent-
induced apoptosis and the role of the low-affinity NGF receptor. J Neurosci. 16: 
3895-3899.  
 
Cosgaya, J. M., Chan, J. R. and Shooter, E. M. (2002) The neurotrophin receptor 
p75NTR as a positive modulator of myelination. Science 298: 1245–1248. 
 
Culmsee, C., Gerling, N., Lehmann, M., Nikolova-Karakashian, M., Prehn, J.H., 
Mattson, M.P. and Krieglstein, J. (2002) Nerve growth factor survival signaling 
in culture hippocampal neurons is mediated through TrkA and requires the 




Dahn, M.S. (1998) The role of growth factors in a wound management of 
diabetic foot ulcers. Fed Pract. 7: 14-19.  
 
Darling, T.L., Petrides, P.E., Beguin, P., Frey, P., Shooter, E.M., Selby, M. and 
Rutter, W.J. (1983) The biosynthesis and processing of proteins in the mouse 7S 
nerve growth factor complex. Cold Spring Harbor Symp Quant Biol. 48: 427-
434.  
 
Dartsch, D.C., Scharfer, A., Boldt, S., Kolch, W and Marquardt, H. (2002) 
Comparison of anthracycline-induced death of human leukemia cells: 
programmed cell death versus necrosis. Apoptosis 7: 537-548.   
 
Datta, S.R., Dudek, H., Tao, X., Masters, S., Fu, H. Gotoh, Y. and Greenberg, 
M.E. (1997) Akt phosphorylation of BAD couples survival signals to the cell-
intrinsic death machinery. Cell 91:1–20. 
 
Datta, S.R., Brunet, A. and Greenberg, M.E. (1999) Cellular survival: a play in 
three Akts. Genes Dev. 13: 2905–2927. 
 
Dawson, R. Jr., Beal, M.F., Bondy, D.A., Di Monte, D.A. and Isom, G.E. (1995) 
Excitotoxins, aging and environmental neurotoxins: implications for 
understanding human neurodegeneration diseases. Toxicol Appl Pharmacol. 
134: 1-17.  
 
Dechant, G. and Barde, Y. A. (2002) The neurotrophin receptor p75 (NTR): 
novel functions and implications for diseases of the nervous system. Nat 
Neurosci. 5: 1131–1136. 
 
DeFreitas, M.F., McQuillen, P.S. and Shatz, C.J. (2001) A novel p75NTR 
signaling pathway promotes survival not death of immunopurified neocortical 
subplate neurons. J Neurosci. 21: 5121-5129.  
 
del Peso, L., Gonzalez-Garcia, M., Page, C., Herrera, R., and Nunez, G. (1997) 
Interleukin-3-induced phosphorylation of BAD through protein kinase Akt. 
Science 278: 687-689.  
 
Diaz-Meco, M.T., Dominguez, I. Sanz, L., Dent, P., Lozano, J., Municio, M.M., 
Bera, E., Hay, R.T., Sturgill, T.W. and Moscat, J. (1994) zeta PKC induces 
phosphorylation and inactivation of I kappa B-alpha in vitro. EMBO J. 13: 2842-
2848.  
 
Dicou, E. (1989) Interaction of antibodies to synthetic peptides of proNGF with 
in vitro synthesized NGF precursors. FEBS Lett. 255: 215-218. 
 
Dicou, E., Pflug, B., Magazin, M., Lehy, T., Djakiew, D., Ferrara, P., Nerriere, 
V., and Harvie, D. (1997) Two peptides derived from the nerve growth factor 




Dowling, P., Ming, X., Raval, S., Husar, W., Casaccia-Bonnefil, P., Chao, M., 
Cook, S. and Blumberg, B. (1999) Up-regulated p75NTR neurotrophin receptor 
on glial cells in MS plaques. Neurology 53: 1676–1682. 
 
Dubois, C.M., Laprise, M.H., Blanchette, F., Gentry, L.E. and Leduc, R. (1995) 
Processing of transforming growth factor beta 1 precursor by human furin 
convertase. J Biol Chem. 270: 10618-10624.  
 
Duggan, D.J., Bittner, M., Chen, Y., Meltzer, P. and Trent, J.M. (1999) 
Expression profiling using cDNA microarrays. Nat Genet. 21: 10-14.   
 
Earl, S.T., Birrell, G.W., Wallis, T.P., St Pierre, L.D., Masci, P.P., de Jersey, J., 
Gorman, J.J. and Lavin, M.F. (2006) Post-translational modification accounts for 
the presence of varied forms of nerve growth factor in Australian elapid snake 
venoms. Proteomics 6: 6554-6565. 
 
Edstrom, A. (1992) Reptiles. In: Venomous and poisonous animals. Krieger 
Publishing Company, Malabar, Florida. Pp: 125 -152. 
 
Edwards, R.H., Selby, M.J., Garcia, P.D. and Rutter, W.J. (1988a) Processing of 
the native nerve growth factor precursor to form biologically active nerve growth 
factor. J Biol Chem. 270: 12297. 
 
Edwards, R.H., Selby, M.J., Mobley, W.C. Weinrich, S.L., Hruby, D.E. and 
Rutter, W.J. (1988b) Processing and secretion of nerve growth factor: expression 
in mammalian cells with a vaccinia virus vector. Mol Cell Biol. 8: 2456-2464.  
 
Eisen, M.B., Spellman, P.T., Brown, P.O. and Botstein, D. (1998) Cluster 
analysis and display of genome-wide expression patterns. Proc Natl Acad Sci 
USA 95: 14863-14868.  
 
Elliot-Hunt, C.R., Kazlauskaite, J., Wilde, G.J.C., Grammatopoulos, D.K. and 
Hillhouse, E.W. (2002) Potential signaling pathways underlying corticotrophin-
releasing hormone-mediated neuroprotection from excitotoxicity in rat 
hippocampus. J Neurochem. 80: 416-425. 
 
Facer, P., Mathur, R., Pandya, S., Singhal, B. and Anand, P. (1998) Correlation 
of quantitative tests of nerve and target organ dysfunction with skin 
immnuohistology in leprosy. Brain 121: 2239-2247. 
 
Facer, P., Mann, D., Matahur, R., Pandya, S., Ladiwala, U., Singhal, B., Hongo, 
J.-A., Sinicropi, D.V., Terenghi, G. and Anand, P. (2000) Do NGF-related 
mechanisms contribute to loss of cutaneous nociception in leprosy? Pain 85: 
231-238.  
 
Fahnestock, M., Michalski, B., Xu, B. and Coughlin, M.D. (2001) The precursor 
pro-nerve growth factor is the predominant form of nerve growth factor in brain 




Fahnestock, M., Yu, G., Michalski, B., Mathew, S., Colquhoun, A., Ross, G.M., 
and Coughlin, M.D. (2004) The nerve growth factor precursor proNGF exhibits 
neurotrophic activity but is less active than mature nerve growth factor. J 
Neurochem. 89: 581-592. 
 
Farhadi, H.F., Mowla, S.J., Petrecca, K., Morris, S.J., Seidah, N.G. and Murphy, 
R.A. (2000) Neurotrophin-3 sorts to the constitutive secretory pathway of 
hippocampal neurons and is diverted to the regulated secretory pathway by 
coexpression with brain-derived neurotrophic factor. J Neurosci. 20: 4059-4068. 
 
Ferri, C.C., Moore, F.A. and Bisby, M.A. (1998) Effects of facial nerve injury 
on mouse motoneurons lacking the p75 low-affinity neurotrophin receptor. J 
Neurobiol. 34: 1-9. 
 
Fischer, W., Wictorin, K., Bjorklund, A., Williams, L.R., Varon, S., and Gage, 
F.H. (1987) Amerlioration of cholinergic neuron atrophy and spatial memory 
impairment in aged rats by nerve growth factor. Nature 329: 65-68.  
 
Fletcher, J.E. and Jiang, M.S. (1993) Possible mechanism of action of cobra 
snake venom cardiotoxin and bee venom mellitin. Toxicon 31: 669-695.   
 
Foehr, E.D., Lin, X., O'Mahony, A., Geleziunas, R., Bradshaw, R.A. and 
Greene, W.C. (2000) NF-kappa B signaling promotes both cell survival and 
neurite process formation in nerve growth factor-stimulated PC12 cells. J 
Neurosci 20: 7556-7563. 
 
Frade, J.M. and Barde, Y.-A. (1999) Genetic evidence for cell death mediated by 
nerve growth factor and the neurotrophin receptor p75 in the developing mouse 
retina and spinal cord. Development 126: 683-690. 
 
Friedman, W.J. (2000) Neurotrophins induce death of hippocampal neurons via 
the p75 receptor. J Neurosci. 20: 6340–6346. 
 
Gahwiler, B.H. (1984) Development of the hippocampus in vitro: cell types, 
synapses and receptors. Neuroscience 11: 751-760. 
 
Gahwiler, B.H., Capogna, M., Debanne, D., McKinney, R.A. and Thompson, 
S.M. (1997) Organotypic slice cultures: a technique has come of age. Trends 
Neurosci. 20: 471-477. Review. 
 
Gavel, Y. and von Heijne, G. (1990) Sequence differences between glycosylated 
and non-glycosylated Asn-X-Thr/Ser acceptor sites: implications for protein 
engineering. Protein Eng. 3: 433–442. 
 
Geetha, T. and Wooten, M.W. (2003) Association of the atypical protein kinase 
C-interacting protein p62/ZIP with nerve growth factor receptor TrkA regulates 
receptor trafficking and Erk5 signaling. J Biol Chem. 278: 4730-4739.  
 
Gendron, F.P., Neary, J.T., Theiss, P.M., Sun, G.Y., Gonzalez, F.A. and 
Weisman, G.A. (2003) Mechanisms of P2X7 receptor-mediated ERK1/2 
 248
References 
phosphorylation in human astrocytoma cells. Am J Physiol Cell Physiol 284: 
C571- C581. 
 
Gentry, J.J., Casaccia-Bonnefil, P. and Carter, B.D. (2000) Nerve growth factor 
activation of nuclear factor kappa B through its p75 receptor is an anti-apoptotic 
signal in RN22 schwannoma cells. J Biol Chem. 275: 7558-7565.  
 
Gentry, J.J., Barker, P.A. and Carter, B.D. (2004) The p75 neurotrophin 
receptor: multiple interactors and numerous functions. Prog Brain Res. 146: 25-
39. 
 
Giehl, K.M., Rohrig, S., Bonatz, H., Gutjahr, M., Leiner, B., Bartke, I., Yan, Q., 
Reichardt, L.F., Backus, C., Welcher, A.A., Dethleffsen, K., Mestres, P. and 
Meyer, M. (2001) Endogenous brain-derived neurotrophic factor and 
neurotrophin-3 antagonistically regulate survival of axotomized corticospinal 
neurons in vivo. J Neurosci. 21: 3492–3502. 
 
Gill, R. and Logde, D. (1997) Pharmacology of AMPA antagonists and their role 
in neuroprotection. Int Rev Neurobiol. 40: 197-232.  
 
Goldberg, M.P., Weiss, J.H., Pham, P.-C. and Choi, D.W. (1987). Methyl-D-
aspartate receptors mediate hypoxic neuronal injury in cortical cultures. J Pharm 
Exp Ther. 243: 784-791. 
 
Goldstein, L.D., Reynolds, C.P. and Perez-Polo, J.R. (1978) Isolation of human 
nerve growth factor from placental tissue. Neurochem Res. 3: 175-183. 
 
Gopalakrishnakone, P., Chou, L.M., Aye, M.M., Lim, F.L.K., Chao, T.C., Lim, 
S. K. and Anantharaman, S. (1990) Clinical features and treatment of specific 
snake bites. In: Snake bites and their treatment. Singapore University Press, 
Singapore. Pp: 34-40. 
 
Greene, L.A. and Rukenstein, A. (1989) The quantitative bioassay of nerve 
growth factor with PC12 cells. In: Nerve Growth Factors. Rush, R.A. (Ed.) 
IBRO Handbook series: Methods in the neurosciences. Chichester, U.K. John 
Wiley & Sons. Vol (12). Pp: 139-147. 
 
Greene, L.A., Shooter, E.M. and Varon, S. (1968) Enzymatic activities of mouse 
nerve growth factor and its subunits. Proc Natl Acad Sci USA 60: 1383-1388.  
 
Greene, L.A. and Tishler, A.S. (1976) Establishment of a noradrenergic clonal 
line of rat adrenal pheochromocytoma cells which respond to nerve growth 
factor. Proc Natl Acad Sci USA 73: 2424-2428. 
 
Grewal, S.S., York, R.D. and Stork, P.J.S. (1999) Extracellular signal-regulated 
kinase signalling in neurons. Curr. Opin. Neurobiol. 9:544–553. 
 
Grob, P. M, Ross, A. H., Koprowski, H. and Bothwell, M. (1985) 
Characterization of the human melanoma nerve growth factor receptor. J Biol 
Chem. 260: 8044. 
 249
References 
Gu, C., Casaccia-Bonnefil P., Srinivasan, A. and Chao M. V.  (1999) 
Oligodendrocyte apoptosis mediated by caspase activation. J Neurosci. 19: 
3043-3049.   
 
Guo, L.Y., Zhu, J.F., Wu, X.F. and Zhou, Y.C. (1999) Cloning of a cDNA 
encoding a nerve growth factor precursor from the Agkistrodon halys Pallas. 
Toxicon 37: 465-470. 
 
Hamanoue, M., Middeton, G., Wyatt, S., Jaffray, E., Hay, R.T. and Davies, A.M. 
(1999) p75-mediated NF-kappa B activation enhances the survival response of 
developing sensory neurons to nerve growth factor. Mol Cell Neurosci. 14: 28-
40.  
 
Haniu, M., Montestruque, S., Bures, E. J., Talvenheimo, J., Toso, R., Lewis-
Sandy, S. Welcher, A.A. and Rohde, M.F. (1997) Interactions between brain-
derived neurotrophic factor and the TRKB receptor: identification of two ligand-
binding domains in soluble TRKB by affinity separation and chemical 
crosslinking. J Biol Chem. 272: 25296–25303. 
 
Harada, T., Morooka, T., Ogawa, S. and Nishida, E. (2001) ERK induces p35, a 
neuron-specific activator of Cdk5, through induction of Egr1. Nat Cell Biol. 3: 
453-459. 
 
Harrington, A.W., Leiner, B., Blechschmitt, C., Arevalo, J.C., Lee, R., Morl, K., 
Meyer, M., Hempstead, B.L., Yoon, S.O., and Giehl, K.M. (2004) Secreted 
proNGF is a pathophysiological death-inducing ligand after adult CNS injury. 
Proc Natl Acad Sci USA 101: 6226-6230. 
 
Harvey, A.L. (1991) Cardiotoxins from cobra venoms. In: Reptile venoms and 
toxinx. Tu, A.T. (Ed). Marcel Dekker, New York. Pp: 85-106.   
 
Hawtin, S.R., Davies, A.R., Matthews, G. and Wheatley, M. (2001) 
Identification of the glycosylation sites utilized on the V1a vasopressin receptor 
and assessment of their role in receptor signalling and expression. Biochem J. 
357: 73-81. 
 
He, X-L. and Garcia, C. (2004) Structure of nerve growth factor complexed 
with the shared neurotrophin receptor p75. Science 304: 870-875. 
 
Hefti, F. (1986) Nerve growth factor (NGF) promotes survival of septal 
cholinergic neurons after fimbrial transaction. J Neurosci. 6: 2155-2162. 
 
Heid, C.A., Stevens, J., Livak, K.J. and Williams, P.M. (1996) Real-time PCR 
quantitative PCR. Genome Res. 6: 986-994.  
 





Hempstead, B.L., Martin-Zanca, D., Kaplan, D.R., Parada, L.F. and Chao, M.V. 
(1991) High-affinity NGF binding requires co expression of the trk proto-
oncogene and the low affinity NGF receptor. Nature 350: 678–683. 
 
Hempstead, B. L. (2002) The many faces of p75NTR. Curr Opin Neurobiol. 12: 
260–267. 
 
Hermans-Borgmeyer, I., Hermey, G., Nykjaer, A. and Schaller,C. (1999) 
Expression of the 100-kDa neurotensin receptor sortilin during mouse 
embryonal development. Brain Res Mol Brain Res. 65: 216-219.  
 
Heymach, J.V., Jr., Kruttgen, A., Suter, U. and Shooter, E.M. (1996) The 
regulated secretion and vectorial targeting of neurotrophins in neuroendocrine 
and epithelial cells.  J Biol Chem. 271: 25430-25437. 
 
Heymach, J.V. Jr and Shooter, E.M. (1995) The biosynthesis of neurotrophin 
heterodimers by transfected mammalian cells. J Biol Chem. 270: 12297-12304. 
 
Hogue-Angeletti, R.A. and Bradshaw, R.A. (1979) Nerve growth factors in 
snake venoms. In: Snake Venoms. (Lee, C.Y., Ed.) Berlin: Springer. Pp: 276-
294. 
 
Holden, P. H., Asopa, V., Robertson, A. G., Clarke, A. R., Tyler, S., Bennett,  
G. S. et al. (1997) Immunoglobulin-like domains define the nerve growth factor 
binding site of the TrkA receptor. Nat Biotechnol. 15: 668–672. 
 
Holgado-Madruga, M., Moscatello, D.K., Emlet, D.R., Dieterich, R., Wong, A.J. 
(1997) Grb2-associated binder-1 mediates phosphatidylinositol- 3-OH kinase 
activation and the promotion of cell survival by nerve growth factor. Proc Natl 
Acad Sci USA 94: 12419–12424. 
 
Hollmann, M., Hartley, M. and Heinemann, S. (1991) Ca2+ permeability of KA-
AMPA-gated glutamate receptor channels depends on subunit composition. 
Science 252: 851-853.  
 
Hosaka, M., Nagahama, M., Kim, W.-S., Watanabe, T., Hatsuzawa, K., Ikemizu, 
J., Murakami, K. and Nakayama, K. (1991) Arg-X-Lys/Arg-Arg motif as a 
signal for precursor cleavage catalyzed by furin within the constitutive secretory 
pathway. J Biol Chem. 266: 12127-12130.  
 
Howard-Jones, N.A. (1995) A CIOMS ethical code for animal experimentation. 
WHO Chronicle 39: 51-56.   
 
Hsu, C.Y., An, G., Liu, J.S., Xue, J.J., He, Y.Y. and Lin, T.N. (1993).Expression 
of immediate early gene and growth factor mRNAs in a focal cerebral ischemia 
model in rat. Stroke 24: I78-I81.  
 
Huang, E.J. and Reichardt, L.F. (2001) Neurotrophins: roles in neuronal 




Huang, E.J. and Reichardt, L.F. (2003) Trk receptors: roles in neuronal signal 
transduction. Annu Rev Biochem. 72: 609-642. Review.  
 
Inagaki, N., Thoenen, H. and Lindholm, D. (1995) TrkA tyrosine residues 
involved in NGF induced neurite outgrowth of PC12 cells. Eur J Neurosci. 
7:1125–1133. 
 
Indo, Y., Tsuruta, M., Hayashida, Y., Karim, M.A., Ohta, K., Kawano, T., 
Mitsubuchi, H., Tonki, H., Awaya, Y. and Matsuda, I. (1996) Mutations in the 
TrkA/NGF receptor gene in patients with congenital insensitivity to pain with 
anhidrosis. Nat Genet. 13: 485-488.  
 
Inoue, S., Oda, T., Koyama, J., Ikeda, K. and Hayashi, K. (1991) Amino acid 
sequences of nerve growth factors derived from cobra venoms. FEBS Lett. 279: 
38-40. 
 
Issaq, H.J., Veenstra, T.D., Conrads, T.P. and Felschow, D. (2002) The SELDI-
TOF MS approach to proteomics: protein profiling and biomarker identification. 
Biochem Biophys Res Commun. 292: 587-592.  
 
Jacobson, M.D., Burne, J.F., King, M.P., Miyashita, T., Reed, J.C. and Raff, 
M.C. (1993) Bcl-2 blocks apoptosis in cells lacking mitochondrial DNA. Nature 
361: 365-369.   
 
Jensen, J.B., Pickering, D.S. and Schousboe, A. (1998) AMPA receptor 
mediated excitotoxicity in neocortical neurons is developmentally regulated and 
dependent upon receptor desensitization. Neurochem Int. 32: 505-513.  
 
Jiang, H., Koubi, D., Zhang, L., Kuo, J., Rodriguez, A.I., Hunter, Gautam, S.C. 
and Levine, R.A. (2005) Inhibitors of iNOS protects PC12 cells against 
apoptosis induced by oxygen and glucose deprivation. Neurosci Lett. 375: 59-
63. 
 
Jing S., Tapley, P. and Barbacid, M. (1992) Nerve growth factor mediates signal 
transduction through trk homodimer receptors. Neuron 9: 1067-1079. 
 
Jonas, P. and Burnashev, N. (1995) Molecular mechanisms controlling calcium 
entry through AMPA-type glutamate receptor channels. Neuron 15: 987-990. 
 
Jorgensen, M., Tygesen, C.K., Andersen, P.H. (1995) Ionotrophic glutatmate 
receptors-focus on non-NMDA receptors. Pharmacol Toxicol. 76: 312-319. 
 
Jullien, J., Guili, V., Reichardt, L.F. and Rudkin, B.B. (2002) Trafficking of 
TrkA-green fluorescent protein chimerae during nerve growth factor-induced 
differentiation. J Biol Chem. 277: 38700-38708. 
 
Kalda, A., Kaasik, A., Vassiljev, V., Pokk, P. and Zharkovsky, A. (2000) 
Neuroprotective action of group I metabotropic glutamate receptor agonists 




Kammermeier, P.J. (2006) Surface clustering of metabotropic glutamate receptor 
1 induced by long Homer proteins. BMC Neurosci. 7: 1. 
 
Kaplan, D.R., Hempstead, B.L., Martin, Z.D., Chao, M.V., Parada, L.F. (1991) 
The Trk proto-oncogene product: a signal transducing receptor for nerve growth 
factor. Science 252: 554-558.  
 
Kaplan, D.R and Miller, F.D. (1997) Signal transduction by the neurotrophin 
receptors. Curr Opin Cell Biol. 9: 213–221. 
 
Kaplan, D.R. and Miller, F.D. (2000) Neurotrophin signal transduction in the 
nervous system. Curr Opin Neurobiol. 10: 381-391. 
 
Kaplan, D.R. and Miller, F.D. (2004) A move to sort life from death. Nature 
427: 798-799. 
 
Karin, M. and Lin, A. (2002) NF-kappa B at the crossroads of life and death. Nat 
Immunol. 3: 221-227.  
 
Kashima, S., Soares, A.M., Roberto, P.G., Pereira, J.O., Astolfi-Filho, S., Cintra, 
A.O., Fontes, M.R., Giglio, J.R., de-Castro Franca, S. (2002) cDNA sequence 
and molecular modeling of a nerve growth factor from Bothrops jararacussu 
venomous gland. Biochimie 84: 675-680. 
 
Keinanen, K., Wisden, W., Sommer, B., Werner, P., Herb, A., Verdoorn, T.A. 
Sakmann, B., Seeburg, P.H. (1990) A family of AMPA-selective glutamate 
receptors. Science 249: 556-560.  
 
Khursigara, G., Bertin, J., Yano H., Moffett, H., DiStefano, P. S. and Chao, M. 
V. (2001) A prosurvival function for the p75 receptor death domain mediated via 
the caspase recruitment domain receptor-interacting protein 2. J Neurosci. 21: 
5854– 5863. 
 
Kim, A.H., Yano, H., Cho, H., Meyer, D., Monks, B., Margolis, B., Birnbaum, 
M.J. and Chao, M.V. (2002) Akt1 regulates a JNK scaffold during excitotoxic 
apoptosis. Neuron 35: 697-609.  
 
Kimpinski, K., Jelinski, S. and Mearow, K. (1999) The anti-p75 antibody, 
MC192, and brain-derived neurotrophic factor inhibit nerve growth factor-
dependent neurite growth from adult sensory neurons. Neuroscience 93: 253-
263. 
 
Kini, R.M. (1997) Phospholipase A2- a complex multifunctional protein puzzle. 
In: Venom phospholipase A2 enzymes: Structure, function and mechanism. Kini, 
R.M. (Ed) John Wiley and Sons Ltd., U.K. pp: 1-28.   
 
Kirschner, P.B., Jenkins, B.G., Schulz, J.B., Finkelstein, S.P., Matthews, R.T., 
Rosen, B.R. and Beal, M.F. (1996) NGF, BDNF and NT-5, but not NT-3 protect 




Kitagawa, K., Matsumoto, M., Tsulimoto, Y., Ohtsuki, T., Kuwabara, K., 
Matsushita, K., Yang, G., Tanabe, H., Martinou, J.C., Hori, M. and Yanagihara, 
T. (1998) Amelioration of hippocampal neuronal damage after global ischemia 
by neuronal overexpression of Bcl-2 in transgenic mice. Stroke 29: 2616-2621. 
 
Klein, D. (2002) Quantification using real-time PCR technology: applications 
and limitations. Trends Mol Med. 8: 257-260.  
 
Kliemannel, M., Golbik, R., Rudolph, R., Schwarz, E. and Lilie, H. (2007) The 
pro-peptide of proNGF: structure formation and intramolecular association with 
NGF. Protein Sci. 16: 411-419. 
 
Koh, D.C., Armugam, A., Jeyaseelan, K. (2004) Sputa nerve growth factor 
forms a preferable substitute to mouse 7S-beta nerve growth factor. 
Biochem J.  383: 149-158. 
 
Koh, D.C., Armugam, A., Jeyaseelan, K. (2006) Snake venom components and 
their applications in biomedicine. Cell Mol Life Sci. 63: 3030-3041. 
 
Koike, T., Uno, S., Ishizawa, M., Takahashi, H., Ikeda, K., Yokota, S. and 
Makishima, M. (2006) The heat shock protein inhibitor KNK437 induces neurite 
outgrowth in PC12 cells. Neurosci Lett. 410: 212-217. 
 
Kolbeck, R., Jungbluth, S. and Barde, Y.A. (1994) Characterization of 
neurotrophin dimers and monomers. Eur J Biochem. 225: 995-1003. 
 
Kong, H., Boulter, J., Weber, J.L., Lai, C. and Chao, M.V. (2001) An 
evolutionarily conserved transmembrane protein that is a novel downstream 
target of neurotrophin and ephrin receptors. J Neurosci. 21:176-185. 
 
Kornfeld, R. and Kornfeld, S. (1985) Assembly of asparagine-linked 
oligosaccharides. Annu. Rev Biochem. 54: 631-664. 
 
Korsching, S., Auburger, G., Heumann, R., Scott, J. and Thoenen, H. (1985) 
Levels of nerve growth factor and its mRNA in the central nervous system of the 
rat correlate with cholinergic innervation. EMBO J. 4: 1389-1393.  
 
Kostiza, T., Dahinden, C.A., Rihs, S., Otten, U. and Meier, J. (1995) Nerve 
growth factor from the venom of the Chinese cobra Naja naja atra: purification 
and description of non-neuronal activities. Toxicon 33: 1249-1261. 
 
Kostiza, T. and Meier, J. (1996) Nerve growth factors from snake venoms: 
chemical properties, mode of action and biological significance. Toxicon 34: 
787-806. 
 
Koubi, D., Jiang, H., Zhang, L., Tang, W., Kuo, J., Rodriguez, A.I., Hunter, T.J., 
Seidman, M.D., Corcoran, G.B and Levine, R.A. (2005) Role of Bcl-2 family of 
proteins in mediating apoptotic death of PC12 cells exposed to oxygen and 




Kristensten, B.W., Noraberg, J. and Zimmer, J. (2001) Comparison of 
excitotoxic profiles of ATPA, AMPA, KA and NMDA in organotypic 
hippocampal slice cultures. Brain Res. 917: 21-44.  
 
Kristian, T. and Siesjo, B.K. (1998) Calcium in ischemic cell death. Stroke 29: 
705-718. Review. 
 
Krohn, A.J., Preis, E. and Prehn, J.H. (1998) Staurosporine-induced apoptosis of 
cultured rat hippocampal neurons involves caspase-1-like proteases as upstream 
initiators and increased production of superoxide as a main downstream effector. 
J Neurosci. 18: 8186-8197. 
 
Krohn, A.J., Wahlbrink, T. and Prehn, J.H. (1999) Mitochondrial depolarization 
is not required for neuronal apoptosis. J Neurosci. 19:7394-7404. 
 
la Cour, T., Gupta, R., Rapacki, K., Skriver, K. Poulsen, F.M. and Brunak, S. 
(2003) NESbase version 1.0 : a database of nuclear export signals. Nucleic Acids 
Res. 31: 393-396.  
 
Lahtinen, H., Autere, A.M., Paalasmaa, P., Lauri, S.E. and Kaila, K. (2001) 
Post-insult activity is a major cause of delayed neuronal death in organotypic 
hippocampal slices exposed to glutamate. Neuroscience 105: 131-137. 
 
Lamballe, F., Klein, R. and Barbacid, M. (1991) TrkC, a new member of the trk 
family of tyrosine protein kinases, is a receptor for neurotrophin-3. Cell 66: 967–
979. 
 
Lee, R., Kermani, P., Teng, K.K. and Hempstead, B.L. (2001) Regulation of cell 
survival by secreted proneurotrophins. Science 294: 1945-1948.  
 
Lees, G.J. and Leong, W. (1993) Differential effects of NBQX on the distal and 
local toxicity of glutamate agonists administered intra-hippocampally. Brain 
Res. 628: 1-7.  
 
Lewin, G.R. and Barde, Y.A. (1996) Physiology of neurotrophins. Annu Rev 
Neurosci. 19: 514-520.  
 
Li, Y., Li. X., Hussain, M. and Sarkar, F.H. (2004) Regulation of microtubule, 
apoptosis, and cell cycle-related genes by taxotere in prostate cancer cells 
analyzed by microarray. Neoplasia 6:158-167. 
 
Liby, K., Wu, H., Ouyang, B., Wu, S., Chen, J. and Dai, W. (2001) Identification 
of the human homologue of the early-growth response gene Snk, encoding a 
serum-inducible kinase. DNA Seq. 11: 527-533. 
 
Lin, H., Hikawa, N., Takenaka, T. and Ishikawa, Y. (2000) Interleukin-12 
promotes neurite outgrowth in mouse sympathetic superior cervical ganglion 




Lindsten, T., Zong, W.X. and Thompson, C.B. (2005) Defining the role of the 
Bcl-2 family of proteins in the nervous system. Neuroscientist 11:10-15. 
 
Lipps, B.V. (1998) Biological and immunological properties of nerve growth 
factor from snake venoms. J Nat Toxins 7: 121-130. 
 
Lipps, B.V. (2000) Isolation of nerve growth factor (NGF) from human body 
fluids; saliva, serum and urine: comparison between cobra venom and cobra 
serum NGF. J Nat Toxins 9: 349-356. 
 
Lipshutz, R. J., Fodor, S. P., Gingeras, T.R. and Lockhart, D.J. (1999). High 
density synthetic oligonucleotide arrays. Nat Genet. 21: 20-24. 
 
Lipton, P. (1999) Ischemic cell death in brain neurons. Physiol Rev. 79: 1431-
1568. 
 
Lockhart, D.J. and Winzeler, E.A. (2000) Genomics, gene expression and DNA 
arrays. Nature 405: 827-836.  
 
Longo, F.M., Manthorpe, M., Xie, Y.M. and Varon, S. (1997) Synthetic NGF 
peptide deriviatives prevent neuronal death via a p75 receptor-dependent 
mechanism. J Neurosci Res. 48: 1-17.  
 
Longo, F.M., Woo, J.E. and Mobley, W.C. (1989) Purification of nerve growth 
factor. In: Nerve growth factor. Rush, R.A. (Ed). IBRO Handbook series: 
Methods in neurosciences. Chichester, U.K.: John Wiley and Sons.  Vol (12). 
Pp: 3-30.  
 
Love, S. (2003) Apoptosis and brain ischemia. Prog Neuropsychopharmacol 
Biol Psychiatry. 27: 267-282. 
 
MacDonald, J. I. and Meakin, S. O. (1996) Deletions in the extracellular domain 
of rat trkA lead to an altered differentiative phenotype in neurotrophin 
responsive cells. Mol Cell Neurosci. 7: 371–390. 
 
Maggirwar, S.B., Samiere, P.D., Dewhurst, S. and Freeman, R.S. (1998) Nerve 
growth factor-dependent activation of NF-kappaB contributes to the survival of 
sympathetic neurons. J Neurosci. 18:10356–10365. 
 
Maggirwar, S.B., Ramirez, S., Tong, N., Gelbard, H.A. and Dewhurst, S. (2000) 
Functional interplay between nuclear factor-kappaB and c-Jun integrated by 
coactivator p300 determines the survival of nerve growth factor-dependent PC12 
cells. J Neurochem. 74: 527-539. 
 
Mahadeo, D., Kaplan, L., Chao, M.V. and Hempstead, B.L. (1994) High affinity 
nerve growth factor binding displays a faster rate of association than p140trk 





Mahoney, M. J. and Saltzman, W. M. (1999) Millimeter-scale positioning of a 
nerve growth factor source and biological activity in the brain. Proc Natl Acad 
Sci USA 96: 4536-4539. 
 
Margarita, G.-C., Erin, P. P., Barbara, L., Rejean, R., Donald W. N. and Nancy, 
A. T. (1998) Inhibition of human caspases by peptide-based and macromolecular 
inhibitors. J Biol Chem. 273: 32608-32613.  
 
Marsh, H.N., Dubreuil, C.I., Quevedo, C., Lee, A., Majdan, M., Walsh, G.S., 
Hausdirff, S., Said, F.A., Zoueva, O., Kozlowski, M., Siminovitch, K., Neel, 
B.G., Miller, F.D. and Kaplan, D.R. (2003) SHP-1 negatively regulates neuronal 
survival by functioning as a TrkA phosphatase. J Cell Biol. 163: 999-1010. 
 
Martin-Zanca, D., Oskam, R., Mitra, G., Copeland, T. and Barbacid, M. (1989) 
Molecular and biochemical characterization of the human trk proto-oncogene. 
Mol Cell Biol. 9: 24-33. 
 
Marton, M.J., DeRisi, J.L., Bennett, H.A., Iyer, V.R., Meyer, M.R., Roberts, 
C.J., Stoughton, R., Burchard, J., Slade, D., Bassett, D.J., Hartwell, L.H., Brown, 
P.O. and Friend, S.H. (1998) Drug target validation and identification of 
secondary drug targets effects using DNA microarrays. Nat Med. 4: 1293-1301.  
 
Massie, B., Couture, F., Lamoureux, L., Mosser, D.D., Guilbault, C., Jolicoeur, 
P., Belanger, F. and Langelier, Y. (1998) Inducible overexpression of a toxic 
protein by an adenovirus with a tetracycline-regulatable expression cassette. J 
Virol. 72: 2289-2296.   
 
Mattson, M.P., Cheng, B. and Smith-Swintosky, V.L. (1993) Mechanisms of 
neurotrophic factor protection against calcium- and free radical-mediated 
excitotoxic injury: implications for treating neurodegenerative disorders. Exp 
Neurol. 124: 89-95.  
 
McArthur, J.C., Yiannoutsos, C., Simpson, D.M., Adornato, B.T., Singer, E.J., 
Hollander, H., Marra, C., Rubin, M., Cohen, B.A., Tucker, T., Navia, B.A., 
Schifitto, G., Katzenstein, D., Rask, C., Zaborski, L., Smith, M.E., Shriver, S., 
Millar, L., Clifford, D.B and the AIDS Clinical Trials Group Team 291 (2000) A 
phase II trial of nerve growth factor for sensory neuropathy associated with HIV 
infection. Neurology 54:1080-1088.  
 
Mcbean, G.J. and Roberts, P.J. (1985). Neurotoxicity of L-glutamate and DL-
threo-3-hydroxyaspartate in the rat striatum. J Neurochem. 44: 247-254. 
 
McCulloch, J. (1991) Ischaemic brain damage--prevention with competitive and 
non-competitive antagonists of N-methyl-D-aspartate receptors. 
Arzneimittelforschung 41: 319-324. 
 
McDonald, N.Q., Lapatto, R., Murray-Rust, J., Gunning, J., Wlodawer, A. and 
Blundell, T.L. (1991) New protein fold revealed by a 2.3-Å resolution crystal 




McDonald, N.Q. and Hendrickson, W.A. (1993). A structural superfamily of 
growth factors containing a cystine knot motif. Cell 73: 421-424. 
 
McNamara, R.K., Huot, R.L., Lenox, R.H. and Plotsky, P.M. (2002) Postnatal 
maternal separation elevates the expression of the postsynaptic protein kinase C 
substrate RC3, but not presynaptic GAP-43, in the developing rat hippocampus. 
Dev Neurosci. 24: 485-494. 
 
Meakin, S.O., MacDonald, J.I.S., Gryz, E.A., Kubu, C.J. and Verdi, J.M. (1999) 
The signaling adapter FRS-2 competes with Shc for binding to the nerve growth 
factor receptor TrkA. J Biol Chem. 274:9861-9870. 
 
Micera, A., Lambiase, A., Puxeddu, I., Aloe, L., Stampachiacchiere, B., Levi-
Schaffer, F. and Bonini, S. (2006) Nerve growth factor effect on human primary 
fibroblastic-keratocytes: Possible mechanism during corneal healing. Exp Eye 
Res. 83: 747-757. 
 
Middleton, G., Hamanoue, M., Enokido, Y., Wyatt, S., Pennica, D., Jaffray, E., 
Hay, R.T. and Davies, A.M. (2000). Cytokine-induced nuclear factor kappa B 
activation promotes the survival of developing neurons. J Cell Biol. 148: 325-
332. 
 
Minton, S.A. (1990). Neurotoxic snake envenoming. Semin Neurol. 10: 52-61.  
 
Mohamed, A.H., Saleh, A.M. and Ahmed, F. (1970) Nerve growth factor from 
Egyptian snake venoms. Toxicon. 9: 201-205.  
 
Monyer, H., Goldberg, M.P.,and Choi, D.W. (1989). Glucose deprivation 
neuronal injury in cortical culture. Brain Res. 483: 347-354. 
 
Morcellin, S., Rossi, C.R., Pilati, P., Nitti, D. and Marincola, F.M. (2003) 
Quantitative real-time PCR: a powerful ally in cancer research. Trend in Mol 
Med. 9: 189-195.  
 
Moriyoshi, K., Masu, M., Ishii, T., Shigemoto, R., Mizuno, N. and Nakanishi, S. 
(1991) Molecular cloning and characterization of the rat NMDA receptor. 
Nature 354: 31-37.  
 
Morrison, T.B., Weis, J.J. and Wittwer, C.T. (1998) Quantification of low-copy 
transcripts by continuous SYBR Green I monitoring during amplification. 
BioTechniques 24: 954-958.  
 
Mowla, S.J., Farhadi, H.F., Pareek, S., Atwal, J.K., Morris, S.J., Seidah, N.G. 
and Murphy, R.A. (2001) Biosynthesis and post-translational processing of the 
precursor to brain-derived neurotrophic factor. J Biol Chem. 276: 12660-12666.  
 
Nadler, J.V., Perry, B.W. and Cotman, C.W. (1978) Intraventricular kainic acid 




Nagasawa, H. and Kogure, K. (1989) Correlation between cerebral blood flow 
and histologic changes in a new rat model of middle cerebral artery occlusion. 
Stroke 20:1037-43. 
 
Nakagomi, S., Suzuki, Y., Namikawa, K., Kiryu-Seo, S. and Kiyama, H. (2003) 
Expression of the activating transcription factor 3 prevents c-Jun N-terminal 
kinase-induced neuronal death by promoting heat shock protein 27 expression 
and Akt activation. J Neurosci. 23: 5187-5196.  
 
Nakagawa, I., Nakata, M., Kawabata, S. and Hamada, S. (1999) Regulated 
expression of the Shiga toxin B gene induces apoptosis in mammalian 
fibroblastic cells. Mol Microbiol. 33: 1190-1199.  
 
Nakanishi, S. and Masu, M. (1994) Molecular diversity and functions of 
glutamate receptors. Ann Rev Biophys Biomol Struct. 23: 319-348.  
 
Nosaka, Y., Arai, A., Miyasaka, N. and Miura, O. (1999) CrkL mediates ras-
dependent activation of the Raf/ERK pathway through the guanine nucleotide 
exchange factor C3G in hematopoietic cells stimulated with erythropoietin or 
interleukin-3. J Biol Chem. 274: 30154-30162. 
 
Nykjaer, A., Lee, R., Teng, K.K., Jansen, P., Madsen, P., Nielsen, M.S., 
Jacobsen, C., Kliemannel, M., Schwarz, E., Willnow, T.E., Hempstead, B.L. and 
Petersen, C.M. (2004) Sortilin is essential for proNGF-induced neuronal cell 
death. Nature 427: 843-848. 
 
Oh, J., Zhong, L.T., Yang, J., Bitler, C.M., Butcher, L.L., Bredsen, D.E. and 
Rabizadeh, S. (1993) Induction of apoptosis of the low-affinity NGF receptor. 
Science 261: 345-348.   
 
Ownby, C.L., Fletcher, J.E. and Colberg, T.R. (1993) Cardiotoxin I from cobra 
(Naja naja atra) venom causes necrosis of skeletal muscle in vivo. Toxicon 31: 
697-709.  
 
Pagano, A., Ruegg, D., Litschig, S., Stoehr, N., Stierlin, C., Heinrich, M., 
Floersheim, P., Prezeau, L., Carroll, F., Pin, J.P., Cambria, A., Vranesic, I., Flor, 
P.J., Gasparini, F. and Kuhn, R. (2000) The non-competitive antagonists 2-
methyl-6-(phenylethynyl)pyridine and 7 hydroxyiminocyclopropan[b]chromen-
1a-carboxylic acid ethyl ester interact with overlapping binding pockets in the 
transmembrane region of group I metabotropic glutamate receptors. J Biol 
Chem. 275: 33750-33758. 
 
Pak, J.H., Huang, F.L., Li, J., Balschun, D., Reymann, K.G., Chiang, C., 
Westphal, H. and Huang, K.P. (2000) Involvement of neurogranin in the 
modulation of calcium/calmodulin-dependent protein kinase II, synaptic 
plasticity, and spatial learning: a study with knockout mice. Proc Natl Acad Sci 
USA 97: 11232-11237. 
 
Palmada M., Kanwal S., Rutkoski N. J., Gufstafson-Brown C., Johnson R. S., 
Wisdom R. et al. (2002) c-jun is essential for sympathetic neuronal death 
 259
References 
induced by NGF withdrawal but not by p75 activation. J Cell Biol. 158: 453–
461. 
 
Palmer, C., Roberts, R.L. and Bero, C. (1994) Deferoxamine posttreatment 
reduces ischemic brain injury in neonatal rats. Stroke 25: 1039-1045. 
 
Pan, Z., Sampath, D. and Jackson, G. (1997) Nerve growth factor and oxidative 
stress in the nervous system. In Brain Plasticity. Plenum. New York.  Pp 173-
193 
 
Paratcha, G., de Stein, M.L., Szapiro, G., Lopez, M., Bevilaqua, L., Cammarota, 
M., de Iraldi, A.P., Izquierdo, I. and Medina, J.H. (2000) Experience-dependent 
decrease in synaptically localized Fra-1. Brain Res Mol Brain Res. 78: 120-130.  
Parkhouse, N. and Le Quesne, P.M. (1988) Impaired neurogenic vascular 
response in patients with diabetes and neuropathic foot lesions. N Engl J Med. 
318: 1306-1309.  
 
Patapoutian, A. and Reichardt, L.F. (2001) Trk receptors: mediators of 
neurotrophin action. Curr Opin Neurobiol. 11: 272-280.
 
Pawson, T and Nash, P. (2000) Protein-protein interactions define specificity in 
signal transduction. Genes Dev. 14:1027–1047. 
 
Pérez, P., Coll, P. M., Hempstead, B. L., Martin-Zanca, D. and Chao, M. V. 
(1995) NGF binding to the trk tyrosine kinase receptor requires the extracellular 
immunoglobulin-like domains. Mol Cell Neurosci. 6: 97–105 
 
Perez-Polo, J. R., Bomar, H., Beck, C., Hall, K., (1978) Nerve growth factor 
from Crotalus adamenteus snake venom.  J Biol Chem. 253: 6140–6148. 
 
Perry, V.H., Anthony, D.C., Bolton, S.J. and Brown, H.C. (1997) The blood– 
brain barrier and the inflammatory response. Mol Med Today 3: 335–341. 
 
Pin, J.P. and Duvoisin, R. (1995) The metabotrophic glutamate receptors: 
structure and functions. Neuropharmacology 34: 1-26.  
 
Pollock, R., Issner, R., Zoller, K., Natesan, S., Rivera, V.M. and Clackson, T. 
(2000) Delivery of a stringent dimerizer-regulated gene expression system in a 
single retroviral vector. Proc Natl Acad Sci USA 97: 13221-13226.  
 
Powell, E. M., Sobarzo, M. R. and Saltzman, W. M. (1990) Controlled release of 
nerve growth factor from a polymeric implant. Brain Res. 515: 309-311. 
 
Pringle, A.K., Iannotti, F., Wilde, G.J.C., Chad, J.E., Seeley, P.J. and Sundstrom, 
L.E. (1997) Neuroprotection by both NMDA and non-NMDA receptor 
antagonists in vitro ischemia. Brain Res. 755: 36-46.  
 
Rabizadeh, S. and Bredesen, D.E. (2003) Ten years on: mediation of cell death 
by the common neurotrophin receptor p75 (NTR). Cytokine Growth Factor Rev. 
14: 225- 239. Review. 
 260
References 
Racke, M.M., Mason, P.J., Johnson, M.P., Brankamp, R.G. and Linnik, M.D.   
(1996) Demonstration of a second pharmacologically active promoter region in 
the NGF gene that induces transcription at the exon 3. Mol Brain Res. 41: 192-
199.  
 
Rattenholl, A., Ruoppolo, M., Flagiello, A., Monti, M., Vinci, F., Marino, G., 
Lilie, H., Schwarz, E. and Rudolph, R. (2001) Pro-sequence assisted folding and 
disulfide bond formation of human nerve growth factor. J Mol Biol. 305: 523-
533.   
 
Reid, A.H. (1964) Cobra-bites. Brit Med J. 2: 540-545.  
 
Reichardt, L.F. and Fariῆas, I. (1997) Neurotrophic factors and their receptors. 
Roles in neuronal development and function. In Molecular and Cellular 
Approaches to Neural Development, (Ed. Cowan W.M., Jessell T.M., Zipursky, 
S.L.) New York: Oxford Univ. Press pp: 220–63.  
 
Riccio, A., Ahn, S., Davenport, C.M., Blendy, J.A. and Ginty, D.D. (1999) 
Mediation by a CREB family transcription factor of NGF-dependent survival of 
sympathetic neurons. Science 286: 2358–2361. 
 
Rodriguez-Tebar, A., Dechant, G. and Barde, Y.-A. (1990) Binding of brain-
derived neurotrophic factor to the nerve growth factor receptor. Neuron 4: 487–
492. 
 
Rodriguez-Tebar, A., Dechant, G., Gotz, R. and Barde, Y. A. (1992) Binding of 
neurotrophin-3 to its neuronal receptors and interactions with nerve growth-
factor and brain-derived neurotrophic factor. EMBO J. 11: 917–922. 
 
Rothman, S. (1988) Non-competitive N-methyl-D-aspartate antagonists affect 
multiple ionic currents. J Pharmac Exp Ther. 246: 137-142. 
 
Roux, P.P., Colicos, M.A., Barker, P.A. and Kennedy, T.E. (1999) p75 
neurotrophin receptor expression is induced in apoptotic neurons after seizure. J 
Neurosci. 19: 6887–6896. 
 
Roux P. P., Bhakar A. L., Kennedy T. E. and Barker P. A. (2001) The p75 
neurotrophin receptor activates Akt (protein kinase B) through a 
phosphatidylinositol 3-kinase-dependent pathway. J Biol Chem. 276: 23097–
23104. 
 
Roux, P. P. and Barker, P. A. (2002) Neurotrophin signaling through the p75 
neurotrophin receptor. Prog Neurobiol. 67: 203-233 
 
Rukenstein, A., Rydel, R.E., Greene, L.A. (1991) Multiple agents rescue PC12 
cells from serum-free cell death by translation- and transcription-independent 
mechanisms. J Neurosci. 11: 2552-2563.  
 
Salehi, A.H., Roux, P.P., Kubu, C.J., Zeindler, C., Bhakar, A., Tannis, L.L., 
Verdi, J.M. and Barker, P.A. (2000) NRAGE, a novel MAGE protein, interacts 
 261
References 
with the p75 neurotrophin receptor and facilitates nerve growth factor-dependent 
apoptosis. Neuron 27: 279–288. 
 
Sambrook, J., Fritsch, F.F. and Maniatis, T. (1989) Molecular cloning: a 
laboratory manual. 2nd Ed. Cold Spring Harbor Laboratory, Cold Spring Harbor, 
N.Y.  
 
Samuels, I.S., Seibenhener, M.L., Neidigh, K.B. and Wooten, M.W. (2001) 
Nerve growth factor stimulates the interaction of ZIP/p62 with atypical protein 
kinase C and targets endosomal localization: evidence for regulation of nerve 
growth factor-induced differentiation. J Cell Biochem. 82: 452-466.  
 
Sanger, F., Nicklen, S. and Coulson, A.R. (1977) DNA sequencing with chain-
terminating inhibitors. Proc Natl Acad Sci USA 74: 5463-5467. 
 
Sarret, P., Krzywkowski, P., Segal, L., Nielsen, M.S., Petersen, C.M., Mazella, 
J., Stroh, T. and Beaudet, A. (2003) Distribution of NTS3 receptor/sortilin 
mRNA and protein in the rat central nervous system. J Comp Neurol. 461: 483-
505. 
 
Saunders, J.J.W. (1966) Death in embryonic systems. Science 154: 604-612.   
 
Schabitz, W.R., Schwab, S. Spranger, M. and Hacke, W. (1997) Intraventricular 
brain-derived neurotrophic factor reduces infarct size after focal cerebral 
ischemia in rats. J Cereb Blood Flow Metab. 17: 500-506
 
Schagger, H. and von Jagow, G. (1987) Tricine-sodium dodecyl sulfate-
polyacrylamide gel electrophoresis for the separation of proteins in the range 
from 1-100kDa. Anal Biochem. 166: 368-379.  
 
Schneider, R. and Schweiger, M. (1991) A novel modular mosaic of cell 
adhesion motifs in the extracellular domains of the neurogenic trk and trkB 
tyrosine kinase receptors. Oncogene 6: 1807–1811. 
 
Schoepp, D.D., Jane, D.E. and Monn, J.A. (1999) Pharmacological agents acting 
at subtypes of metabotropic glutamate receptors. Neuropharmacology 38:1431-
1476. Review. 
 
Schulze, A. and Downward, J. (2001) Navigating gene expression using 
microarrays- a technology review. Nat Cell Biol. 3: E190-195.  
 
Schwab, M., Otten, U., Agid, Y and Thoenen, H. (1979) Nerve growth factor 
(NGF) in the rat CNS: absence of specific retrograde axonal transport and 
tyrosine hydroxylase induction in locus coeruleus and substantia nigra. Brain 
Res. 168: 473-483.  
 
Sealy, L., Mota, F., Rayment, N., Tatnell, P., Kay, J., Chain, B. (1996) 
Regulation of cathepsin E expression during human B cell differentiation in 




Seidah, N.G., Benjannet, S., Pareek, S., Savaria, D., Hamelin, J., Goulet, B., 
Laliberte, J., Lazure, C., Chretien, M. and Murphy, R.A. (1996) Cellular 
processing of the nerve growth factor precursor by the mammalian pro-protein 
convertase. Biochem J. 314: 951-960.   
 
Selby, M.J., Edwards, R., Sharp, F. and Rutter, W.J. (1987) Mouse nerve growth 
factor gene: structure and expression. Mol Cell Biol. 7: 3057-3064. 
 
Server, A.C., Herrup, K., Shooter, E.M., Hogue-Angeletti, R.A., Frazier, W.A. 
and Bradshaw, R.A. (1976) Comparison of the nerve growth factor proteins from 
cobra venom (Naja naja) and mouse submaxillary gland. Biochemistry 15: 35-
39. 
 
Sheardown, M.J., Nielsen, E. ∅., Hansen, A.J., Jacobsen, P. and Honore, T. 
(1990). 2, 3-Dihydroxy-6-nitro-7-sulfamoyl-benzo (F)quinoxaline: a  
neuroprotectant for cerebral ischemia. Science 247: 571-574.  
 
Shetty, V.P., Anita, N.H. and Jacobs, J.M. (1988) The pathology of early 
leprosy. J Neurol Sci. 88: 115-131. 
 
Siigur, J., Arumae, U., Neumann, T. and Saarma, M. (1987) Monoclonal 
antibody immunoaffinity chromatography of the nerve growth factor from snake 
venoms. Comp Biochem Physiol. 87B: 329-334.  
 
Siigur, J., Arumae, U., Siigur, E., Paalme, V., Neumann, T. and Saarma, M. 
(1992) Nerve growth factor from snake venoms. Comparative aspects. In: 
Recent Advances in Toxinology Research. Gopalakrishnakone, P. and Tan, C.K 
(Eds). 1: 154-191.  
 
Smith, P.J., Brandt, W.F., Stickells, B.J. and von Holt, C. (1992) Bitis arierans 
nerve growth factor is a disulphide-linked homodimer. Comp Biochem Physiol. 
103B: 975-980.  
 
Sommer, B., Keinanen, K., Verdoorn, T.A., Wisden, W., Burnashev, N., Herb, 
A., Kohler, M., Takagi, T., and Sakmann, B. (1990) Flip and flop: a cell-specific 
functional switch in glutamate-operated channels of the CNS. Science 249: 
1580-1585.  
 
Stefan, E., Wiesner, B., Baillie, G.S., Mollajew, R., Henn, V., Lorenz, D., 
Furkert, J., Santamaria, K., Nedvetsky, P., Hundsrucker, C., Beyermann, M., 
Krause, E., Pohl, P., Gall, I., MacIntyre, A.N., Bachmann, S., Houslay, M.D., 
Rosenthal. W. and Klussmann, E. (2007) Compartmentalization of cAMP-
dependent signaling by phosphodiesterase-4D is involved in the regulation of 
vasopressin-mediated water reabsorption in renal principal cells. J Am Soc 
Nephrol. 18:199-212. 
 
Stephens, R.M., Loeb, D.M., Copeland, T.D., Pawson, T., Greene, L.A. and 
Kaplan, D.R. (1994) Trk receptors use redundant signal transduction pathways 




Stoppini, L., Buchs, P.A. and Muller, D. (1991) A simple method for 
organotypic cultures for nervous tissue. J Neurosci Methods. 37: 173-182.  
 
Strasser, U. and Fisher, G. (1995) Protection from neuronal damage induced by 
combined oxygen and glucose deprivation in organotypic hippocampal cultures 
by glutamate receptor antagonists. Brain Res. 687:167-174. 
 
Suter, U., Heymach, J.V. Jr and Shooter, E.M. (1991) Two conserved domains 
in the NGF propeptide are necessary and sufficient for the biosynthesis of 
correctly processed and biologically active NGF. EMBO J. 10: 2395-2400. 
 
Sutter, A., Riopelle, R.J., Harris Warrick, R.M. and Shooter, E.M. (1979) Nerve 
growth factor receptors. Characterization of two distinct classes of binding sites 
on chick embryo sensory ganglia cells. J Biol Chem. 254: 5972-5982. 
 
Swanson, R.A. and Choi, D.W. (1993). Glial glycogen stores affect neuronal 
survival during glucose deprivation in vitro. J Cereb Blood Flow Metab. 13: 
162-169. 
 
Synder, E.M., Philpot, B.D., Huber, K.M., Dong, X., Fallon, J.R., Bear, M.F. 
(2001) Internalization of ionotrophic glutamate receptors in response to mGluR 
activation. Nat Neurosci. 4: 1079-1085.  
 
Syroid, D. E., Maycox, P. J., Soilu-Hanninen, M., Petratos, S., Bucci, T., 
Burrola, P., Murray, S., Cheema, S., Lee, K.F., Lemke, G. and Kilpatrick, T.J. 
(2000) Induction of postnatal schwann cell death by the low-affinity 
neurotrophin receptor in vitro and after axotomy. J Neurosci. 20: 5741–5747. 
 
Tabakman, R., Lazarovici, P. and Kohen, R. (2002) Neuroprotective effects of 
carnosine and homocarnosine on pheochromocytoma PC12 cells exposed to 
ischemia. J Neurosci Res. 68: 463-469.  
 
Tabakman, R., Jiang, H., Shahar, I., Arien-Zakay, H., Levine, R.A. and 
Lazarovici. (2005) Neuroprotection by NGF in the PC12 in vitro OGD model. 
Involvement of mitogen-activated protein kinases and gene expression. Ann N Y 
Acad Sci. 1053: 84-96.  
 
Taglialatela, G., Robinson, R. and Perez-Polo, J.R. (1997) Inhibition of nuclear 
factor kappa B (NFkappaB) activity induces nerve growth factor-resistant 
apoptosis in PC12 cells. J Neurosci Res. 47:155–162. 
 
Takai, S., Yamada, K., Kawakami, H., Tanaka, K. and Nakamura, S. (1995) 
Localization of the gene (SLC1A3) encoding human glutamate transporter 
(GluT-1) to 5p13 by fluorescence in situ hybridization. Cytogenet Cell Genet. 
69: 209-210. 
 
Tan, N.H. (1982) Cardiotoxins from the venom of Malayan cobra (Naja naja 
sputatrix ). Arch Biochem Biophy. 218: 51-58.  
 
Tan, N.H. (1983) Improvement of Malayan cobra antivenom. Toxicon 21: 75-79.  
 264
References 
Tan, N.H. and Armugam, A. (1989a) Isolation and characterization of a lethal 
acidic phospholipase A2 from Malayan cobra (Naja naja sputatrix). Biochem Int. 
18: 785-792.  
 
Tan, N.H. and Armugam, A. (1989b) The anticoagulant activity of Malayan 
cobra (Naja naja sputatrix) venom and venom phospholipase A2 enzymes. 
Biochem Int. 19: 803-810.  
 
Tan, N.H. and Armugam, A. (1990) In vivo interactions between neurotoxin, 
cardiotoxin and phospholipase A2 isolated from Malayan cobra (Naja sputatrix) 
venom. Toxicon 28: 1193-1198.  
 
Thiagarajan, P. and Tait, J.F. (1990) Binding of annexin V/ placental 
anticoagulant protein I to platelets. Evidence for phosphatidylserine exposure in 
the procoagulant response to activated platelets. J Biol Chem. 265: 17420-
17423.  
 
Thomas, P.K. and Tomlinson, D.R. (1993) Diabetic and hypoglycemic 
neuropathy. In: Dyck, P.J., Thomas, J.W., Griffin, J.W., P.A Low and Poduslo, 
J.F. (Eds), Peripheral neuropathy, 3rd edition. WB Saunder & Co, 
Philadelphia/London, pp: 1219-1250. 
 
Thompson, J.D., Higgins, D.G. and Gibson, T.J. (1994) CLUSTAL W: 
improving the sensitivity of progressive multiple sequence alignment through 
sequence weighting, position-specific gap penalties and weight matrix choice. 
Nucleic Acids Res. 22: 4673-4680. 
 
Troy, C.M., Friedman, J.E. and Friedman, W.J. (2002) Mechanisms of p75-
mediated death of hippocampal neurons. Role of caspases. J Biol Chem. 277: 
34295-34302.  
 
Tu, J.C., Xiao, B., Yuan, J.P., Lanahan, A.A., Leoffert, K., Li, M., Linden, D.J. 
and Worley, P.F. (1998) Homer binds to a novel proline-rich motif and links 
group I metabotrophic glutmate receptors with IP3 receptors. Neuron 21: 717-
726.  
 
Tuszynski, M.H. ,Thal, L., Pay, M., Slamon, D.P., U, H.S., Bakay, R., Patel, P.,  
Blesch, A., Vahlsing, H.L., Ho, G., Tong, G., Potkin, S.G., Fallon, J., Hansen, 
L., Mufson, E.J., Kordower, J.H., Gall, C. and Conner, J. (2005) A phase 1 
clinical trial of nerve growth factor gene therapy for Alzheimer disease. Nat 
Med. 11: 551-555.  
 
Tuttle, J.B., Etheridge, R. and Creedon, D.J. (1993) Receptor-mediated 
stimulation and inhibition of nerve growth factor secretion by vascular smooth 
muscle. Exp Cell Res. 208: 350-361. 
 
Tuveri, M.A., Generini, S., Matucci-Cerinic, M. and Aloe, L. (2000) NGF, a 
useful tool in the treatment of chronic vasculitic ulcers in rheumatoid arthritis. 




Tuveri, M.A., Triaca, V. and Aloe, L. (2006) The nerve growth factor induces 
cutaneous ulcer healing in "non-responder" tranplanted skin. Ann Ist Super 
Sanita. 42: 94-96. 
 
Tweedie, M.W.F. (1983) The snakes of Malaya. Singapore National Printers, 
Singapore. 
 
Ullrich, A., Gray, A., Berman, C. and Dull, T.J. (1983) Human beta-nerve 
growth factor gene sequence highly homologous to that of mouse. Nature 303: 
821-825.  
 
Ultsch, M.H., Wiesmann, C., Simmons, L.C., Henrich, J., Yang, M., Reilly, D., 
Bass, S.H. and de Vos, A.M. (1999) Crystal structures of the neurotrophin-
binding domain of TrkA, TrkB and TrkC. J Mol Biol. 290:149-159. 
 
Urfer, R., Tsoulfas, P., O’Connell, L., Hongo, J.A., Zhao, W. and Presta, L.G. 
(1998). High resolution mapping of the binding site of TrkA for nerve growth 
factor andTrkC for neurotrophin-3 on the second immunoglobulin-like domain 
of the Trk receptors. J Biol Chem. 273: 5829- 5840. 
 
Vaillant, A.R., Mazzoni, I., Tudan, C., Boudreau, M., Kaplan, D.R. and Miller, 
F.D. (1999) Depolarization and neurotrophins converge on the 
phosphatidylinositol 3-kinase-Akt pathway to synergistically regulate neuronal 
survival. J Cell Biol. 146: 955–966. 
 
Vanden Heuvel, J.P., Tyson, F.L. and Bell, D.A. (1993) Construction of 
recombinant RNA templates for use in internal standards in quantitative RT-
PCR. BioTechniques 14: 395-398.  
 
Vaudry, D., Stork, P.J., Lazarovici, P. and Eiden, L.E. (2002) Signaling 
pathways for PC12 differentiation: making the right connections. Science 296: 
1648-1649.  
 
Viravan, C., Veeravat, U., Warrell, M.J., Theakston, R.D.G. and Warrell, D.A. 
(1986) ELISA confirmation of acute and past envenoming by the monocellate 
Thai cobra (Naja kaouthia). Am J Trop Med Hyg. 35: 173-181.  
 
Vornov, J.J., Tasker, R.C. and Coyle, J.T. (1994). Direct observation of the 
agonist specific regional vulnerability to glutamate, NMDA and kainite 
neurotoxicity in organotypic hippocampal cultures. Exp Neurol. 114: 11-22. 
 
Vornov, J.J., Tasker, R.C. and Park, J. (1995). Neurotoxicity of acute glutamate 
transport blockade depends on coactivation of both NMDA and AMPA/Kainate 
receptors in organotypic hippocampal cultures. Exp Neurol. 133: 7-17. 
 
Wahl, P., Schousboe, A., Honore, T. and Drejer, J. (1989) Glutamate-induced 
increase in intracellular Ca2+ in cerebral cortex neurons is transient in immature 




Wang, H.D., Fukuda, T., Suzuki, T., Hashimoto, K., Liou, S.Y., Momoi, T., 
Kosaka, T., Yamamoto, K., Nakanishi, H. (1999) Differential effects of Bcl-2 
overexpression on hipppocampal CA1 neurons and dentate granule cells 
following hypoxic ischemia in adult mice. J Neurosci Res. 57: 1-12.  
 
Wang, S., Bray, P., McCaffrey, T., March, K., Hempstead, B.L. and Kraemer, 
R., (2000) p75NTR mediates neurotrophin-induced apoptosis of vascular smooth 
muscle cells. Am J Pathol. 157: 1247–1258. 
 
Weeraratna, A.T., Nagel, J.E., Mello-Coelho, V.D. and Taub, D.D. (2004) Gene-
expression profiling: From microarrays to medicine. J Clin Immunol. 24: 213-
224.  
 
Welker, P., Grabbe, J., Gibbs, B., Zuberbier, T. and Henz, B.M. (2000) Nerve 
growth factor-beta induces mast-cell marker expression during in vitro culture of 
human umbilical cord blood cells. Immunology 99: 418-426. 
 
Whitehouse, P.J., Price, D.L., Struble, R.G., Clark, A.W., Coyle, J.T. and Delon, 
M.R. (1982) Alzheimer's disease and senile dementia: loss of neurons in basal 
forebrain. Science 215: 1237–1239. 
 
Whittemore, S.R., Ebendal, T., Larkfors, L., Olson, L., Seigerm A., Stromberg, 
I. and Persson, H. (1986) Developmental and regional expression of β-nerve 
growth factor messenger RNA and protein in the rat central nervous system. 
Proc Natl Acad Sci USA 83: 817-821.  
 
Whittemore, S.R., Friedman, P.L., Larmammar, D., Persson, H., Gonzalez-
Carvajal, M. and Holets, V.R. (1988) Rat β-nerve growth factor sequence and 
the site of synthesis in the adult rat hippocampus. J Neurosci Res. 20: 403-410.  
 
Wiesmann, C., Ultsch, M.H., Bass, S.H. and de Vos, A.M. (1999) Crystal 
structure of nerve growth factor in complex with the ligand-binding domain of 
TrkA receptor. Nature 401: 184-188.  
 
Wiesmann, C. and de Vos, A.M. (2001) Nerve growth factor: Structure and 
function. Cell Mol Life Sci. 58: 748-759.  
 
Wilde, A., Beattie, E.C., Lem, L., Riethof, D.A., Liu, S.H., Mobley, W.C., 
Soriano, P. and Brodsky, F.M. (1999) EGF receptor signaling stimulates SRC 
kinase phosphorylation of clathrin, influencing clathrin redistribution and EGF 
uptake. Cell 96: 677-687. 
 
Wilhelm, J. and Pingoud, A. (2003) Real-time Polymerase Chain Reaction. 
ChemBioChem. 4: 1120-1128.  
 
Williams, B.J., Eriksdotter-Jonhagen, M. and Granholm, A.C. (2006) Nerve 
growth factor in treatment and pathogenesis of Alzheimer's disease. 




Williams, L., Varon, R. S., Peterson, G., Wictorin, K., Fischer, W., Bjorklund, 
A. and Gage, F.H. (1986) Continuous infusion of nerve growth factor prevents 
basal forebrain neuronal cell death after fimbria–fornix transaction. Proc Natl 
Acad Sci USA 83: 9231–9236. 
 
Winzeler, E., Shoemaker, D.D., Astromoff, A., Liang, H., Anderson, K., Andre, 
B., Bangham, R., Benito, R., Boeke, J.D., Bussey, H., Chu, A.M. Connelly, C., 
Davis, K., Dietrich, F., Dow, S.W., El Bakkoury, M., Foury, F., Friend, S.H., 
Gentalen, E., Giaever, G., Hegemann, J.H., Jones, T., Laub, M., Liao, H., 
Liebundguth, N., Lockhart, D.J., Lucau-Danila, A., Lussier, M., M'Rabet, N., 
Menard, P., Mittmann, M., Pai, C., Rebischung, C., Revuelta, J.L., Riles, L., 
Roberts, C.J., Ross-MacDonald, P., Scherens, B., Snyder, M., Sookhai-
Mahadeo, S., Storms, R.K., Veronneau, S., Voet, M., Volckaert, G., Ward, T.R., 
Wysocki, R., Yen, G.S., Yu, K., Zimmermann, K., Philippsen, P., Johnston, M. 
and Davis, R.W. (1999) Functional characterization of the Saccharomyces 
cerevisiae genome by precise deletion and parallel analysis. Science 287: 873-
880.  
 
Wisden, W. and Seeburg, P.H. (1993) Mammalian ionotrophic glutamate 
receptors. Curr Opin Neurobiol. 3: 291-298. 
 
Wolfsberg, T.G. (1999) Candidate regulatory sequence elements for cell cycle-
dependent transcription in Saccharomyces cerevisiae. Genome Res. 9: 775-792.  
 
Wong E.H.F., Kemp, J.A., Priestly, T., Knight, A.R., Woodruff, G.N. and 
Iversen, L.L. (1986) The anticonvulsant MK-801 is a potent N-methyl-D-
aspartate antagonist. Proc Natl Acad Sci USA 83: 7104-7108.  
 
Wooten, M.W., Seibenhener, M.L., Mamidipudi, V., Diaz-Meco, M.T., Barker, 
P.A. and Moscat, J. (2001) The atypical protein kinase C-interacting protein p62 
is a scaffold for NF-kappaB activation by nerve growth factor. J Biol Chem. 
276: 7709-7712.  
 
Wright, J.H., Drueckes, P., Bartoe, J., Zhao, Z., Shen, S.H. and Krebs, E.G. 
(1997) A role for the SHP-2 tyrosine phosphatase in nerve growth-induced PC12 
cell differentiation. Mol Biol Cell 8:1575-1585. 
 
Wyllie, A.H. (1980) Glucocorticoid-induced thymocyte apoptosis is associated 
with endogenous endonuclease activation. Nature 284: 555-556.  
 
Xiao, B., Tu, J.C., Petralia, R.S., Yuan, J.P., Doan, A., Breder, C.D. Ruggiero, 
A., Lanahan, A.A., Wenthold, R.J. and Worley, P.F. (1998) Homer regulates the 
association of group I metabotrophic glutamate receptors with multivalent 
complexes of homer-related, synaptic proteins. Neuron 21: 707-716.  
 
Xing, J., Ginty, D.D. and Greenberg. M.E. (1996) Coupling of the RAS-MAPK 





Xing, J., Kornhauser, J.M., Xia, Z., Thiele, E.A. and Greenberg, M.E. (1998) 
Nerve growth factor activates extracellular signal-regulated kinase and p38 
mitogen-activated protein kinase pathways to stimulate CREB serine 133 
phosphorylation. Mol Cell Biol. 18:1946-1955. 
 
Yamada, M., Ohnishi, H., Sano, S.I., Nakatami, A., Ikeuchi, T. and Hatanaka, H. 
(1997) Insulin receptor substrate (IRS)-2 and IRS-2 are tyrosine-phosphorylated 
and associated with phosphatidylinositol 3-kinase in response to brain-derived 
neurotrophic factor in cultured cerebral cortical neurons. J Biol Chem. 48: 
30334–30339. 
 
Yamamoto, S., Yoshimine, T., Fujita, T., Kuroda, R., Irie, T., Fujioka, K. and 
Hayakawa, T. (1992) Protective effect of NGF atelocollagen mini-pellet on the 
hippocampal delayed neuronal death in gerbils. Neurosci Lett. 141: 161-165. 
 
Yamashita, T., Tucker, K. L. and Barde, Y.-A. (1999) Neurotrophin binding to 
the p75 receptor modulates Rho activity and axonal outgrowth. Neuron 24: 585–
593. 
 
Yao, F., Svensjo, T., Winkler, T., Lu, M., Eriksson, C. and Eriksson, E. (1998) 
Tetracycline repressor, tetR, rather than the tetR-mammalian cell transcription 
factor fusion deriviatives, regulates inducible gene expression in mammalian 
cells. Hum Gene Ther. 9: 1939-1950.  
 
Yao, R., Osada, H. and Yoshihara, M. (1997) Specific activation of a c-Jun 
NH2-terminal kinase isoform and induction of neurite outgrowth in PC-12 cells 
by staurosporine. J Biol Chem. 272: 18261-18266. 
 
Yoon S. O., Casaccia-Bonnefil P., Carter B. and Chao M. V. (1998) Competitive 
signaling between TrkA and p75 nerve growth factor receptors determine cell 
survival. J Neurosci. 18: 3273–3281. 
 
York, R.D., Yao, H., Dillon, T., Ellig, C.L., Eckert, S.P., McCleskey, E.W. and 
Stork P.J. (1998) Rap1 mediates sustained MAP kinase activation induced by 
nerve growth factor. Nature 393: 622–626. 
 
York, R.D., Mollivar, D.C., Grewal, S.S., Steinberg, P.E., McCleskey, E.W. and 
Stork, P.J.S. (2000) Role of phosphoinositide 3-kinase and endocytosis in NGF 
induced extracellular signalregulated kinase activation via Ras and Rap1. Mol 
Cell Biol. 20:18069–18083. 
 
Yuan, J. and Yankner, B.A. (2000) Apoptosis in the nervous system. Nature 
407: 802–809. 
 
Zha, H. and Reed, J.C. (1997) Heterodimerization-independent functions of cell 
death regulatory proteins Bax and Bcl-2 in yeast and mammalian cells. J Biol 




Zhang, H., Hoang, T., Saeed, B. and Ng, S.C. (1996) Induction of apoptosis in 
prostatic tumor cell line DU14S by staurosporine, a potent inhibitor of protein 
kinases. Prostate 26: 69-76.  
 
Zhang, Y. and Pardridge, W.M. (2006) Blood-brain barrier targeting of BDNF 
improves motor function in rats with middle cerebral artery occlusion. Brain 
Res. 1111: 227-229. 
 
Zhao, Q., Pahlmark, K., Smith, M.L. and Siesjo, B.K. (1994) Delayed treatment 
with the spin trap alpha-phenyl-N-tert-butyl nitrone (PBN) reduces infarct size 
following transient middle cerebral artery occlusion in rats. Acta Physiol Scand. 
152: 349-350. 
 
Zhou, A.W., Li, W.X., Guo, J. and Du, Y.C. (1997) Facilitation of AVP (4-8) on 
gene expression of BDNF and NGF in rat brain. Peptides 18: 1179-1187. 
 
Zou, L. L., Huang, L., Hayes, R.L., Black, C., Qiu, Y. H., Perez-Polo, J. R., Le, 
W., Clifton, G. L. and Yang, K. (1999) Liposome-mediated NGF gene 
transfection following neuronal injury: potential therapeutic applications. Gene 




































Biochem. J. (2004) 383, 149–158 (Printed in Great Britain) 149
Sputa nerve growth factor forms a preferable substitute to mouse 7S-β
nerve growth factor
Dawn C.-I. KOH, A. ARMUGAM and K. JEYASEELAN1
Department of Biochemistry, Faculty of Medicine, National University of Singapore, 8 Medical Drive, Singapore 117597, Singapore
The NGF (nerve growth factor) from Naja sputatrix has been puri-
fied by gel filtration followed by reversed-phase HPLC. The pro-
tein showed a very high ability to induce neurite formation in
PC12 cells relative to the mouse NGF. Two cDNAs encoding
isoforms of NGF have been cloned and an active recombinant
NGF, sputa NGF, has been produced in Escherichia coli as a His-
tagged fusion protein. Sputa NGF has been found to be non-toxic
under both in vivo and in vitro conditions. The induction of neurite
outgrowth by this NGF has been found to involve the high-affinity
trkA–p75NTR complex of receptors. The pro-survival mechanism
of p75NTR has been mediated by the activation of nuclear factor κB
gene by a corresponding down-regulation of inhibitory κB gene.
Real-time PCR and protein profiling (by surface-enhanced laser-
desorption–ionization time-of-flight) have confirmed that sputa
NGF up-regulates the expression of the endogenous NGF in PC12
cells. Preliminary microarray analysis has also shown that sputa
NGF is capable of promoting additional beneficial effects such
as the up-regulation of arginine vasopressin receptor 1A, voltage-
dependent T-type calcium channel. Hence, sputa NGF forms a
new and useful NGF.
Key words: Naja sputatrix, nerve growth factor (NGF), neurite
outgrowth, PC12 cells, sputa NGF.
INTRODUCTION
In the past decade, the neurotrophin family has gathered much in-
terest as potentially useful therapeutic agents against neurological
disorders. The neurotrophin family is made up of NGF (nerve
growth factor), BNDF (brain-derived growth factor), NT-3 (neuro-
trophin-3), NT-4 and a newly discovered NT-6. Neurotrophins are
made up of small, homodimeric proteins and they use two dif-
ferent receptors (i) Trk (tropomyosin-related kinase) receptor
tyrosine kinase and (ii) p75 neurotrophin receptor [a member
of the TNF (tumour necrosis factor) receptor superfamily]. The
binding of neurotrophin to its receptors has been shown to me-
ditate the survival, differentiation, growth or apoptosis of neurons.
Both receptors have been found in the same cell and are known
to act synergistically to bring about the targeted response of neuro-
trophins from the neurons during the development of the nervous
system [1]. NGF is required for the survival of the differentiated
cells. Both p75NTR and TrkA receptors act synergistically to
mediate the trophic effects of NGF in cells that produce them
(e.g. PC12 cells). Co-expression of p75NTR has also been found
to enhance the biological response of cells expressing TrkA [2].
Interestingly, the TrkA receptor activates positive signals such
as increased survival and growth, whereas the p75NTR receptor is
known to activate both positive and negative signals. Complexes
of p75NTR with TrkA have been found to enhance the neurotrophin-
binding affinity and TrkA-associated signalling pathway [3].
Neuroprotection by NGF and activation of NF-κB (nuclear factor
κB, a pro-survival transcription factor) have also been shown to
be dependent on the expression of p75NTR in PC12 cells [4].
NGF has been detected in various animals including snakes
[5–7]. NGFs from human placental tissues and body fluids have
been documented by Goldstein et al. [8] and Lipps [7]. However,
the most extensively studied NGF has been obtained from the
male mouse submaxillary glands (mouse NGF; [9]). NGF from
snakes, particularly from cobras, has been reported to be superior
in inducing neurite outgrowth on PC12 cells when compared
with NGFs derived from other types of snakes [9]. Server et al.
[10] reported that NGFs from cobra, Naja naja, and mouse sub-
maxillary glands could also elicit neurite outgrowth from chick
embryonic dorsal root ganglion.
NGF is normally produced as a pre-pro-precursor, which is then
processed to a mature protein by endopeptidases [11]. The NGF
from snakes has also been produced as a pre-pro-NGF molecule
with 241 amino acids, which is later processed to form a mature
NGF comprising 119 amino acids. Approx. 60% homology has
been seen between the NGF from snakes and rodents. cDNAs
encoding mouse, human, bovine, chick and snake NGFs have also
been cloned and sequenced [5,6]. In the present study, we describe
the cloning and sequencing of two new cDNAs encoding the
NGF in the venom glands of a spitting cobra, Naja sputatrix.
The expressed and refolded recombinant protein, sputa NGF, has
been found to be equally active as the mouse NGF in forming neur-
ites in PC12 cells. Functional studies have shown that the sputa
NGF promotes neurite outgrowth via the TrkA and p75NTR re-
ceptors. Activation of NF-κB gene showed that the pro-survival
mechanism of p75NTR-mediated signalling is initiated after the ad-
dition of sputa NGF. Furthermore, the endogenous NGF in the
PC12 cells has been found to be up-regulated only after treatment
with sputa NGF. Oligoprobe microarray analysis also showed
that the sputa NGF, although acting through similar mechanisms
to mouse NGF, may be capable of bringing about additional
beneficial effects.
Abbreviations used: AKAP, A-kinase anchoring protein; ATF3, activating transcription factor 3; BAD, Bcl-2/Bcl-XL-antagonist, causing cell death; CaM,
calmodulin; CE, cathepsin E; CNS, central nervous system; Egr 1, early growth response 1; IκB, inhibitory κB; IL-12, interleukin-12; NF-κB, nuclear factor
κB; NGF, nerve growth factor; NT-3, neurotrophin-3; RT, reverse transcription; SELDI-TOF, surface-enhanced laser-desorption–ionization-time-of-flight;
SHP-1, Src homology 2 domain-containing tyrosine phosphatase-1; Trk, tropomyosin-related kinase; V1a, vasopressin receptor 1A.
1 To whom correspondence should be addressed (email bchjeya@nus.edu.sg).
The nucleotide sequence data reported have been submitted to the DDBJ, EMBL, GenBank® and GSDB Nucleotide Sequence Databases under the
accession numbers AY527215 and AY527216.
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MATERIALS AND METHODS
Venom, venom glands and PC12 cells
An adult snake (N. sputatrix) obtained from Singapore Zoological
Gardens (Singapore), kept undisturbed, was milked and the venom
was freeze-dried and stored at − 20 ◦C. The venom glands from
the same snake were frozen in liquid nitrogen immediately
after killing the animal and stored at − 85 ◦C. PC12 cells were
obtained from A.T.C.C. (Manassas, VA, U.S.A.) and maintained
in Dulbecco’s modified Eagle’s medium supplemented with 10%
(v/v) fetal bovine serum and 1% antibiotics (penicillin and
streptomycin; [12]) at 37 ◦C in 5% CO2. The ability of the sputa
NGF to elicit neurite outgrowth on PC12 cells was determined as
described by Greene and Tishler [13].
Purification of native cobra NGF
Freeze-dried crude venom (50 mg) was reconstituted in 1 ml of
water and subjected to gel filtration followed by reversed-phase
HPLC (Vision system; Applied Biosystems, Foster City, CA,
U.S.A.) using a Sephasil C18 column as described by Armugam
et al. [14]. Fractions showing neurite outgrowth on PC12 cells
were used for further studies.
Cloning and sequencing of cDNAs
Total RNA was isolated from the venom glands using the guani-
dine isothiocyanate method [15], and the integrity of the total
RNA was analysed by denaturing formaldehyde agarose electro-
phoresis. Oligonucleotide primers were synthesized by Oswel
DNA Services (Southampton, U.K.) based on the sequence at the
5′- and 3′-untranslated regions of cDNA encoding NGF in Agki-
strodon halys Pallas [6]. Total RNA (3 µg) was reverse-trans-
cribed and amplified by PCR as described by Armugam et al.
[14].
The PCR products were cloned into pT7Blue (R) vector
(Novagen, Madison, WI, U.S.A.) and transformed into
Escherichia coli DH5α: supE44 lacU169 (80lacZm15)
hsdR17 recA1 endA1 gyrA96 thi-1 relA1 [16]. The recombinant
plasmids from the transformants were subjected to Sanger di-
deoxy DNA sequencing using M13/pUC forward and reverse
primers [14,17] on an automated DNA sequencer (Model 3100;
Applied Biosystems).
Expression and purification of recombinant sputa NGF
The cDNA-encoding NGF was amplified using sense and anti-
sense primers, 5′-cctggatccgaagatcatcctgtg-3′ and 5′-ctcaagctttca-
gtttccagtt-3′ respectively, and subcloned into pQE-30 expres-
sion vector (Qiagen, Chatsworth, CA, U.S.A.) between BamHI
and HindIII sites.
The expression of the sputa NGF was induced by isopropyl β-D-
thiogalactoside (1 mM) at 37 ◦C for 3 h and the protein was puri-
fied under denaturing conditions (8 M urea) on a Ni2+-nitrilotri-
acetate Sepharose resin (Qiagen) column. The purified fractions
were analysed by Tris/Tricine SDS/10%-(w/v)-PAGE [18].
In vitro renaturation [19] of the denatured proteins was performed
overnight at room temperature (25 ◦C) in 1 × PBS (pH 8.0), con-
taining 4 mM GSH and 2 mM GSSG.
CD spectral analysis
CD spectra for both the native NGF and recombinant sputa NGF
were recorded on a Jasco spectropolarimeter (J715) equipped
with an interfaced personal computer. It was calibrated with am-
monium d-10-camphorsulphonate. Data collected and averaged
from at least five recordings were considered acceptable. Spectral
measurements were performed at appropriate concentrations
using cells of 0.1 cm path-length [19].
Western-blot analysis
Western blotting was performed as described by Cher et al. [20],
using either monoclonal anti-phosphotyrosine (AG10; Upstate
Biological, Lake Placid, NY, U.S.A.) or polyclonal anti-TrkA
and affinity-purified polyclonal anti-p75NTR (Advanced Targeting
Systems, San Diego, CA, U.S.A.) at 1 µg/ml or monoclonal anti-
β-actin (Sigma Chemicals, St. Louis, MO, U.S.A.) at a dilution of
1:2500. Anti-β-actin was used as a reference for quantification.
Real-time quantitative PCR
Total RNA from PC12 cells was extracted by a single-step method
using TRIzol® reagent (Invitrogen, Carlsbad, CA, U.S.A.). Gene-
specific primers for TrkA, p75NTR, endogenous NGF, NF-κB and
IκB (inhibitory κB) were designed using the PrimerExpress 2.0
software (Applied Biosystems) and their corresponding mRNA
sequences. The primers were designed to yield amplicons of
< 100 bp and synthesized by Alpha-DNA (Montreal, Quebec,
Canada). β-Actin was used as an internal calibrator. The primer
sequences were as follows: TrkA, 5′-catggagaacccacagtacttcag-3′
(sense) and 5′-ctagctcccacttgagaatgatgtc-3′ (antisense); p75NTR,
5′-gtggtcgtgggccttgtg-3′ (sense) and 5′-gcgccttgtttattttgtttgc-
3′ (antisense); rat endogenous NGF, 5′-catggtacaatccctttcaac-3′
(sense) and 5′-ccaacccacacactgacactg-3′ (antisense); NF-κB,
5′-gaagagtcctttcaatggaccaa-3′ (sense) and 5′-tcgggaaggcacagc-
aata-3′ (antisense); IκB, 5′-gctgcccgagagtgcggat-3′ (sense) and
5′-cagtcatcgtagggcaactcatc-3′ (antisense); β-actin 5′-agggaaatc-
gtgcgtgaca-3′ (sense) and 5′-gccatctcctgctcgaagtc-3′ (antisense).
In the present study, a two-step RT (reverse transcription)–PCR
was used. RT was performed as described in [20]. PCR mix-
tures contained RT products, forward and reverse primers each
at 125 nM and SYBR® Green master mixture (Applied Biosys-
tems). The PCR amplification was then performed for 1 cycle at
50 ◦C for 2 min and 95 ◦C for 10 min followed by 40 cycles with
each cycle at 94 ◦C for 15 s and 60 ◦C for 1 min. All reactions
were performed in triplicate using the ABI Prism 7000 SDS
(Applied Biosystems).
Protein profiling [SELDI-TOF (surface-enhanced
laser-desorption–ionization time-of-flight)]
PC12 cells showing neurite outgrowth were rinsed with 0.9%
NaCl and lysed with lysis buffer (50 mM Tris/HCl, pH 7.4,
0.4 mM NaCl, 0.25 M sucrose and 1 mM EDTA, containing 8 M
urea). The supernatant was fractionated on hydrophobic reverse-
phase chip (H4 Protein Chip TM) using SELDI-TOF MS (Protein
Biology System II) both from Ciphergen (Palo Alto, CA, U.S.A.)
according to the manufacturer’s instructions.
Microarray GeneChipTM analysis
Microarray analysis was performed as described by Cher et al.
[20] with the following modifications. Total RNA isolated from
control and treated (mouse NGF or sputa NGF) PC12 cells were
processed and hybridized to each array of the rat expression 230A
GeneChipTM Array set according to the methods described in
the GeneChipTM expression analysis package (Affymetrix, Santa
Clara, CA, U.S.A.). Relative mRNA expression levels were ex-
pressed as positive or negative fold changes when compared with
untreated controls based on the Microarray Suite software 5.0
(Affymetrix). All genes showing a change of 2-fold or more were
included in subsequent analysis. Members in each cluster
were classified according to their biological functions as de-
scribed in the NetAffix database (Affymetrix).
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Table 1 Neurite outgrowth in PC12 cells
Protein concentrations at 100 ng/ml were used unless otherwise stated. ‘+’ denotes neurite
outgrowth observed.
Sample Neurite outgrowth
Mouse NGF (positive control; 100 ng/ml) +++
B. candidus (250 ng/ml) ++
N. sputatrix (250 ng/ml) ++++
A. superbus (250 ng/ml) ++
P. textilis (250 ng/ml) +++
Chinese scorpion (250 ng/ml) ++
Indian scorpion (250 ng/ml) +
Bee venom (250 ng/ml) ++
















Fraction 8 (1 ng/ml) ++++++
Fraction 9 +++
Fraction 10 +
Denatured and refolded recombinant NGF
Denatured recombinant NGF (100 ng/ml) ++
Refolded recombinant NGF (100 ng/ml) ++++
RESULTS
Bioassay of NGF on PC12 cells
Venoms from several elapids, N. sputatrix, Bungarus candidus,
Pseudonaja textilis and Austrelaps superbus, as well as venoms
from Chinese and Indian scorpions (Buthus martensi Karsch and
Mesobuthus tumulus) and honey bee (Apis mellifera) were tested
for neurite outgrowth in PC12 cells. β-NGF (7Sβ-NGF) from
the mouse submaxillary gland was used as a positive control. The
highest neurite outgrowth was observed for N. sputatrix crude
venom at 250 ng/ml. Mouse NGF (7S) showed a comparable ac-
tivity at 100 ng/ml (Table 1).
Identification of a NGF in N. sputatrix venom
The N. sputatrix venom was chromatographed on Biogel P10 (Fig-
ure 1A). The first peak, Peak I, consisted of high-molecular-mass
proteins (14–50 kDa), whereas Peak II contained the low-mole-
cular-mass proteins (4–10 kDa). Each fraction (100 ng/ml) was
tested for its ability to promote neurite growth (Table 1). The
corresponding fraction was also subjected to SDS/PAGE analysis
to verify their homogeneity and to determine the molecular mass.
The fraction showing the highest neurite outgrowth was purified
further on HPLC (Figure 1B). One homogeneous protein peak was
obtained, which showed neurite outgrowth at 1 ng/ml (Table 1).
This active protein was 14 kDa in mass (Figure 1B, inset). The
N-terminal amino acid sequence of this protein was found to be
-ETHPVHNRGEYSV- and the protein was found to be non-lethal
up to 1 µg/g in mouse.
Figure 1 Purification of NGF
(A) Gel-filtration chromatography of crude N. sputatrix venom. (B) Reversed-phase
chromatography of the active fraction obtained from gel filtration. Inset shows the protein (native
sputa NGF fraction) analysed by SDS/PAGE. (C) Purification and refolding of recombinant
NGF (sputa NGF). Lane 1, protein molecular mass standards (sizes indicated in kDa); lane 2,
E. coli cell lysate before induction; lane 3, E. coli cell lysate (inclusion bodies) after 3 h induction;
lane 4, purified sputa NGF; lane 5, refolded sputa NGF. (D) CD spectrum obtained from refolded
recombinant sputa NGF and (E) CD spectrum of native NGF protein.
Cloning and expression of the NGF from N. sputatrix
The cDNA encoded for a 22-amino-acid signal peptide, a 112-
amino-acid pre-pro-domain of NGF and a mature NGF protein
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Figure 2 Comparison of amino acid sequences of various NGF
Sputa nsngfI and nsngfII refer to the two isoforms of NGF from N. sputatrix; bmNGF is from Bungarus multicinctus (S56212); agpngf is from Agkistrodon halys Pallas [6]; mousengf (K01759) and
human ngf (humNGF, X52599). The pro-NGF region is underlined and the mature peptides are shown in boldface letters. Identical amino acids are shown by (*) and the proteolytic cleavage site (KR)
for the mature peptide is indicated by ∧∧ . The variant residues between nsngfI and nsngfII are shown by +.
consisting of 117 amino acid residues. Analysis of the sequences
indicated the presence of two isoforms (nsNGFI and nsNGFII) of
venom NGF (Figure 2). The cDNA encoding the mature protein
of nsNGFI (identical with the NGF isolated from the venom,
Figure 1B) was expressed as a His6-tagged fusion protein (sputa
NGF) and analysed on an SDS/12% (w/v) polyacrylamide gel
(Figure 1C, lane 3). The sputa NGF protein was purified by affinity
chromatography using a Ni2+-nitrilotriacetate column (Figure 1C,
lane 4) and was renatured in the presence of GSSG and GSH
(Figure 1C, lane 5). The yield of the refolded protein was found
to be approx. 3 mg/l. Both the denatured and refolded recombi-
nant NGFs varied in their potency to induce neurite outgrowth
on PC12 cells (Table 1). Both the mouse and sputa NGF were
found to exhibit comparable levels of biological activity (Fig-
ures 3A–3D). The CD spectrum of the refolded recombinant
sputa NGF has been found to correlate well with that of the
native NGF protein (Figures 1D and 1E). Quantification of neurite
outgrowth in the presence of either mouse or sputa NGF (i) with
increasing concentration (Figure 3E) and (ii) with increasing
duration of NGF treatment (Figure 3G) has shown that the re-
folded sputa NGF exhibits a comparable activity with that of
mouse NGF. The native NsNGF has also been found to induce
neurite outgrowth in a dose-dependent manner but at relatively
lower protein concentrations (1–10 ng/ml; Figure 3F).
Expression of TrkA and p75 receptors
Western-blot analysis of the PC12 cells treated separately with
the mouse and sputa NGF for 15 min showed that the sputa
NGF increased the production of the precursor gp110trkA receptors
when compared with the mouse NGF. However, the mature
gp140trkA receptor was found in equal amounts for both treatments
(Figures 3H and 3I). Neurite extensions can be observed only
after 12 h of treatment (optimal at 16–18 h). Under this condition,
the cells showed higher concentrations of TrkA and p75NTR re-
ceptors than the untreated control. These results were also
confirmed by real-time PCR (Figure 3J). Figure 3(J) also shows
the expression patterns of endogenous NGF, NF-κB and IκB. The
expression of IκB (inhibitor of NF-κB gene) has been found to
be negatively regulated. Interestingly, an increased expression of
the endogenous NGF gene has been observed only after treatment
with the sputa NGF (Figure 3J).
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Figure 3 Neurite extension and receptor protein expression after treatment with mouse and sputa NGF
PC12 cells at 1 × 106 were plated and grown overnight. On the following day, cells were treated with either mouse or sputa NGF, at 200 ng for 16–18 h unless otherwise stated. (A, B) Neurite
extensions observed after treatment with mouse NGF. (C, D) Neurites induced by sputa NGF. (E) Neurite extensions quantified for mouse (black bars) and sputa (white bars) NGF (10, 50 and
100 ng). (F) Neurite outgrowth observed for native nsNGF (stippled bars) at 1, 5 and 10 ng. (G) Time-course induction of neurite outgrowth by mouse (black bars) and sputa (white bars) NGF.
(H) Activation of TrkA receptor determined by Western-blot analysis. Cells were treated for 15 min and total protein was extracted. Equal amounts of protein were separated on a SDS/7.5 %
polyacrylamide gel and subsequently blotted on to nitrocellulose membrane. (i) Phosphorylated TrkA receptors (gp110 and gp140) were detected using monoclonal anti-phosphotyrosine antibody.
The same membrane was stripped and probed with (ii) anti-TrkA and (iii) β-actin antibodies. Lane 1, mouse NGF-treated cells; lane 2, sputa NGF-treated cells and lane 3, untreated control cells.
(I) Ratios of the phosphorylated TrkA and β-actin (internal control) levels measured by densitometry. (J) Quantitative gene analysis via SYBR Green assay. The RNAs from treated and untreated
samples were used to study the expression of five genes: TrkA, p75NTR, NF-κB and IκB.
Protein profiling (SELDI-TOF) analysis
Protein profiling identified five proteins that showed signi-
ficant changes after NGF treatment (Figure 4). The analysis
showed changes in expression of both growth-related (NGF pre-
cursor and neurogranin) and an apoptotic protein (BAD, Bcl-
2/Bcl-XL-antagonist, causing cell death). Cells treated with sputa
NGF (Figure 4A) showed a decrease (approx. 6-fold) in an 8 kDa
protein and an increase (approx. 2-fold) in an 11.4 kDa protein.
Cells treated with mouse NGF (Figure 4B) showed a down-
regulation (approx. 10-fold) of a 13.9 kDa protein. Comparison
between sputa NGF and mouse NGF treatments (Figure 4C)
showed that sputa NGF caused an increase in the growth-asso-
ciated proteins similar to AKAP (A-kinase anchoring protein,
11.4 kDa) and the endogenous NGF precursor (13.9 kDa) when
compared with pro-apoptotic protein (BAD). Expression of pro-
tein at 8 kDa (possibly neurogranin) was greatly decreased (app-
rox. 5-fold), whereas proteins at 22.3 kDa (BAD) and
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Figure 4 Protein profiling analysis
Total protein extracts from cells treated with either mouse NGF or sputa NGF for 16–18 h
were used. (A) Protein profiles obtained from cells treated with sputa NGF versus untreated
control. (B) Protein profiles obtained from cells treated with mouse NGF versus untreated con-
trol. (C) Protein profiles obtained for sputa NGF versus mouse NGF.
67.2 kDa [SHP-1 (Src homology 2 domain-containing tyrosine
phosphatase-1)] showed a marginal up and down-regulation
respectively (Figure 4C).
Microarray analysis of NGF-treated PC12 cells
The global gene expression after treatment with both NGFs was
studied using oligoprobe microarrays. The genes whose expres-
sion is altered by 2-fold or more were taken as significant from
approx. 730 genes examined in our study. These probe sets were
subjected to a self-organizing map (Data Mining Tool; Affy-
metrix) clustering and were grouped according to their expression
patterns. The genes were also further assigned to categories ac-
cording to their biological functions. Some of them are shown in
Table 2. Most of these genes were found to be involved in the cell
cycle and growth pathways.
DISCUSSION
Cloning and expression of a new recombinant NGF protein
A widely studied and commercially available NGF, β-NGF, is
from the mouse submaxillary gland. Lipps [9] reported that the
NGFs from venomous sources are of the highest potency and
particularly the NGF from snakes is approx. 1000-fold more active
than the commercially available mouse NGF. The crude venom
(250 ng/ml) from four untested snakes when assayed for neurite
outgrowth on PC12 cells showed that the venom of N. sputatrix,
Malayan spitting cobra, exhibited the highest activity. This was
followed by the venom from an Australian elapid, P. textilis. Thus
the NGF from N. sputatrix venom was purified, and its activity and
properties were compared with those of mouse NGF. The mole-
cular mass of the native sputa NGF was found to be 14 kDa, thus
indicating that it is a monomer belonging to β-NGF family as
suggested by Inoue et al. [21].
The cDNA encoding NGF from Agkistrodon halys Pallas has
been reported previously [6]. In the present study, we report the
cloning of cDNAs encoding two isoforms of sputa NGF from
N. sputatrix. Each cDNA encoded a signal peptide, pre-pro-
domain and the mature protein. The mature protein-coding region
for N. sputatrix was identified from its N-terminal amino acid se-
quence as well as from the amino acid sequence of Naja atra NGF
[21,22]. Comparison of sequences from the venom-derived NGFs
with those of mouse NGF showed distinct variations at their N-ter-
minal ends. The snake NGF shows higher homology (approx.
80%) with the mammalian-derived NGFs, thus suggesting similar
function to the mammalian homologue. The pro-region of the
cobra NGF however shows approx. 50% homology to the mam-
malian counterpart. Pro-NGF has long been postulated to contain
a biologically active peptide that could induce phosphorylation of
the tyrosine residue of the TrkA receptor protein [23]. On the other
hand, secreted pro-NGF has been reported to activate cell death
in brain following an injury via p75 and sortilin receptors [24],
thus indicating a pathophysiological role for the pro-NGF during
CNS (central nervous system) injury. In contrast, Fahnestock
et al. [25] have shown that the pro-NGF is in abundance in CNS
tissues where mature NGF is not detected. The researchers have
demonstrated that this pro-NGF is responsible for the biological
activity normally attributed by mature NGF, in the CNS tissues.
The pro-NGF in snakes shows approx. 50% homology to the
mammalian pro-NGF. Furthermore, a deletion of five amino acids
can be observed in the mammalian pro-NGF sequence. Hence,
their functions may be different. The snake pro-NGF could pos-
sibly be involved in the positioning of NGF moiety for proper
proteolytic processing and activation of proper in vitro folding of
the mature peptide [26]. The death-inducing property, if any,
of the pro-NGF from snakes remains to be elucidated.
The venom-derived NGFs showed approx. 80–90% homology
among them, and the two isoforms of N. sputatrix NGF (nsNGFI
and nsNGFII) showed approx. 80% homology between them.
nsNGFI and nsNGFII showed 70 and 60% homology to the mam-
malian NGF respectively. Whereas the mature protein region for
both nsNGFI and nsNGFII showed high homology, the pro-region
showed considerable variation among them. Owing to its higher
homology to the mammalian homologue, nsNGFI was selected
for the expression of recombinant protein in E. coli and termed
sputa NGF. This recombinant molecule appears to have two pairs
of β-sheets that are linked by three disulphide bonds. We were able
to refold it in redox solution containing 2 mM GSSG and 4 mM
GSH. The refolded recombinant protein showed a CD spectrum
similar to that of the native protein, and it showed enhanced
activity when compared with the unfolded NGF (Table 1). This
refolded sputa NGF was also found to be non-toxic to PC12 cells
at 1 µg/ml. It was able to bring about enhanced neurite outgrowth
in a dose-dependent manner from 100 to 500 ng/ml.
Expression of TrkA and p75 receptors
The sputa NGF has been found to elicit neurite outgrowth via the
TrkA–p75NTR complex. Two protein forms of TrkA that predomi-
nate in cell extracts are: (i) the 110 kDa N-glycosylated precursor
form, gp110TrkA and (ii) the 140 kDa fully matured form, gp140TrkA
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Table 2 Classification of genes from microarray
Genes were grouped based on their biological functions. Notable changes in gene expression are shown in boldface.
Mouse NGF Sputa NGF
Category of genes Description (fold change) (fold change)
Cell cycle Growth arrest and DNA-damage-inducible 45α 3.63 3.18
Proliferating cell nuclear antigen − 2.07 − 1.74
ret proto-oncogene 2.87 2.91
ret proto-oncogene 4.06 4.41
Cyclin-dependent kinase inhibitor 1A 4.99 4.26
Growth-associated protein 43 2.27 2.10
Apoptosis Apoptotic death agonist BID 3.36 2.85
Bcl-2-like-1 2.22 1.77
Eicosanoid synthesis Prostaglandins endoperoxide synthase 1 4.59 2.36
IL-12 p35 subunit 6.19 4.72
Transcription factors Core promoter element-binding protein 2.53 1.57
fos-like antigen 1 8.57 3.51
Nuclear transcriptional factor-Y-β 2.01 1.14
ISL1 transcriptional factor, LIM/homeodomain 1 2.75 1.74
Global ischaemia-induced protein GIIG15B − 2.38 − 2.07
DNA polymerase β 2.20 1.88
GATA-binding protein 4 1.39 2.17
Myelin transcription factor 1-like − 2.20 − 1.33
Signal transducer and activator of transcription 3 2.04 1.66
ATF3 2.2 −1.54
Egr 1 15.14 12.91
Translational factors Eukaryotic initiation factor-5 2.03 1.60
Eukaryotic initiation factor-2B, subunit 3 2.04 1.82
Others Meprin 1α 2.55 2.10
CE 11.08 8.22
Mast cell protease 7 88.65 71.51
Plysia ras-related homologue A2 2.69 2.33
Small GTP-binding protein rab5 2.20 1.79
GTP cyclohydrolase 1 3.20 2.10
Phospholipase D 2.41 2.55
Kinesin family member 1B 1.45 2.01
Procollagen, type XII, α1 2.30 1.41
Integrin β1 2.31 2.39
Insulin receptor substrate 1 2.06 1.27
Double cortin and calcium/CaM-dependent protein kinase-like 1 2.69 1.84
Gap junction membrane channel protein β5 2.79 2.04
Jun-B oncogene 2.28 2.39
Opioid receptor-like 2.13 2.73
Arginine V1a 5.43 20.25
Purinergic receptor P2X, ligand-gated ion channel 2 −2.91 −1.59
Purinergic receptor P2X, G-protein coupled 2 2.06 2.11
Adenosine monophosphate deaminase 3 2.48 1.85
Myelin basic protein 1.04 2.35
Prolactin receptor 2.17 1.54
Serum-inducible kinase 7.26 3.12
Syntaxin 2.71 1.45
Dynamin 1 − 2.07 − 1.39
Guanosine diphosphate dissociation inhibitor 3 2.17 2.39
Annexin 5 3.03 2.77
Neural receptor protein-tyrosine kinase 9.19 3.16
Moesin 2.97 2.48
Vesicle-associated membrane protein, associated proteins B and C 1.71 2.10
ADP-ribosylation-like 4 2.71 2.28
Solute carrier family 1, member 3 6.28 4.99
Solute carrier family 9, member 4 − 1.44 2.23
Syndecan 1 2.95 2.39
Myosin IXA 2.22 1.99
Potassium inwardly rectifying channel, subfamily J, member 6 2.20 1.95
Protein kinase, cAMP-dependent regulatory, type I, α 2.53 2.08
Coated vesicle membrane protein 2.00 1.89
Regulator of G-protein signalling protein 2 2.25 1.38
Cold-inducible RNA-binding protein 1.97 2.30
Microtubule-associated protein 1b 2.31 1.29
Acid phosphatase 5 2.01 1.91
Profilin II 2.38 2.06
Glutamate receptor, ionotrophic, NMDA2C − 2.50 − 1.91
Lysosomal membrane glycoprotein 2 − 1.97 − 2.20
NGF receptor-associated protein − 2.03 − 1.55
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Table 2 (contd.)
Mouse NGF Sputa NGF
Category of genes Description (fold change) (fold change)
Calcium-related pathway Very-low-density lipoprotein receptor 2.16 1.83
Very-low-density lipoprotein receptor 2.57 2.00
Very-low-density lipoprotein receptor 2.22 2.10
Calcium-binding protein p22 3.66 2.19
S-100-related protein, clone 42C 3.36 2.71
S-100-related protein A4 2.06 1.95
Cadherin − 3.14 − 2.33
Calcium channel, voltage-dependent, T-type, αII subunit 5.54 7.21
Protein phosphatase 3, regulatory subunit B, α isoform, type 1 2.23 1.78
[27]. PC12 cells are known to respond rapidly to NGF within
minutes, with a reproducible burst of tyrosine phosphorylation
of many cellular proteins and include the TrkA receptors. We
observed that the ratio of gp140TrkA to gp110 TrkA decreased on both
mouse and sputa NGF treatments for the purpose of replenishing
the mature gp140TrkA at the cell surface as described by Jullien
et al. [28]. TrkA and p75NTR receptors work in concert to co-ordi-
nate and modulate responses of neurons to NGF. A competitive
study using specific receptor antibodies on the percentage of neur-
ite outgrowth showed that sputa NGF is more sensitive to receptor
inhibition compared with that of mouse NGF. Reduced TrkA
activation in both PC12 cells and sympathetic neurons has been
observed after the addition of p75NTR-specific antibodies [29].
The researchers have also shown that any alteration in the optimal
TrkA–p75NTR interaction or direct activation of p75NTR at the ex-
pense of TrkA, will result in an inhibition of NGF-dependent
neurite outgrowth in adult sensory neurons. In the present study,
inhibition by TrkA and p75NTR receptor-specific antibodies caused
a reduction in neurite outgrowth for both mouse and sputa NGF by
34 and 70% for TrkA and 10 and 40% for p75NTR respectively.
Thus the greater reduction in neurite formation on sputa NGF
treatment implicates that the sputa NGF is more specific to TrkA
and p75NTR, and stimulates signalling using the TrkA–p75NTR high-
affinity complex as for mouse NGF. This antibody-based com-
petitive study is in agreement with the quantitative analysis of the
receptor (TrkA and p75NTR) genes examined via real-time PCR.
The expression of both receptors was higher with sputa NGF
when compared with mouse NGF. Activation of TrkA and p75NTR
has been reported to induce the expression of NF-κB, which in
turn is known to cause neurite extension in PC12 cells [30]. Real-
time PCR (Figure 3C) showed a down-regulation of the NF-κB
inhibitor, IκB, in both NGF treatments, implying that NF-κB will
be made available to activate and promote neurite extension in
PC12 cells. However, an increase in NF-κB expression is observed
for sputa NGF treatment compared with mouse NGF treatment
and such an NGF-induced increase in NF-κB is beneficial for the
survival of neurons [31]. Similarly, the endogenous NGF level
was up-regulated after treatment with sputa NGF in contrast with
mouse NGF. Several studies have shown that neurotrophic factors,
including NGF, constitute an important class of endogenous
modulators of excitotoxicity, and are known to protect neurons
against injury from several causes [32]. NGF has caused increase
in glutathione levels of PC12 cells [33], and hence up-regulation
(of NF-κB and endogenous NGF genes) by sputa NGF may have
potential neuroprotective roles.
Global gene and protein analysis
Microarray analysis (Table 2) showed for the first time the global
changes in gene expression after treatment with either mouse NGF
or sputa NGF on PC12 cells. This study also yielded comparable
data between the two NGFs. The differentiation pathway after
NGF treatment is characterized by expression of immediate early
genes [such as Egr 1 (early growth response 1) and serum-in-
ducible kinase] and delayed response genes (such as Fos-like
antigen, Fra-1 and prostaglandin-endoperoxide synthase 1). It was
shown that Egr 1 acts via the extracellular-signal-regulated kinase
pathway to produce eventually neurite outgrowth in PC12 cells
[34]. Liby et al. [35] have shown that serum-inducible kinase has
a role in cell proliferation. Expression of transcription factors,
e.g. Fra-1, may participate in long-term neural responses [36],
whereas overexpression of ATF3 (activating transcription factor 3)
inhibited apoptosis [37]. Enhanced expression of transcription
factors (Fra-1, ATF3 and Egr 1) may also cause subsequent in-
crease in CE (cathepsin E) expression [38]. This explains the
increase in CE observed in the present study (Table 2). CE is an
aspartic protease, which has been implicated in antigen proces-
sing in the class II MHC pathway and is known to be up-regulated
late in B-cell activation [39]. The concurrent up-regulation of mast
cell protease 7 in the present study is in agreement with the pre-
viously reported effects of NGF on mast-cell development and
differentiation [40].
Arginine V1a (vasopressin receptor 1A) was observed to be
highly expressed by sputa NGF treatment when compared with
mouse NGF. V1a is widely distributed and known to regulate
nearly all the physiological actions of the neuropeptide, vaso-
pressin (AVP), except antidiuresis (V2) and corticotrophin se-
cretion (V1b; [41]). In addition to these, channel transporter genes
(solute carrier family 1, member 3; SLC1A3, voltage-dependent
calcium channel and purinergic P2X receptors) were found to
be affected by the NGF treatment. Mouse NGF activated both
the expression of SLC1A3 and P2X receptor genes, whereas
sputa NGF activated the voltage-dependent calcium channel gene.
The SLC1A3 gene encodes the glutamate receptor GLAST (gluta-
mate/aspartate transporter) responsible for the removal of
glutamate to terminate neurotransmission and prevent neuronal
cell death [42], whereas the expression of voltage-dependent
calcium channel subunit II is restricted to neuronal tissues for the
maintenance of the neuronal physiology [43]. In the present
study, the down-regulation of P2X receptor was observed in
both NGF treatments. This proved to be beneficial as P2X is
postulated to be involved in astrocyte-mediated inflammation and
neurodegeneration [44]. Up-regulation of IL-12 (interleukin-12)
and prostaglandin-endoperoxide synthase 1 seen in both cases
also supports their beneficial roles. Prostaglandin-endoperoxide
synthase 1 is believed to have a physiological role in neuronal
differentiation of PC12 cells [45]. Similarly, IL-12 is known
to play an important role in neuronal regeneration [46]. Hence,
both NGFs showed similar activities, except for V1a expression.
Arginine vasopressin that acts mainly through the V1a receptor
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is known to enhance NGF secretion in vascular smooth muscles
and rat brain cells [47,48].
Protein profiling and real-time PCR results confirmed that an
endogenous NGF synthesis is up-regulated after treatment with
sputa NGF. Hence, sputa NGF could possibly be acting through
V1a receptor to enhance the endogenous NGF production, an
effect that will prove to be useful under conditions that require
neuronal regeneration and differentiation.
The sputa NGF is also found to enhance the production of
growth-associated proteins such as AKAP. The AKAP (11.4 kDa)
belongs to a family of scaffolding proteins that bind to the
regulatory subunits of protein kinase A, which regulates the phos-
phorylation of various proteins including those involved in syn-
aptic plasticity. AKAP induction is known to stimulate protein
kinase A-dependent phosphorylation of the pro-apoptotic pro-
tein BAD (protein at 22.3 kDa), thereby inhibiting the release of
cytochrome c from mitochondria and protecting the cells from
apoptosis [49]. Although sputa NGF showed a marginal increase
in BAD protein when compared with mouse NGF, with AKAP
up-regulated approx. 2-fold more than BAD, the pro-apoptotic
property of BAD could be suppressed. This interpretation was
confirmed experimentally by measuring for caspase activity on
PC12 cells treated with sputa NGF. No caspase activity could be
determined in these cells.
The mechanisms by which NGF exerts its neuroprotective ef-
fects are currently unknown. However, in vitro studies have shown
that NGF can stabilize intracellular calcium by preventing ac-
cumulation of intracellular calcium and subsequent neuronal
damage [50]. The protein profiling results showed a down-regul-
ation in neurogranin (8 kDa). Neurogranin is a neural-specific
Ca2+-sensitive CaM (calmodulin)-binding protein. It is believed
that phosphorylated neurogranin has the potential to modulate
neuronal free-Ca2+ and CaM levels [51]. Gene knock-out experi-
ments leading to a total absence of neurogranin have resulted in
deficiency of hippocampal synaptic plasticity and hippocampus-
dependent spatial learning [51]. McNamara et al. [52] predicted
that an increase in neurogranin expression would perturb Ca2+-
CaM signalling that may in turn impair the formation and/or main-
tenance of synapses. Thus a decreased level of free neurogranin
detected after treatment with sputa NGF indicates that a basal level
of intracellular Ca2+ is maintained for neuronal differentiation and
function.
Protein tyrosine phosphatase (SHP-1; 67.2 kDa) was identified
as a phosphotyrosine phosphatase, which negatively regulates the
expression of TrkA. It was shown in sympathetic neurons that ex-
pression of SHP-1 induces apoptosis and TrkA dephosphorylation
[53]. Hence, a down-regulation of SHP-1 expression is also
in agreement with TrkA activation after treatment with both
NGFs.
In conclusion, sputa NGF seems to exert potentially life-sus-
taining and neuroprotective (NF-κB and endogenous NGF genes)
effects in a manner similar to that of mouse NGF. The life-
sustaining effects have been observed at both gene (microarray)
and protein (SELDI-TOF) levels. Sputa NGF has also been found
to increase the expression of V1a and endogenous NGF genes as
well as the NGF precursor and the AKAPs. However, both neuro-
granin and SHP-1 proteins have been found to be down-regulated
after treatment with sputa NGF. Real-time PCR analysis has
revealed additional pro-survival effects of sputa NGF such as en-
hanced expression of NF-κB and the endogenous NGF genes.
These effects could have potential neuroprotective roles.
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Abstract. Snake envenomation is a socio-medical prob-
lem of considerable magnitude. About 2.5 million people 
are bitten by snakes annually, more than 100,000 fatally. 
However, although bites can be deadly, snake venom is a 
natural biological resource that contains several compo-
nents of potential therapeutic value. Venom has been used 
in the treatment of a variety of pathophysiological condi-
tions in Ayurveda, homeopathy and folk medicine. With 
the advent of biotechnology, the efficacy of such treat-
ments has been substantiated by purifying components of 
venom and delineating their therapeutic properties. This 
review will focus on certain snake venom components 
and their applications in health and disease.
Keywords. Venom, snake, neurotoxin, platelet aggregation, blood coagulation, receptor.
Introduction
Snakes have been a subject of fascination, fear and myths 
throughout history. In ancient Egypt, the cobra was wor-
shipped and its replica was used to decorate the crowns 
of Roman emperors, while in the ancient Greek world, 
the god of medicine was depicted with a stick entwined 
with a snake, the symbol that is still used to represent 
the guilds of medicine and pharmacy. Snake venoms are 
complex mixtures of proteins, nucleotides and inorganic 
ions. These combinations confer a formidable array of 
toxic properties on the venom, the peptides and polypep-
tides being responsible for a variety of toxic properties. 
Annually, about 2.5 million people around the world are 
the victims to snake bites, of whom about 100,000 lose 
their lives. Most morbidity and mortality occurs in rural 
areas in the tropics [1, 2]. The populations of temperate 
western countries are not spared from wild snake bites, 
but they occur at a lower frequency. In addition, there are 
substantial incidents of envenomation by exotic captive 
snakes. The clinical manifestations of snakebite are de-
pendent on two factors, the intrinsic toxicity and amount 
of venom injected. There are many signs and symptoms 
following envenomation by snakes, but the major ones 
with clinical significance can be divided into a few broad 
categories: (a) flaccid paralysis; (b) systemic myolysis; 
(c) coagulopathy and haemorrhage; (d) renal damage and 
failure; (e) cardiotoxicity and (f ) local tissue injury at the 
bite site. The symptoms suggest that snake venoms affect 
various systems, particularly the central nervous system 
(CNS), cardiovascular system, muscular and vascular 
system. The aim of this review is to highlight some of the 
snake venom components that can be used as molecular 
probes in human health and disease.
Toxins affecting the CNS
The main toxins from snake venom that affect the CNS 
are neurotoxins (Table 1) and dendrotoxins. The general 
observation from neurotoxin envenomation is the devel-
opment of cranial nerve palsies, which are characterized 
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by ptosis, blurred vision, difficulty in swallowing, slurred 
speech and weakness in facial muscle. Similarly, dendro-
toxins have been demonstrated to block particular subtypes 
of voltage-dependent potassium channels in neurons.
Neurotoxins
Neurotoxins form one of the largest families of proteins 
with established primary structures. Among the best stud-
ied snake neurotoxins are the α-neurotoxins that bind to 
nicotinic acetylcholine receptors (nAChRs). They are 
capable of reversibly blocking nerve transmission by 
competitively binding to the nAChR located at the post-
synaptic membranes of skeletal muscles and neurons, 
preventing neuromuscular transmission and thereby 
leading to death by asphyxiation [3]. The post-synaptic 
(α) neurotoxins are classified into four major groups: (a) 
short neurotoxin, (b) long neurotoxin, (c) κ-neurotoxins 
and (d) other unconventional neurotoxins called the weak 
neurotoxins.
The high specificity of neurotoxins for nAChRs has been 
utilized as a tool in understanding the structure and func-
tion of the nervous system. In particular, α-neurotoxins 
have been crucial for the isolation and characterization 
of the nAChR at the motor end plate [4]. Figure 1 shows 
the structure of α-neurotoxins binding to their molecular 
target nAChR. Figure 1a shows the binding between 5 α-
neurotoxin to the acetylcholine receptor subunit while its 
interaction with a specific peptide of the nAChR isolated 
from Torpedo californica is shown in Figure 1b. The func-
tion of the neurotoxins of some elapids can be compared 
with curare or with the auto-antibodies detected in myas-
thenia gravis. A comprehensive review of neurotoxins can 
be found in Siew et al. [5] and Tsetlin and Hucho [3].
Activation of central cholinergic pathways by nicotine 
and nicotinic agonists has been shown to elicit anti-no-
ciceptive effects in a variety of species and pain tests [6, 
7]. Neurotoxins isolated from cobra venoms have shown 
significant analgesia in animal models. Cobrotoxin, a 
short-chain post-synaptic α-neurotoxin and α-cobra-
toxin, a long-chain α-neurotoxin isolated from Naja atra, 
have been reported to show analgesic activity. Cobrotoxin 
is a specific ligand for the muscle-based α1 nAChR and 
it produces strong, centrally mediated analgesic effects 
through an opiate-independent mechanism while the α-
cobratoxin shows high affinity for the neuronal α7 nAChR 
and elicits an opiate-independent, anti-nociceptive effect 
[8]. Additionally, evidence is emerging that cobrotoxin 
can substitute for morphine and suppress the effects of 
morphine withdrawal [8]. Similarly, an α-neurotoxin 
from the king cobra, Ophiophagus hannah, has also been 
reported to exhibit potent analgesic activity [9].
Neurotoxins that recognize the muscarinic acetylcho-
line receptors (mAChRs) have been isolated from green 
mamba venom [10]. Due to their potency and selectivity, 
the muscarinic toxins (MT1–7) can be useful pharmaco-
logical tools for investigating the physiological roles of the 
muscarinic receptor subtypes [11–13]. These muscarinic 
receptors are of great interest in the treatment of neurode-
generative diseases, such as Alzheimer’s and Parkinsons, 
and it is hoped that selective blocking of these receptors 
will greatly aid in restoring normal movement. In fact, the 
involvement of muscarinic receptors in Azheimer’s dis-
ease was elucidated using these subtype-specific mamba 
toxins [14]. Potential sources of nicotinic and muscarinic 
neurotoxins are summarized in Table 1.
The β-neurotoxins, on the other hand, act presynaptically 
by affecting the release of acetylcholine via mechanisms 
Table 1. Snake venom neurotoxins and their targets in the CNS.
Type of neurotoxin Functional target Source
Short-chain neurotoxins post-synaptic toxin; high affinity to skeletal and 
Torpedo nAChR; bind to neuronal α7 nAChR with 
lower affinity or none.
elapids and hydrophids (cobras, sea snakes, kraits, 
Australian elapids)
Long-chain neurotoxins post-synaptic toxin; comparatively higher affin-
ity towards neuronal α7 nAChR than the skeletal 
receptors.
elapids and hydrophids (cobras, sea snakes, kraits, 
Australian elapids)
Weak neurotoxins post-synaptic toxin; weak affinity to both the 
 skeletal and neuronal nAChRs
elapids (cobras, kraits, Australian elapids)
Taipoxin presynaptic toxin; binds specifically to neuronal 
plasma membranes especially at the neuromuscular 
junction.
Australian elapid (taipan)
β-Bungarotoxins presynaptic toxin; presynaptic voltage dependent 
K+ channel
elapids (kraits)
Muscarinic toxins specific to mAChR subtype and bind with high 
 affinity 
elapids (mamba, kraits and cobras)
nAChR, nicotinic acetylcholine receptor; mAChR, muscarinic acetylcholine receptor.
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that differ for different β-neurotoxins. They are responsi-
ble for high toxicity and ultimately respiratory paralysis. 
They act by causing the disappearance of acetylcholine-
containing vesicles, preventing the controlled release of 
acetylcholine and blocking impulse transmission. The 
pre-synaptic neurotoxins that have been thoroughly inves-
tigated to date are crotoxin (from Crotalus durissus ter-
rificus), β-bungarotoxin (from Bungarus multicinctus), 
notexin (from Notechis scutatus) and taipoxin from the 
Australian taipan (Oxyuranus scutellatus) [15]. Crotoxin, 
a pre-synaptic neurotoxin with cytotoxic activity, is cur-
rently being used in phase 1 clinical trials. This toxin has 
been tried on advanced cancer patients, as an anti-cancer 
agent and is believed to act through a novel mechanism 
of action [16].
Dendrotoxins
Apart from the classical α-neurotoxins, another type of 
neurotoxin that has been identified in other snake venoms 
are the dendrotoxins isolated from the African mamba, 
Dendroaspis sp. The best-characterized dendrotoxins are 
highly potent blockers of KV1.1, KV1.2 and KV1.6 potas-
sium channels and are derived from the venom of the green 
mamba (Dendroaspis angusticeps). Mambas belong to 
the elapid family and have venom that contains toxins to 
potentiate acetylcholine release and subsequent synaptic 
transmission at the neuromuscular junction, leading to ex-
cessive muscular activity, trembling and fasciculation of 
the prey. This action has been ascribed to a small protein, 
dendrotoxin, that selectively blocked voltage-dependent 
potassium channels in neurons [17]. In the past 20 years, 
structural analogues of dendrotoxins have aided in defining 
the molecular recognition properties of different types of 
potassium channels, and radiolabelled dendrotoxins have 
been used to identify other toxins binding to potassium 
channels. They are also important markers for subtypes 
of potassium channels in vivo, and have been widely used 
as probes for studying the function of potassium channels 
both in physiological and pathophysiological conditions 
[17], and hence have been implicated in the development 
of new drugs for the treatment of neurodegenerative dis-
orders, such as Alzheimer’s disease (www.chemsoc.org/
chembytes/ezine/1999/berressem-apr99.htm).
Toxins affecting the cardiovascular system
The first venom-based drug captopril discovered in 1975 
also formed the first oral angiotensin-converting enzyme 
(ACE) inhibitor. This success story started with the ob-
servation of the toxic effect of venom from a Brazilian 
viper (Bothrops jararaca) that caused a sudden, massive 
drop in blood pressure. This piqued the interest of No-
bel Prize winner Sir John Vane, who found that the vi-
per venom was a potent inhibitor of ACE. Vane took this 
discovery to the pharmaceutical company Squibb where 
two scientists, David Cushman and Miguel Ondetti, cre-
ated captopril, the first oral ACE inhibitor [18]. With the 
success of captopril, snake venoms have been explored 
for potential applications pertaining to the cardiovascular 
system. The binding of the anti-hypertensive drug capto-
pril to its substrate ACE is shown in Figure 1c.
A toxin isolated from Indian cobra venom in the late 
1940s was named cardiotoxin because it caused cardiac 
arrest when injected into experimental animals. Cardio-
toxins, also known as cytotoxins are found exclusively in 
the venom of cobras and ringhals [19, 20], and are direct 
lytic factors and membrane-active polypeptides. They 
are single-chain, highly hydrophobic, basic, short poly-
peptides closely related to the α-neurotoxin that binds to 
nAChR, but cardiotoxins do not show any significant af-
finity for the receptors [21]. The main targets of cardio-
toxins are on excitable cells. They cause depolarization 
and contracture of cardiac, skeletal and smooth muscles, 
and depolarization and loss of excitability of nerves. 
Figure 1. (a) Structure of the α-cobratoxin-AChBP complex (1YI5) [from ref. 88]. (b) Nuclear magnetic resonance structure of an AChR-
peptide (Torpedo californica, alpha subunit residues 182–202) in complex with α-bungarotoxin (1L4W) [from ref. 89]. (c) Complex of the 
anti-hypertensive drug captopril and the human testicular angiotensin I-converting enzyme (1UZF) [from ref. 90]. (d ) Structural Basis of 
venom citrate-dependent heparan sulphate-mediated cell surface retention of cobra cardiotoxin A3 (1XT3) [from ref. 91]. (e) Interactions 
of a specific non-steroidal anti-inflammatory drug with group I phospholipase A2 (PLA2): crystal structure of the complex formed between 
PLA2 and niflumic acid at 2.5Å resolution (1TD7) [from ref. 92]. 
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These toxins are pore-forming agents [22] that lead to the 
depolarization and degradation of the plasma membrane 
of skeletal muscle cells. The mechanism of action of de-
generation is most probably calcium dependent, involv-
ing the direct activation of calcium-dependent proteases 
and the eventual failure of mitochondrial respiration due 
to a calcium overload [23]. Cobra cardiotoxins may be 
useful probes in a number of cellular processes, including 
lipid metabolism and calcium ion regulation in skeletal as 
well as cardiac muscle [24]. Cardiotoxins have also been 
shown to be membrane-active proteins that recognize the 
proteoglycans of the membrane. Their cardiotoxicity is 
attributed to specific binding to the glycosaminoglycans, 
the sulphated carbohydrate moieties that occur abundantly 
in cells of cardiovascular tissues [25]. Figure 1d shows 
the binding of cardiotoxin to the heparan sulphate moiety. 
Cardiotoxin is currently being used in a phase 1 clinical 
trial for cancer treatment along with crotoxin (a pre-syn-
aptic neurotoxin) in a combined therapy [26]. Cardio-
toxin expression at higher levels (60% of the venom dry 
weigh) has been attributed to the difference in promoter 
activity [27]. The promoter activity of α-neurotoxin from 
Naja sputatrix was down-regulated by the presence of a 
24 nucleotide (nt -678 to -655) silencer at the 5′-flanking 
region. These findings indicated that snakes produce ven-
oms that contain highly lethal and specific toxins at lower 
levels than the multi-functional toxins like cardiotoxins. 
A study by Cher et al. [28] has revealed that the changes 
at the molecular level and physiological states in a vic-
tim upon cobra envenomation are initially due to cardio-
toxins followed by the synergistic effects of all the other 
components including neurotoxins and phospholipase A2 
(PLA2) and the spreading factor, hyaluronidase.
Toxins affecting the muscular system
There are three main classes of venom components that 
initiate cycles of degeneration and regeneration of skel-
etal muscle: (a) myotoxins, which are small polypeptides 
that can be isolated from the venoms of the New World 
viper subfamily Crotalinae, and which specifically act 
on skeletal muscles [29]; (b) cardiotoxins, polypeptides 
of 60–65 amino acids that can be isolated from venoms 
of cobras and which act on smooth muscles (see above) 
and (c) PLA2, which can be isolated from venoms of a 
number of snake families, including Viperidae, Elapidae 
and Hydrophiidae. The PLA2s can have either myotoxic, 
cardiotoxic or neurotoxic actions [30, 31].
Myotoxins
Myotoxins are also called myonecrotic toxins and are 
found in venoms from rattlesnakes and other pit vipers. 
One of the best-known myotoxins is myotoxin-a, isolated 
from the venom of the Prairie rattlesnake C. viridis viri-
dis [29]. It is a small (4600 Da), basic protein devoid of 
enzymatic activity. Mytotoxin-a binds specifically to the 
sarcoplasmic reticulum of muscles, causing a change in 
ion permeability of the sarcoplasmic reticulum (an im-
portant calcium regulatory system) leading to swelling 
and disintegration of both the sarcoplasmic reticulum and 
muscle fibrils. Hence antibody to myotoxin-a has been 
used to treat myonecrosis resulting from Prairie rattle-
snake venom poisoning [32].
Phospholipase A2
PLA2 enzymes may be single-chain polypeptides of 
around 120 amino acid residues or mixtures of two to 
five complementary polypeptides, and are Ca2+ enzymes. 
The structure of the complex formed between PLA2 and 
the non-steroidal anti-inflammatory drug, niflumic acid, 
is shown in Figure 1e.
These enzymes catalyze the hydrolysis of phospholipids 
at the sn-2 position of the glycerol backbone to release 
fatty acid and corresponding 1-acyl lysophospholipid 
[33]. PLA2s from snake venoms exhibit a wide variety of 
pharmacological effects by interfering in normal physi-
ological processes [34].
PLA2 triggers a cascade of inflammatory events charac-
terized by increased microvascular permeability and oe-
dema formation, leukocyte recruitment into tissues, no-
ciception and release of inflammatory mediators which 
mimic a number of systemic and local inflammatory dis-
orders in humans. These studies have helped to clarify 
the pathophysiological roles of these proteins in diverse 
inflammatory processes. In addition, knowledge of the 
mechanism of action of myotoxic PLA2s has provided im-
portant clues for understanding snakebite envenomation 
and has formed a template for the design of new alterna-
tives to conventional anti-venoms.
Anti-inflammatory and anti-neoplasmic activities 
of PLA2 . Naturally occurring anti-toxic factors that 
neutralize PLA2 from the blood of both venomous and 
non-venomous animals have been isolated and studied 
[35–37]. Snake PLA2 inhibitors (PLIs) are large multi-
meric, serum proteins that form soluble complexes with 
PLA2 enzymes, thereby inhibiting their actions. The 
first PLIs were isolated from the serum of Habu snake, 
Trimeresurus flavoviridis (Protobothrops flavoviridis; 
EMBL Reptile Database) [38]. PLIs show specific af-
finities for various PLA2 enzymes and some have been 
shown to have anti-enzymatic, anti-myotoxic, anti-oe-
dema-inducing, anti-cytotoxic and anti-bacterial activi-
ties [39]. In addition to its role in various extra-neuronal 
(extra-cerebral) inflammatory processes, PLA2 is also 
thought to be crucial in inflammatory processes present 
in numerous acute and chronic neurological disorders as-
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sociated with neurodegenerative diseases, such as neural 
trauma, Alzheimer’s disease and Parkinson’s disease, and 
in some brain tumours [40]. Treatment of these disorders 
with non-specific inhibitors has met with limited suc-
cess. Hence specific PLIs derived from animal sources 
might provide potentially more specific pharmacological 
tools. PLA2 isolated from Bothrops neweidii venom and 
Indian cobra, Naja naja venom, was found to be cytotoxic 
towards B16 F10 melanoma and Ehrlich ascites tumour 
cells, respectively, suggesting its employment as an anti-
cancer drug [41].
Toxins affecting the haemostatic system
The major symptoms from snakebite affecting the hae-
mostatic system are (a) reduced coagulability of blood, 
resulting in an increased tendency to bleed, (b) bleeding 
due to the damage to blood vessels, (c) secondary effects 
of increased bleeding, ranging from hypovolaemic shock 
to secondary-organ damage, such as intracerebral haem-
orrhage, anterior pituitary haemorrhage or renal damage 
and (d) direct pathologic thrombosis and its sequelae, par-
ticularly pulmonary embolism [42]. More recently, snake 
venoms have been used in the development of platelet 
aggregation and blood-clotting inhibitors.
Venoms from vipers and some Australian snakes are rich 
sources of proteases that strongly affect the haemostatic 
mechanism [43]. Coagulant enzymes include activators 
of the blood coagulation factors II (prothrombin), V 
and X, while anti-coagulants include protein C activa-
tors, inhibitors of prothrombin complex formation and 
fibrinogenases (based on their specificity for the alpha, 
beta and gamma chains of fibrinogen). Intermediates 
between the true coagulants and true anti-coagulants are 
the thrombin-like enzymes which bring about clotting in 
Figure 2. Blood coagulation pathways and the steps in which snake venom proteins interfere. SVTLE, snake venom thrombin-like en-
zymes; RVV-V, Russell’s viper venom factor V activator; RVV-X, Russell’s viper venom factor X activator; VLFXa, Vipera lebetina factor 
X activator. Activation by venom protein is denoted by  ; inhibition by  .
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vitro but defribination (anti-coagulation) in vivo. Snake 
venoms (including the disintegrins, a group of RGD-
containing proteins) also affect platelets by inducing or 
inhibiting platelet aggregation, fibrinolytic activators and 
haemorrhagins (alpha-fibrinogenases) to cause haemor-
rhage by acting via platelets or proteolysis of the blood 
vessel wall [44]. Snake venom proteins that affect the 
blood coagulation cascade are summarized in Figure 2. 
It appears that for every factor involved in the blood co-
agulation cascade, there is a counterpart among the snake 
venom compounds that could either activate or inactivate 
the factors. These activators or inhibitors usually belong 
to various families such as serine proteases, metallopro-
teinases, C-type lectins, disintegrins and phospholipases. 
The structure of a protein C activator from Agkistrodon 
contortrix contortrix, Protac, is shown in Figure 3a.
Thrombin-like enzymes and fibrinogen studies
Approximately 100 snake venom toxins have been identi-
fied as ‘thrombin-like’ enzymes [45]. Thrombin is able 
to cleave both fibrinopeptide A (FPA) and fibrinopep-
tide B (FPB) from fibrinogen and activating factor XIII 
(fibrin-stabilizing factor). While some actions of these 
snake venom thrombin-like enzymes (SVTLEs) mimic 
the effects of thrombin, they usually cleave FPA alone; 
only a few cleave FPB. Thus, without cleavage of both 
FPA and FPB, they are unable to activate factor XIII 
and the clots produced can easily be broken down. The 
failure of the clots to be cross-linked leads to a break-
down in the fibrinolytic system and effective removal of 
fibrinogen from the plasma. The most widely used SV-
TLEs are those from Bothrops atrox venom (Batroxobin, 
Reptilase) (Pentapharm, Basel, Switzerland) and from 
Callosellasma rhodostoma venom (Ancrod). Ancrod 
has been shown to be effective in limiting infarct vol-
ume [46]. The fibrinogenase family from snake venom 
that is able to cleave specifically one or more fibrinogen 
chains has received more attention in the last few years. 
The fibrin(ogen)olytic enzymes are either serine prote-
ases or metalloproteinases. Though targeting a different 
factor (fibrin or fibrinogen), these proteins break down 
the fibrin-rich clots and prevent progression of clot for-
mation. Fibrolase from southern copperhead (A. contor-
trix) snake venom can degrade both the α and β chains of 
fibrin and shows potential as a thrombolytic agent [47]. 
Other enzymes that dissolve blood clots both in vitro and 
in vivo include afaacytin from horned viper (Cerastes ce-
rastes) venom [48], atroxase from western diamondback 
rattlesnake venom [49] and fibrinogenase from Vipera 
lebetina (Microvipera lebetina, EMBL Reptile Data-
base) venom [50]. In 2001, alfimeprase, produced as a 
truncated recombinant form of fibrolase, was produced 
and introduced into clinical trials [51]. It is presently in 
a phase II clinical trial for two indications: (a) treatment 
of peripheral arterial occlusions and (b) clearance of oc-
cluded vascular excess catheters, in direct competition 
with plasminogen activators [52].
Prothrombin
Snake venoms are rich sources of prothrombin activators 
and hence are utilized in prothrombin assays, especially 
for studying dysprothrombinaemias and for preparing 
meizothrombin and non-enzymatic forms of prothrom-
bin. Russell’s viper (Daboia russelli) venom (RVV) con-
tains toxins which have been used to assay blood clotting 
factors V, VII, X, platelet factor 3 and, importantly, lu-
pus anti-coagulants (LAs). Other prothrombin activators 
(from the taipan, Australian brown snake and saw-scaled 
viper) have also been used to assay for LA. Protein C and 
activated protein C resistance can be measured by RVV 
and Protac, a fast-acting inhibitor from southern copper-
head snake venom. A C-type lectin-like protein, botroce-
tin, isolated from B. jararaca venom can be used to study 
the von Willebrand factor [53]. These proteins are useful 
tools for elucidating the mechanisms involved in clotting 
and platelet activation as well as the structure-function 
relationships of both blood-clotting factors and platelet 
glycoproteins.
Platelet aggregation inhibitors
Many snake venom toxins affect platelet function [54]. 
They can be grouped into a few major families, such as 
enzymes like serine proteinases, zinc-dependent PI-PIV 
metalloproteinases of the reprolysin family and group II 
PLA2 isoenzymes as well as proteins with no enzymatic 
activity, such as C-type lectins, CRISP and disintegrins 
[55]. Of these, disintegrins and C-type lectins [54, 56] 
have been considered as useful modulators of platelet 
function.
Disintegrins. Snake venom disintegrins are natural prod-
ucts that have been investigated as potent inhibitors of 
Figure 3. (a) Structure of native protein C activator from the venom 
of the copperhead snake Agkistrodon contortrix contortrix (2AIP) 
[from ref. 93]. (b) Structure of EMS16, an Antagonist of collagen 
receptor integrin α2β1 (GPIa/IIa; 1UKM) [from ref. 94].
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various integrins, and major progress has been made in the 
functional characterization of disintegrins. Functionally, 
disintegrins can be divided into three groups according to 
their integrin selectivity and the presence of specific and 
active motifs. The specific adhesion molecule recogni-
tion motifs, their respective sequences and the specific 
targets are listed in Table 2. They are (a) those interacting 
with RGD motif-dependent integrins, (b) leukocyte inte-
grin-binding disintegrins and (c) the α1β1 integrin-bind-
ing disintegrins. The first group includes most of the mo-
nomeric disintegrins that contain the RGD motif, as well 
as disintegrins without the RGD motif but with inhibitory 
activity against RGD-dependent integrins such as KGD, 
MVD, MGD and WGD disintegrins. The second group 
is represented by MLD motif – containing disintegrins 
which interact with α4β1, α4β7 and α9β1 integrins. The 
last group consists of the recently discovered, KTS motif-
containing disintegrins, obtustatin and viperistatin. These 
disintegrins are potent and selective inhibitors of α1β1, 
characterized as specific receptors for collagen IV [57].
Targeting and inhibiting RGD-dependent integrins is a 
major goal of the pharmacological research for many 
diseases. In thromboembolic disorders, the main aim is 
to block the fibrinogen receptor αIIβ3 integrin on the 
platelet. The structure of disintegrins has been used as a 
template to design compounds that bind to endogenous 
fibrinogen with higher affinity. This resulted in the in-
troduction of two drugs, eptifibatide and tirofiban. Ep-
tifibatide (integrelin) was modelled on the active site 
of barbuorin, (Sistrurus m. barbouri) and is, in fact, a 
KGD-containing protein [58], while tirofiban (Aggra-
stat) which was designed from echistatin (a disintegrin) 
is a synthetic compound that mimics RGD [59, 60]. Both 
drugs have been approved for the therapy of acute coro-
nary ischaemic syndrome and the prevention of throm-
botic complications in patients undergoing percutaneous 
coronary intervention such as balloon angioplasty and 
stenting [61, 62].
Blockers of platelet integrins and especially αIIbβ3 could 
have applications in certain types of cancer treatment. It 
is well known that platelets contribute to tumor growth, 
angiogenesis and metastasis [63]. The calcium-depen-
dent glycoprotein IIb/IIIa complex is the most prevalent 
platelet cell surface receptor and may combine with one 
of the four adhesive proteins, fibrinogen, fibronectin, 
von Willebrand factor and vitronectin, all containing the 
RGD-motif. The RGD-containing snake venom proteins 
interfere with platelet aggregation by reversibly blocking 
the GPIIb/IIIa receptor. The most studied disintegrins 
include trigramin [Trimeresurus gramineus; 64], rhodos-
tomin [C. rhodostoma; 65] and triflavin [T. f lavoviridis 
(P. f lavoviridis (EMBL Reptile Database); 66].
Snake venom RGD-disintegrins have been the target for 
investigation of αvβ3 integrin as a potential target for 
the suppression of cancer. These disintegrins are use-
ful tools to decipher the mechanisms that occur during 
αvβ3-dependent angiogenesis. Monomeric RGD-disin-
tegrins, accutin [67], triflavin [68], salmosin [69], rho-
dostomin [70, 71], and the homodimeric RGD-disinteg-
rin, contortrostatin [72], inhibit angiogenesis by binding 
to endothelial cells via αvβ3. It has been suggested that 
the binding of disintegrins to endothelial cells inhibits 
Table 2. Adhesion molecule recognition motifs in snake venom disintergins.
Motifs recognized by 
adhesion molecules
Amino acid sequence Physiological target Examples/source
RGD arginine-glycine-aspartate blocks the GPIIb/IIIa receptor and binds 
to integrins αIIbβ3, α8β1, αvβ3, αvβ5 
and/or α5β1
trigramin (Trimeresurus gramineus); 
contortrostatin (Agkistrodon 
 contortrix contortrix)
KGD lysine-glycine-aspartate binds specifically to integrin αIIbβ3 barbuorin (Sistrurus m. barbouri) 
MVD methionine-valine-aspartate potent inhibitor of both collagen- and 
ADP-stimulated platelet aggregation
atrolysin-E/D (Crotalus atrox)
MGD methionine-glycine-aspartate potent and selective inhibitor of α5β1 EMF10 (Eristocophis macmahoni)
WGD tryptophan-glycine-aspartate potent inhibitor of the RGD-dependent 
integrins α5β1, αvβ3, and αIIbβ3.
CC8 (Cerastes cerastes)
MLD methionine-leucine-aspartate binds α4β1, α4β7, α9β1, α5β1 and 
αIIbβ3 integrins
EC5 (Echis carinatus sochureki), 
VLO5 (Vipera lebetina obtusa)
KTS lysine-tryptophan-serine selective integrin α1β1 inhibitors obtustatin (Vipera lebetina obtusa)
RTS arginine-tryptophan-serine selectively blocks integrin α1β1 jerdostatin (Trimeresurus jerdonii)
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their motility and proliferation, possibly by induction 
of apoptosis in endothelial cells. Snake venom RGD-
disintegrins showed direct interaction in several tumor 
cell lines. The blocking of αvβ3 integrin in tumor cells 
inhibited their adhesion to the extracellular matrix and 
significantly reduced their motility, subsequently inhib-
iting metastasis. This effect was noted for monomeric 
medium-sized disintegrins, such as salmosin [69] and 
triflavin [68] and the homodimeric disintegrin, contor-
trostatin [73]. These drugs may be considered as alter-
natives to the humanized monoclonal antibodies used in 
cancer therapy.
Another RGD-dependent integrin that is targeted by cer-
tain snake venom disintegrins is fibronectin receptor, 
α5β1 integrin. This cell surface receptor has been studied 
in the pathology of several diseases such as Alzheimer’s 
disease [74], vascular diseases [75] and cancer [76]. This 
integrin is the target for regulation of angiogenesis [77, 
78]. Most of the monomeric RGD-disintegrins are inhibi-
tors of α5β1 integrin. MLD- and KTS-disintegrins are 
specific for leukocyte integrins and collagen receptors, 
respectively, and are also being investigated as new areas 
in pharmaceutical research [57].
C-type lectin-like proteins. C-type lectins such as the 
mannose-binding proteins bind a sugar moiety in the 
presence of Ca2+ and contain the carbohydrate recogni-
tion domain (CRD). C-type lectins are a class of proteins 
widely distributed in nature that display various func-
tions in important physiological processes. The C-type 
lectin-like proteins are an important group of proteins 
among the haemorrhagic components in snake venom. 
Most C-type lectin-like proteins in snake venom do not 
contain the classic calcium/sugar-binding loop and they 
have evolved to bind a wide range of physiologically 
important proteins and receptors [79]. Based on their 
structural and functional entities, these proteins in snake 
venom have been classified into the true C-type lectins 
(contains the CRD domain) that bind a sugar molecule 
and the C-type lectin-like proteins with CRD-related 
non-carbohydrate-binding C-type lectin-like domains 
(CTLDs) that do not bind a sugar moiety [80]. They are 
further divided into CRD-containing proteins, factor IX/
X-binding proteins and those that bind to the platelet re-
ceptors [81].
Snake C-type lectin-like proteins bind to a wide range 
of coagulation factors that are important in haemostasis 
and to platelet receptors and display both anti-coagu-
lant- and platelet-modulating activities. They activate 
platelets by binding to von Willebrand factor or specific 
receptors such as GPIb, α2β1 and GPVI. Heterodimeric 
GPIb-binding molecules mainly inhibit platelet func-
tions, while the multimeric binding molecules activate 
platelets. Some tetrameric snake venom C-type lec-
tin-like proteins activate platelets by binding to GPVI, 
while others affect platelet function via integrin α2β1. 
Some act by inducing von Willebrand factor to bind to 
GPIb as well, or activate platelets via α2β1 and GPIb 
[81].
While the earliest described C-type lectin, botrocetin, 
clearly activates platelets by inducing interactions be-
tween GPIb and von Willebrand factor, many GPIb-bind-
ing C-type lectins are described as inhibitory [82]. In the 
last decade, numerous C-type lectin-like proteins, in-
cluding IX/X-binding protein, CA-1, RVV-X, Convulxin, 
EMS16, botocetin and flavocetin-A, have been isolated 
from various snake venoms, sequenced and character-
ized. Echicetin, isolated from the Echis carinatus, spe-
Table 3. Drugs/clinical diagnostic kits from snake venoms.
Drug/trade name® Target and function/treatment Source
Captopril; enalapril ACE inhibitor/high blood pressure Bothrops jaracusa (Brazilian arrowhead viper)
Integrilin (eptifibatide) platelet aggregation inhibitor/acute coronary  
syndrome
Sisturus miliarus barbouri (south-eastern pigmy 
rattlesnake)
Aggrastat (tirofiban) GPIIb-IIIa inhibitor/myocardial infarct, refractory 
 ischaemia
Echis carinatus (African saw-scaled viper)
Ancrod (Viprinex) Fibrinogen inhibitor/stroke Agkistrodon rhodostoma (Malayan pit viper)
Defibrase thrombin and protrhombin inhibitor/acute cerebral 
 infarction, unspecific angina pectoris
Bothrops moojeni
Hemocoagulase thrombin-like effect and thromboplastin activity/
prevention and treatment of haemorrhage
Bothrops atrox
Protac/protein C activator protein C activator/clinical diagnosis of  
haemostatic disorder
Agkistrodon contortix contortix (American 
 copperhead)
Reptilase diagnosis of blood coagulation disorder Bothrops jaraca (South American lance adder)
Ecarin prothrombin activator/diagnostic E. carinatus
Exanta; ximelagatran blood thinner/anti-coagulant, thrombin inhibitor Cobra
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cifically binds platelet GPIb and blocks platelet binding 
with von Willebrand factor and thrombin [83], while 
convulxin, isolated from C. durissus terrificus, activates 
platelets through interaction with GPVI [84]. The inhibi-
tor protein isolated from Echis multisquamatus, EMS16, 
is a potent and selective inhibitor of integrin α2β1 [85] 
while aggretin (C. rhodostoma [86] activates platelets 
by binding to α2β1 and GPIb. The structure of EMS16 
is shown in Figure 3b. Therefore, the C-type lectin-like 
proteins could be useful tools for elucidating the mecha-
nisms involved in clotting and platelet activation as well 
as providing new possibilities in diagnosis and treatment 
through their interaction with platelets, plasma and the 
vascular wall [81, 87].
Conclusion
Nature has been a source of medicinal products for thou-
sands of years, among which snake venoms form a rich 
source of bioactive molecules, such as peptides, proteins 
and enzymes with important pharmacological activities. 
Moreover, blood and bile duct from snakes have been 
widely used in Chinese traditional medicine. With the 
advent of protein fold structures, a rich source of pep-
tides that interact specifically and with high affinity with 
human protein can be developed. This will help not only 
in understanding the implications of each interaction but 
will also lead to the development of effective drugs tar-
geted to particular protein functions. Examples of drugs 
that have been derived from snake venom proteins and 
have progressed the clinic are listed in Table 3. From the 
initial discovery of captopril, the first oral ACE inhibitor 
to the recent application of disintegrins for the potential 
treatment of cancer, the various components of snake 
venoms have never failed to reveal amazing new prop-
erties. Snake venoms have been used in the coagulation 
laboratory for the routine assay of coagulation factors and 
as reagents to study both coagulopathy and haemostasis. 
A number of useful compounds have been identified; 
most notably, the disintegrins (eptifibatide and tirofiban) 
have been shown both in vitro and in vivo to be powerful 
anti-platelet aggregates. While the original native snake 
venom compounds are usually unsuitable as therapeutics, 
interventions by medicinal chemists as well as scientists 
and clinicians in pharmaceutical R & D have made it pos-
sible to use the snake venom proteins as therapeutics for 
multiple disorders based on the available structural and 
functional information. Snake venoms, with their cock-
tail of individual components, have great potential as 
therapeutic agents for human diseases.
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Influence of prenatal irradiation by 131-I on the
heparin-binding activity of newborn rat brain proteins
T. V. Belousova and G. A. Ushakova
Dniepropetrovsk National University, Ukraine; Dniepropetrovsk
Division of the International Center of Molecular Physiology,
National Academy of Science of Ukraine
Prenatal low-dose irradiation leads to decrease of brain cell number, breach of cell
migration and neuronal net formation but in most cases some compensatory
mechanisms prevent rude changes of brain structure and functions during further
ontogenesis. The possible participators of compensatory reconstruction are
HSPGs, which as known take part in control of brain development process due
to interactions with numerous heparin-binding proteins. We investigated heparin-
binding site localisation and total heparin-binding activity of proteins (HBAP) in
the brains of newborn rats under the inﬂuence of 131I (150 lCu) on different stage
of embryogenesis. Results of histochemical analysis revealed that the nucleus of
progenitor cells are the main heparin-positive compounds of newborn rat brain as
under the normal so under the experimental conditions. Less intensive speciﬁc
staining was noted on the levels of internal granular layer in cerebellum, layer of
pyramidal neurons in CA1–CA3 ﬁelds and granular neurons of dentate gyrus in
hyppocampus. Moreover our data suggest that heparin-positivity of nucleus
connects with presence of heparin-binding sites in the structure of some nucleus
cytoskeletal proteins. Consequences of 131I inﬂuence – decrease of progenitor-cell
number as a result of the irradiation and reduction of cell proliferation level as
result of hypothyroidism – lead to strong increase of heparin-positivity, with
maximal changes after 131I-injection on 16 e.d. Obtained data allow suggest that
inﬂuence of HSPGs to cell proliferation depend on their concentration and
compartmentalization.
Keywords: brain development, glycosaminoglycans.
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Cannabinoid inhibition of neuronal differentiation
I. Galve-Roperh, D. Rueda, A. Martı´nez-Serrano and M. Guzma´n
Department of Biochemistry and Molecular Biology I, Complutense
University, Madrid, Spain
Cannabinoids, the active components of Cannabis sativa, exert their effects by
mimicking a family of endogenous lipid ligands such as anandamide and
2-arachidonoylglycerol. In the brain cannabinoids act through their seven
transmembrane receptor CB1, and exert an important neuromodulatory role
inhibiting the release of several neurotransmitters. In addition, cannabinoids can
regulate the cell fate decision of different neural cell types. Thus, cannabinoids
induce apoptosis of transformed glial cells whereas they are effective neuropro-
tective mediators against different brain insults. Therefore we investigated the
potential regulation of neurogenesis by the endocannabinoid system. Anandamide
treatment of cortical neuron precursors inhibited neuronal generation. Thus
anandamide, via CB1 receptor, decreased the number of neurite-bearing cells and
diminished and delayed the appearance of the neuronal markers b-tubulin III and
Neu N. Signal transduction studies using PC12 cells show that cannabinoid-
mediated inhibition of neuronal differentiation relies on their ability to inhibit
NGF-induced sustained extracellular signal-regulated kinase (ERK) activation.
Cannabinoids attenuate NGF-evoked Rap-1 and B-Raf activation, crucial
upstream mediators of sustained ERK activation. In addition, neurogenesis was
determined in vivo in the dentate gyrus of adult rats treated with cannabinoids.
Cannabinoid administration decreased the number of newly generated cells
(BrdU+) that acquire and differentiate into a neuronal phenotype (Neu N+),
whereas the CB1 antagonist enhanced neurogenesis. In summary, our results
suggest that endocannabinoids constitute a new endogenous system involved in
the regulation of neurogenesis.
Keywords: Cannabis, MAP kinase, neural progenitors, NGF, PC12 cells.
P17-03
Molecular cloning and characterization of a novel glial
cell line-derived neurotrophic factor family receptor
a-like gene
Z. Li, Z. Li, B. Wang and J. Zhou
Institute of Biochemistry and Cell biology, Shanghai Institutes for
Biological Sciences, Chinese Academy of Sciences, 320 Yueyang
Road, Shanghai, China
Members of the glial cell line-derived neurotrophic factor (GDNF) family
comprising GDNF, neurturin, persephin, and enovin/artemin, are crucial for the
development and maintenance of distinct sets of central and peripheral neurons.
All ligands signal through the oncogene c-RET which is activated only if the
ligand is ﬁrst bound to GDNF family receptor-a (GFRa) receptors, which are
linked to the plasma membrane by a GPI anchor. Four different GFRa receptors
have been identiﬁed (GFRa 1–4), which determine the ligand speciﬁcity of the
GFRa–RET complex. Here we described the cloning of a novel gene that may be
related to the GFRa receptor family. Using bioinformatics tools and rapid
ampliﬁcation of cDNA ends (RACE), a full-length cDNA (2013 bp) was cloned
from mouse brain that shows moderate homology to members of GFRa receptor
family. The gene contains a putative signal peptide at its N terminal and shares
conserved spacing of cystine residues which were also present in other GFRa
receptors. At least two splice variants of the gene existed in mouse brain, differing
at their respective COOH termini. One of the splice variants encoded a
transmembrane form of the gene, while the other encoded a secreted one. RT-
PCR analysis suggested that the mRNA is expressed primarily in the central
nervous system, although at low levels, but not in peripheral organs. The putative
transmembrane variant was localized on plasma membrane, determined by
ﬂuorescence immunohistochemistry. Further investigations on its biological
function and potential signaling cascades are currently under way.
Keywords: GDNF, receptor a.
P17-04
Evaluation of neuronal maturation following sustained
exposure to static magnetic field in cultured rat
hippocampal neurons
T. Hirai and Y. Yoneda
Laboratory of Molecular Pharmacology, Kanazawa University
Graduate School of Natural Science and Technology, Kanazawa,
Ishikawa, Japan
In the present study, we have investigated the inﬂuence of sustained exposure to
static magnetic ﬁeld on mechanisms underlying cellular maturation and differen-
tiation in cultured rat hippocampal neurons and astrocytes as a guidepost for
possible functional alterations induced by magnetism in the brain. Hippocampal
neurons and astrocytes were cultured for different days in vitro (DIV) under
sustained exposure to static magnetic ﬁeld at 100 mT generated by permanent
magnets equipped at both sides of culture dishes. Sustained exposure to static
magnetic ﬁeld signiﬁcantly decreased the expression of microtubule-associated
protein 2 and neuronal nuclei in hippocampal neurons cultured for 1–9 DIV,
without markedly affecting that of growth associated protein-43. Although
sustained exposure led to a signiﬁcant increase in the expression of glial ﬁbrillary
acidic protein (GFAP) in hippocampal neuronal preparations cultured for 6–9 DIV
under sustained exposure to magnetism, sustained exposure did not markedly
affect the expression of both GFAP and proliferating cell nuclear antigen in
cultured astrocytes irrespective of cellular maturity. No signiﬁcant alteration was
seen with the cell survivability quantiﬁed by 3-[4,5-dimethylthiazol-2-yl]-2,5-
diphenyltetrazolium bromide reduction assay in cultured hippocampal neurons and
astrocytes. These results suggest that cultured rat hippocampal neurons may be
more sensitive to sustained exposure to static magnetic ﬁeld than cultured rat
hippocampal astrocytes in terms of modulation of mechanisms associated with
cellular maturation and development, but not survivability.
Keywords: hippocampus, MAP2, maturation.
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Riluzole enhances expression of BDNF with consequent
proliferation of granule precursor cells in the rat
hippocampus
R. Katoh-Semba, T. Asano, H. Ueda, R. Morishita, R. Kaneko,
I. K. Takeuchi and K. Kato
Institute for Developmental Research, Aichi Human Service Center,
Kasugai, Aichi, Japan
The dentate gyrus of the hippocampus, generating new cells throughout life,
is essential for normal recognition memory performance. Reduction of brain-
derived neurotrophic factor (BDNF) in this structure impairs its functions. To
elucidate the association between BDNF levels and hippocampal neurogen-
esis, ﬁrst, we have conducted a search for compounds that stimulate
endogenous BDNF production in the hippocampal granule neurons. Among
ion channel modulators tested, an intraperitoneal injection of riluzole, a
neuroprotective agent with anticonvulsant properties that is approved for
treatment of amyotrophic lateral sclerosis, was highly effective as a single
dose, causing a rise in BDNF localized in dentate granule neurons, the hilus
and the stratum radiatum of the CA3 region. Repeated, but not single,
injections resulted in prolonged elevation of hippocampal BDNF and,
moreover, was associated with increased numbers of newly generated cells in
the granule cell layer. This appeared due to promoted proliferation, rather
than survival, of precursor cells, a large amount of which differentiated into
neurons. Intraventricular administration of BDNF-speciﬁc antibodies blocked
such riluzole effects, suggesting that BDNF increase is necessary for the
promotion of precursor proliferation. We also report on mechanisms of
riluzole-induced BDNF production.
Keywords: BDNF, granule cells, hippocampus, neurotrophins, stem cells.
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Secretoneurin promotes pertussis toxin-sensitive neurite
outgrowth in cerebellar granule cells
A. Saria,* M. C. Gasser,* I. Berti,* K. F. Hauser and
R. Fischer-Colbrie
*Department of Psychiatry, Division of Neurochemistry, Innsbruck,
Austria; Department of Anatomy and Neurobiology, University of
Kentucky College of Medicine, Lexington, KY, USA; Department of
Pharmacology, University of Innsbruck, Innsbruck, Austria
The neuropeptide secretoneurin (SN) is an endoproteolytic product of the
chromogranin secretogranin II. We investigated the possibility that SN, like
other structurally similar neuropeptides, might inﬂuence the differentiation of
immature cerebellar granule cells derived from the external granular layer.
SN caused concentration-dependent increases in neurite outgrowth, which
was taken as a parameter of differentiation. The maximum effect was reached
at a concentration of 100 nM SN. SN immunoneutralization using selective
antiserum signiﬁcantly decreased neurite outgrowth; however, neurite
morphology was altered, presumably due to extraneous growth factors in
the rabbit serum. An afﬁnity chromatography puriﬁed antibody inhibited the
outgrowth response to SN signiﬁcantly (p < 0.001) without altering the
morphology. Binding studies suggest the existence of speciﬁc G-protein
coupled receptors on the surface of monocytes that recognize SN. Assuming
SN promotes neurite outgrowth in EGL cells by acting through a similar
G-protein coupled mechanism, we treated SN-stimulated EGL cultures with
pertussis toxin (PTx). Exposure to PTx (0.1 lg/mL) showed a signiﬁcant
inhibition of the SN-induced outgrowth. To establish a second messenger
pathway we used the protein kinase C inhibitor staurosporine. These data
indicate that SN is a novel trophic substance that can affect cerebellar
maturation, primarily by accelerating granule cell differentiation through a
signaling mechanism that is coupled to pertussis toxin-sensitive G-proteins.
Keywords: cerebellum, G protein-coupled receptors, neuropeptides, recep-
tor.
P17-07
Effect of retinoic acid differentiation of c6 glioma cells
on free radical scavengers and NCAM expression
J. Singh and G. Kaur
Neurochemistry and Neuroendocrinology Laboratory, Department
of Biotechnology, Guru Nanak Dev University, Amritsar, India
Glial cells are the most abundant cell type in the central nervous system and
provide structural and metabolic support to the neurons and modulate
synaptic activity. Accordingly impairment of glial functions during various
metabolic insults can critically inﬂuence neuron survival. Cells exposed to
oxidants develop multiple ultrastructural alterations. These alterations are
more pronounced in differentiated in comparison with the undifferentiated
cells. Recent evidence however, in both neuronal and non-neuronal cells,
suggests that reactive oxygen molecules also function as messenger
molecules in processes such as synaptic plasticity. Accordingly we studied
the oxidant defense system and changes in neural cell adhesion molecule
(NCAM) expression in undifferentiated and retinoic acid (RA) induced
differentiated C6 glioma cells. The strong inhibitory effects of RA on
proliferation and clear changes in morphological features such as shrinkage
in cell size and elongation of cell processes conﬁrmed differentiation. A
signiﬁcant increase was observed in the activity of catalase and CuZn
superoxide dismutase (CuZn-SOD), while there was a decrease in the activity
of GPx in differentiated as compared to undifferentiated C6 cells. Total
glutathione content (GSH) increased marginally under same set of condi-
tions.The neural cell adhesion molecule expression was studied in undiffer-
entiated and in RA induced differentiated cultures. Results suggest an
increase in the expression of NCAM120 and NCAM 140 isoforms. RA
induced differentiation of C6 glioma cell line in the present study is
associated with the upregulation of both oxidative stress scavenger proﬁle
and NCAM expression.
Keywords: antioxidant, free radicals, glioma, NCAM, retinoic acid.
P17-08
Involvement of multiple signaling pathways in insulin-
like growth factor-I-mediated survival of oligodendrocyte
progenitor
Q.-L. Cui and G. Almazan
Department of Pharmacology and Therapeutics, McGill University,
Montreal, Quebec, Canada
Insulin-like growth factor-I (IGF-I) protects oligodendrocyte progenitors
(OGP) from apoptosis induced by a variety of pathologic stimuli. The
underlying mechanisms are not fully understood. We have investigated
involvement of phosphatidylinositol 3-kinase (PI3K), mitogen-activated
protein kinase (MEK1) and Src family tyrosine kinases (SFTK) in IGF-I
signaling in OGP. We cultured rat primary OGP in medium deprived of
growth factors to induce apoptosis. MTT and TUNEL assays were used to
detect cell survival and apoptosis. Changes in levels of PI3K/Akt (a
downstream target of PI3K) cascade and caspase3 were detected by Western
blotting. We observed that (1) IGF-I promoted a twofold increase in cell
survival and reduced apoptotic cells by 60% of control; (2) IGF-I sustained
Akt activation, and inhibited caspase3 activation induced by growth-factor
withdrawal. LY294002 or Wortmannin, speciﬁc inhibitors of PI3K, inhibited
cell survival and anti-apoptotic effects of IGF-I, and reversed IGF-I-induced
Akt activation and caspase3 inhibition; (3) MEK1 speciﬁc inhibitors,
PD98059 or U0126, had no signiﬁcant effects on IGF-I-mediated changes;
(4) a SFTK inhibitor, PP2, reduced cell survival and inhibited Akt activation
produced by IGF-I, but did not reverse the anti-apoptotic effect of IGF-I.
These data indicate that (1) PI3K/Akt cascade is implicated in IGF-I-
mediated survival and anti-apoptotic effects; (2) SFTK is involved in
IGF-I-mediated survival effect by regulating Akt activation.
Keywords: IGF-I, oligodendrocyte progenitor, PI3K, Src family tyrosine
kinases, survival.
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Upregulation of GFAP in astrocytes is associated with
decreased expression of EPO, proliferation and survival
of the cells
C. Schneider, S. Harsch, S. Kugi, H. Wiesinger, M. Weller,
M. Morgalla, G. H. Buniatian, C. H. Gleiter and L. Danielyan
Department of Clinical Pharmacology, University Hospital,
Tuebingen, Germany
Erythropoietin (EPO) exerts neurotrophic and neuroprotective activities in
different in vivo and in vitro models of brain damage. In the present study, we
used double immunoﬂuorescence technique and real-time RT-PCR to examine the
correlation between the expression of GFAP and the synthesis of EPO and
proliferative cell nuclear antigen (PCNA) in early (day 7) and late (day 21)
astroglial primary cultures. In order to examine the inﬂuence of EPO on the
survival of GFAP-positive cells, the human astrocytic cell line SV-40 FHAS was
studied. The number of the cells grown under hypoxic and normoxic conditions in
EPO-free and EPO-supplemented medium was determined. There was an inverse
correlation of the dynamics of EPO synthesis and the expression of GFAP. These
results were conﬁrmed by real-time RT-PCR studies which showed decreased
EPO-mRNA levels in late astroglial primary cultures. As judged from the
expression of PCNA, proliferation decreased during the differentiation of
astrocytes. Down-regulation of EPO in astrocytes which lost their capacity to
proliferate and strongly expressed GFAP, a protein that supports the cytoskeleton
of the cells during pathological situations, suggested a role for EPO in the survival
of astrocytes. To address this question, human astrocytes were cultured under
hypoxic conditions in the presence and as control in the absence of EPO. Addition
of EPO blocked the massive disappearance of the cells under hypoxic conditions.
In conclusion, EPO may be involved in the mechanisms regulating the survival
and the proliferation of astrocytes, that might play an important role in diseases of
the central nervous system.
Keywords: astrocytes, cell proliferation, differentiation, glial ﬁbrillary acidic
protein, hypoxia.
P17-10
Transferrin (Tf) mRNA is inversely correlated with MBP
and P0 in the sciatic nerve of the rat
C. P. Setton-Avruj, C. Salis, E. F. Soto and J. M. Pasquini
Department of Biochemical Chemistry, School of Pharmacy and
Biochemistry, University of Buenos Aires, Buenos Aires, Argentina
Tf is an iron carrier protein playing a key role in cell metabolic activity that is
regarded as a growth, survival and differentiation factor. Previous studies have
demonstrated the presence of Tf mRNA in oligodendrocytes (1). The mRNA levels
were highly correlated with the myelination peak in the central nervous system
(CNS) (2). The aim of the present study was to evaluate the presence of the
mRNA of Tf in embryonic and mature sciatic nerves of the rat and its possible
correlation with the mRNA of MBP and P0, the major proteins of peripheral
myelin. Sciatic nerves from 15 embryonic day old rats (E15) and from 4-day-
old rats (P4) were dissected out and their total RNAwas isolated.The presence
of the mRNA for Tf, MBP and P0 was detected by Northern blot, using
speciﬁc probes for each protein. We have been able to demonstrate for the ﬁrst
time that the mRNA of Tf is present in sciatic nerve at E15 when the nerve is
still immature, while it is absent when total RNA was isolated from rats of
4 days of age. In contrast the mRNA of MBP and P0 appeared only in the
postnatal period, when the most of the Schwann cell (SC) population of the
sciatic nerve function as myelin forming cells. Taking into consideration the
absence of Tf mRNA in neuron cells, these results appear to suggest that Tf
may play an important role in the maturation of SC, as in the rat these cells are
completely mature at the time of birth. At variance with what occurs in the
CNS, the mRNA of Tf decreases with the appearance of the mRNA of two
important peripheral myelin markers such as MBP and P0.
Keywords: mRNA, myelin proteins, myelination, peripheral nerve, transferrin.
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Pctaire1 regulates the neurite outgrowth and dendritic
development in primary cortical neurons
W.-Y. Fu, K. Cheng, A. K. Fu and N. Y. Ip
Department of Biochemistry, Molecular Neuroscience Center and
Biotechnology Research Institute, Hong Kong University of Science
and Technology, Clear Water Bay, Hong Kong, China
Pctaire1, a Cdk-related protein kinase, is prominently expressed in terminal
differentiated tissues such as brain and testis. Based on a yeast two-hybrid screen,
we have demonstrated that Pctaire1 interacts with p35, a speciﬁc Cdk5 activator.
Serine 95 (S95) of Pctaire1 is the major phosphorylation site for Cdk5. More
importantly, Pctaire1 activity is enhanced by S95 phosphorylation. Similar to
Cdk5 and p35, Pctaire1 is expressed along the neurites and at the growth cones of
developing cortical neurons. The kinase activity and S95 phosphorylation of
Pctaire1 increase in primary cortical neurons during the process of neuronal
differentiation in culture. The temporal proﬁle of changes in Pctaire1 activity
correlates with that observed for Cdk5 kinase activity. To further explore the
functional roles of Pctaire1 kinase in neuronal development, various Pctaire1
constructs (including wild type, dominant negative and S95A mutant) are
transfected into cortical cultures. Expression of dominant negative and S95A
mutants of Pctaire1 inhibits neurite outgrowth as well as the formation of dendritic
arborization. On the other hand, wild type Pctaire1 increases neurite branching and
dendritic arborization in cortical neurons. Taken together, our ﬁndings demonstrate
that the activity of Pctaire1 is regulated by Cdk5 and suggest that Pctaire1 is
involved in the regulation of neuronal development.
Keywords: dendrite, neurite outgrowth, neuronal differentiation, protein kinase.
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Leukemia inhibitory factor receptor signaling negatively
modulates NGF-induced neurite outgrowth
Y. P. Ng, W. He and N. Y. Ip
Department of Biochemistry, Biotechnology Research Institute and
Molecular Neuroscience Center, Hong Kong University of Science
and Technology, Clear Water Bay, Hong Kong, China
Nerve growth factor (NGF) is required for the development of sympathetic
neurons and subsets of sensory neurons. Our current knowledge on the
molecular mechanisms underlying the biological functions of NGF is in part
based on the studies with PC12 rat pheochromocytoma cells, which
differentiate into sympathetic neuron-like cells upon NGF treatment. Here
we report that the expression of leukemia inhibitory factor receptor (LIFR),
one of the signaling molecules shared by several neuropoietic cytokines of
the IL-6 family, is upregulated in PC12 cells following treatment with NGF.
Attenuation of LIFR signaling through stable transfection of antisense or
dominant negative LIFR constructs enhances NGF-induced neurite extension
in PC12 cells. On the contrary, overexpression of LIFR retards the growth of
neurites. More importantly, while NGF-induced Rac1 activity is enhanced in
AS-LIFR and DN-LIFR expressing PC12 cells, it is reduced in LIFR
expressing PC12 cells. In sympathetic neurons lacking LIFR, both neurite
length and branching are enhanced when compared with control neurons.
Taken together, our ﬁndings suggest that LIFR signaling, besides its known
function in cell survival and phenotype development, can be speciﬁcally
induced by NGF and exert negative regulatory effect on neurite extension
and branching of sympathetic neurons.
Keywords: CNTF, LIFR, nerve growth factor, neuronal differentiation,
sympathetic nerves.
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EGF and FGF cooperate with estradiol to promote
neuroglia differentiation
R. Wong, A. Chen, E. Thung, G. Chinn, H. Ra and P. S. Timiras
Department of Molecular and Cell Biology, University of
California, Berkeley, CA, USA
Administration of epidermal growth factor (EGF) and ﬁbroblast growth
factor (FGF) stimulates cell proliferation. Increased cell proliferation may be
associated with increased responsiveness to steroid hormones. In this study,
we investigated whether simultaneous administration of EGF or FGF with
estradiol would enhance neuroglia response to the hormone. We used C-6 rat
glioma 2B-clone cells, a mixture of astrocytes and oligodendrocytes. They
were cultured for 8 days with EGF (50 ng/mL) or FGF (80 ng/mL), the
lowest doses effective in promoting cell proliferation. Both growth factors
alone stimulated cell proliferation, with FGF being more active. When
estradiol was added to the culture containing EGF or FGF, even small
concentrations of estradiol (0.05 mM) were capable of inhibiting cell
proliferation and promoting cell differentiation. Cell differentiation was
measured by increased activity of glutamine synthetase, GS (the marker for
astrocytes) and 2¢,3¢-cyclic nucleotide 3¢-phosphohydrolase, CNP (the
marker for oligodendrocytes). In all cases, there was a dose-dependent
response in promoting GS and CNP activity, even with very low doses of
estradiol. These data show that maintaining neuroglia cells in a highly
proliferative state makes them more responsive to low doses of estradiol. The
data also suggests possible interventive therapies, whereby the dose of a
hormone, potentially carcinogenic as estradiol, may be signiﬁcantly lowered
by the administration of growth factors, without affecting its desired action of
promoting neuroglia cell differentiation.
Keywords: epidermal growth factor, estradiol, ﬁbroblast growth factor, glial
cells.
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Early and late patterns of caveolins expression in
differentiating C6 astroglia
W. Silva,* J. Miranda,* G. Vela´zquez,* F. Valentı´n,* M. Quin˜ones,*
N. Mayol and H. Maldonado
*Physiology Department, University of Puerto Rico School of
Medicine, San Juan, Puerto Rico; Department of Pharmacology,
Universidad Central del Caribe, School of Medicine, Bayamo´n,
Puerto Rico
The discovery of caveolae (CAV) and caveolins (caveolin-1, -2 and -3) in the
brain has led to increased interest to elucidate their neurobiological role(s).
Here we evaluated the temporal and spatial patterns of caveolins expression
in C6 differentiation from an oligodendrocyte-like to an astrocyte-like
phenotype. Time course analysis of the expression of caveolin-1 and -2 using
semi-quantitative RT-PCR and Western blots, shows that both isoforms are
gradually up-regulated late (12–48 h postinduction) in the differentiation
process. In contrast, caveolin-3 displays an early pattern of up-regulation
(4–12 h postinduction). Indirect immunoﬂuorescence analysis reveals that
caveolin-l and -2, display similar perinuclear and punctuate distribution
patterns in the oligodendrocyte-like phenotype. After induction of differ-
entiation these are more evident as plasmalemma micropatches in the cellular
processes, suggestive of the expression of caveolae. In contrast, caveolin-3 is
restricted in distribution in both glial phenotypes, to the soma of C6 cells.
Therefore, the C6 astroglia model system permits the assessment of the role
of CAV and caveolins in glial cell maturation and differentiation. The C6
differentiation process is akin to developmental events of gliogenesis, and to
the astrogliosis, seen in neurological insults, therefore the value of this model
system to further the understanding of the relevance of CAV and caveolins in
these physiological and pathophysiological events.
Keywords: astrocytes, caveolins, cell culture, glial cells, plasma membrane.
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Neurotrophins facilitate neuronal differentiation of
cultured neural stem cells via induction of basic HLH
transcription factors
S. Furukawa, H. Ito, A. Nakajima and H. Nomoto
Laboratory of Molecular Biology, Gifu Pharmaceutical University,
Mitahora-higashi 5-6-1, Gifu, Japan
Neurogenesis is promoted by basic helix-loop-helix (bHLH) transcription
factors Mash1, Math1 and/or NeuroD but suppressed by another set, Hes1
and Hes5. It is still unknown what kinds of extracellular signals are involved
in their regulation. Therefore, the effects of neurotrophins on the expression
of bHLH factors and neuronal differentiation were investigated by the use of
cultured mouse neural stem cells. Each neurotrophin increased Mash1 and
Math1 mRNAs of the stem cells growing in the presence of ﬁbroblast growth
factor-2 (FGF-2), but did not alter Hes1, Hes5 or NeuroD mRNA levels.
Simultaneously, most of the cells expressed nestin, but not microtubule-
associated protein 2 (MAP2), and still remained undifferentiated. FGF-2
removal from the medium reduced the levels of Hes1 and Hes5 mRNAs and
increased those of Mash1, Math1, and NeuroD mRNAs, resulting in
substantial neuronal differentiation. However, when the cells were pretreated
with a neurotrophin, brain-derived neurotrophic factor, FGF-2 removal
enhanced earlier NeuroD expression and generated many more MAP2-
positive cells. The high level of Mash1 and Math1 that had been elevated at
FGF-2 withdrawal accelerated NeuroD expression in cooperation with the
reduced Hes1 and Hes5 expression. Our present results suggest that
neurotrophins stimulate neuronal differentiation via altering the balance of
expression of various bHLH transcription factors.
Keywords: BDNF, neural stem cells, neurotrophins, transcription factors.
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NGF form cobra venom, promotes the expression of the
endogenous NGF in PC12 cells
K.-C. I. Dawn, P. N. Ramkishen, A. Armugam and K. Jeyaseelan
Department of Biochemistry, Faculty of Medicine, National
University of Singapore, Singapore 117597
The nerve growth factor (NGF) from the cobra, Naja sputatrix, has been
puriﬁed by gel ﬁltration followed by reverse-phase HPLC. The protein
showed about 1000-fold higher activity than the mouse NGF in forming
neurite outgrowths on PC12 cells. Two cDNAs (NsNGFI & II; 700 bp)
encoding isoforms of NGF have been cloned from the venom gland mRNA.
These cDNAs show 60–70% homology to the 7S-beta NGF. The mature
protein coding region NsNGFII has been produced as a his-tagged fusion
protein in Escherichia coli. The inclusion bodies formed were solubilised in
8 M urea, puriﬁed by afﬁnity chromatography and then refolded to yield an
active protein. The functional analysis of the recombinant NGF showed
similar results to that of the native protein. SELDI-TOF (surface-enhanced
laser desorption/ionization-time of ﬂight), protein-proﬁling conﬁrmed that
cobra NGF promotes endogenous expression of NGF in PC12 cells a
beneﬁcial effect, which could not be seen with mouse beta-NGF in.
Keywords: cobra venom, neurite outgrowth, NGF, PC12 cells.
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The roles of the chondroitin sulfate proteoglycan
versican V1 isoform in neuronal differentiation and
neurite outgrowth
Y. Wu,*, L. Chen,*, W. Sheng,*, H. Dong,*, V. Lee,*,
F. Lu,*,§ S. Wong,*,§ W.-Y. Lu*, and B. B. Yang*,
*Sunnybrook & Women’s College Health Sciences Centre;
Department of Laboratory Medicine and Pathobiology, University
of Toronto; Department of Anaesthesia, University of Toronto;
§Department of Radiation Oncology, University of Toronto
The chondroitin sulfate proteoglycan versican is one of the major extracellular
components in the developing and developed brain, but little is known of its
functions in the neuronal system. We have previously demonstrated that the C-
terminal domain of versican interacts with b1-integrin and this interaction
modulates cell adhesion (1). Here we show that different isoforms of versican play
different roles in neuronal differentiation and neurite outgrowth. In PC12 cells, the
versican V1 isoform induced complete differentiation, while V2 induced an
incomplete differentiation accompanied by early apoptosis. V1 promoted neurite
outgrowth of primary hippocampal neurons, while V2 inhibited this process. V1
up-regulated expression of epidermal growth factor receptor and integrins and
facilitated sustained-ERK/MAPK phosphorylation. Blockade of the epidermal
growth factor receptor, integrin b1, or Src signiﬁcantly inhibited neuronal
differentiation. V1 expression altered NGF-induced expression and current
patterns of nicotinic acetylcholine receptor (nAChR) in PC12 cells. Finally, we
demonstrated that versican V1 isoform also induced neuronal stem cell
differentiation and neurite outgrowth. Our results have implications for under-
standing how versican regulates neuron development and repair.
Keywords: PC12 cell, Neurons, proteoglycams, neuronal differentiation, neurite
outgrowth.
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The neural NPDC-1 protein interacts with several
regulatory proteins
C. Evrard and P. Rouget
Unite´ de Ge´ne´tique Oncologique, Institut Gustave Roussy,
Villejuif, France
We identiﬁed a gene expressed in neural cells, which is involved in the control of
proliferation and differentiation. The strategy was to clone cDNAs that both
hybridized with HLH probes and corresponded to RNAs expressed preferentially
when neural precursor cells stopped dividing. This led to the isolation of NPDC-1
cDNA and then of the genomic sequence (1). The stable introduction of NPDC-1
cDNA into dividing neural precursor cells resulted in the inhibition of cell
proliferation and in the induction of differentiation (2). We observed that the
protein was able to interact directly with the E2F-1 transcription factor and with D-
cyclins (3). This interaction reduced the binding of E2F-1 to DNA and its
transcriptional activity. Taken together, the data suggest that NPDC-1 may play a
role in the regulation of neural cell proliferation and differentiation, through
interactions with E2F-1. Recent results showed that NPDC-1 was also able to
interact with Rab3-GDP/GTP Exchange Protein (Rab3-GEP) which is involved in
presynaptic vesicles trafﬁcking and release of neurotransmitters. With the aim to
elucidate the biological function of NPDC-1, we are studying the phenotype of
transgenic mice carrying the npdc-1 gene inactivated by homologous recombi-
nation.
Keywords: cell proliferation, differentiation, gene expression, transgenic mouse.
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Role of ciliary neurotrophic factor (CNTF) family growth
factors in the survival and neurite outgrowth of retinal
ganglion cells
S. C. Yeung, R. C. C. Chang and H. K. Yip
Department of Anatomy, Faculty of Medicine, University of
Hong Kong, 5 Sassoon Rd, Hong Kong, China
Although mature mammalian retinal ganglion cells (RGCs) normally fail to
regrow injured axons, exposure to the molecular environment of the peripheral
nervous system stimulates regenerative growth. The present study uses dissociated
RGCs to examine the role of ciliary neurotropic factor (CNTF) and its related
cytokines in promoting RGC survival and neurite outgrowth. Postnatal 1-day-old
SD rats are anesthetized and their RGCs are retrogradely labeled from superior
colliculi by ﬂuorescent dye, DiASP. The pups are killed after 3–4 days for retinal
cell culture. Cytokines (IL-1, etc.) are added to the retinal cell culture in 96-well
plate for appropriate time periods. The number of RGCs will be counted by using a
ﬂuorescent inverted microscope using a FITC ﬁlter. The effect of cytokines, alone
or in combination with neurotrophic factors (BDNF, NGF) on the survival of
RGCs is examined. In addition, we investigate whether the survival effect of those
factors is mediated through the JAK-STAT and/or PI-3 pathway. To evaluate the
importance of the JAK-STAT pathway in the effect of CNTF-related cytokines, the
JAK inhibitor AG490 at 25 mM is used. To analyze the participation of PI-3 on
signal transduction of those factors a speciﬁc inhibitor of PI-3, LY294002 at 25 lM
is also tested.
Keywords: cell culture, CNTF, JAK/stat, retinal ganglion cell.
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PEDF expression and promoter activity is regulated by
retinoic acid
J. Tombran-Tink and C. J. Barnstable
University Missouri-Kansas City, MO, USA and Yale University,
New Haven, CT, USA
Retinoic acid (RA) controls differentiation and apoptosis in the developing
nervous system. RA effects are mediated through a group of cytoplasmic receptors
(RAR) that regulate transcription of genes containing RAR-binding motifs. An
RAR motif is present in the PEDF promoter. This study determined the effects of
all trans RA (ATRA) on PEDF promoter activity and tested the effects of PEDF on
the expression of RARs in PEDF-producing and PEDF-target cells. Two human
cell lines expressing PEDF, ARPE19 and Y79, and primary mouse Mu¨ller glial
cells, were treated for 5 days with 1–10 nM of ATRA in serum-free medium and
PEDF expression analyzed. Cells were also treated with PEDF for 48 h, harvested,
and RNA extracted for transcriptional proﬁling. To test the effect of RA on the
PEDF promoter, the 5¢ ﬂanking region of the PEDF gene, )869/+59, was cloned
into pGL3 vector upstream of a luciferase genev and used to transfect cells. PEDF
mRNA levels in treated cells and PEDF levels in conditioned-medium of treated
cells were elevated about 3X. ATRA increased luciferase activity in cell lines
treated following transfection with the PEDF promoter pGL3 plasmid. Array data
indicated that PEDF induces expression of the RAR gamma and RAR orphan C by
ﬁvefold and twofold, respectively, but downregulates the RAR alpha by twofold.
Both ATRA and PEDF can regulate cell differentiation and cell death. By
regulating the activity of each other, they may have complementary effects in these
processes.
Keywords: apoptosis, neurodegeneration, retina, retinoic acid.
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